KR101642363B1 - 신경내분비계 질환의 억제 - Google Patents
신경내분비계 질환의 억제 Download PDFInfo
- Publication number
- KR101642363B1 KR101642363B1 KR1020117000251A KR20117000251A KR101642363B1 KR 101642363 B1 KR101642363 B1 KR 101642363B1 KR 1020117000251 A KR1020117000251 A KR 1020117000251A KR 20117000251 A KR20117000251 A KR 20117000251A KR 101642363 B1 KR101642363 B1 KR 101642363B1
- Authority
- KR
- South Korea
- Prior art keywords
- cys
- phe
- trp
- lys
- thr
- Prior art date
Links
- 208000015706 neuroendocrine disease Diseases 0.000 title abstract description 3
- 230000001629 suppression Effects 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 218
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 139
- 239000004365 Protease Substances 0.000 claims abstract description 123
- 229920001184 polypeptide Polymers 0.000 claims abstract description 123
- 108091005804 Peptidases Proteins 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 100
- 238000011282 treatment Methods 0.000 claims abstract description 93
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims abstract description 59
- 108010056088 Somatostatin Proteins 0.000 claims abstract description 52
- 102000005157 Somatostatin Human genes 0.000 claims abstract description 47
- 229960000553 somatostatin Drugs 0.000 claims abstract description 46
- 201000011519 neuroendocrine tumor Diseases 0.000 claims abstract description 45
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 42
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims abstract description 35
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims abstract description 35
- 230000008685 targeting Effects 0.000 claims abstract description 18
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102100034845 KiSS-1 receptor Human genes 0.000 claims abstract description 6
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims abstract description 6
- 108091008039 hormone receptors Proteins 0.000 claims abstract description 6
- 101150056450 UTS2R gene Proteins 0.000 claims abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 8
- 102000056271 Prolactin-releasing peptide receptors Human genes 0.000 claims abstract 3
- 108700024163 Prolactin-releasing peptide receptors Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims description 191
- 108090000623 proteins and genes Proteins 0.000 claims description 191
- 230000004927 fusion Effects 0.000 claims description 186
- 230000027455 binding Effects 0.000 claims description 49
- 102000005962 receptors Human genes 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 40
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 34
- 108010005430 cortistatin Proteins 0.000 claims description 34
- 231100000065 noncytotoxic Toxicity 0.000 claims description 33
- 230000002020 noncytotoxic effect Effects 0.000 claims description 33
- 101710142969 Somatoliberin Proteins 0.000 claims description 32
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 30
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 26
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 22
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 claims description 19
- 102100030851 Cortistatin Human genes 0.000 claims description 18
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 18
- 206010000599 Acromegaly Diseases 0.000 claims description 17
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 17
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 17
- 229930185483 Cortistatin Natural products 0.000 claims description 16
- 208000010916 pituitary tumor Diseases 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 12
- 101800001586 Ghrelin Proteins 0.000 claims description 10
- 210000000172 cytosol Anatomy 0.000 claims description 9
- 210000001163 endosome Anatomy 0.000 claims description 9
- 230000005945 translocation Effects 0.000 claims description 8
- 108010011107 Urotensins Proteins 0.000 claims description 7
- 108010051479 Bombesin Proteins 0.000 claims description 6
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 108010073466 Bombesin Receptors Proteins 0.000 claims description 4
- 102000005593 Endopeptidases Human genes 0.000 claims description 4
- 108010059378 Endopeptidases Proteins 0.000 claims description 4
- 108010016122 Ghrelin Receptors Proteins 0.000 claims description 4
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 claims description 4
- 210000001640 nerve ending Anatomy 0.000 claims description 4
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 3
- 108010087786 Prolactin-Releasing Hormone Proteins 0.000 claims description 2
- 102100028850 Prolactin-releasing peptide Human genes 0.000 claims description 2
- 230000012202 endocytosis Effects 0.000 claims description 2
- 210000000416 exudates and transudate Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 6
- 239000000813 peptide hormone Substances 0.000 claims 1
- 239000002877 prolactin releasing hormone Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 abstract description 32
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 6
- 101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 abstract description 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 189
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 159
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 99
- 239000000306 component Substances 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 78
- 206010028980 Neoplasm Diseases 0.000 description 76
- 235000001014 amino acid Nutrition 0.000 description 73
- 229940024606 amino acid Drugs 0.000 description 71
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 69
- 150000001413 amino acids Chemical class 0.000 description 67
- 125000000539 amino acid group Chemical group 0.000 description 66
- 108020001507 fusion proteins Proteins 0.000 description 61
- 102000037865 fusion proteins Human genes 0.000 description 59
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 51
- 230000000694 effects Effects 0.000 description 47
- 108010051696 Growth Hormone Proteins 0.000 description 43
- 102100038803 Somatotropin Human genes 0.000 description 43
- 239000000122 growth hormone Substances 0.000 description 43
- 208000024891 symptom Diseases 0.000 description 41
- 241000894007 species Species 0.000 description 40
- 239000002581 neurotoxin Substances 0.000 description 39
- 231100000618 neurotoxin Toxicity 0.000 description 39
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 36
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 35
- 238000001356 surgical procedure Methods 0.000 description 35
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 33
- 108030001720 Bontoxilysin Proteins 0.000 description 33
- 230000001066 destructive effect Effects 0.000 description 32
- 101710138657 Neurotoxin Proteins 0.000 description 31
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 30
- 239000012634 fragment Substances 0.000 description 29
- 230000003248 secreting effect Effects 0.000 description 28
- 241000193403 Clostridium Species 0.000 description 27
- -1 methylafon Chemical compound 0.000 description 27
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 26
- 102100022831 Somatoliberin Human genes 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 102000003946 Prolactin Human genes 0.000 description 22
- 108010057464 Prolactin Proteins 0.000 description 22
- 206010057190 Respiratory tract infections Diseases 0.000 description 22
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 22
- 229940097325 prolactin Drugs 0.000 description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 21
- 241000700159 Rattus Species 0.000 description 21
- 238000003776 cleavage reaction Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 20
- 230000007017 scission Effects 0.000 description 19
- 230000014616 translation Effects 0.000 description 19
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 18
- 108700012941 GNRH1 Proteins 0.000 description 18
- 229940088597 hormone Drugs 0.000 description 18
- 239000005556 hormone Substances 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 210000004899 c-terminal region Anatomy 0.000 description 17
- 125000006850 spacer group Chemical group 0.000 description 17
- 206010012735 Diarrhoea Diseases 0.000 description 16
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 16
- 238000002595 magnetic resonance imaging Methods 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 108091008146 restriction endonucleases Proteins 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 102400000921 Gastrin Human genes 0.000 description 14
- 108010052343 Gastrins Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 14
- 235000013372 meat Nutrition 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 13
- 241001112695 Clostridiales Species 0.000 description 13
- 231100001102 clostridial toxin Toxicity 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 102400000739 Corticotropin Human genes 0.000 description 12
- 101800000414 Corticotropin Proteins 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 108010016076 Octreotide Proteins 0.000 description 12
- 206010061538 Pituitary tumour benign Diseases 0.000 description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 12
- 229960000258 corticotropin Drugs 0.000 description 12
- 230000000799 fusogenic effect Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 102000011727 Caspases Human genes 0.000 description 11
- 108010076667 Caspases Proteins 0.000 description 11
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 11
- 102000051325 Glucagon Human genes 0.000 description 11
- 108060003199 Glucagon Proteins 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 11
- 201000005746 Pituitary adenoma Diseases 0.000 description 11
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 11
- 108010092854 aspartyllysine Proteins 0.000 description 11
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 11
- 229960004666 glucagon Drugs 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000010253 intravenous injection Methods 0.000 description 11
- 108010034529 leucyl-lysine Proteins 0.000 description 11
- 208000021310 pituitary gland adenoma Diseases 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 10
- 108700010070 Codon Usage Proteins 0.000 description 10
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 10
- 206010020880 Hypertrophy Diseases 0.000 description 10
- 239000013256 coordination polymer Substances 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 229940090044 injection Drugs 0.000 description 10
- 229910052759 nickel Inorganic materials 0.000 description 10
- 229960002700 octreotide Drugs 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 9
- 208000008454 Hyperhidrosis Diseases 0.000 description 9
- 108010041948 SNARE Proteins Proteins 0.000 description 9
- 102000000583 SNARE Proteins Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 108010077245 asparaginyl-proline Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000003890 endocrine cell Anatomy 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 108010051242 phenylalanylserine Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 238000009534 blood test Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108010031719 prolyl-serine Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 7
- 206010006784 Burning sensation Diseases 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 108030001722 Tentoxilysin Proteins 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 108010038633 aspartylglutamate Proteins 0.000 description 7
- 108010047857 aspartylglycine Proteins 0.000 description 7
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 108010057821 leucylproline Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 230000002797 proteolythic effect Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000016261 weight loss Diseases 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 6
- 108010013369 Enteropeptidase Proteins 0.000 description 6
- 102100029727 Enteropeptidase Human genes 0.000 description 6
- 102400000442 Ghrelin-28 Human genes 0.000 description 6
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 6
- 101150088952 IGF1 gene Proteins 0.000 description 6
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 6
- CTONFVDJYCAMQM-IUKAMOBKSA-N Thr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)N CTONFVDJYCAMQM-IUKAMOBKSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000002228 disulfide group Chemical group 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 6
- 108010077515 glycylproline Proteins 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- YPFNACALNKVZNK-MFNIMNRCSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1- Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CN)[C@@H](C)O)C1=CC=CC=C1 YPFNACALNKVZNK-MFNIMNRCSA-N 0.000 description 5
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 5
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- LEDRIAHEWDJRMF-CFMVVWHZSA-N Ile-Asn-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LEDRIAHEWDJRMF-CFMVVWHZSA-N 0.000 description 5
- UWLHDGMRWXHFFY-HPCHECBXSA-N Ile-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@@H]1C(=O)O)N UWLHDGMRWXHFFY-HPCHECBXSA-N 0.000 description 5
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 5
- FGBRXCZYVRFNKQ-MXAVVETBSA-N Ile-Phe-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N FGBRXCZYVRFNKQ-MXAVVETBSA-N 0.000 description 5
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 5
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 5
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 5
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 5
- 101800001639 Neuromedin-B Proteins 0.000 description 5
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 5
- 241000710961 Semliki Forest virus Species 0.000 description 5
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 5
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 5
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- ZOBLBMGJKVJVEV-BZSNNMDCSA-N Tyr-Lys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O ZOBLBMGJKVJVEV-BZSNNMDCSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 108010068265 aspartyltyrosine Proteins 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000003737 chromaffin cell Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 5
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 108010081551 glycylphenylalanine Proteins 0.000 description 5
- 229930186900 holotoxin Natural products 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 230000037315 hyperhidrosis Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 108010017391 lysylvaline Proteins 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 229940075620 somatostatin analogue Drugs 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 108010078580 tyrosylleucine Proteins 0.000 description 5
- 108010003137 tyrosyltyrosine Proteins 0.000 description 5
- RWBLWXCGQLZKLK-USVTTYPOSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxob Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(C)C)C1=CN=CN1 RWBLWXCGQLZKLK-USVTTYPOSA-N 0.000 description 4
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 4
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 4
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 4
- VRTWYUYCJGNFES-CIUDSAMLSA-N Arg-Ser-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O VRTWYUYCJGNFES-CIUDSAMLSA-N 0.000 description 4
- PPMTUXJSQDNUDE-CIUDSAMLSA-N Asn-Glu-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PPMTUXJSQDNUDE-CIUDSAMLSA-N 0.000 description 4
- ANPFQTJEPONRPL-UGYAYLCHSA-N Asn-Ile-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O ANPFQTJEPONRPL-UGYAYLCHSA-N 0.000 description 4
- LTZIRYMWOJHRCH-GUDRVLHUSA-N Asn-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N LTZIRYMWOJHRCH-GUDRVLHUSA-N 0.000 description 4
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 4
- LSJQOMAZIKQMTJ-SRVKXCTJSA-N Asn-Phe-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LSJQOMAZIKQMTJ-SRVKXCTJSA-N 0.000 description 4
- POTCZYQVVNXUIG-BQBZGAKWSA-N Asp-Gly-Pro Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O POTCZYQVVNXUIG-BQBZGAKWSA-N 0.000 description 4
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 4
- SEMWSADZTMJELF-BYULHYEWSA-N Asp-Ile-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O SEMWSADZTMJELF-BYULHYEWSA-N 0.000 description 4
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 4
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 4
- UTLCRGFJFSZWAW-OLHMAJIHSA-N Asp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UTLCRGFJFSZWAW-OLHMAJIHSA-N 0.000 description 4
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 4
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 4
- 206010057671 Female sexual dysfunction Diseases 0.000 description 4
- HXOLDXKNWKLDMM-YVNDNENWSA-N Gln-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HXOLDXKNWKLDMM-YVNDNENWSA-N 0.000 description 4
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 4
- OKARHJKJTKFQBM-ACZMJKKPSA-N Gln-Ser-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OKARHJKJTKFQBM-ACZMJKKPSA-N 0.000 description 4
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 4
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 4
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 4
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 4
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 4
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 4
- QNJNPKSWAHPYGI-JYJNAYRXSA-N Glu-Phe-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 QNJNPKSWAHPYGI-JYJNAYRXSA-N 0.000 description 4
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 4
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 4
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 4
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 4
- VHHYJBSXXMPQGZ-AVGNSLFASA-N His-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N VHHYJBSXXMPQGZ-AVGNSLFASA-N 0.000 description 4
- PZAJPILZRFPYJJ-SRVKXCTJSA-N His-Ser-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O PZAJPILZRFPYJJ-SRVKXCTJSA-N 0.000 description 4
- RNVUQLOKVIPNEM-BZSNNMDCSA-N His-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O RNVUQLOKVIPNEM-BZSNNMDCSA-N 0.000 description 4
- 206010020850 Hyperthyroidism Diseases 0.000 description 4
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 4
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 4
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 4
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 4
- BATWGBRIZANGPN-ZPFDUUQYSA-N Ile-Pro-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BATWGBRIZANGPN-ZPFDUUQYSA-N 0.000 description 4
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 4
- MGUTVMBNOMJLKC-VKOGCVSHSA-N Ile-Trp-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C(C)C)C(=O)O)N MGUTVMBNOMJLKC-VKOGCVSHSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 4
- 108010021290 LHRH Receptors Proteins 0.000 description 4
- 102000008238 LHRH Receptors Human genes 0.000 description 4
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 4
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 4
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 description 4
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 4
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 4
- KPJJOZUXFOLGMQ-CIUDSAMLSA-N Lys-Asp-Asn Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N KPJJOZUXFOLGMQ-CIUDSAMLSA-N 0.000 description 4
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 4
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 4
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- DGNZGCQSVGGYJS-BQBZGAKWSA-N Met-Gly-Asp Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O DGNZGCQSVGGYJS-BQBZGAKWSA-N 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 102100038819 Neuromedin-B Human genes 0.000 description 4
- 101800001638 Neuromedin-C Proteins 0.000 description 4
- LXVFHIBXOWJTKZ-BZSNNMDCSA-N Phe-Asn-Tyr Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O LXVFHIBXOWJTKZ-BZSNNMDCSA-N 0.000 description 4
- HQVPQHLNOVTLDD-IHRRRGAJSA-N Phe-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N HQVPQHLNOVTLDD-IHRRRGAJSA-N 0.000 description 4
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 4
- DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 4
- QRUOLOPKCOEZKU-HJWJTTGWSA-N Phe-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)N QRUOLOPKCOEZKU-HJWJTTGWSA-N 0.000 description 4
- HBXAOEBRGLCLIW-AVGNSLFASA-N Phe-Ser-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HBXAOEBRGLCLIW-AVGNSLFASA-N 0.000 description 4
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 4
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 4
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 4
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 4
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 4
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 4
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 4
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 4
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 4
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 4
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 4
- QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 4
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 4
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 4
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 4
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 4
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- PKXHGEXFMIZSER-QTKMDUPCSA-N Thr-Arg-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O PKXHGEXFMIZSER-QTKMDUPCSA-N 0.000 description 4
- GCXFWAZRHBRYEM-NUMRIWBASA-N Thr-Gln-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O GCXFWAZRHBRYEM-NUMRIWBASA-N 0.000 description 4
- WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 4
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 4
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 4
- VGNKUXWYFFDWDH-BEMMVCDISA-N Thr-Trp-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@@H]3C(=O)O)N)O VGNKUXWYFFDWDH-BEMMVCDISA-N 0.000 description 4
- SAKLWFSRZTZQAJ-GQGQLFGLSA-N Trp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SAKLWFSRZTZQAJ-GQGQLFGLSA-N 0.000 description 4
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 4
- NRFTYDWKWGJLAR-MELADBBJSA-N Tyr-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O NRFTYDWKWGJLAR-MELADBBJSA-N 0.000 description 4
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 4
- QSFJHIRIHOJRKS-ULQDDVLXSA-N Tyr-Leu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QSFJHIRIHOJRKS-ULQDDVLXSA-N 0.000 description 4
- XUIOBCQESNDTDE-FQPOAREZSA-N Tyr-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O XUIOBCQESNDTDE-FQPOAREZSA-N 0.000 description 4
- 102000050488 Urotensin II Human genes 0.000 description 4
- 108010018369 Urotensin II Proteins 0.000 description 4
- 102000026557 Urotensins Human genes 0.000 description 4
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 4
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 4
- AUMNPAUHKUNHHN-BYULHYEWSA-N Val-Asn-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N AUMNPAUHKUNHHN-BYULHYEWSA-N 0.000 description 4
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 4
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 4
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 4
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 108010011559 alanylphenylalanine Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 208000017758 growth hormone-producing pituitary gland adenoma Diseases 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 108010012058 leucyltyrosine Proteins 0.000 description 4
- 108010064235 lysylglycine Proteins 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 4
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 201000002859 sleep apnea Diseases 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 108700004896 tripeptide FEG Proteins 0.000 description 4
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 description 4
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 3
- CDMVTQHQSAPTJJ-OCZUONHDSA-N (2r)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CS)C1=CC=CC=C1 CDMVTQHQSAPTJJ-OCZUONHDSA-N 0.000 description 3
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 3
- NPJIOCBFOAHEDO-AVWFULIKSA-N (3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1h-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](C)C(=O)N1)=O)C(C)C)C1=CC=C(O)C=C1 NPJIOCBFOAHEDO-AVWFULIKSA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- 101150026173 ARG2 gene Proteins 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 3
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 3
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 3
- WXVGISRWSYGEDK-KKUMJFAQSA-N Asn-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N WXVGISRWSYGEDK-KKUMJFAQSA-N 0.000 description 3
- FTNRWCPWDWRPAV-BZSNNMDCSA-N Asn-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTNRWCPWDWRPAV-BZSNNMDCSA-N 0.000 description 3
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 3
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 3
- QOVWVLLHMMCFFY-ZLUOBGJFSA-N Asp-Asp-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QOVWVLLHMMCFFY-ZLUOBGJFSA-N 0.000 description 3
- CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 3
- KCSDYJSCUWLILX-BJDJZHNGSA-N Cys-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N KCSDYJSCUWLILX-BJDJZHNGSA-N 0.000 description 3
- DGQJGBDBFVGLGL-ZKWXMUAHSA-N Cys-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N DGQJGBDBFVGLGL-ZKWXMUAHSA-N 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 101100338242 Drosophila virilis His1.1 gene Proteins 0.000 description 3
- BLOXULLYFRGYKZ-GUBZILKMSA-N Gln-Glu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BLOXULLYFRGYKZ-GUBZILKMSA-N 0.000 description 3
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 3
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 3
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 3
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 3
- 206010020112 Hirsutism Diseases 0.000 description 3
- DAKSMIWQZPHRIB-BZSNNMDCSA-N His-Tyr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DAKSMIWQZPHRIB-BZSNNMDCSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- SACHLUOUHCVIKI-GMOBBJLQSA-N Ile-Arg-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SACHLUOUHCVIKI-GMOBBJLQSA-N 0.000 description 3
- QSPLUJGYOPZINY-ZPFDUUQYSA-N Ile-Asp-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QSPLUJGYOPZINY-ZPFDUUQYSA-N 0.000 description 3
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 3
- NGKPIPCGMLWHBX-WZLNRYEVSA-N Ile-Tyr-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NGKPIPCGMLWHBX-WZLNRYEVSA-N 0.000 description 3
- 108010065920 Insulin Lispro Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 3
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 3
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 3
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 3
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 3
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 3
- DNEJSAIMVANNPA-DCAQKATOSA-N Lys-Asn-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DNEJSAIMVANNPA-DCAQKATOSA-N 0.000 description 3
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 3
- YCJCEMKOZOYBEF-OEAJRASXSA-N Lys-Thr-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YCJCEMKOZOYBEF-OEAJRASXSA-N 0.000 description 3
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 3
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 3
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 3
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 3
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 3
- OLTFZQIYCNOBLI-DCAQKATOSA-N Pro-Cys-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O OLTFZQIYCNOBLI-DCAQKATOSA-N 0.000 description 3
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- SNVIOQXAHVORQM-WDSKDSINSA-N Ser-Gly-Gln Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O SNVIOQXAHVORQM-WDSKDSINSA-N 0.000 description 3
- 208000016191 TSH-secreting pituitary adenoma Diseases 0.000 description 3
- JTEICXDKGWKRRV-HJGDQZAQSA-N Thr-Asn-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JTEICXDKGWKRRV-HJGDQZAQSA-N 0.000 description 3
- YDWLCDQXLCILCZ-BWAGICSOSA-N Thr-His-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YDWLCDQXLCILCZ-BWAGICSOSA-N 0.000 description 3
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 description 3
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 3
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 3
- CVIXTAITYJQMPE-LAEOZQHASA-N Val-Glu-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CVIXTAITYJQMPE-LAEOZQHASA-N 0.000 description 3
- YDVDTCJGBBJGRT-GUBZILKMSA-N Val-Met-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N YDVDTCJGBBJGRT-GUBZILKMSA-N 0.000 description 3
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 3
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010013835 arginine glutamate Proteins 0.000 description 3
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 208000031424 hyperprolactinemia Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 3
- 108010021336 lanreotide Proteins 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 108010084572 phenylalanyl-valine Proteins 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 102220170373 rs886048117 Human genes 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 229920000260 silastic Polymers 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 108010080244 somatostatin(3-6) Proteins 0.000 description 3
- 108010043680 somatostatin(7-10) Proteins 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 2
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
- VPTPBEUWKCLZGU-OOSWLFMASA-N (2s)-6-amino-n-[(2s)-1-[[(2s)-1-[[(2r)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=C(O)C=C1 VPTPBEUWKCLZGU-OOSWLFMASA-N 0.000 description 2
- FHSGULRVYLHXFO-FFNFELIASA-N (3s,6s,9s,12r,15s,18s)-9-(4-aminobutyl)-3,15-dibenzyl-6-[(1r)-1-hydroxyethyl]-12-(1h-indol-3-ylmethyl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosane-2,5,8,11,14,17-hexone Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 FHSGULRVYLHXFO-FFNFELIASA-N 0.000 description 2
- VVEJUSYNERNRME-XGFVQVCISA-N (4r,7s,10r,13s,16r,19s,22r,25s,28r,31s)-13,28-bis(4-aminobutyl)-25-(2-amino-2-oxoethyl)-31-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-19,22-dibenzyl-10-[(1r)-1-hydroxyethyl]-7-(hydroxymethyl)-16-(1h-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo- Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 VVEJUSYNERNRME-XGFVQVCISA-N 0.000 description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 2
- KBXJEGQBFLLJFL-ILNSAXFWSA-N (4s,7r,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2s)-2-amino-3-phenylpropanoyl]amino]-n-[(2s,3r)-3-hydroxy-1-oxobutan-2-yl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N[C@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(=O)N[C@H](C=O)[C@@H](C)O)=O)C(C)C)C1=CC=C(O)C=C1 KBXJEGQBFLLJFL-ILNSAXFWSA-N 0.000 description 2
- LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- 208000028112 ACTH-producing pituitary gland adenoma Diseases 0.000 description 2
- 201000008530 ACTH-secreting pituitary adenoma Diseases 0.000 description 2
- 108091007505 ADAM17 Proteins 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 2
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IOTKDTZEEBZNCM-UGYAYLCHSA-N Asn-Asn-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOTKDTZEEBZNCM-UGYAYLCHSA-N 0.000 description 2
- YGHCVNQOZZMHRZ-DJFWLOJKSA-N Asn-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N YGHCVNQOZZMHRZ-DJFWLOJKSA-N 0.000 description 2
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 2
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 2
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 2
- XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 2
- KSZHWTRZPOTIGY-AVGNSLFASA-N Asn-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O KSZHWTRZPOTIGY-AVGNSLFASA-N 0.000 description 2
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 2
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 2
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 2
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 2
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 2
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 description 2
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 2
- 108010059033 BIM 23027 Proteins 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 208000035985 Body Odor Diseases 0.000 description 2
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 2
- JEKIARHEWURQRJ-BZSNNMDCSA-N Cys-Phe-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CS)N JEKIARHEWURQRJ-BZSNNMDCSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- NUMFTVCBONFQIQ-DRZSPHRISA-N Gln-Ala-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NUMFTVCBONFQIQ-DRZSPHRISA-N 0.000 description 2
- KDXKFBSNIJYNNR-YVNDNENWSA-N Gln-Glu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KDXKFBSNIJYNNR-YVNDNENWSA-N 0.000 description 2
- FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 2
- HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 2
- NKSGKPWXSWBRRX-ACZMJKKPSA-N Glu-Asn-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N NKSGKPWXSWBRRX-ACZMJKKPSA-N 0.000 description 2
- VAZZOGXDUQSVQF-NUMRIWBASA-N Glu-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)O VAZZOGXDUQSVQF-NUMRIWBASA-N 0.000 description 2
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 2
- ITVBKCZZLJUUHI-HTUGSXCWSA-N Glu-Phe-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ITVBKCZZLJUUHI-HTUGSXCWSA-N 0.000 description 2
- BXSZPACYCMNKLS-AVGNSLFASA-N Glu-Ser-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BXSZPACYCMNKLS-AVGNSLFASA-N 0.000 description 2
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 2
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000002993 Growth Hormone-Secreting Pituitary Adenoma Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 2
- 101500024338 Homo sapiens Somatostatin-14 Proteins 0.000 description 2
- 206010060377 Hypergastrinaemia Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 2
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 2
- WIYDLTIBHZSPKY-HJWJTTGWSA-N Ile-Val-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WIYDLTIBHZSPKY-HJWJTTGWSA-N 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 2
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 2
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 2
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 2
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 2
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 2
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 2
- RZXLZBIUTDQHJQ-SRVKXCTJSA-N Leu-Lys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O RZXLZBIUTDQHJQ-SRVKXCTJSA-N 0.000 description 2
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 2
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 2
- HGZHSNBZDOLMLH-DCAQKATOSA-N Lys-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N HGZHSNBZDOLMLH-DCAQKATOSA-N 0.000 description 2
- JYXBNQOKPRQNQS-YTFOTSKYSA-N Lys-Ile-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JYXBNQOKPRQNQS-YTFOTSKYSA-N 0.000 description 2
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 2
- QVTDVTONTRSQMF-WDCWCFNPSA-N Lys-Thr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CCCCN QVTDVTONTRSQMF-WDCWCFNPSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 description 2
- HAQLBBVZAGMESV-IHRRRGAJSA-N Met-Lys-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O HAQLBBVZAGMESV-IHRRRGAJSA-N 0.000 description 2
- OOLVTRHJJBCJKB-IHRRRGAJSA-N Met-Tyr-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OOLVTRHJJBCJKB-IHRRRGAJSA-N 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 2
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000035977 Rare disease Diseases 0.000 description 2
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 2
- CTLVSHXLRVEILB-UBHSHLNASA-N Ser-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N CTLVSHXLRVEILB-UBHSHLNASA-N 0.000 description 2
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 2
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 2
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 2
- VEVYMLNYMULSMS-AVGNSLFASA-N Ser-Tyr-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEVYMLNYMULSMS-AVGNSLFASA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 206010040904 Skin odour abnormal Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102400000820 Somatostatin-14 Human genes 0.000 description 2
- 101800001707 Spacer peptide Proteins 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 2
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 2
- MEBDIIKMUUNBSB-RPTUDFQQSA-N Thr-Phe-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MEBDIIKMUUNBSB-RPTUDFQQSA-N 0.000 description 2
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- BDWDMRSGCXEDMR-WFBYXXMGSA-N Trp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BDWDMRSGCXEDMR-WFBYXXMGSA-N 0.000 description 2
- NFVQCNMGJILYMI-SZMVWBNQSA-N Trp-Met-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O NFVQCNMGJILYMI-SZMVWBNQSA-N 0.000 description 2
- BEIGSKUPTIFYRZ-SRVKXCTJSA-N Tyr-Asp-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O BEIGSKUPTIFYRZ-SRVKXCTJSA-N 0.000 description 2
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 2
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 2
- BIVIUZRBCAUNPW-JRQIVUDYSA-N Tyr-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O BIVIUZRBCAUNPW-JRQIVUDYSA-N 0.000 description 2
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 2
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 2
- XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 2
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 2
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 2
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 2
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 238000009557 abdominal ultrasonography Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- UUXIFHBKTREDJD-UHFFFAOYSA-N cephalosol Natural products O1C(=O)C2=C(O)C=C(OC)C=C2C2=C1C(=O)OC2(C)CC(=O)OC UUXIFHBKTREDJD-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 2
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 201000011523 endocrine gland cancer Diseases 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000037376 facial hyperhidrosis Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960004207 fentanyl citrate Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108010068501 gastrin releasing peptide (21-27) Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960002437 lanreotide Drugs 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000002406 microsurgery Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 210000000607 neurosecretory system Anatomy 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 108700024539 octapeptide-Trp(8)- somatostatin Proteins 0.000 description 2
- 230000009996 pancreatic endocrine effect Effects 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960000208 pralmorelin Drugs 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 108010079317 prolyl-tyrosine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102220005372 rs281860646 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 108010036625 somatosin Proteins 0.000 description 2
- NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000000780 urotensin Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- RZENOPCSYJWNKU-VIFPVBQESA-N (2s)-2-(aminomethylamino)-3-phenylpropanoic acid Chemical group NCN[C@H](C(O)=O)CC1=CC=CC=C1 RZENOPCSYJWNKU-VIFPVBQESA-N 0.000 description 1
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- OLMICDUONLWRJA-ZETCQYMHSA-N (2s)-2-[amino(cyclohexyl)amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(N)C1CCCCC1 OLMICDUONLWRJA-ZETCQYMHSA-N 0.000 description 1
- KZDNJQUJBMDHJW-VIFPVBQESA-N (2s)-2-amino-3-(5-bromo-1h-indol-3-yl)propanoic acid Chemical compound C1=C(Br)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 KZDNJQUJBMDHJW-VIFPVBQESA-N 0.000 description 1
- XKDUODGOACYEEU-VIFPVBQESA-N (2s)-2-azaniumyl-3-(5-nitro-1h-indol-3-yl)propanoate Chemical compound C1=C([N+]([O-])=O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 XKDUODGOACYEEU-VIFPVBQESA-N 0.000 description 1
- FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 1
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
- PYFASGMPUKCEMS-ZETCQYMHSA-N (2s)-6-[carbamimidoyl-(diaminomethylideneamino)amino]-2-(dimethylamino)hexanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCCN(C(N)=N)NC(N)=N PYFASGMPUKCEMS-ZETCQYMHSA-N 0.000 description 1
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
- HMTCBXPQKWFOMG-QWXJMLLVSA-N (2s)-6-amino-n-[(2s,3r)-1-[[(2s)-1-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropano Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](N)CC=1C=CC=CC=1)[C@@H](C)O)C1=CC=CC=C1 HMTCBXPQKWFOMG-QWXJMLLVSA-N 0.000 description 1
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
- CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- JNMPZUZCPFIJGJ-OCZUONHDSA-N (4r,7s,10s,13s,16r,19s,22s,25r)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1r)-1-hydroxyethyl]-16-(1h-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxamide Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)C(N)=O)=O)[C@H](O)C)C1=CC=CC=C1 JNMPZUZCPFIJGJ-OCZUONHDSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- OTFKRHOATUETFR-UHFFFAOYSA-N 1-(4-phenylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C(=O)CC)CCN1C1=CC=CC=C1 OTFKRHOATUETFR-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QWTLUPDHBKBULE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QWTLUPDHBKBULE-UHFFFAOYSA-N 0.000 description 1
- BKQQPCDQZZTLSE-UHFFFAOYSA-N 2-amino-3-naphthalen-1-ylpropanoic acid;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 BKQQPCDQZZTLSE-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-M 2-naphthoate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-M 0.000 description 1
- XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
- BBHJTCADCKZYSO-UHFFFAOYSA-N 4-(4-ethylcyclohexyl)benzonitrile Chemical compound C1CC(CC)CCC1C1=CC=C(C#N)C=C1 BBHJTCADCKZYSO-UHFFFAOYSA-N 0.000 description 1
- HULKIXRFKRCRHD-UHFFFAOYSA-N 4-[(2-acetamido-4-methylpentanoyl)amino]-5-[[1-[[3-carboxy-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]propan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C=1C=C2C(C(F)(F)F)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(NC(C)=O)CC(C)C)CC1=CN=CN1 HULKIXRFKRCRHD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- OYNANFOWNSGDJL-UHFFFAOYSA-N 4-sulfanylpyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)C1CC(S)CN1 OYNANFOWNSGDJL-UHFFFAOYSA-N 0.000 description 1
- INPQIVHQSQUEAJ-UHFFFAOYSA-N 5-fluorotryptophan Chemical compound C1=C(F)C=C2C(CC(N)C(O)=O)=CNC2=C1 INPQIVHQSQUEAJ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KGLGUDHEKBYBDR-UHFFFAOYSA-N 6-amino-N-[1-[[1-[[1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-2-[[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(N)=O)NC(=O)C(CS)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CS)NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=C(O)C=C1 KGLGUDHEKBYBDR-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-CRKDRTNXSA-N 9-α-D-ribofuranosyl-9H-Purin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-CRKDRTNXSA-N 0.000 description 1
- 108030001751 ADAM 17 endopeptidases Proteins 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 101150007499 Acyp2 gene Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- PXKLCFFSVLKOJM-ACZMJKKPSA-N Ala-Asn-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PXKLCFFSVLKOJM-ACZMJKKPSA-N 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
- XHNLCGXYBXNRIS-BJDJZHNGSA-N Ala-Lys-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XHNLCGXYBXNRIS-BJDJZHNGSA-N 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- NYZGVTGOMPHSJW-CIUDSAMLSA-N Arg-Glu-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N NYZGVTGOMPHSJW-CIUDSAMLSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- DDBMKOCQWNFDBH-RHYQMDGZSA-N Arg-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O DDBMKOCQWNFDBH-RHYQMDGZSA-N 0.000 description 1
- JBQORRNSZGTLCV-WDSOQIARSA-N Arg-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N)=CNC2=C1 JBQORRNSZGTLCV-WDSOQIARSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- MFFOYNGMOYFPBD-DCAQKATOSA-N Asn-Arg-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MFFOYNGMOYFPBD-DCAQKATOSA-N 0.000 description 1
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 1
- ZPMNECSEJXXNBE-CIUDSAMLSA-N Asn-Cys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ZPMNECSEJXXNBE-CIUDSAMLSA-N 0.000 description 1
- JZDZLBJVYWIIQU-AVGNSLFASA-N Asn-Glu-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JZDZLBJVYWIIQU-AVGNSLFASA-N 0.000 description 1
- ACKNRKFVYUVWAC-ZPFDUUQYSA-N Asn-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ACKNRKFVYUVWAC-ZPFDUUQYSA-N 0.000 description 1
- LVHMEJJWEXBMKK-GMOBBJLQSA-N Asn-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N LVHMEJJWEXBMKK-GMOBBJLQSA-N 0.000 description 1
- XLZCLJRGGMBKLR-PCBIJLKTSA-N Asn-Ile-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XLZCLJRGGMBKLR-PCBIJLKTSA-N 0.000 description 1
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
- BZWRLDPIWKOVKB-ZPFDUUQYSA-N Asn-Leu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BZWRLDPIWKOVKB-ZPFDUUQYSA-N 0.000 description 1
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 1
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 1
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 1
- XIDSGDJNUJRUHE-VEVYYDQMSA-N Asn-Thr-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O XIDSGDJNUJRUHE-VEVYYDQMSA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- DGKCOYGQLNWNCJ-ACZMJKKPSA-N Asp-Glu-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DGKCOYGQLNWNCJ-ACZMJKKPSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 description 1
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- YWLDTBBUHZJQHW-KKUMJFAQSA-N Asp-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N YWLDTBBUHZJQHW-KKUMJFAQSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 1
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 1
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102100028169 BET1-like protein Human genes 0.000 description 1
- 101710138653 BET1-like protein Proteins 0.000 description 1
- 108700003245 BIM 23052 Proteins 0.000 description 1
- 108010059916 BIM 23056 Proteins 0.000 description 1
- 108700016019 BIM 23268 Proteins 0.000 description 1
- VQOGEJIWEPIWJK-UHFFFAOYSA-N B[Sn] Chemical compound B[Sn] VQOGEJIWEPIWJK-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- UMJHAEUVYNEBNP-RXYCCRQDSA-N C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=C(O)C=C1 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N1)=O)[C@H](O)C)C1=CC=C(O)C=C1 UMJHAEUVYNEBNP-RXYCCRQDSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- IJZREAUAKHBJFZ-NSHDSACASA-N C1C2=CC=CC=C2C(=C[C@@]1(C(=O)O)N)N Chemical compound C1C2=CC=CC=C2C(=C[C@@]1(C(=O)O)N)N IJZREAUAKHBJFZ-NSHDSACASA-N 0.000 description 1
- GDTJSTTZUQNYSC-UHFFFAOYSA-N CC(C(=O)N)C.COC1=C(C=CC=C1)C1CCNCC1 Chemical compound CC(C(=O)N)C.COC1=C(C=CC=C1)C1CCNCC1 GDTJSTTZUQNYSC-UHFFFAOYSA-N 0.000 description 1
- 108010015060 CYN 154806 Proteins 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- SFUUYRSAJPWTGO-SRVKXCTJSA-N Cys-Asn-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SFUUYRSAJPWTGO-SRVKXCTJSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 239000007755 F10 Nutrient Mixture Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- REJJNXODKSHOKA-ACZMJKKPSA-N Gln-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N REJJNXODKSHOKA-ACZMJKKPSA-N 0.000 description 1
- IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 1
- GQTNWYFWSUFFRA-KKUMJFAQSA-N Gln-Met-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GQTNWYFWSUFFRA-KKUMJFAQSA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- RJONUNZIMUXUOI-GUBZILKMSA-N Glu-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N RJONUNZIMUXUOI-GUBZILKMSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- KVBPDJIFRQUQFY-ACZMJKKPSA-N Glu-Cys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O KVBPDJIFRQUQFY-ACZMJKKPSA-N 0.000 description 1
- GFLQTABMFBXRIY-GUBZILKMSA-N Glu-Gln-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GFLQTABMFBXRIY-GUBZILKMSA-N 0.000 description 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- DAHLWSFUXOHMIA-FXQIFTODSA-N Glu-Ser-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O DAHLWSFUXOHMIA-FXQIFTODSA-N 0.000 description 1
- JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
- PMSDOVISAARGAV-FHWLQOOXSA-N Glu-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PMSDOVISAARGAV-FHWLQOOXSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- JSNNHGHYGYMVCK-XVKPBYJWSA-N Gly-Glu-Val Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JSNNHGHYGYMVCK-XVKPBYJWSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 1
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 1
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108700015863 His(5)-Trp(7)-Tyr(8)- LHRH Proteins 0.000 description 1
- 101001071515 Homo sapiens Gastrin-releasing peptide Proteins 0.000 description 1
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 description 1
- 101000841490 Homo sapiens Unique cartilage matrix-associated protein Proteins 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010048803 Hypoglycaemic seizure Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 1
- SCHZQZPYHBWYEQ-PEFMBERDSA-N Ile-Asn-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SCHZQZPYHBWYEQ-PEFMBERDSA-N 0.000 description 1
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 1
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 1
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 1
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 1
- DSDPLOODKXISDT-XUXIUFHCSA-N Ile-Leu-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DSDPLOODKXISDT-XUXIUFHCSA-N 0.000 description 1
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 1
- SAVXZJYTTQQQDD-QEWYBTABSA-N Ile-Phe-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SAVXZJYTTQQQDD-QEWYBTABSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- BCISUQVFDGYZBO-QSFUFRPTSA-N Ile-Val-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O BCISUQVFDGYZBO-QSFUFRPTSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- UCDHVOALNXENLC-KBPBESRZSA-N Leu-Gly-Tyr Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UCDHVOALNXENLC-KBPBESRZSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- DGWXCIORNLWGGG-CIUDSAMLSA-N Lys-Asn-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O DGWXCIORNLWGGG-CIUDSAMLSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 1
- XREQQOATSMMAJP-MGHWNKPDSA-N Lys-Ile-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XREQQOATSMMAJP-MGHWNKPDSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 1
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- RPWQJSBMXJSCPD-XUXIUFHCSA-N Lys-Val-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(O)=O RPWQJSBMXJSCPD-XUXIUFHCSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MQASRXPTQJJNFM-JYJNAYRXSA-N Met-Pro-Phe Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MQASRXPTQJJNFM-JYJNAYRXSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- 102220477707 Mitochondrial inner membrane protease subunit 1_E54A_mutation Human genes 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100459248 Mus musculus Mxra8 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010049146 Neck mass Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- SKGLAZSLOGYCCA-PEFXOJROSA-N Neuromedin N (1-4) Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H]([C@H](C)CC)C(O)=O)CC1=CC=C(O)C=C1 SKGLAZSLOGYCCA-PEFXOJROSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- MRNRMSDVVSKPGM-AVGNSLFASA-N Phe-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRNRMSDVVSKPGM-AVGNSLFASA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 1
- FMMIYCMOVGXZIP-AVGNSLFASA-N Phe-Glu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O FMMIYCMOVGXZIP-AVGNSLFASA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 1
- APMXLWHMIVWLLR-BZSNNMDCSA-N Phe-Tyr-Ser Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 APMXLWHMIVWLLR-BZSNNMDCSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- LCUOTSLIVGSGAU-AVGNSLFASA-N Pro-His-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LCUOTSLIVGSGAU-AVGNSLFASA-N 0.000 description 1
- BBFRBZYKHIKFBX-GMOBBJLQSA-N Pro-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@@H]1CCCN1 BBFRBZYKHIKFBX-GMOBBJLQSA-N 0.000 description 1
- WOIFYRZPIORBRY-AVGNSLFASA-N Pro-Lys-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WOIFYRZPIORBRY-AVGNSLFASA-N 0.000 description 1
- VGVCNKSUVSZEIE-IHRRRGAJSA-N Pro-Phe-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O VGVCNKSUVSZEIE-IHRRRGAJSA-N 0.000 description 1
- YYARMJSFDLIDFS-FKBYEOEOSA-N Pro-Phe-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YYARMJSFDLIDFS-FKBYEOEOSA-N 0.000 description 1
- CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000774655 Protobothrops mucrosquamatus Snake venom metalloproteinase TM-1 Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 206010037855 Rash erythematous Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- RJHJPZQOMKCSTP-CIUDSAMLSA-N Ser-His-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O RJHJPZQOMKCSTP-CIUDSAMLSA-N 0.000 description 1
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- BUYHXYIUQUBEQP-AVGNSLFASA-N Ser-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CO)N BUYHXYIUQUBEQP-AVGNSLFASA-N 0.000 description 1
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010053803 Sermorelin Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000006384 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Human genes 0.000 description 1
- 108010019040 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 102000003629 TRPC3 Human genes 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- XTCNBOBTROGWMW-RWRJDSDZSA-N Thr-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XTCNBOBTROGWMW-RWRJDSDZSA-N 0.000 description 1
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 1
- KKPOGALELPLJTL-MEYUZBJRSA-N Thr-Lys-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKPOGALELPLJTL-MEYUZBJRSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- KRCPXGSWDOGHAM-XIRDDKMYSA-N Trp-Lys-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O KRCPXGSWDOGHAM-XIRDDKMYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 1
- PDKILSUYSUGCAO-JBACZVJFSA-N Tyr-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N PDKILSUYSUGCAO-JBACZVJFSA-N 0.000 description 1
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 1
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 1
- ZMDCGGKHRKNWKD-LAEOZQHASA-N Val-Asn-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZMDCGGKHRKNWKD-LAEOZQHASA-N 0.000 description 1
- OGNMURQZFMHFFD-NHCYSSNCSA-N Val-Asn-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N OGNMURQZFMHFFD-NHCYSSNCSA-N 0.000 description 1
- NWDOPHYLSORNEX-QXEWZRGKSA-N Val-Asn-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N NWDOPHYLSORNEX-QXEWZRGKSA-N 0.000 description 1
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 1
- COSLEEOIYRPTHD-YDHLFZDLSA-N Val-Asp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 COSLEEOIYRPTHD-YDHLFZDLSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- OUUBKKIJQIAPRI-LAEOZQHASA-N Val-Gln-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OUUBKKIJQIAPRI-LAEOZQHASA-N 0.000 description 1
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000003788 cerebral perfusion Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 108010025198 decaglycine Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108010070965 hexarelin Proteins 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 108091014681 hormone receptor binding proteins Proteins 0.000 description 1
- 102000025480 hormone receptor binding proteins Human genes 0.000 description 1
- 102000045304 human GHRH Human genes 0.000 description 1
- 102000045305 human SST Human genes 0.000 description 1
- 102000056782 human Ucma Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- GCHPUFAZSONQIV-UHFFFAOYSA-N isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- BLBNZDPYFWVOAN-UHFFFAOYSA-N methyl 3-[(4-methylphenyl)carbamoyl]naphthalene-2-carboxylate Chemical compound COC(=O)C1=CC2=CC=CC=C2C=C1C(=O)NC1=CC=C(C)C=C1 BLBNZDPYFWVOAN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AFRBPRLOPBAGCM-UHFFFAOYSA-N n-[2-(1h-indol-4-yl)ethyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CCC1=CC=CC2=C1C=CN2 AFRBPRLOPBAGCM-UHFFFAOYSA-N 0.000 description 1
- KHARCSTZAGNHOT-UHFFFAOYSA-N naphthalene-2,3-dicarboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(C(=O)O)=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 229940066939 octreotide injection Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 108700017947 pasireotide Proteins 0.000 description 1
- 229960005415 pasireotide Drugs 0.000 description 1
- NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108700037519 pegvisomant Proteins 0.000 description 1
- 229960002995 pegvisomant Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108010091618 preprourotensin II Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108700034465 rat GOPC Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MEFOUWRMVYJCQC-UHFFFAOYSA-N rimsulfuron Chemical compound CCS(=O)(=O)C1=CC=CN=C1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 MEFOUWRMVYJCQC-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108010038851 tannase Proteins 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
본 발명은 신경내분비계 질환의 억제방법에 관한 것이다. 이 치료방법은 바람직하게는, 소마토스타틴이나 코르티스타틴 수용체, GHRH 수용체, 그렐린 수용체, 봄베신 수용체, 우로텐신 수용체, 멜라닌-농축 호르몬 수용체 1; KiSS-1 수용체나 프로락틴-방출 펩티드 수용체 등을 경유하여, 신경내분비 종양 세포를 표적으로 하는 비-세포독성 프로테아제를 사용하는 것을 포함한다. 상기의 프로테아제가 표적에 전달되면, 내부화되어 (즉, 표적 속으로 들어가) 상기 종양 세포로부터의 물질 분비를 억제한다. 본 발명은 또한 상술한 방법에 사용하기 적합한 폴리펩티드 및 핵산도 제공한다.
Description
본 발명은 신경 내분비계 질환 및 병리 상태의 치료제 및 이에 상응하는 치료방법에 관한 것이다.
신경 내분비계는 배아 신경능, 신경 외배엽 및 내배엽에서 유래된 세포로 구성된다. 이는 분비기관 및 확산 분포된 다른 기관들, 즉, 넓게 흩어진 신경 내분비계를 구성하는 세포 종류로 분류될 수 있다. 첫번째 그룹은 뇌하수체, 부갑상선 및 부신수질을 구성하는 세포들을 포함한다. 두번째 그룹은 피부, 폐, 흉선, 췌장, 또한 위장관(GI), 담도 및 비뇨생식관 등의 세포들을 포함한다. 신경 내분비계 종양은 이러한 모든 위치에서 발생할 수 있으며, 국지적인 압력을 야기하거나 주변 장기에 침투하는 물리적 크기, 또는 다양한 호르몬 및 생활성 분자의 이상 분비 등에 의해 통증을 일으킬 수도 있다. 이들 분자는 보통 치밀한 생리적 조절하에 생리학적 적정량으로 비종양 세포로부터 분비된다. 그러나 이들 세포가 종양을 형성할 경우, 과다 분비되어 질병을 유도할 수 있다.
과다분비 질환을 치료하는 최근의 방법은 외과적 종양제거, 통상의 화학적 항암치료, 인터페론 요법, 방사선 요법 및, 예컨대 소마토스타틴 유사체를 이용한 기타의 치료방법 등을 포함한다. 초기 치료에 선호되는 방법은 상담 의사의 판단에 따라 다르며 이러한 접근법이 성공적일 때도 있으나 항상 바람직한 것은 아니다.
종양 절제시 크기나 위치에 따라 수술이 위험할 수도 있으며 종양이 완전히 절제되지 않을 때도 있다. 화학적 항암요법, 인터페론 요법 및 방사선 요법은 때로 환자가 견디기 힘들며 또는 다른 여러가지 이유로 금기시 되기도 한다.
또한 종양세포가 사멸에 이르는 치료법은 종양용해증후군(TLS)을 야기할 가능성이 있다. TLS 는 종양 치료시의 합병증으로서 매우 위험하며 때로 생명을 위협하기도 한다. 상기의 병리를, 자발적 혹은 치료에 따른 종양괴사나 전격성 세포자살(fulminant apoptosis)의 결과로 생긴 대사이상의 집합체로 정의할 수 있다. TLS 환자에게서 관찰되는 대사이상은: 고칼륨혈증, 고뇨산혈증 및 2차 저칼슘혈증을 수반하는 고인산혈증 등을 포함한다. TLS 는 또한 급성신부전(ARF)을 야기할 수도 있다.
전이성 칼시노이드 및 췌장 내분비계 종양 환자들은 대부분 옥트레오티드 등의 최신 의약으로 치료하면 설사, 탈수, 작열감, 저칼륨혈증, 궤양 발생, 저혈당 발작 및 괴사성 피부손상 등의 임상적 증후를 신속히 개선할 수 있다 ( Kvols et al . 1986, 1987, Ruszniewski et al .1996, Caplin et al . 1998, Kulke & Mayer 1999, Wymenga et al . 1999). 그러나, 옥트레오티드 및 란레오티드를 수주 내지 수개월 이용할 경우, 대부분의 환자는 호르몬 분비 억제에 대해 무감응을 나타낸다. 이처럼 현재의 치료법은 한계가 있다.
위장관췌장 내분비 종양 및 뇌하수체 종양을 포함한 신경 내분비계 종양은 흔하지 않으며 이질적인 질환이다 (표 1). 따라서, 이 질환의 전개과정 및 장기 생존율은 현재 공지되어 있지 않다. 생존 가능성과 관계없이, 종양의 과다 분비물은 당사자의 삶의 질에 큰 영향을 미칠 수 있으므로 해당 환자의 삶의 질을 적절한 수준으로 유지하기 위해 이러한 이상 기능은 효과적으로 치료할 필요가 있다.
종양의 종류 | 발병률 |
칼시노이드 종양 | 연간 약 5,000건이 칼시노이드 종양으로 진단되고 있다. 국가암연구소(NCI)에 따르면 이들 종양의 약 74%는 위장관에서 기원하며 25%는 호흡기관에서 발병한다. 칼시노이드는 소아에겐 드물고 50세 이상의 환자에게 흔한 질병이다. 또한 남성에게서 2배 이상 흔하다. 기관의 칼시노이드 종양은 보통 양성이며 20세 내지 40세의 연령에서 자주 발생한다. |
인슐린 종양 | 발병률은 대체로 연간 100만명당 4건이며 유병률 역시 연간 100만명 당 4명 정도이다. |
가스트린종 | 산발적으로 발병하거나 또는 다발성 신경내분비 종양 제1형(MEN-1)의 합병증으로 발병하는 가스트린종의 발병률은 100만명 당 0.1 내지 3명이다. MEN-1의 유병률은 10만명 당 0.2 내지 2명이다. 가스트린종 환자의 30 내지 38%가 MEN-1으로 진단되며, 반면 환자의 20 내지 61%는 ZES(졸링거-엘리슨 증후군)의 합병 증세로서 가스트린종에 걸리는 것으로 확인되었다. |
장폴리펩티드 분비종 | 유병률= 100만명 당 1.12명 |
글루카곤종 | 글루카곤종은 국가보건연구소(NIH)의 희귀질병부(ORD)에 "희귀 질환"으로 상장되어 있다. 유병률 = 미국 총 2,720,000명 당 약 1명 |
프로락틴 분비종 | 발병률: 연간 100만명 당 6 내지 10명 유병률: 100만명 당 60 내지 100명 |
소마토트로피노마 | 말단비대증 유병률: 환자 100만명당 40 내지 60명; 말단비대증 (연간) 발병률: 연간 100만명 당 3건 |
코르티코트로피노마 | 발병률: 연간 100만명당 2 내지 3명 유병률; 100만명당 20 내지 30명 |
크롬친화성 세포종 | 서구에서 크롬친화성 세포종의 유병률은 1:6,500 내지 1:2,500으로 추산되며, 미국의 경우 연간 발병률이 500 내지 1,100건에 달한다. |
티로트로피노마 | 희귀함 |
일반적으로, 상기 종양의 증세는 종양 종류에 따라 다른데 이는 종양이 분비하는 각종 호르몬이 상이한 증세를 유발하기 때문이다 (표 2).
표 2. 신경내분비 종양의 과다분비물에 의해 야기되는 증세나 질환
종양의 종류 |
병태생리 및 증상
(종양 크기가 아닌 과다분비물로 인한) |
칼시노이드 종양 | 칼시노이드 종양이 생성하는 호르몬 혹은 호르몬 유사물질 (예, 세로토닌, 가스트린, ACTH, 히스타민) 이 분비되어 복합적인 증세를 일으킨다. 이러한 증세로는 작열감, 설사, 쥐어짜는 듯한 복통, 피부나 얼굴 및 목의 종괴, 천명, 체중증가, 체모 및 안면의 발모 증가, 당뇨, 두통, 부종, 누액, 쇠약, 폐고혈압, 짧은 호흡을 동반하는 심부전 증세 등을 포함한다. |
인슐린 종양 | 눈이 침침함, 복시, 쇠약, 두근거림, 혼란 및 이상 행동. 저혈당증은 식후 5시간쯤에 일어나는 경향이 있으며 합병증세는 다이어트, 음주 및 운동 등에 의해 일어나기도 한다. |
가스트린종 | 설사, 위염, 역류성 식도염 |
장폴리펩티드 분비종 | 물처럼 묽은 설사 (매일 3 내지 20리터), 저칼륨혈증, 저마그네슘혈증, 고칼슘혈증, 산혈증, 작열감, 이완성 방광확장, 장폐색/유사장폐색 등. 당뇨나 내당능장애 역시 흔하게 발생한다 |
글루카곤종 | 괴사형 홍반성 발진 (안면, 사지 및 간찰부에 자주 발생), 빈혈, 체중 감소, 내당능장애, 혈전증 및 설사 |
코르티코트로피노마 | 코르티졸 과다순환을 유발하는 ACTH에 의한 쿠싱병 |
소마토트로피노마 | 말단비대증 |
프로락틴 분비종 | 여성의 경우 희발월경/무월경, 유루증, 질 건조증, 성욕감퇴; 남성의 경우 성기능부전 (불능), 유루증, 여성형 유방 등 |
크롬친화성 세포종 |
카테콜라민 순환 관련 대사 및 혈행작용으로 인한 광범위한 증세. 지속적 혹은 발작성 고혈압이 환자의 90% 이상에서 발견되는 가장 일반적인 임상징후이며 이와 더불어; 심박감소; 두통, 두근거림, 창백, 메스꺼움, 작열감, 체중 감소, 피로감, 불안/공황, 기립성 저혈압, 고혈당 |
티로트로피노마 | 갑상선 기능항진증 (갑상선의 과잉활성), 식욕증진에도 불구한 체중감소, 빠른 심장박동, 미세떨림, 신경과민 및 불안정한 감정 증가, 더위를 참지못함, 다한증, 안구돌출, 갑상선 확대 등의 증세; 전체 환자의 약 1/3에게서 성장호르몬이 과다분비되어 가벼운 말단비대증을 야기한다 |
현재의 치료법은 각 환자가 경험하는 증세들이 상이하고 또한 시간 경과에 따라 변화하므로 각 환자의 증세에 따라 세분화된다. 환자를 치료함에 있어 3가지 목표는, (1) 종양 제거, (2) 종양 성장을 늦추거나 중지시키는 것 또는 (3) 종양의 과다분비물에 의해 야기되는 증세를 완화시키는 것으로서, 이러한 3가지 목표를 종합적으로 추구하기도 한다. 가장 일반적인 치료법은 하기에 기술되는 바와 같다.
칼시노이드
종양/
칼시노이드
증후군
칼시노이드 증후군의 치료는 보통 양방향 접근법을 이용하는데, 먼저 외과적 수술로 종양을 제거하거나 크기를 축소하고 뒤이어 화학요법이나 인터페론으로 치료한다. 간색전술로 알려진 방법을 사용하여 칼시노이드 종양에서 간으로 퍼진 암을 제어하기도 한다; 이는 간에 대한 혈액공급을 감소시켜 종양세포에 영양이 공급되는 것을 차단함으로써 증세를 줄이는데 도움을 준다. 두번째 접근방법은 다양한 약품, 즉, 심장질환의 경우 이뇨제, 천명증세에는 기관지 확장제, 또한 천명, 설사 및 작열감 등에는 소마토스타틴 유사물을 각각 사용함으로써 증세를 치료하는 것을 포함한다.
인슐린 종양
인슐린 종양에 따른 증세는 때로 식이조절 요법으로 치료되기도 한다 (예, 서방성 복합 탄수화물의 섭취; 구아검). 악성 인슐린 종양의 경우, 주변 림프절 및 간에 전이성 병변이 발견되기도 한다. 수술전 혹은 수술중에 종양을 국소화 시킬 수 없을 경우, 원위부 췌장절제술을 통해 제거하기도 한다.
가스트린종
가스트린종 환자에서, 양성자 펌프 억제제 등의 분비 억제제를 이용하여 위산의 과다분비를 제어한다. 환자가 이 약제를 수용할 수 없을 경우, 위전절제술을 권장한다. 외과적 수술은 30% 이상의 5년 완치율을 보이며 간의 전이성 병변, MEN1, 혹은 생명에 지장을 줄 수 있는 복합적인 의학적 병리가 없는 환자에게 권장한다 (가스트린종 환자 중 95%가 암을 동반한다). 전이성 질환을 가진 환자는 화학요법 혹은, 화학요법이 실패할 경우, 옥트레오티드가 효과적일 수도 있다.
장폴리펩티드
분비종
체액 및 전해질을 재충전하여 심각한 저칼슘혈증, 탈수 및 대사성 산혈증을 바로 잡는 것이 장폴리펩티드 분비종의 1차적 치료이다. 환자에게 규칙적으로 매일 최고 5리터의 체액과 350mEq 칼륨을 공급한다. 장폴리펩티드 분비종에 대한 최적의 처치는 초기암일 때 수술로 제거하는 것이다.
글루카곤종
글루카공종의 영향을 완화하거나 종양크기를 축소하는데는 수술이 이용되지만, 환자의 약 2/3는 종양을 성공적으로 국소화 한 후에도 수술로는 완전히 치유되지 않으며 전이성 질환이 관찰된다. 글루카곤종 치료용 활성약물은 현재 존재하지 않는다.
프로락틴
분비종
약제 치료는 보통 도파민 길항근 브로모크립틴이나 카베르골린을 이용한다. 이들 약물은 환자 중 약 80%에 대해 종양을 수축하고 프로락틴 농도를 정상으로 회복시킨다. 그러나, 상기 길항근을 사용하면 메스꺼움, 현기증 같은 부작용이 동반된다. 수술은 약제 치료를 견딜 수 없거나 프로락틴 농도 저하, 정상 회복 및 뇌화수체 기능 회복, 및 종양크기 축소 등을 달성할 수 없을 때에 한하여 선택한다. 그러나 수술 결과는, 신경계 외과의사의 기술 및 경험뿐만 아니라 종양 크기 및 프로락틴 농도에 따라서도 크게 달라진다. 연구에 따르면, 종양크기 및 종양의 제거방식에 따라 약 20 내지 50%가 통상 5년 이내에 재발한다.
소마토트로피노파
(예, 말단비대증 유발 종양)
현재, 말단비대증 환자의 치료방법은 수술, 방사선요법 및 약물요법 등이 있다. 치료방식은 종양의 크기와 양, 및 심각한 치료후유증을 가져오는 호르몬 기능을 신속히 중단시켜야 할 필요성 등에 의존한다. 표준 치료법으로는 수술후 방사선 치료가 동반되거나 없는 수술 (대개는 경접형동 접근수술), 브로모크립틴 치료, 옥트레오티드 치료 및, 최근의 예로는, 페그비소만트 치료 등을 포함한다. 상술한 치료법은 성공 케이스가 다수 있다.
코르티코트로피노마
부신자극호르몬 세포선종 환자의 경우 경접형동 미세수술을 선택한다. 그러나 대부분의 경우 현재 보고된 완치율이 약 70 내지 90% 정도이다. 약물 요법은 상술한 경접형동 미세수술을 보조하는 것으로서, 잔류 종양을 처리하고 또한 방사선요법의 효과를 기다리는 환자에게 적용하는 치료법이다. 약물 요법시 미토탄, 메티라폰, 케토코나졸 및 아미노글루에트이미드 등을 포함하는 스테로이드 생성 억제제을 사용한다. 내성 측면에서 가장 우수한 약제는 케토코나졸이지만 환자 중 70% 정도에게만 효과가 있다. 방사선 요법은 외과적 수술을 시행하기 부적합한 환자에게 사용해왔으며 또한 종양이 잔류하거나 재발한 환자에 대해서도 보조적인 치료법으로 이용했다.
크롬친화성 세포종
이 암종의 경우, 복강경을 통한 종양제거가 바람직한 방법이다. 그러나 수술전 적절한 약물 치료를 행하여 수술중 생명을 위협할 수도 있는 카테콜라민에 의한 심각한 합병증, 예컨대 고혈압 위기, 심장 부정맥, 폐부종, 심허혈 등을 방지함으로써 수술 합병증을 최소화 해야 한다. 전통적인 치료제는 α-아데노셉터 차단제, 복합 α/β-아데노셉터 차단제, 칼슘-채널 차단제 등을 포함하는데 이들은 모두 수술 전후에 부적절한 영향을 미칠 수 있다.
티로트로피노마
갑상선 선종 환자의 경우 부신경접형동 수술이 선택된다. 환자가 정상기능을 나타낸다고 하더라도 수술로는 치유가 되지 않아 재발을 피할 수 없는 경우 보조적으로 방사선 요법을 사용하며, 이러한 방사선 요법은 충분한 효과를 발휘하기까지 수개월 혹은 수년이 소요된다. 수술 및 방사선 치료에도 불구하고 여전히 갑상선 기능항진 증세를 나타내는 환자에게는 약물 요법이 필요할 수도 있다.
드물게 발생하지만 인간의 생명을 위협하는 신경내분비 종양은 전세계적으로 동물의 건강에 중대한 문제가 되고 있다. 그러므로 상술한 문제점을 해결할 수 있는 새로운 혹은 개선된 치료제 및 치료법이 요구되고 있다.
어떤 경우에서든 수술은 환자에 미치는 고유의 위험성과 더불어 성공 측면에서도 제한적일 수 있다. 또한, 최근의 약물 치료 역시 증세 완화 측면에서 모든 환자에 대한 성공을 보장할 수 없다.
본 발명은 상술한 바와 같이 수술인 기존의 약물 치료에 수반하는 하나 이상의 문제점 또는 위험을 해소하기 위한 것으로서, 부적절한 (예, 비정상적인) 종양 분비물을 억제하고 이로인해 발생되는 질병을 최소화 혹은 이를 역전시킬 수 있는 새로운 범주의 비-세포독성제를 제공한다.
더욱 구체적으로, 본 발명의 첫번째 측면은 신경내분비 종양으로부터의 과다 분비물을 억제하기 위한 폴리펩티드를 제공하는 것이며 이 폴리펩티드는:
(a) 신경내분비 종양 세포에 함유된 세포외배출성 융합체(exocytic fusion apparatus)의 단백질을 절단할 수 있는 비-세포독성 프로테아제;
(b) 신경내분비 종양 세포의 결합부위에 결합하는 것으로서, 상기 결합부위는 세포내이입(endocytosis)의 대상이 되어 상기 신경내분비 종양 세포 내부의 엔도솜에 통합(incoproate)될 수 있는 것인 표적화 성분(Targeting Moiety, TM); 및
(c) 상기 프로테아제를 엔도솜 외부로, 엔도솜막을 관통하여, 및 상기 신경내분비 종양 세포의 사이토졸 속으로 이동시키는 전위(translocation) 도메인을 포함한다.
사용시, 본 발명의 폴리펩티드는 신경내분비 종양 세포에 결합하고 그 후 전위 성분의 작용으로 프로테아제 성분이 종양 세포의 사이토졸로 이동한다. 마지막으로, 내부에서, 프로테아제가 신경내분비 종양 세포의 세포외배출성 융합작용을 억제한다. 이에 따라 신경내분비 종양 세포의 세포외배출성 융합체를 비활성화 함으로써, 본 발명의 폴리펩티드는 상기 융합체의 분비작용을 억제할 수 있다. 따라서, 본 발명의 폴리펩티드는 상기 표 2에 열거된 1종 이상의 병태생리학적 상태나 증세를 억제/치료한다.
본 발명의 1차 표적세포는, 병태생리학적 상태를 야기하는 1종 이상의 호르몬 (또는 기타의 생활성 분자)을 분비하는 신경내분비계 기원의 종양 세포이다.
본 발명은 호르몬 및/또는 기타의 생활성 분자가 신경내분비 종양으로터 분비되는 것을 억제할 수 있는 (또한 그 용도로 사용할 수 있는) 폴리펩티드를 제공한다.
이에 관련된 본 발명의 또다른 측면에서, 환자의 신경내분비 종양을 치료하는 방법을 제공하며 이 방법은 본 발명의 폴리펩티드를 치료학적 유효량으로 환자에게 투여하는 것을 포함한다.
특별한 이론에 근거하지 않아도, 본 발명자는 생리학적 활성분자가 신경내분비 종양으로부터 부적절하게 (즉, 비정상적인 농도로) 분비됨으로써 환자의 병리상태를 야기 및 지속시키는 것으로 생각한다. 따라서, 이러한 분비작용을 억제하면 질병의 진행을 중단시킬 수 있고 또한 그 증세를 반전, 즉, 개선할 수 있다.
본 발명의 폴리펩티드는 특히, 호르몬을 분비하는 전이성 병변, 신경내분비 종양전 상태 및 그 증세를 모두 포함하는 신경내분비 종양을 치료하는데 적합하다. 이 경우, '치료'란 종양 세포로부터의 과다분비물을 감소시키거나 없애는 것을 포함한다.
예를 들어, 본 발명의 중요한 신경내분비 종양 표적세포는 뇌하수체 선종 및/또는 위장관췌장 신경내분비 종양 (GEP-NETs)을 포함한다. GEP-NETs는 주로 위, 장 혹은 췌장에 있으며 정상적으로는 생리학적 조절하에 저농도로 분비되어야할 호르몬 및 기타 생활성 분자를 과다량으로 분비한다. 이러한 분비물은 환자가 겪는 증세들에 일조한다. GEN-NETs는 칼시노이드와 비-칼시노이드계 아형(subtype)으로 나눌 수 있다.
칼시노이드 GEP-NETs (전체 GEP-NETs의 55%)는 이들의 조직 위치에 따라 분류되는 경향이 있고, 유병률 순서대로 충수(맹장)(38%), 회장(23%), 결장(13%)및, 기관지(11.5%)의 세포로부터 생성되는 물질을 포함한다.
비-칼시노이드계 GEP-NETs는 과량의 인슐린을 분비하는 췌장섬의 인슐린 종양(17%), 비공지 형태의 종양(15%), 과량의 가스트린을 분비하는 십이지장이나 췌장의 가스트린종(9%), 췌장의 장폴리펩티드 분비종, 혈관작용성 소장 폴리펩티드를 과량으로 분비하는 폐 혹은 신경절의 신경종, 또한 과량의 글리카곤을 분비하는 췌장섬의 종양으로서 글루카곤종 등을 포함한다.
분비물 종류나 세포 동일성 등에 따라 분류되는 경향이 있는 뇌하수체 종양은, 프로락틴 분비종 (가장 일반적인 것), 소마토트로피노마 (성장 호르몬), 코르티코트로피노마 (부신피질 자극 호르몬),티로트로피노마(갑상선 자극호르몬), 고나도트로피노마 (FSH, LH),및 기타의 비-기능성 뇌하수체 선종류를 포함한다.
기타의 분비형 종양으로서 갑상선 수질암, 소세포/비소세포 폐암, 머켈 세포종, 및 크롬친화성 세포종 등이 있다. 상기 후자는 과다 분비된 아드레날린이 심각한 고혈압을 유발하므로 치명적일 수 있다. 이러한 과다분비 탓으로 암종 절제 수술이 불가할 수도 있기 때문에, 유독 사이클을 개선하는 방안이 제기되고 있으며 분비작용을 최소화 하는 종양 치료방법이 요구된다.
본 발명에서 개시하는 특히 바람직한 하위그룹의 신경내분비 종양 세포는, 인슐린 종양, 가스트린종, 장폴리펩티드 분비종, 글루카곤종, 프로락틴 분비종, 소마토트로피노마, 코르티코트로피노마, 티로트로피노마 및 크롬친화성 세포종 등이다.
신경내분비 종양 세포 (상술한 하위그룹의 종양 세포 등)의 분비기능을 억제함으로써, 본 발명은 특히 쿠싱병, 말단비대증, 칼시노이드 증후군, 저혈당증, 괴사형 홍반성 발진, 졸링거-엘리슨 증후군 및 베르너-모리슨 증후군 등의 병리상태를 치료하는 방법을 제공한다. 또한 부적절한 신경내분비 종양 분비물에서 유래하는 증세를 치료하는 방법을 제공한다 (표 2 참조).
본 발명의 폴리펩티드에 함유된 '생활성'성분은 비-세포독성 프로테아제에 의해 수득된다. 이 특수 프로테아제군은, SNARE 단백질 (예, SNAP-25, VAMP, 또는 신탁신)으로 알려진 세포내 이동단백질을 단백질분해 방식으로 절단하는 작용을 한다. (Gerald K (2002) "세포 및 분자 생물학" (4판) John Wiley & Sons , Inc . 참조). SNARE 는 "가용성 NSF 부착 수용체 ( S oluble N SF A ttachment Re ceptor)"의 머릿글자를 딴 것이며 여기서 NSF는 N-에틸말레이미드-감지 인자 ( N -ethylmaleimide- S ensitive F actor)의 머릿글자이다. SNARE 단백질은 세포내 소포체의 형성에 반드시 필요하며, 따라서 세포로부터 소포체의 이동을 통한 분자의 분비작용에 불가결한 요소이다. 따라서 원하는 표적세포에 전달되면, 비-세포독성 프로테아제는 표적세포로부터 세포 분비물이 방출되는 것을 억제할 수 있다.
비-세포독성 프로테아제는 세포를 죽이지 않는 분자들로 된 또다른 부류에 속하며; 세포를 죽이는 대신, 단백질 합성을 제외한 세포적 기능을 억제하는 작용을 한다. 비-세포독성 프로테아제는 다양한 설비에서 또한 다양한 미생물 예컨대 클로스트리듐 sp. 및 네이세리아 sp. 등에 의하여, 크기가 큰 독소 분자의 일부 형태로 생성된다.
클로스트리듐 신경독소는 주요 비-세포독성 독소 분자군을 대표하고 디설파이드 결합에 의해 서로 접합된 2개의 폴리펩티드 사슬을 갖는다. 상기 두 사슬은 각각 분자량이 약 100 kDa 정도인 중사슬(H-사슬) 및 50 kDa 의 경사슬(L-사슬)이라고 한다. 프로테아제 기능을 보유하며 세포외방출 과정에 수반되는 소포체 및/또는 혈장막 결합 단백질(SNARE)에 대한 높은 기질특이성을 나타내는 것이 L-사슬이다 (예, 시납토브레빈, 신탁신, SNAP-25). 이러한 기질은 신경분비 체계에서 중요하다.
N. 고노로에아에(N. gonorrhoeae)종에서 가장 중요한 네이세리아 sp. 및 S.뉴모니아에(S. pneumoniae)종에서 가장 중요한 스트렙토코쿠스 sp.는 기능적으로 서로 비슷한 비-세포독성 독소 분자를 생성한다. 이러한 비-세포독성 프로테아제의 예로는 IgA 프로테아제가 있다 (본원에 참고로서 수록한 WO99/58571를 참조한다). 그러므로, 본 발명의 비-세포독성 프로테아제는 클로스트리듐 세포독소 프로테아제나 IgA 프로테아제가 바람직하다.
다시 본 발명의 표적화 성분(TM)에 대하여 살피면, 이는 본 발명의 폴리펩티드를 신경내분비 종양 세포에 결합하는 성분이다.
그러므로 본 발명의 TM은 신경내분비 종양 세포 상의 수용체에 결합한다. 예를 들어, 본 발명의 TM는: 짜깁기 변이체(예, sst1, sst2, sst3, sst4 및 sst5)를 포함한 소마토스타틴(sst) 수용체; 성장호르몬-분비 호르몬(GHRH) 수용체(GRF 수용체라고도 함); 그렐린 수용체; 봄베신 수용체 (예, BRS-1, BRS-2, BRS-3 등); 우로텐신 수용체 (예, 우로텐신 II형 수용체); 멜라닌농축 호르몬 제1형 수용체; 프로락틴-분비 호르몬 수용체; 제1형 및/또는 제2형 GnRHR 수용체 등의 고나도트로핀-분비 호르몬 수용체 (GnRHR); 및/또는 KiSS-1 수용체로 이루어진 군에서 선택된 수용체에 결합할 수 있다.
한 구현예에서, 본 발명의 TM은 소마토스타틴(SST) 수용체에 결합한다. 적절한 SST 펩티드 TMs의 예를 들면, 전길이 SST 및 코르티스타틴(CST) 또한 다음과 같은 이들의 절단체 및 펩티드 유사물을 포함한다: 즉,
SANSNPAMAPRERKAGCKNFFWKTFTSc(SST-28);
AGCKNFFWKTFTSC (SST-14);
QEGAPPQQSARRDRMPCRNFFWKTFSSCK(CST-29);
QERPPLQQPPHRDKKPCKNFFWKTFSSCK(CST-29);
QERPPPQQPPHLDKKPCKNFFWKTFSSCK(CST-29);
DRMPCRNFFWKTFSSCK (CST-17);
PCRNFFWKTFSSCK (CST-14); 및 PCKNFFWKTFSSCK (CST-14);
D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2 (BIM 23052),
D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-D-Nal-NH2 (BIM 23056) 또는
c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 (BIM23268); 옥트레오티드 펩티드, 란레오티드 펩티드, BIM23027, CYN154806, BIM23027, 바프레오티드 펩티드, 세글리티드 펩티드, 및 SOM230 등이 있다. 이러한 TMs는 sst 수용체, 예컨대, 본 발명에 관련한 신경내분비 종양 세포에 존재하는 sst1, sst2, sst3, sst4 및 sst5 수용체에 결합한다 (표 3 참조). SST 및 CST는 구조적 상동성이 우수하며 공지의 모든 sst 수용체에 결합한다
표 3. 위장관췌장 신경내분비 종양 내 소마토스타틴 수용체 아형의 발현(%)
sst1 | sst2 | sst3 | sst4 | sst5 | |
모든 종양 | 68 | 86 | 46 | 93 | 57 |
인슐린 종양 | 33 | 100 | 33 | 100 | 67 |
가스트린종 | 33 | 50 | 17 | 83 | 50 |
글루카곤종 | 67 | 100 | 67 | 67 | 67 |
장폴리펩티드 분비종 | 100 | 100 | 100 | 100 | 100 |
비기능성 종괴 | 80 | 100 | 40 | 100 | 60 |
중장 NETs | 80 | 95 | 65 | 35 | 75 |
또다른 구현예에서, 본 발명의 TM은 성장호르몬 분비 호르몬(GHRH) 수용체에 결합한다. GHRH는 또한 성장-호르몬-방출 인자(GRF 또는 GHRF) 혹은 소마토크리닌으로 알려져 있다. 적절한 GHRH 펩티드는 전길이 GHRH (1-44) 펩티드, GHRH(1-27, 1-28, 1-29), GHRH(1-37), GHRH(1-40, 1-43)-OH 등의 이들의 절단체, 또한 다음과 같은 펩티드 유사체 등을 포함한다: BIM 28011 또는 NC-9-96; [MeTyr1,Ala15,22,Nle27]-hGHRH(1-29)-NH2; MeTyr1,Ala8,9,15,22,28,Nle27]-hGHRH(1-29)-NH2; 시클로(25-29)[MeTyr1,Ala15,DAsp25,Nle27,Orn29+ ++]-hGHRH(1-29)-NH2; (D-Tyr1)-GHRH (1-29)-NH2; (D-AIa2)-GHRH (1-29)-NH2; (D-Asp3)-GHRH (1-29)-NH2; (D-Ala4)-GHRH (1-29)-NH2; (D-Thr7)-GHRH (1-29)-NH2; (D-Asn8)-GHRH (1-29)-NH2; (D-Ser9)-GHRH (1-29)-NH2; (D-Tyr10)-GHRH (1-29)-NH2; (Phe4)-GHRH (1-29)-NH2; (pCl-Phe6)-GHRH (1-29)-NH2; (N-Ac-Tyr1)-GHRH (1-29)-NH2; (N-Ac-Tyr1, D-Ala2)-GHRH (1-29)-NH2; (N-Ac-D-Tyr1, D-Ala2)-GHRH (1-29)-NH2; (N-Ac-D-Tyr1, D-AIa 2, D-Asp3)-GHRH (1-29)-NH2; (D-Ala2, NLeu27)-GHRH (1-29)-NH2; (His1, D-Ala2, NLeu27)-GHRH (1-29)-NH2; (N-Ac-His1, D-AIa2, N-Leu27)-GHRH (1-29)-NH2; (His1, D-AIa 2, D-Ala 4, Nleu27)-GHRH (1-29)-NH2; (D-AIa2, D-Asp3, D-Asn8, NLeu27)-GHRH (1-29)-NH2; (D-Asp3, D-Asn8, NLeu27)-GHRH (1-29)-NH2; [His1, NLeu27]-hGHRH(1-29)-NH2; [NLeu27]-hGHRH(1-29)-NH2; H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2; H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2; H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala-Lys-Val-Arg-Leu-NH2; His-Val-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Asn-Arg; His-Val-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Gly-Ala 등이다.
또다른 구현예에서, 본 발명의 TM은 그렐린 수용체에 결합한다. 이에 관련한 적절한 TMs의 예를 들면, 전길이 그렐린 (eg. 그렐린117) 같은 그렐린 펩티드와 이의 절단체 및 다음과 같은 펩티드 유사체를 포함한다: 그렐린24 -117, 그렐린52 -117, [Trp3, Arg5]-그렐린(1-5), des-Gln-그렐린, 코르티스타틴-8, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, 성장 호르몬 방출형 펩티드(e.g. GHRP-6), 또는 헥사렐린 등이다.
또다른 구현예에서, TM은 봄베신 수용체 (예, BRS-1, BRS-2, BRS-3 등)에 결합한다. 이에 관련한 적절한 봄베신 펩티드의 예를 들면, 전길이 봄베신으로서 예컨대, 개구리 피부에서 분리된 14-아미노산 펩티드 (pGlu-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2); 및 포유류에 존재하는 2종의 공지된 동종체 즉, 뉴로메딘 B 및 다음과 같은 가스트린 방출형 펩티드(GRP)를 포함한다: 즉, 돼지 GRP-Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2; 및 인간 GRP-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 등이다. 봄베신 펩티드는 뉴로메딘 B 및 GRP과 같은 유사체, 이의 절단체와 펩티드 유사체 등도 포함한다.
또다른 구현예에서, 본 발명의 TM은 우로텐신 수용체에 결합한다. 이에 관련한 적절한 TM은 고리형 뉴로펩티드인 우로텐신-II(U-II) 등의 우로텐신 펩티드를 포함한다. U-II의 C-말단 고리 영역은 다양한 종에서 변함없이 보존되고 있으며, 또한 구조적으로 소마토스타틴-14의 중심 영역(-Phe-Trp-Lys-Thr-)과 비슷한 6개의 아미노산 잔기 (-Cys Ple-Trp-Lys-Tyr-Cys-)를 포함한다. 본 발명의 우로텐신 펩티드는 프레프로-우로텐신-II (2종의 인간 124 및 139 이성체를 포함하여) 등의 U-II 전구 펩티드와, 또한 11-잔기 성숙 펩티드형 같은 펩티드 유사체 및 절단체를 포함한다.
또다른 구현예에서, 본 발명의 TM은 멜라닌-농축 호르몬 수용체 1에 결합한다. 이에 관련한 적절한 TM의 예를 들면, 전길이 MCH 같은 멜라닌-농축 호르몬(MCH) 펩티드, 이의 절단체와 유사체 등을 포함한다.
또다른 구현예에서, 본 발명의 TM은 프로락틴 분비 호르몬 수용체에 결합한다. 이에 관련하여 적절한 TM의 예는 프로락틴 방출형 펩티드, 이의 절단체와 유사체 등을 포함한다.
또다른 구현예에서, 본 발명의 TM은 고나도트로핀-분비 호르몬(GnRH) 수용체에 결합한다. GnRH는 또한 루테인화-호르몬 분비 호르몬(LHRH)로 알려져 있다. 이에 관련한 적절한 GnRH 수용체 TM의 예를 들면, GnRHI 펩티드, GnRHII 펩티드 및 GnRHIII 펩티드를 포함하며, 예컨대, 다음과 같은 데카펩티드 등의 전길이 92-아미노산 GnRH 전구 폴리펩티드와 이의 절단체를 들 수 있다: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly CONH2.
또다른 구현예에서, 본 발명의 TM은 KiSS-1 수용체에 결합한다. 이에 관련한 적절한 TM의 예를 들면, 키스펩틴-10, 키스펩틴-54 펩티드, 이의 절단체 및 유사체 등을 포함한다.
본 발명의 두번째 측면에 따르면, 예컨대:
(a) 신경내분비 종양 세포에 함유된 세포외배출성 융합체의 단백질을 절단할 수 있는 비-세포독성 프로테아제;
(b) 신경내분비 종양 세포의 결합부위에 결합하는 것으로서, 상기 결합부위는 세포내이입의 대상이 되어 상기 신경내분비 종양 세포의 내부에 있는 엔도솜에 통합될 수 있는 것인 표적화 성분(TM); 및
(c) 상기 프로테아제를 엔도솜 외부로, 엔도솜막을 관통하여, 및 상기 신경내분비 종양 세포의 사이토졸 속으로 이동시키는 전위 도메인을 포함하는 것인 폴리펩티드로 이루어진 조성물을 제공한다.
본 발명의 첫번째 측면에서 구현되는 모든 특징은 상술한 두번째 측면에도 동등하게 적용된다.
상술한 본 발명의 첫번째 및/또는 두번째 측면의 바람직한 구현예에서, TM은 인간 펩티드 아미노산 서열을 갖는다. 더욱 바람직한 TM은 인간 SST 펩티드, 인간 CST 펩티드 혹은 인간 GHRH 펩티드이다.
폴리펩티드 제조
본 발명의 폴리펩티드는 3개의 기본 성분 즉, '생활성' 성분 (예. 비-세포독성 프로테아제), TM 및 전위 도메인을 포함한다. 융합단백질의 제조에 관한 일반적인 기술은 종종 재표적화된 독소 기술이라고도 한다. 이러한 종래 기술의 예를 들면, WO94/21300; WO96/33273; WO98/07864; WO00/10598; WO01/21213; WO06/059093; WO00/62814; WO00/04926; WO93/15766; WO00/61192; 및 WO99/58571등이 있으며 이들 공보의 내용을 본원에 참고로서 수록한다.
보다 상세하게, 본 발명의 TM 성분은 프로테아제 성분이나 본 발명의 전위 성분에 융합될 수 있다. 이러한 융합은 바람직하게는 공유결합, 예컨대, 직접 공유결합이나 혹은 스페이서/링커 분자를 경유한 결합 방식에 따른다. 프로테아제 성분 및 전위 성분은 바람직하게는 공유결합, 예컨대, 직접 공유결합이나 혹은 스페이서/링커 분자를 경유하는 결합 방식을 통해 서로 연결된다. 적절한 스페이서/결합 분자는 당해 분야에 공지되어 있으며 통상은 5 내지 40, 바람직하게는 10 내지 30개의 아미노산 잔기로 된 길이의 아미노산계 서열을 포함한다.
사용시의 폴리펩티드는 2-사슬 구조를 가지며 이 구조는 프로테아제 성분과 전위 성분이 디설파이드 결합을 통해 서로 연결되어 있는 형태이다.
본 발명의 폴리펩티드는 종래의 화학적 접합기술에 따라 제조되기도 하며 이 방법 역시 당해 분야에 널리 공지되어 있다. 예를 들어, Hermanson, G.T. (1996), Bioconjugate techniques, Academic Press, and to Wong, S.S. (1991), '단백질 접합 및 가교반응 화학', CRC Press, Nagy et al., PNAS 95 p1794-99 (1998)을 참조한다. 합성 TMs을 본 발명의 폴리펩티드에 부착하는 방법에 관한 기술은 예컨대 EP0257742에 상세히 개시되어 있다. 상술한 접합 관련 공보문헌을 본원에 참고로서 수록한다.
다른 예로서, 폴리펩티드는 단일 폴리펩티드 융합단백질의 재조합법에 따라 제조할 수도 있다 (예컨대 WO98/07864 참조). 이 기술은 자연발생의 클로스트리듐 신경독소(예, 홀로톡신)가 생성되는 체내 박테리아 메커니즘(기전)에 기초한 것으로서, 이에 의해 다음과 같은 '단순화된' 구조적 배열을 갖는 융합단백질을 얻는다:
NH2-[프로테아제 성분]-[전위 성분]-[TM]-COOH
WO98/07864에 따르면, TM은 융합단백질의 C-말단에 배향된다. 상기 융합단백질은, 프로테아제 성분과 전위 성분의 사이를 절단하는 프로테아제로 처리함으로써 활성화된다. 이 결과로 2-사슬 단백질이 생성되며 이 단백질은-전위 성분 및 TM을 모두 함유하는 단일 폴리펩티드 사슬에 (디설파이드 브릿지를 통해) 공유 부착되는 또다른 단일 폴리펩티드 사슬인-프로테아제 성분을 포함한다.
또다른 예로서 WO 06/059093에 따르면, 융합단백질의 TM 성분은 프로테아제 분절부위 및 전위 성분 사이에서 선형 융합단백질 서열의 중간부쪽으로 배향한다. 이 결과로서, TM이 전위 도메인에 확고히 부착되며 (예, 천연 클로스트리듐 홀로톡신의 경우와 같이), 다만 이경우 상기 두 성분은 천연 홀로톡신에 대하여 순서가 뒤바뀌게 된다. 프로테아제 분절부위에서 일어나는 후속 절단에 따라 TM의 N-말단부가 노출되며, 또한 2-사슬 폴리펩티드 융합단백질을 얻는다.
상술한 프로테아제 분절서열은 공지 기술 예컨대 부위지정(site-directed) 돌연변이 등에 따라 소정의 DNA 농도로써 도입된다 (또는 고유 분절서열이 제거된다). 분절서열의 존재 여부는 스크리닝법으로 확인하며 이 방법은 수작업으로 혹은 컴퓨터 소프트웨어를 이용하여 실시할 수 있다 (예, DNASTAR 사의 MapDraw 프로그램). 아니면 임의의 프로테아제 분절부위를 이용할 경우 (예, 클로스트리듐계 또는 비-클로스트리듐계), 다음의 것이 바람직하다:
엔테로키나제 (DDDDK↓)
Xa 인자 (IEGR↓/ IDGR↓)
TEV(담배식각 바이러스) (ENLYFQ↓G)
트롬빈 (LVPR↓GS)
프로시션 (LEVLFQ↓GP).
또다른 프로테아제 분절부위는 비-세포독성 프로테아제, 예컨대, 클로스트리듐 신경독소에 의해 절단되는 인지서열을 포함한다. 이들은 클로스트리듐 신경독소 등의 비-세포독성 프로테아제에 의해 절단되는 SNARE (예, SNAP-25, 신탁신, VAMP) 단백질 인지서열을 포함한다. 구체적인 예는 US2007/0166332에 개시되어 있으며 이 문헌의 내용 전반을 본원에 참고로서 수록한다.
또한, 프로테아제 분절부위에 포함되는 것으로 자가-절단형 서열인 '인테인'이 있다. 자가-절단 반응은 예컨대 환원제 농도를 달리하여 조절할 수 있다. 상술한 '활성화' 분절부위는 또한 본 발명의 폴리펩티드에 삽입되는 '파괴형' 분절부위(하기 검토)로 이용되기도 한다.
한 바람직한 구현예에서, 본 발명의 융합단백질은 N-말단 및/또는 C-말단에 위치한 정제태그(tag)를 하나 이상 포함하기도 한다. 정제태그를 이용할 경우 다음의 것들이 바람직하다: 바람직하게는 C-말단 및/또는 N-말단 태그로서의 His-태그 (예, 6×히스티딘), 바람직하게는 N-말단 태그로서의 MBP-태그 (말토스 결합 단백질), 바람직하게는 N-말단 태그로서의 GST-태그 (글루타티온-S-전이효소), 바람직하게는 N-말단 태그로서의 His-MBP-태그, 바람직하게는 N-말단 태그로서의 GST-MBP-태그, 바람직하게는 N-말단 태그로서의 티오레독신-태그, 바람직하게는 N-말단 태그로서의 CBD-태그 (키틴 결합 도메인) 등이다.
하나 이상의 펩티드 스페이서/링커 분자가 융합단백질에 포함될 수 있다. 예를 들어 펩티드 스페이서를 정제태그와 융합단백질 분자의 나머지 부분 사이에 삽입할 수 있다.
그러므로, 본 발명의 세번째 측면은 상술한 바와 같이 (즉, 본 발명의 두번째 측면에 따른) 폴리펩티드를 암호화하는 핵산(즉, DNA)의 서열을 제공하는 것이다.
상술한 핵산은 선택적으로 복제원, 핵산 통합부위, 프로모터, 터미네이터 및 리보솜 결합부위 중 하나 이상을 가질 수 있는 플라스미드 등과 같은 벡터 형태로 존재한다.
본 발명은 또한 상술한 핵산 서열 (즉, 본 발명의 세번째 측면에 따른)을 숙주 세포 특히, 대장균에 직접적으로 혹은 바큘로바이러스 발현 체계를 통하여 발현하는 방법을 제공한다.
본 발명은 또한 본 발명의 폴리펩티드를 활성화하는 방법도 포함하며 이 방법은, 비-세포독성 프로테아제 성분과 전위 성분 사이에 위치하는 인지부위(분절부위)에서 폴리펩티드를 절단하는 프로테아제와 상기의 폴리펩티드를 접촉시키는 것을 포함하고, 이에 따라 폴리펩티드가 2-사슬 폴리펩티드로 전환되며 여기서 상기 비-세포독성 프로테아제 및 전위 성분은 디설파이드 결합에 의해 서로 접합되어 있다. 한 바람직한 구현예에서, 이러한 인지부위는 자연발생의 클로스트리듐 신경독소 및/또는 자연발생의 IgA 프로테아제가 갖는 고유적인 특성은 아니다.
비-표적화 영역으로 전파될 때 일어나는 부작용을 감소시키거나 이를 방지하기 위해, 본 발명의 폴리펩티드를 추가로 개질할 수 있다. 이 구현예에 따르면, 상기 폴리펩티드는 파괴형 분절부위를 갖는다. 이러한 파괴형 분절부위는 '활성화' 부위 (즉, 2-사슬을 형성하는 부위)와 뚜렷이 구별되며, 제2의 프로테아제에 의해 절단되는 반면 비-세포독성 프로테아제에 의해서는 절단되지 않는다. 또한, 파괴형 분절부위가 상기 제2의 프로테아제에 의해 절단되면 폴리펩티드의 효능이 감소한다 (즉, 지정된 표적세포에 대한 결합능의 감소, 전위 활성의 감소 및/또는 비-세포독성 프로테아제의 활성 감소 등). 마지막으로, 상기의 제2의 분절부위를 본 발명에 따른 폴리펩티드의 '활성화' 부위로 이용할 수도 있다.
따라서 상기의 구현예에 따르면, 본 발명은 오프부위(off-site)에서의 비활성화 및/또는 파괴 작용을 조절할 수 있는 폴리펩티드를 제공한다.
한 바람직한 구현예에서, 파괴형 분절부위는 순환형 프로테아제(예, 혈청 프로테아제나 혈액응고용 프로테아제와 같은 세포외 프로테아제), 조직계 프로테아제 (예, 근육 MMP 등의 기질금속 단백분해효소(MMP)) 및 세포내 프로테아제 (바람직하게는 표적세포에 결핍된 프로테아제)로 이루어진 군에서 선택된 제2의 프로테아제 (즉, 파괴형 프로테아제)에 의해 인지 및 절단된다.
본 발명의 폴리펩티드는 사용시 지정된 표적세포에서 벗어나 분산되거나 및/또는 비-표적세포에 의해 포획되어야 하며, 이에 따라 폴리펩티드는 (제2 프로테아제에 의해) 파괴형 분절부위가 절단됨으로써 비활성화한다.
한 구현예에서, 파괴형 분절부위는 오프부위 세포에 존재하는 제2 프로테아제에 의해 인지 및 절단된다. 이 구현예에서, 상기 오프부위 세포 및 표적세포는 서로 상이한 세포 종류이다. 또다른 예로서 (혹은 상기와 더불어), 파괴형 분절부위는 오프부위의 위치 (예, 표적세포로부터 멀리 떨어진)에 존재하는 제2 프로테아제에 의해 인지 및 절단된다. 따라서 파괴형 절단이 세포의 외측으로부터 일어날 경우, 표적세포와 오프부위 세포는 서로 동일 또는 상이한 종류의 세포일 수 있다. 이에 관련하여, 표적세포와 오프부위 세포는 본 발명의 동일한 폴리펩티드가 결합되는 수용체를 각각 보유한다.
본 발명의 파괴형 분절부위는, 폴리펩티드가 오프부위 위치의 안쪽 혹은 이 위치에 존재할 경우, 폴리펩티드를 활성화 및/또는 파괴하는 역할을 한다. 이에 관련하여, 파괴형 분절부위에서 절단시 폴리펩티드 효능이 최소화된다 (이 파괴형 분절부위가 없거나 혹은 이와 동일하지만 절단되지 않은 형태의 파괴부위를 포함하는 동일한 폴리펩티드와 비교시). 상기의 효능 감소는 예를 들어: (포유류 세포 수용체에 대한) 결합 감소 및/또는 (포유류 세포의 엔도솜막을 거쳐 사이토졸로 이동하는) 전위의 감소; 및/또는 SNARE 단백질의 절단 감소 등을 포함한다.
본 발명에 있어서 파괴형 분절부위(들)을 선택할 때 이 파괴형 분절부위(들)은, 본 발명의 폴리펩티드 제조 공정의 일부 즉 폴리펩티드의 전위후 변형을 위해 별도로 사용가능한 임의의 프로테아제를 위한 기질이 아닌 것이 바람직하다. 이에 관련하여, 본 발명의 비-세포독성 프로테아제는 통상 프로테아제 활성화 작용(본 발명의 파괴형 분절부위와 구조적으로 상이한 별개의 '활성화' 프로테아제 분절부위를 경유한)을 이용한다. 활성화 분절부위는 비-세포독성 프로테아제와 본 발명에 따른 폴리펩티드의 전위 성분 혹은 결합 성분 사이의 펩티드 결합을 절단하는 것이 목적이며, 이에 따라 상기 두 성분이 디설파이드 결합을 통해 서로 연결되어 있는 특징의 '활성화된' 2-사슬 폴리펩티드를 제공한다.
따라서 본 발명에 따른 폴리펩티드의 파괴형 분절부위(들)이 '활성화' 분절부위 및 후속의 디설파이드 결합을 형성함에 있어 악영향을 미치지 않도록 하기 위해, 상기 전자는 본 발명의 폴리펩티드에 있어서 '활성화' 분절부위로부터 벗어나 적어도 20개, 30개, 40개, 50개 및 더욱 바람직하게는 적어도 60개, 70개, 80개의 (인접) 아미노산 잔기 위치에 도입되는 것이 바람직하다.
파괴형 분절부위(들) 및 활성화 분절부위는 폴리펩티드의 고유성분들에 있어서 외인성 (즉, 가공되거나 합성된 것)이 바람직하다. 다시 말해서, 이들 분절부위는 이에 상응하는 폴리펩티드의 고유성분들이 갖는 고유 특성이 아닌 것이 바람직하다. 예를 들어, BoNT/A L-사슬이나 H-사슬에 (각각) 기반한 프로테아제 혹은 전위 성분은 분절부위를 갖도록 본 발명에 따라 가공될 수 있다. 그러나 상기 분절부위는 이에 상응하는 BoNT의 고유 L-사슬이나 H-사슬에는 존재하지 않는다. 마찬가지로, 폴리펩티드의 TM 성분을 가공하여 프로테아제 분절위치를 갖게될 때 이 분절부위는 상기 TM의 상응하는 고유서열에는 존재하지 않는다.
본 발명의 바람직한 구현예에서, 파괴형 분절부위(들)과 '활성화' 분절부위는 동일한 프로테아제를 이용하여 절단하지 않는다. 한 구현예에서, 각 인지서열 내의 적어도 하나, 바람직하게는 적어도 2개, 더욱 바람직하게는 적어도 3개, 또한 가장 바람직하게는 적어도 4개의 내성 아미노산이 서로 상이하므로 2개의 분절부위가 서로 구별된다.
예를 들어, 클로스트리듐 L-사슬과 HN 성분 사이에 Xa 인자 '활성화' 부위가 있는 폴리펩티드 키메라(공생체)의 경우, 상기 Xa 인자 부위를 제외한 부위인 파괴형 분절부위를 이용하는 것이 바람직하며, 이 부위는 L-사슬, 및/또는 HN 및/또는 TM 성분 어디에나 삽입될 수 있다. 이 방안에 따르면, 폴리펩티드를 변형하여 L-사슬과 HN 성분 사이에 또다른 '활성화' 부위 (예컨대, 엔테로키나제 분절부위)를 제공할 수 있으며, 이 경우 각 Xa 인자 분절부위는 파괴형 분절부위로서 폴리펩티드 내의 어느 곳에나 삽입될 수 있다. 이와 또다르게, L-사슬과 HN 성분 사이에 있는 기존의 Xa 인자 '활성화' 부위를 유지하는 한편 또다른 분절부위, 예를 들어, 트롬빈 분절부위를 파괴형 분절부위로서 삽입할 수 있다.
분절부위를 봉입하기 위한 위치로서 본 발명에 따른 임의 성분의 기본서열 내에 있는 적절한 부위를 정동할 때, 삽입할 분절부위와 거의 일치하는 기본서열을 선택하는 것이 바람직하다. 이에 따라 폴리펩티드의 구조적 변화를 최소화 할 수 있다. 예를 들어, 분절부위는 보통 적어도 3개의 인접한 아미노산 잔기를 포함한다. 그러므로 바람직한 구현예에 있어서, 새로운 분절부위의 도입에 요구되는 적어도 하나, 바람직하게는 적어도 2개의 아미노산 잔기를 이미 보유하고 있는 분절부위를 선택한다. 예를 들어 한 구현예에서 카스파제 3-분할부위(DMQD)를 도입할 수 있다. 이 경우, 예컨대, Dxxx, xMxx, xxQx, xxxD, DMxx, DxQx, DxxD, xMQx, xMxD, xxQD, DMQx, xMQD, DxQD 및 DMxD 중에서 선택된 기본서열을 이미 보유하는 삽입위치가 바람직한 것으로 확인되었다.
마찬가지로 분절부위를 표면 노출영역에 도입하는 것이 바람직하다. 표면 노출영역 내에 있는 기존의 루프 영역이 바람직하다.
본 발명의 한 바람직한 구현예에서, 파괴형 분절부위(들)은 BoNT/A의 기본 아미노산 서열에 근거하여 다음의 위치(들)중 하나 이상에 도입된다. BoNT/A를 기준으로 삼아 삽입위치를 정동하면서 (편의를 위해), 또다른 프로테아제 도메인 및/또는 전위 도메인의 기본 아미노산 서열을 상기 BoNT/A 위치를 이용하여 쉽게 정렬할 수 있다.
프로테아제 성분의 경우, 다음 중 하나 이상의 위치가 바람직하다: 27-31, 56-63, 73-75, 78-81, 99-105, 120-124, 137-144, 161-165, 169-173, 187-194, 202-214, 237-241, 243-250, 300-304, 323-335, 375-382, 391-400, 및 413-423. 이러한 번호매기기는 본 발명에 따른 프로테아제 성분의 N-말단에서부터 카운트하는 것이 바람직하다.
한 바람직한 구현예에서, 파괴형 분절부위(들)은 프로테아제 성분의 N-말단부터 카운트하여 8개의 아미노산 잔기보다 더 먼 위치, 바람직하게는 10개의 아미노산 잔기, 더 바람직하게는 25개의 아미노산 잔기, 특히 바람직하게는 50개의 아미노산 잔기보다 더 먼 위치에 놓인다. 마찬가지로, 한 바람직한 구현예에서, 파괴형 분절부위(들)은 프로테아제 성분의 C-말단부터 카운트하여 20개의 아미노산 잔기, 바람직하게는 30개의 아미노산 잔기, 더 바람직하게는 40개의 아미노산 잔기, 특히 바람직하게는 50개의 아미노산 잔기보다 더 먼 위치에 놓인다.
전위 성분의 경우, 다음 중 하나 이상의 위치가 바람직하다: 474-479, 483-495, 507-543, 557-567, 576-580, 618-631, 643-650, 669-677, 751-767, 823-834, 845-859. 상술한 번호매기기는 발명에 따른 전위 성분의 N-말단쪽인 449가 시작 위치이고 종결 위치는 동일한 전위 성분의 C-말단쪽인 871임을 표시한다.
한 바람직한 구현예에서, 파괴형 분절부위(들)은 전위 성분의 N-말단부터 카운트하여 10개의 아미노산 잔기, 바람직하게는 25개의 아미노산 잔기, 더 바람직하게는 40개의 아미노산 잔기, 특히 바람직하게는 50개의 아미노산 잔기보다 먼 위치에 놓인다. 마찬가지로, 또다른 바람직한 구현예에서, 파괴형 분절부위(들)은 전위 성분의 C-말단부터 카운트하여 10개의 아미노산 잔기, 바람직하게는 25개의 아미노산 잔기, 더 바람직하게는 40개의 아미노산 잔기, 특히 바람직하게는 50개의 아미노산 잔기보다 먼 위치에 놓인다.
바람직한 구현예에서, 파괴형 분절부위(들)은 TM 성분의 N-말단부터 카운트하여 10개의 아미노산 잔기, 25개의 아미노산 잔기, 더 바람직하게는 40개의 아미노산 잔기, 특히 50개의 아미노산 잔기보다 더 먼 위치에 놓인다. 유사하게, 한 바람직한 구현예에서, 파괴형 분절부위(들)은 TM 성분의 C-말단부터 카운트하여 10개의 아미노산 잔기, 바람직하게는 25개의 아미노산 잔기, 더 바람직하게는 40개의 아미노산 잔기, 특히 바람직하게는 50개의 아미노산 잔기보다 더 먼 위치에 놓인다.
본 발명의 폴리펩티드는 하나 이상 (예, 2개, 3개, 4개, 5개 이상)의 파괴형 프로테아제 분절부위를 포함할 수 있다. 하나 이상의 분절부위가 포함되어 있을 때, 각 분절부위는 동일하거나 상이할 수 있다. 이에 관련하여, 하나 이상의 분절부위를 사용하면 오프부위 비활성화 작용을 개선할 수 있다. 마찬가지로, 2개 이상의 상이한 파괴형 분절부위를 이용시 설계의 유연성을 도모할 수 있다.
파괴형 분절부위를 다음과 같은 폴리펩티드 구성분 내에 형성할 수 있다: 즉, 비-세포독성 프로테아제 성분; 전위 성분; 표적화 성분; 또는 스페이서 펩티드 (존재할 경우). 이 경우, (표적화/결합 영역 및/또는 전위 도메인에 대한 효과, 및/또는 비-세포독성 프로테아제 도메인에 대한 효과를 최소화 함으로써) 폴리펩티드의 효능에 미치는 부작용을 최소화 하는 한편, 폴리펩티드를 불안정하게 하여 이의 표적부위/표적세포로부터 떨어져 나오게 할 수 있는 파괴형 분절부위를 선택한다.
바람직한 파괴형 분절부위 (및 이에 상응하는 제2 프로테아제)를 하기의 표에 수록한다. 표에 수록된 분절부위는 예시를 위한 것일 뿐 본 발명을 한정하기 위한 것은 아니다.
제2 프로테아제 | 파괴형 분절부위 인지서열 | 내성 인지서열의 변형 P4 - P3 - P2 - P1 -▼- P1' - P2' - P3 |
||||||
P4 | P3 | P2 | P1 | P1 | P2 | P3 | ||
트롬빈 | LVPR▼GS | A,F,G,I,L,T,V or M | A,F,G,I,L,T,V,W or A | P | R | Not D or E | Not D or E | --- |
트롬빈 | GR▼G | G | R | G | ||||
Xa 인자 | IEGR▼ | A,F,G,I,L,T,V or M | D or E | G | R | --- | --- | --- |
ADAM17 | PLAQA▼VRSSS | |||||||
인간 기관-트립신형 프로테아제(HAT) | SKGR▼SLIGRV | |||||||
ACE (펩티딜-디펩티다제 A) | --- | --- | --- | --- | Not P | Not D or E | N/A | |
엘라스타제 (백혈구) |
MEA▼VTY | M, R | E | A, H | V, T | V, T, H | Y | --- |
퓨린 | RXR/KR▼ | R | X | R or K | R | |||
그랜자임 | IEPD▼ | I | E | P | D | --- | --- | --- |
제1 카스파제 | F,W,Y,L | --- | H,A,T | D | Not P,E.D.Q.K or R | --- | --- | |
제2 카스파제 | DVAD▼ | D | V | A | D | Not P,E.D.Q.K or R | --- | --- |
제3 카스파제 | DMQD▼ | D | M | Q | D | Not P,E.D.Q.K or R | --- | --- |
제4 카스파제 | LEVD▼ | L | E | V | D | Not P,E.D.Q.K or R | --- | --- |
제5 카스파제 |
L or W | E | H | D | --- | --- | --- | |
제6 카스파제 | V | E | H or I | D | Not P,E.D.Q.K or R | --- | --- | |
제7 카스파제 | DEVD▼ | D | E | V | D | Not P,E.D.Q.K or R | --- | --- |
제8 카스파제 | I or L | E | T | D | Not P,E.D.Q.K or R | --- | --- | |
제9 카스파제 | LEHD▼ | L | E | H | D | --- | --- | --- |
제10 카스파제 | IEHD▼ | I | E | H | D | --- | --- | --- |
기질금속 단백분해효소(MMPs)가 본 발명의 바람직한 파괴형 프로테아제 그룹이다. 이 그룹에는, ADAM17 (EC 3.4.24.86, 또한 TACE 라고도 함)이 바람직하며 다양한 막고정된 세포-표면 단백질을 절단하여 세포외 도메인을 '박리(shed)'시킨다. 또한, 바람직한 MMPs로서 아다말리신, 세랄리신 및 아스탁신을 포함한다.
또다른 바람직한 파괴형 프로테아제 그룹은, 트롬빈, 응집형 VIIa 인자, 응집형 IXa 인자, 응집형 Xa 인자, 응집형 XIa 인자, 응집형 XIIa 인자, 칼리크라인, 단백질 C, 또한 MBP-결합된 세린 프로테아제 등의 포유류 혈액 프로테아제이다.
본 발명의 한 구현예에서, 상기의 파괴형 분절부위는 적어도 3개나 4개, 바람직하게는 적어도 5개나 6개, 더 바람직하게는 적어도 6개나 7개, 특히 바람직하게는 적어도 8개의 인접한 아미노산 잔기를 보유한 인지서열을 갖는다. 이 경우, 인지서열이 길수록 (인접한 아미노산 잔기 측면에서) 임의의 제2 프로테아제에 의한 파괴형 분절부위의 비-특이적 절단은 감소한다.
본 발명의 파괴형 분절부위는 프로테아제 성분 및/또는 표적화 성분(TM)에 도입되거나, 및/또는 전위 성분 및/또는 스페이서 펩티드에 도입될 수 있다. 상술한 4종류의 성분 중 프로테아제 성분이 특히 바람직하다. 따라서, 폴리펩티드는 비-세포독성 프로테아제 및/또는 결합 성분이나 전위 성분을 직접 파괴함으로써 신속히 비활성화 할 수 있다.
폴리펩티드 전달
사용시, 본 발명은 폴리펩티드와 더불어 약제학적 수용가능한 담체, 부형제, 보조제, 추진제 및/또는 염 중 선택된 1종의 성분을 포함하는 약제학적 조성물을 이용한다.
본 발명의 폴리펩티드는 경구용, 비경구용 연속 주입식, 임플란트, 흡입식 혹은 국소 도포용 등으로 제형화할 수 있다. 주사에 적합한 조성물은 용액, 현탁액이나 유액, 또는 사용전 적절한 전색제(비히클)에 용해하거나 현탁시키는 건조 분말 등의 형태로 만들기도 한다.
국소 전달수단은 에어로졸 혹은 기타의 분무제 (예, 연무제)를 포함할 수 있다. 이 때, 에어로졸 제형은 폐 및/또는 비강이나 기타 기관지 경로에 폴리펩티드를 전달할 수 있다.
바람직한 투여 경로는, 전신(예, 정맥주사), 복강경 및/또는 국소주사 (예컨대, 종양에 대한 경접동형 직접주사) 등에서 선택된다.
주사 제형의 경우, 선택 사양으로서, 폴리펩티드를 투여부위에 유지하거나 혹은 이로부터 제거되는 것을 감소시키는데 도움이 되는 약제학적 활성물질을 더 포함할 수도 있다. 이러한 약제학적 활성물질의 한가지 예로서, 아드레날린 같은 혈관수축제가 있다. 이러한 제형은 폴리펩티드 투여뒤 체류 시간을 연장하는 장점이 있으며 따라서 그 효능을 증가 및/또는 향상시킨다.
본 발명에 따른 폴리펩티드의 투약량 범위는 원하는 치료효과를 달성하는데 충분한 정도로 한다. 이러한 투약량의 범위는 폴리펩티드나 그 조성물의 정확한 특성, 투여경로, 제형의 특성, 환자의 연령, 환자의 병리상태의 특성, 정도 혹은 위중도, 금기사항, 및 담당의사의 결정 등에 따라 다르다는 것을 충분히 이해할 것이다. 투약량의 변화는 최적화를 위한 경험적 표준 루틴 (standard empirical routines for optimization)을 이용하여 조정할 수 있다.
일일 적정 복용량 (환자 체중 1kg 당)은 0.0001 내지 1mg/kg, 바람직하게는 0.0001 내지 0.5mg/kg, 더 바람직하게는 0.002 내지 0.5mg/kg, 특히 바람직하게는 0.004 내지 0.5mg/kg의 범위이다. 단위 복용량은 1mg 미만 내지 30mg 범위에서 달리할 수 있으나, 통상은 1회 복용시 0.01 내지 1mg의 범위이며 매일 또는 이보다 적은 횟수, 예컨대 매주나 6개월 간격 등으로 투여할 수 있다.
특히 바람직한 투약 처방은 1회 복용시 2.5ng 폴리펩티드에 기초한다. 이 경우, 바람직한 복용횟수는 1회 내지 100회 (즉, 2.5 내지 250ng)이다.
유체형 투약 제형은 보통 폴리펩티드와 무균 전색제를 이용하여 조제한다. 폴리펩티드는 전색제 및 사용 농도에 따라 이 전색제에 용해 혹은 현탁할 수 있다. 용액 제조시 폴리펩티드를 전색제에 용해할 수 있으며, 필요할 경우, 여기에 염화나트륨을 첨가해 등장액으로 만들고 무균화 기술에 따라 이를 다시 멸균필터에 통과시켜 멸균처리한 후에 적절한 멸균 유리병이나 앰플에 충전 및 밀봉할 수 있다. 또는, 용액의 안정도가 양호할 경우 밀봉 용기에 담긴 용액을 오토클레이브 처리로 멸균할 수도 있다. 완충제, 가용화제, 안정화제, 보존제나 살균제, 현탁제, 유탁제, 및 국소마취제 등의 유익한 첨가제를 전색제에 용해시킬 수도 있다.
사용전에 적절한 전색제에 용해 혹은 현탁하는 건조 분말은, 무균화 기술에 따라 사전멸균처리된 성분들을 멸균된 장소에서 멸균용기에 담아 조제할 수 있다. 이와 또다르게, 멸균된 장소에서 무균화 기술에 따라 상기 성분들을 적절한 용기에 담아 용해할 수도 있다. 이 결과물은 동결건조하고 용기는 무균 밀봉한다.
근육주사, 피하주사 혹은 피내주사 등에 적절한 비경구용 현탁액은 실질적으로 위와 유사한 방식으로 조제하되, 단, 멸균 성분들을 용해처리 하는 대신 멸균 전색제에 현탁하므로 여과처리로 멸균효과를 달성할 수 없다는 점이 상이하다. 이들 성분은 멸균상태로 분리되거나 또는 분리후 예컨대, 감마선 조사 등에 따라 멸균처리할 수 있다.
조성물에 폴리비닐피롤리돈 같은 현탁제를 가하여 성분들의 균일한 분포를 촉진하면 유리하다.
용어 정의
표적화 성분(TM)은 기능적으로 결합부위와 상호작용하여 본 발명의 폴리펩티드와 표적세포(통상 포유류 세포, 특히 인간 세포)의 표면간에 물리적인 연계를 야기하는 화학적 구조를 말한다. TM은 또한 표적세포 상의 결합부위에 결합할 수 있는 분자 (즉, 자연발생 분자나 이의 화학적/물리적 개질된 변이체)도 포함하고, 상기의 결합부위가 내부화 (예, 엔도솜 형성)할 수 있으며 이를 수용체-매개된 세포내이입(endocytosis)라고도 한다. TM은 엔도솜막 전위 기능을 보유하며, 이 경우 각각의 TM 및 전위 도메인 성분들이 본 발명의 작용제에 존재할 필요는 없다. 본원의 상세한 설명 전반에서 특이적 TMs에 대해 기술하였다. 상술한 TMs은 예시의 목적에 불과하며, 본 발명은 신경내분비 종양 세포 상의 결합부위에 대한 기본결합 (즉, 표적화) 능력을 보유한 이들의 변이체 및 유도체를 모두 포함하고 결합부위는 내부화될 수 있다.
본 발명의 TM은 표적세포에 결합 (바람직하게는 특이적 결합)한다. 여기서 '특이적 결합'이란 특정의 TM이 106 M-1 이상, 바람직하게는 107 M-1 이상, 혹은 108 M-1 이상이나 109 M-1 이상의 결합친화력(Ka)으로 표적세포 (예, sst 수용체)에 결합하는 것을 말한다. 본 발명의 TMs는 (유리된 형태일 때, 즉, 프로테아제 및/또는 전위 성분으로부터 분리되어 있는 경우) 표적 수용체 (예, SST 수용체)에 대한 결합친화력 (IC50)이 0.05 내지 18nM 범위인 것이 바람직하다.
본 발명의 TM은 밀배아응집소(WGA) 펩티드가 아닌 것이 바람직하다.
본원 명세서에 개시된 TM은 표적세포에 대한 결합능력이 있는 TM절편 및 변이체도 포함한다. 예를 들어, 변이체는 기준 TM에 대해 적어도 80%, 바람직하게는 적어도 90%, 더 바람직하게는 적어도 95%, 또한 가장 바람직하게는 적어도 97%나 적어도 99%의 아미노산 서열 상동성을 나타내는 것으로서, 이때 상기의 기준TM은 본원에서 언급하는 임의의 TM 서열이다. 따라서, 변이체는 아미노산 (예, 비천연 아미노산)의 하나 이상의 유사체 또는 치환된 결합을 포함할 수 있다. 또한 예를 들어, 상기의 '절편'이라는 용어는 TM에 관련하여 사용할 경우, 기준 TM의 적어도 5개, 바람직하게는 적어도 10개, 더 바람직하게는 적어도 20개, 가장 바람직하게는 적어도 25개의 아미노산 잔기를 보유한 펩티드를 말한다. 또한 이 절편은 상술한 변이체와도 관계가 있다. 따라서, 예를 들어, 본 발명의 절편은 적어도 7개, 10개, 14개, 17개, 20개, 25개, 28개, 29개 혹은 30개의 아미노산을 갖는 펩티드이며, 이때의 펩티드 서열은 상기 기준 펩티드의 상응하는 펩티드 서열 (인접 아미노산의)에 대해 80% 이상의 서열 상동성을 나타낸다.
예를 들어, 소마토스타틴(SST)과 코르티스타틴(CST)는 구조적으로 높은 상동성을 나타내며 현재 공지된 모든 SST 수용체에 결합한다. 전길이 SST는 다음과 같은 아미노산 서열을 갖는다:
MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEPNQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC.
또한 전길이 CST는 다음과 같은 아미노산 서열을 갖는다:
MYRHKNSWRLGLKYPPSSKEETQVPKTLISGLPGRKSSSRVGEKLQSAHKMPLSPGLLLLLLSGATATAALPLEGGPTGRDSEHMQEAAGIRKSSLLTFLAWWFEWTSQASAGPLIGEEAREVARRQEGAPPQQSARRDRMPCRNFFWKTFSSCK.
이들 TMs의 예를 들면, 다음의 절편 (및 이에 상응하는 변이체)을 포함한다:
NFFWKTF;
(R 또는 K)NFFWKTF;
C(R 또는 K)NFFWKTF;
(P 또는 G)C(R 또는 K)NFFWKTF;
NFFWKTF(S 또는 T);
NFFWKTF(S 또는 T)S;
NFFWKTF(S 또는 T)SC;
(R 또는 K)NFFWKTF(S 또는 T);
(R 또는 K)NFFWKTF(S 또는 T)S;
(R 또는 K)NFFWKTF(S 또는 T)SC;
C(R 또는 K)NFFWKTF(S 또는 T);
C(R 또는 K)NFFWKTF(S 또는 T)S;
C(R 또는 K)NFFWKTF(S 또는 T)SC;
(P 또는 G)C(R 또는 K)NFFWKTF(S 또는 T);
(P 또는 G)C(R 또는 K)NFFWKTF(S 또는 T)S; 또는
(P 또는 G)C(R 또는 K)NFFWKTF(S 또는 T)C.
상기의 서열에 있어서, (P 또는 G)의 양자택일 조건에서 P는 CST TM일 때 바람직하며 G는 SST TM일 때 바람직하다. 또한 (R 또는 K)의 양자택일에서, R은 CST TM에 바람직하고 K는 SST TM에 바람직하다. 마찬가지로, (S 또는 T)의 양자택일에서 S는 CST TM의 경우에 바람직한 반면 T는 SST TM의 경우에 바람직하다.
바람직한 절편은 적어도 7개나 10개의 아미노산 잔기, 바람직하게는 적어도 14개나 17개의 아미노산 잔기, 또한 더 바람직하게는 적어도 28개나 29개의 아미노산 잔기를 포함한다. 예를 들어, 바람직한 서열은 다음을 포함한다:
SANSNPAMAPRERKAGCKNFFWKTFTSc(SST-28);
AGCKNFFWKTFTSC (SST-14);
QEGAPPQQSARRDRMPCRNFFWKTFSSCK (CST-29);
QERPPLQQPPHRDKKPCKNFFWKTFSSCK (CST-29);
QERPPPQQPPHLDKKPCKNFFWKTFSSCK (CST-29);
DRMPCRNFFWKTFSSCK (CST-17);
PCRNFFWKTFSSCK (CST-14); 및
PCKNFFWKTFSSCK (CST-14).
TM이 신경내분비 종양 세포, 바람직하게는 신경내분비 종양 세포 상의 SST나 CST 수용체에 결합할 수 있다면, 상기 TM은 보다 더 긴 아미노산 서열, 예를 들어, 적어도 30개나 35개의 아미노산 잔기, 혹은 적어도 40이나 45개의 아미노산 잔기를 포함하기도 한다. 이 경우, TM은 전길이 SST나 CST의 절편인 것이 바람직하나, 코어서열 "NFFWKTF" 혹은 상기와 같이 형성된 기본 아미노산 서열 중 하나를 포함하고 있다.
또다른 예로서, 본 발명의 GHRH 펩티드는 다음의 서열을 포함한다:
YADAIFTASYRKVLGQLSARKLLQDILSR;YADAIFTASYRNVLGQLSARKLLQDILSR;
YADAIFTNSYRKVLGQLSARKLLQDIM; YADAIFTNSYRKVLGQLSARKLLQDIMS;
ADAIFTNSYRKVLGQLSARKLLQDIMSR;
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL;
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA;
YADAIFTNAYRKVLGQLSARKLLQDIMSR; YADAIFTNSYRKVLGQLSARKALQDIMSR;
YADAIFTASYKKVLGQLSARKLLQDIMSR; YADAIFTASYKRVLGQLSARKLLQDIMSR;
YADAIFTASYNKVLGQLSARKLLQDIMSR; YADAIFTASYRKVLGQLSAKKLLQDIMSR;
YADAIFTASYKKVLGQLSAKKLLQDIMSR; YADAIFTASYRKVLGQLSANKLLQDIMSR;
YADAIFTASYRNVLGQLSARKLLQDIMSR; YADAIFTASYRKVLGQLSARNLLQDIMSR;
YADAIFEASYRKVLGQLSARKLLQDIMSR; YADAIFTASERKVLGQLSARKLLQDIMSR;
YADAIFTASYRKELGQLSARKLLQDIMSR; YADAIFTASYRKVLGQLSARKLLQDIMSR;
YADAIFTESYRKVLGQLSARKLLQDIMSR; YADAIFTNSYRKVLAQLSARKLLQDIM;
YADAIFTNSYRKVLAQLSARKLLQDIMSR; YADAIFTASYRKVLAQLSARKLLQDIMSR;
YADAIFTAAYRKVLAQLSARKALQDIASR; YADAIFTAAYRKVLAQLSARKALQDIMSR;
HVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGA;
HVDAIFTQSYRKVLAQLSARKALQDILSRQQG; HVDAIFTSSYRKVLAQLSARKLLQDILSR;
HVDAIFTTSYRKVLAQLSARKLLQDILSR; YADAIFTQSYRKVLAQLSARKALQDILNR;
YADAIFTQSYRKVLAQLSARKALQDILSR.
TM이 표적으로 선택된 세포에 결합하는지 여부를 확인하는 것이 정례이다. 예를 들어 신경내분비 종양 세포를 대표하는 조직이나 세포를, 과량의 무표지 TM이 있는 조건에서, 표지화된 (예, 유사분열된) TM 에 노출하는 간단한 방사선 변위실험을 실시할 수 있다. 상기의 실험에서, 비-특이적 및 특이적 결합간 상대비율을 평가함으로써 TM이 표적세포에 결합하고 있는지의 여부를 확인할 수 있다. 선택적으로, 상기의 평가에는 하나 이상의 결합 길항제가 수반될 수 있으며 또한 TM 결합의 손실을 관찰하는 것도 상기 평가에 포함될 수 있다. 이러한 실험의 예는 공지 문헌에서 찾아 볼 수 있으며, 예컨대, Hulme, E.C. (1990), Receptor-binding studies, a brief outline, pp. 303-311, In Receptor biochemistry, A Practical Approach, Ed. E.C. Hulme, Oxford University Press 등을 참조한다.
본원의 상세한 설명에서, 펩티드 TM (예, SST 펩티드, CST 펩티드, 혹은 GHRH 펩티드 등)에는 펩티드 유사체도 포함되며 단 이러한 유사 TM이, 상기의 상응하는 '기준' TM이 결합하는 동일한 수용체에 결합하는 것을 조건으로 한다. 상기의 유사체는 다음과 같은 합성 잔기를 가질 수 있다:
β-Nal = β-나프틸알라닌; β-Pal =β-피리딜알라닌, hArg(Bu) = N-구아니디노-(부틸)-호모아르기닌; hArg(Et)2 = N,N'-구아니디노-(디메틸)-호모아르기닌; hArg(CH2CF3)2 = N,N'-구아니디노-비스-(2,2,2,-트리플루오로에틸)-호모아르기닌; hArg(CH3, hexyl) = N,N'-구아니디노-(메틸, 헥실)-호모아르기닌; Lys(Me) = Ne-메틸리신; Lys(iPr) = Ne-이소프로필리신; AmPhe = 아미노메틸페닐알라닌; AChxAla = 아미노시클로헥실알라닌; Abu = α-아미노부티르산; Tpo = 4-티아프롤린; MeLeu = N-메틸류신; Orn = 오르니틴; Nle - 노르류신; Nva = 노르발린; Trp(Br) = 5-브로모-트립토판; Trp(F) = 5-플루오로-트립토판; Trp(N02) = 5-니트로-트립토판; Gaba = γ-아미노부티르산; Bmp = J-메르캅토프로피오닐; Ac = 아세틸; 및 Pen = 펜실라민 등이다.
상기의 펩티드 유사체에 대하여, 특이적 펩티드 TMs, 예컨대, SST 펩티드, GHRH 펩티드, 봄베신 펩티드, 그렐린 펩티드, GnRH (아카 LHRH 펩티드), 및 우로텐신 펩티드 등을 참조하여 보다 상세히 설명하나 이러한 기본 원리는 본 발명에 따른 다른 모든 TMs에 대해서도 마찬가지로 적용된다.
본 발명을 실시하는데 이용할 수 있는 소마토스타틴 유사체는 특별히 한정되지는 않으나 다음과 같은 공지 문헌상에 개시된 것을 포함하며 이들 문헌을 본원에 참고로서 수록한다: Van Binst, G. et al. Peptide Research 5: 8 (1992); Horvath, A. et al. Abstract, "항암활성이 있는 소마토스타틴 유사체의 구조", 22nd European peptide Symposium, September 13-19,1992, Interlaken, Switzerland; US5,506,339; EP0363589; US4,904,642; US4,871,717; US4,725,577; US4,684,620; US4,650,787; US4,585,755; US4,725,577; US4,522,813; US4,369,179; US4,360,516; US4,328,214; US4,316,890; US4,310,518; US4,291,022; US4,238,481; US4,235,886; US4,211,693; US4,190,648; US4,146,612; US4,133,782; US5,506,339; US4,261,885; US4,282,143; US4,190,575; US5,552,520; EP0389180; EP0505680; US4,603,120; EP0030920; US4,853,371; WO90/12811; WO97/01579; WO91/18016; WO98/08529 and WO98/08528; WO/0075186 and WO00/06185; WO99/56769; and FR 2,522,655.
바람직한 유사체로서 다음을 포함한다:
시클로(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) 또는 H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH2; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Cys-Phe-Phe-D-Trp-Lys-Thr-NH2; H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Phe-Phe-Phe-D-Trp-Lys-Thr-NH2; H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-THr-NH2; H-Cys-Phe-Tyr(l)-D-Trp-Lys-Thr-Phe-Cys-NH2; H-D-Phe-p-클로로-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2, H-D-Phe-p-NO2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2, H-D-β-Nal-p-클로로-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2, H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2, H-D-Phe-p-클로로-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2, H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-D-β-Nal-NH2; H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2; H-D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH; H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH; H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH; H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol; H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp*-Thr-NH2 (Lys* 과 Asp*사이에 형성된 아미드 브릿지); Ac-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (Et) 2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-L-hArg (Et) 2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2; Ac-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt; Ac-L-hArg (CH2-CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NHEt; Ac-hArg (CH3, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; H-hArg (헥실2)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt; Ac-D-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2; 프로피오닐-D-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys (iPr)-Thr-Cys-Thr-NH2; Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et) 2-NH2; Ac-D-Lys (iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; Ac-D-hArg (CH2CF3) 2-D-hArg (CH2CF3) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH2; Ac-D-hArg (Et) 2-D-hArg (Et) 2-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2; c-Cys-Lys-Asn-4-CI-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH2; H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH2; H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-CI-Phe-NH2; H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Nal-NH2; H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H-펜타플루오로-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; Ac-D-β-Nal-Cys-펜타플루오로-Phe-D-Trp-Lys-Val-Cys-Thr-NH2; H-D-i-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-p-Nal-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2; H-D-, SNal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H-D-p-CI-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; Ac-D-p-CI-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H-D-Phe-Cys-p-Nal-D-Trp-Lys-Val-Cys-Thr-NH2; H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2; 시클로(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); 시클로(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); 시클로 (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe); 시클로(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe); 시클로(Pro-Tyr-D-Trp-Lys-Thr-Phe); 시클로(Pro-Phe-D-Trp-Lys-Thr-Phe); 시클로(Pro-Phe-L-Trp-Lys-Thr-Phe); 시클로(Pro-Phe-D-Trp (F)-Lys-Thr-Phe); 시클로(Pro-Phe-Trp (F)-Lys-Thr-Phe); 시클로(Pro-Phe-D-Trp-Lys-Ser-Phe); 시클로(Pro-Phe-D-Trp-Lys-Thr-p-CI-Phe); 시클로(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe); 시클로(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe); 시클로(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe); 시클로(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr); 시클로(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); 시클로(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe); 시클로(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); 시클로(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); 시클로 (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe); 시클로(Pro-Phe-D-Trp-4-Amphe-Thr-Phe); 시클로(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba); 시클로(Asn-Phe-D-Trp-Lys-Thr-Phe); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH (CH2) 4CO); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe->Ala); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH; 시클로(Phe-Phe-D-Trp-Lys-Thr-Phe); 시클로(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly); 시클로(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly); 시클로(Asn-Phe-Phe-D-Trp (F)-Lys-Thr-Phe-Gaba); 시클로(Asn-Phe-Phe-D-Trp(NO2)-Lys-Thr-Phe-Gaba); 시클로(Asn-Phe-Phe-Trp (Br)-Lys-Thr-Phe-Gaba); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe (l)-Gaba); 시클로(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr (But)-Gaba); 시클로(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH; 시클로(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH; 시클로(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH; 시클로(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH; 시클로(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba); 시클로 (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba); 시클로(Phe-Phe-D-Trp (5F)-Lys-Thr-Phe-Phe-Gaba); 시클로(Asn-Phe-Phe-D-Trp-Lys (Ac)-Thr-Phe-NH-(CH2) 3-CO); 시클로(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); 시클로(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); 시클로(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH2; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH2; H-Cys-Phe-Tyr (l)-D-Trp-Lys-Thr-Phe-Cys-NH2
유사체 합성방법은 상술한 특허 등 종래의 문헌에 널리 공지되어 있다. 예를 들어, H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2의 합성은 EP 0395417A1의 실시예 1에 개시된 프로토콜에 따라 달성할 수 있다. 마찬가지로, 치환 N-말단을 가진 유사체는 WO 88/02756, EP 0329295 및 US 5,240,561에 개시된 프로토콜에 따라 성공적으로 합성할 수 있다.
선형 SST 유사체의 바람직한 예로서, 다음을 포함한다: H-D-Phe-p-클로로-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; H-D-Phe-p-N02-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H-D-*Nal-p-클로로-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2; H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H-D-Phe-p-클로로-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; 및 H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-D-베타-Nal-NH2.
하나 이상의 화학적 부분, 예를 들어, 당 유도체, 모노-혹은 폴리-히드록시(C2-C12)알킬기, 모노-혹은 폴리-히드록시(C2-C12)아실기, 또는 피페라진 유도체 등은 SST 유사체, 예컨대 WO 88/02756, EP0329295 및 US 5,240,561에 개시된 내용을 참조하면, N-말단 아미노산에 부착될 수 있다.
본 발명에서 TM에 이용할 수 있는 SST 유사체의 또다른 예는 다음과 같다: D-Cpa-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Phe-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Phe-시클로[Cys-p-NH2-Phe-D-Trp-Lys-Val-Cys]-Thr-NH2; N-Me-D-Phe-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Phe-시클로[Cys-Tyr-D-Pal-Lys-Val-Cys]-Thr-NH2; Ac-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Phe-시클로 [Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-OH; ED-Phe-시클로[Cys-Nal-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Nal-시클로[Cys-Tyr-D-Nal-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-D-Cys]-Nal-NH2; D-Trp-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Nal-NH2; Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-D-Nal-NH2; (AcO-CH2)3-C-NH-CO-(CH2)2-CO-D-Nal-시클로(Cys-Tyr-D-Trp-Lys-Val-Cys]Thr-NH2; [3-O-(2,5,6-트리아세틸 아스코르빅)아세틸-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2; Phe-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2; 3-O-(아스코르빅)-부티릴-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; 3-O-(아스코르빈산)Ac-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Bpa-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Bpa-NH2; Tris-Suc-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; D-Dpa-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH2; D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Dpa-NH2; Ac-D-Nal-시클로[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; 시클로-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2; NmeCpa-cyclo (DCys-3-Pal-DTrp-Lys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(NMeDCys-3-Pal-DTrp-Lys-Thr-Cys)-2-Nal-NHMe; Cpa-시클로(DCys-NMe3-Pal-DTrp-Lys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-NMeDTrp-Lys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-Lys-NMeThr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-Lys-Thr-NMeCys)-2-Nal-NH2; Cpa-시클로 (DCys-3-Pal-DTrp-Lys-Thr-Cys)-Nme2-Nal-NH2; Cpa-시클로(NMeDCys-3-Pal-DTrp-Lys-Thr-Cys)-Dip-NHMe; Cpa-시클로(DCys-3-Pal-NMeDTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-Tyr-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Tfm-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; Nal-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; 3-Pal-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; NmeCpa-시클로(DCys-3-Pal-DTrp-Lys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-NMeDTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-Tyr-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; Nal-시클로 (DCys-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; 또는 3-Pal-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; NmeCpa-시클로(DCys-3-Pal-DTrp-Lys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-3-Pal-NMeDTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로 (DCys-Tyr-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; 또는 Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-DTrp-NH2; Cpa-시클로(DCys-3-Pal-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; Cpa-시클로(DCys-Tyr-DTrp-NMeLys-Thr-Cys)-2-Nal-NH2; 메틸프로피온산-Tyr-D-Trp-ys-Val-Cys-Thr-NH2; 메틸프로피온산-Tyr-D-Trp-ys-Val-Cys-Phe-NH2; 메틸프로피온산-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH2; 메틸프로피온산-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2; D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2; D-Phe-Phe-Tyr-D-Trp-Lys-val-Phe-Thr-NH2; D-Phe-p-클로로-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; 또는 D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-β-D-Nal-NH2; H2-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[D-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[Cys-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH2, 또는 H2-c[Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[Cys-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[D-Cys-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[Cys-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[D-Cys-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[D-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[Cys-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[Cys-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys]-NH2, or H2-c[D-Cys-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[Cys-Asn-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c [D-Cys-Asn-Phe-Trp-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c [Cys-Asn-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[D-Cys-Asn-Phe-His-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c[ Cys-Asn-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Asn-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[Cys-Asn-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[D-Cys-Asn-Phe-Trp-D-Trp-Lys-Ser-Phe-Cys ]-NH2, H2-c [Cys-Asn-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c [D-Cys-Asn-Phe-His-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c [Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c [D-Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys]-NH2, H2-c [Cys-Asn-Phe-Tyr(I)-D-rp-Lys-Ser-Phe-Cys]-NH2, H2-c [D-Cys-Asn-Phe-Tyr(I)-D-Trp-Lys-Ser-Phe-Cys]-NH2, H2-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2; Ac-D-Phe-Tyr-시클로(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH2; Nal-Tyr-시클로(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2; Nal-Tyr-시클로(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; D-Dip-Tyr-시클로(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Dip-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Nal-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Dip-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2; Nal-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2; 시클로(D-Phe-Tyr-cyclo(D-Cys-D-Trp-Lys-Cys)-Abu-Thr); Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH2; (G(z))aeg-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-β-Ala-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH2; Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Nle-Phe-NH2; Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-Nle-NH2; Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-Phe-NH2; Cpa-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Gaba-NH2; Cpa-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Tyr-NH2; Pip-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-NH2; Pip-Phe-c(Cys-D-Trp-Lys-Cys)-Gaba-NH2; or Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-NH2; Phe-시클로(Cys-D-Trp-Lys-Cys)-Thr-NH2; Phe-Tyr-시클로(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH2; Ac-D-Phe-Tyr-시클로(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH2; Nal-Tyr-시클로(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2; Nal-Tyr-시클로(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Dip-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Nal-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2; Dip-Tyr-시클로 (D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2; Nal-Tyr-시클로(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH2, Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH2; (G(z))aeg-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; D-Cpa-시클로(Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Cpa-시클로(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-β-Ala-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Aic-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH2; (T)aeg-시클로(D-Cys-D-Trp-Lys-D-Cys)-(A)aeg-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-A4c-Nal-NH2; Cpa-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Nal-NH2; Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Nal-NH2; Pro-Phe-시클로(Cys-D-Trp-Lys-D-Cys)-Val-NH2; Pro-Phe-시클로(D-Cys-D-Trp-Lys-Cys)-Val-NH2; Pip-4-NO2-Phe-시클로(D-cys-D-Trp-Lys-D-Cys)-Nle-NH2; (G)aeg-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Thr(Bzl)-(C)aeg-NH2; or (C)aeg-Pal-시클로(D-Cys-D-Trp-Lys-D-Cys)-Thr (Bzl)-(G)aeg-NH2; Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-Phe-시클로(Cys-Tyr-D-Trp-Lys-Cys)-Thr-NH2, D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Ac-D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-4-NO2-Phe-Pal-시클로(D-Cys-Phe (4-O-Bzl)-D-Trp-Lys-Cys)-Tyr-NH2; Cpa-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; 4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; D-Nal-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; Pro-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; Cpa-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Nal-NH2; Ser(Bzl)-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (A)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (G)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-4-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Phe-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr (Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Ser(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Phe(4-O-Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-A5c-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Abu-Tyr-NH2; D-Cpa-시클로(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (C)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; D-Cpa-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(Pen-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Trp-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Phe-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Orn-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-hLys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-lamp-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Cha(4-am)-D-Cys) Thr (Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)-Ser(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-D-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys) Thr (Bzl)-Trp-NH2; (T) aeg-c(D-Cys-Pal-D-Trp-Lys-D-Pen)Thr(Bzl)-Tyr-NH2; (C)aeg-c(D-Cys-Phe-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; Ina-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; Mnf-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; Inp-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-thr(Bzl)-Tyr-NH2; Nua-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-Pal-c(D-Cys-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-Pal-c(D-Cys-D-Trp-Lys-D-Cys)Tyr(Bzl)-Thr-NH2; (C)aeg-Phe-c(D-Cys-D-Trp-Lys-D-Cys) Thr(Bzl)-Tyr-NH2; or (T)aeg-D-Trp-c(D-Cys-Pal-Lys-D-Cys)Thr(Bzl)-Leu-NH2; Hca-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Ac-Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Ac-D-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Ac-D-Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-Nal-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-Phe-시클로(Cys-Tyr-D-Trp-Lys-Cys)-Thr-NH2; D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; Ac-D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH2; D-4-NO2-Phe-Pal-시클로(D-Cys-Phe(4-O-Bzl)-D-Trp-Lys-Cys)-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; Cpa-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-NH2; D-4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr (Bzl)-Tyr-NH2; D-4-NO2-Phe-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; 4-NO2-Phe-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; D-Nal-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr (Bzl)-Tyr-NH2; Pro-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; Cpa-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Nal-NH2; Ser(Bzl)-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (C)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; Aic-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (C(z))aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (A(z))aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (A)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (G)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-4-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr (Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Phe-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Ser(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Phe(4-O-Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-A5c-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-Cys)-Abu-Tyr-NH2; D-Cpa-시클로(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-p-Me-Phe-NH2; Ac-(T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Nal-NH2; D-Cpa-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Nal-NH2; (A)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (C)aeg-시클로(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (C)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; D-Cpa-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(Pen-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Trp-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Phe-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Orn-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-hLys-D-Cys)Thr(Bzl)-Tyr-NH2, (T)aeg-c(D-Cys-Pal-D-Trp-lamp-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Cha(4-am)-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)-Ser(Bzl)-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr (Bzl)-D-Tyr-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Trp-NH2; (T)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Pen)Thr(Bzl)-Tyr-NH2; (C)aeg-c(D-Cys-Phe-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; Ina-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; Mnf-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; Inp-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; Nua-c(D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH2; (T)aeg-Pal-c(D-Cys-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; (T)aeg-Pal-c(D-Cys-D-Trp-Lys-D-Cys)Tyr(Bzl)-Thr-NH2; (C)aeg-Phe-c(D-Cys-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH2; 또는 (T)aeg-D-Trp-c(D-Cys-Pal-Lys-D-Cys)Thr(Bzl)-Leu-NH2; 시클로(Trp-D-Trp-Lys-Phe(4-O-Bzl)-Phe-(T)aeg); 시클로(Trp-D-Trp-Lys-Pal-Phe-(T)aeg); 시클로(Phe-Phe-D-Trp-Lys-Thr-(T)aeg); 또는 H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (또는 란레오티드라고도 함); 시클로(Pro-Phe-D-Trp-Lys-Thr-Phe), 시클로(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); D-베타-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; D-Phe-Cys-Tyr-D-Trp-Lys-α-아미노부티르산-Cys-Thr-NH2; 펜타플루오로-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 ; N-Ac-D-베타-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;D-베타-Nal~Cys-펜타플루오로-Phe-D-Trp-Lys-Val-Cys-Thr-NH2; D-/3-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; D-Phe-Cys-/3-Nal-D-Trp-Lys-Val-Cys-Thr-NH2; D-베타-Nal-Cys-Tyr-D-Trp-Lys-α-아미노부티르산-Cys-Thr-NH2; D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-α-아미노부티르산-Cys-Thr-NH2; 아세틸-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-α-아미노부티르산-Cys-Thr-NH2; 시클로(Pro-Phe-D-Trp-Lys-Thr-Phe); 시클로(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); D-베타-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2; D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol); D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)-(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)-(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)-(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)-(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-0-Nal-D-Cys-Pal-D-Trp-Lys-Val-Lys-Thr-NH2; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(CH3CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-beta-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-beta-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; H(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(CH3CO)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H2-Phe-D-Cys-Pal-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H2-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Pen-베타-Nal-NH2; H2-Phe-D-Pen-Pal-D-Trp-Lys-Thr-Pen-Thr-NH2; H2-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH2; H2-F5-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-F5-Phe-NH2; H2-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-m-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-m-F-Phe-NH2 H2-o-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-o-F-Phe-NH2; H2-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-F-Phe-NH2; H2-F5-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-F5-Phe-NH2; H2-F5-Phe-D-Cys-2-Pal-D-Trp-Lys-Val-Cys-F5-Phe-NH2; H2-베타-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-D-Dip-NH2; H2-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH2; H2-베타-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-Trp-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Ile-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Gly-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Ala-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Leu-Cys-베타-Nal-NH2; H2-Bip-D-Cys-Tyr-D-Trp-Lys-Ile-Cys-Bip-NH2; H2-p-F-Phe-D-Cys-His-D-Trp Lys-Val-Cys-p-F-Phe-NH2; H2-Npa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Tyr-NH2; H2-m-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-m-F-Phe-NH2; H2-o-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-o-F-Phe-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH2; H2-Cpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Cpa-NH2; H2-Igl-D-Cys-Pal-D-Trp-Lys-Val-Cys-Igl-NH2; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-Dip-NH2; H2-베타-Nal-D-Cys-3-I-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-p-CN-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-CN-Phe-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Dip-NH2; H2-베타-Nal-D-Cys-Bta-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-Bpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Bpa-NH2; H2-Iph-D-Cys-Pal-D-Trp-Lys-Val-Cys-Iph-NH2; H2-Trp-D-Cys-Pal-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH2; H2-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Cha-Cys-p-Cl-Phe-NH2; H2-p-Cl-Phe-D-Cys-Tr(I)-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH2; H2-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-p-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-p-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; H2-p-N02-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-beta-Nal-NH2; H2-p-N02-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-p-NO2-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-p-NO2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Tyr-NH2; H2-p-NO2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-p-NO2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-P-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-베타-Nal-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr(Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH2; H2-D-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H2-D-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; H2-D-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-D-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; H2-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; H2-D-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H2-D-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H2-D-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-베타-Nal-NH2; H2-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH2; H2-D-Bip-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-D-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; H2-D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-베타-Nal-NH2; H2-D-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH2; p-N02-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH2; p-N02-D-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-p-NO2-P-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-p-NO2-P-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH2; (H) (5-페닐프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(3-페닐프로피오닐)-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(3-페닐프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(3-페닐프로피오닐)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(3-페닐프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(3-페닐프로피오닐)-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(3-페닐프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(3-페닐프로피오닐)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(3-[2-나프닐]프로피오닐)-D-Cys-Pal-D-Trp-Lys-Val-Cys-베타-Nal-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-베타-Nal-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(3-[2-나프틸]프로피오닐)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2; (H)(3-[p-히드록시페닐])-D-Cys-Tyr-D-Trp-Lys-Val-Cys-베타-Nal-NH2;
(H)(3-나프틸]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; (H)(3-나프닐]프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; (H)(3-페닐일프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-베타-Nal-NH2; 또는 (H)(3-페닐일프로피오닐)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-al-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드옥시에틸)-1-피페리진에탄술포닐) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드옥시메틸)-3-히드록시)프로필아미드; H(CH3CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸-피페리진에탄술포닐) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(CH3CO)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-베타-Nal-D-ys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(CH3CO)-베타-Nal-D-Cys-Tyr-P-Trp-Lys-Vai-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-D-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(CH,CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(CH,CO)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; H2-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(CH3CO)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-P-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(CH3CO)Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프닐)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1l-피페리진에탄술포닐)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-나프틸)에틸아미드; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프닐)에틸아미드; (H)(CH3CO)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-P-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(CH3CO)Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)Phe-P-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-나프틸)에틸아미드; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-나프틸)에틸아미드; H2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-나프틸)에틸아미드; H2-베타-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; 또는 H2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R,3R-(2-히드록시메틸)-3-히드록시)프로필아미드; H2-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; H2-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H2-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H2-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H2-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2; H2-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라진에탄술포닐)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; H2-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(CH3CO)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2; (H)(4-(2-히드록시에틸)-1-피페라진에탄술포닐)-베타-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2; H2-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2; (H)(CH3CO)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페라지닐아세틸)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2; (H)(4-(2-히드록시에틸)-1-피페리진에탄술포닐)-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2; H2-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2-; 또는 H2-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H2-D-베타-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH2; H2-D-베타-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2; H2-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; H2-D-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2; 또는 H2-D-베타-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-베타-Nal-NH2.
GHRH 펩티드 유사체는 1990년대로 거슬러 올라가면 '표준 길항제' [Ac-Tyr', D-Arg2]hGH-RH (1-29)Nha를 포함한다. 미국특허 제4,659,693호 (본원에 참고로서 수록)는 N,N'-디알킬-오메가-구아니디노 알파-아미노아실 잔기가 GH-RH(1-29) 서열의 제2 위치에 존재하는 GH-RH 길항제형 유사체에 대해 개시한다. 다음의 문헌을 본원에 참고로서 수록한다. WO 91/16923에 따르면, hGH-RH 변형 방법은: Tyr1, Ala2 또는 Asp3를 이들의 D-이성체로 대체하고; Asn8을 L-혹은 D-Ser, D-Arg, Asn, Thr, Gln 혹은 D-Lys로 대체하며; Ser9를 Ala로 대체하여 해당 영역의 양쪽친화성을 향상시키고; 또한 Goy's를 Ala 이나 Aib로 대체하는 단계를 포함한다. 미국특허 제5,084,555호는 R9와 R10 잔기 사이에 유사펩티드 결합 (즉, [CH2-NH] 결합으로 환원된 펩티드 결합)이 존재하는 유사체 [Se-psi [CH2-NH]-TyrI°lhGH-RH (1-29)를 개시한다. 또한 미국특허 제5,550,212호, 제5,942,489호 및 제6,057,422호는 GH-RH (1-29) NH2의 N-말단에서 각종 아미노산을 방향족 혹은 비극성 산으로 대체 및 아실화 처리하여 제조된 hGH-RH(1-29) NH2 유사체에 대해 기술한다. 미국특허 제5,942,489호 및 제6,057,422호에 기술된 길항제의 종양 억제 특성은, 실험용 인체 암 모델의 이종이식편을 심은 누드 생쥐를 이용하여 입증한 것이다. 구체적인 예를 들면 다음과 같다: [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Amp9, Tyr (Me010, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl)6, Amp9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, His9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl)6, Amp9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [HOOc(CH2) 8CO-Tyr1, D-Arg2, Phe (pCl) 6, Amp9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [HOOc(CH2) 2CO-Tyr1, D-Arg2, Phe (pCi) 6, Amp9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl)6, Amp9, Tyr (Me)10, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Cit8, Amp9, Tyr (Me)10, His", Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [1-nac-Tyr1, D-Arg2, Phe (pCl) 6, Cit8, Amp9, Tyr (Me)10, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Cit8, Amp9, Tyr (Me)10, His", Abu'5, Nle27, D-Arg28, Har'] hGH-RH (1-29) NH2; [HOOc(CH2) 12CO-Tyr', D-Arg2, Phe (pCl) 6, Cit8, Amp9, Tyr (Me)10, His", Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29)NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl)6, Cit8, Amp9, Tyr (Me)10, His11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Cit8, His9, Tyr (Et010, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl) 6, Alpe, His9, Tyr (Et)10, His11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [HOOc(CH2) 8CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, His9, Tyr(Et)10, His11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [HOOC(CH2)12CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, His9, Tyr(Et)10, His11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl)6, Ala8, His9, Tyr (Et)10, His11, Abu15, His20, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl)6, Ala8, Amp9, Tyr (Et)10, His11, Abu15, His20, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [HOOc(CH2)1 2CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Tyr (Et)10, His11, Abu15, His20, Nle27, D-Arg28, Har2lhGH-RH' (1-29) NH2; [HOOC(CH2)12CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, Amp9, Tyr(Et)10, His11, Abu15, His20, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [1-Nac-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Tyr (Et)10, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCI) 6, His9, Tyr (Et)'0, His", Abu'5, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl)6, Ala8, His9, Cit15, Nle27, D-Arg28, har29]hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, His9, tyr(Et)10, His11, His15, His20, Nle27, D-Arg28 Har29]hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Ala8, His9, Tyr (Et)10, His11, Orn12, Abu15, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Alas, His9, Tyr (Et)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl)6, Ala8, His9, Tyr (Et)", His", Abu", Nie 2', D-Arg2, Har29]hGH-RH (1-29) NHEt; [CH3 (CH2) 8CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Tyr (Et)10, His11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [CH3 (CH2) 10CO-Tyr1, D-Arg2 Phe (pCI) 6 Ala8, His9, Tyr(Et)10, His11, Abu15, Nle27, D-Arg28 Har29] hGH-RH (1-29) NHEt; [Hca-Tyr1, D-Arg2, Phe(pCl)6, Ala8, His9, Tyr(Et)10, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NHEt; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Ala8, His9, Tyr (Et)10, His11, Abu15, nle27, D-Arg28, Har29] hGH-RH (1-29)NHMe; [HOOc(CH2) 12CO-Tyr', D-Arg2, Phe (pCl) 6, Alas, His9, Tyr (Et)10, His11, Orn12, Abu15, His20, Orn21, Nle27 D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe Cl)6, Ala8, Amp9, Tyr(Et)10, His11, Orn12, Abu15, His20, Orn21 Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3(CH2)6CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Dip10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Ala8, His9, Phe (pNO2)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3(CH2)6CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, His9, Tyr(Et)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [HOOC 9CH2)12CO-Tyr1, D-Arg2, Phe (pCl) 6, Alas, Amp9, Tyr (Et)10, His", Orn, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [HOOc(CH2) 2CO-Tyr1, D-Arg2 Phe (pCl) 6, Ala8, His9, Dip'0, His", Orn12, Abu'5, His, Orn21, Nie D-Arg28, Har29]hGH-RH (1-29) NH2; [HOOC(CH2)12CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Phe (pNO2)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [HOOc(CH2) 12CO-Tyr', D-Arg2, Phe (pCl) 6, Alas, His9, Tyr (Et)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [CH3(CH2)6CO-Tyr1, D-Arg2, Phe (pCI) 6, Ala8, Amp9, Dip10, His11, Orn12, Abu15, His20, Orn21, Nle27, d-Arg28, Har29]hGH-RH (1-29) NH2; [CH3(CH2)6CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, Amp9, Phe(pNO2)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, har29]hGH-RH(1-29)NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe(pCl)6, Ala8, Amp9, Tyr(Et)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29]hGH-RH(1-29) NHEt; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, His9, Dip10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29]hGH-RH (1-29) NHEt; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl) 6, Aia8, His9, Phe (pN02)10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [HOOC(CH2) 12CO-Tyr', D-Arg2, Phe (pCl)6, Ala8, Amp9, Dip10, His", Orn12, Abu15, His20, Orn21, Nie27 D-Arg Har29] hGH-RH (1-29) NH2; [HOOC(CH2)12CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, Amp9, Phe (pN02) 10, His11, Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala', Amp9 Dip'0, His", Orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29]hGH-RH (1-29) NHEt; [CH3 (CH2) 6CO-Tyr', D-Arg2, Phe (pCl) 6, Ala8, Amp9, Phe (pNO2)10, His11, orn12, Abu15, His20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [HOOc(CH2) 12CO-Tyr1, D-Arg2, Phe (pCl) 6, Ala8, Amp9, Dip10, His11, Orn12, Abu15, his20, Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [HOOC(CH2)1 2CO-Tyr1, D-Arg2, Phe (pCl) 6, Alas, Amp9, Phe (pNO2)10, His", Orn12, Abu15, His20 Orn21, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [CH3 (CH2) 4CO-Tyr1, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [HOOC(CH2) 4CO-Tyr', D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [CH3 (CH2) 6CO-Tyr1, D-Arg2, Phe (pCl) 6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [HOOC(CH2)6CO-Tyr1, D-Arg2, Phe(pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3(CH2)8CO-Tyr1, D-Arg2, Phe (pCI) 6, Arg9, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [HOOC(CH2)8CO-Tyr1, D-Arg2, Phe(pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3 (CH2)1 0CO-Tyr1, D-Arg2 Phe Cl)6, Arg9, Abu15, Nle27, D-Arg26, Har29]hGH-RH(1-29)NH2; [HOOC(CH2) 0CO-Tyr1, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [CH3 (CH2) 12CO-Tyr', D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [HOOC(CH2) i2CO-Tyr\ D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [CH3 (CH2) 4CO-Tyr1 D-Arg2, Phe (pCl) 6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [HOOC(CH2) 4CO-Tyr1, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [CH3 (CH2) CO-Tyr1, D-Arg2, Phe(pCl)6, Arg9, Abu15, Nle27, Har28, D-Arg29]hGH-RH(1-29)NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Arg9, Abu'5, Nle27, Har28, D-Arg29] hGH-RH (1-29) NH2; [CH3 (CH2) 4CO-Phe0, D-Arg2, Phe (pCl) 6, Arg9, Abu15, Nle27, D-Arg28, har29] hGH-RH (1-29) NH2; [CH3 (CH2) 14CO-D-Phe0, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Arg0, D-Arg2, Phe (pCi) 6, Arg9, Abu'5, NLe27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-D-Arg0, D-Arg2, Phe (pCl) 6, Arg9, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyrl, D-Arg2, Phe (pCl) 6, Cite, Arg9 Abut5 Nie27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Cite, Cit9, Abu15, Nle27, D-Arg28, har29]hGH-RH(1-29)NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Cit8, Arg9, Abu'5, Nle27, Har28, D-Arg29]hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl)6, Cit8, Cit9, Abu15, Nle27, Har28, D-Arg29]hGH-RH (1-29) NH2; [HOOC(CH2) i2CO-Tyr\ D-Arg2, Phe (pCl)6, Cit8, Cit9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl) 6, D-Ala8, Arg9, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl) r3, Abu3, Arg9, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl)6, Cit9, Abu15, Nle27, Har28, D-Arg29]hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCI) 6, Arg9, Amp'0, Abu'5, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCI) 6, Har9, Amp10 Abu5, Nle27, D-Arg28, Har29 hGH-RH (1-29) NH2; PhAc-Tyr1, D-Arg2, Phe (pCI) 6 Arg9, His'0, Abu'5, Nle 27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Arg9, Cha10, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr', D-Arg2, Phe (pCl)6, Har9, Tpi10, Abu15, Nle27, D-Arg28, har29]hGH-RH (1-29) NH2; PhAc-Tyr1, D-Arg2, Phe(pCl)6, Har9, 2-Nal10, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Dip10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe(pCl)6, Har9, Phe (pNH2)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2 Phe (pCI) zu Har9, Trpt0, Abu15 Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr1, D-Arg2, Phe(pCl)6, Har9, Phe(pNO2)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl)6, Har9, 3-Pal10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyrl, D-Arg2, Phe (pCl) 6, Har9, Tyr (Et)0, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-His', D-Arg2, Tyr6, Har9, Bpa10, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr', D-Arg2, Phe (pCI) 6, Arg9, Har12, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [Hca-Tyr', D-Arg2, Phe (pCI) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NHEt; [PhAc-Tyr'D-Arg2, Phe (pCI) 6 Har9, Tyr(Me)10, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [Hca-Tyr1, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29[hGH-RH(1-29) NHEt; PhAc-Tyr1, D-Arg2 Phe Cl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29 NHEt; [PhAc-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Aib15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Orn12, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NHEt; [Hca-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Agm29]hGH-RH (1-29); [PhAc-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)'0, Abu15, Nle27, D-Arg28, Agm29]hGH-RH(1-29); [Hca-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Har30]hGH-RH(1-30) NH2; [Dat-Tyr1, D-Arg2, Phe (pCl)6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Har30]hGH-RH (1-30) NH2; [Ipa-Tyr1, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Har30]hGH-RH(1-30)NH2; [Hca-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Har30] hGH-RH (1-30) NHEt; [Hca-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me10), Abu15, Nle27, D-Arg28, D-Arg29, Har30]hGH-RH(1-30) NH2; [Hca-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, D-Arg30]hGH-RH(1-30) NH2; [Hca-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Agm30] hGH-RH (1-30); [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29, Agm30] hGH-RH (1-30); [PhAc-Tyr', D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, His11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc-Tyr1, D-Arg2, Phe(pCl)6, Har9, Tyr(Me)10, Har11, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2
[PhAc-Tyr1, D-Arg2, Phe(pCl)6, Har9, Tyr (Me)10, Amp11, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl)6, Har9, Tyr (Me)10, Cit", Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl)6, Har9, Tyr (Me)0, Abu15, His20, Nle, D-Arg28, Har29]hGH-RH(1-29) NH2; [PhAc-Tyr', D-Arg2, Phe(pCl)6, Har9, Tyr (Me)10, His", Abu15, His20, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc-Tyr1, D-Arg2, Phe (pCl) 6, Arg9, Cit15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [PhAc0, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [IndAc0, D-Arg2, Phe(pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [PhAc0, D-Arg2, Phe pCl) r, Har9, Tyr(Me)10, Abu15, Nle27, D-Arg28, Har29]hGH-RH (1-29) NH2; [PhAc0, D-Arg2, Phe(pCl)6, Arg9, Tyr(Me)10, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, His', D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29) NH2; [Nac0, His', D-Arg2, Phe (pCl) 6, Arg9, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, D-Arg2, Phe (pCl) 6 Arg9, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [IndAc0, D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, D-Arg2, Phe (pCl) 6, Har9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, D-Arg2, Phe (pCl) 6, Arg9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, His', D-Arg2, Phe (pCl)6, Arg9, Abu15, Nle27, D-Arg28, Har29]hGH-RH(1-29)NH2; [Nac0, His', D-Arg2, Phe(pCl)6, Arg9, Abu'5, Nle27, D-Arg28, Har29] hGH-RH (1-29) NH2; [PhAc0, D-Arg2, Phe(pCI)fi, Ala15, Nle27, Asp28]hGH-RH(1-28)Agm; [lbu0, D-Arg2, Phe(pCI)8 10, Abu15, Nle27]hGH-RH(1-28)Agm; [PhAc0, D-Arg2, Phe(pCI)6, Abu15, Nle7]hGH-RH(1-28)Agm; [PhAc0, D-Arg2, Phe(pCI)6, Ala15, Nle27]hGH-RH(1-29)-NH2; [PhA0, D-Arg2,Phe(pCI)6,Abu8,Ala15,Nle27]hGH-RH(1-29)NH2; [PhAc0, D-Arg2, Phe(pCl)6, Abu8 ,28, Ala15, Nle27]hGH-RH(1-29)-NH2; cyclo8 ,12[PhAc0, D-Arg2,Phe(pCI)6,Gluβ,Ala15,Nle27]hGH-RH(1-29)-NH2; cyclo17 , 21 [PhAc0, D-Arg2,Phe(pCI)6,Ser8,Ala15,Glu1 7,Nle27]hGH-RH(1-29)-NH2; cyclo8 ,12;21,25[PhAc0, D-Arg2,Phe(pCl)6, Glu8 ,25, Abu15, Nle27]hGH-RH(1-28)Agm; cyclo8,12;21,25[PhAc0, D-Arg2,D-Asp3,Phe(pClI)8,Glu8 ,25,D-Lys12,Ala16,Nle27]hGH-RH(1-29)-NH2; cyclo8 ,12;21,25[[PhAc0, D-Arg2, Phe(pCI)6, Glu8 ,25, D-Lys12, Ala15, Nle27] hGH-RH(1-29)-NH2. 그 밖의 GHRH 유사체의 구체적인 예가 WO 96/032126, WO 96/022782, WO 96/016707, WO 94/011397, WO 94/011396 등에 소개되어 있으며 이들 문헌을 본원에 참고로서 수록한다.
본 발명에서 사용하기 적합한 봄베신 유사체의 예로서, D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (코드명: BIM-26218), D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 (코드명: BIM-26187); D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-φ[CH2NH]-Phe-NH2 (코드명: BIM-26159), 및 D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-φ[CH2NH]-Cpa-NH2 (코드명: BIM-26189); D-Phe-Gln-Trp-Ala-Val-N-메틸-D-Ala-His-Leu-메틸에스테르, 및 D-Fg-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-메틸에스테르로 이루어진 TMs 을 포함한다.
봄베신 유사체는 구조적으로 동류인 자연발생의 펩티드류, 즉, 봄베신, 뉴로메딘 B, 뉴로메딘 C, 리토린 및 GRP 등으로부터 유래된 펩티드를 포함한다. 이들 자연발생 펩티드와 관련된 아미노산 서열은 다음과 같다: 봄베신 (마지막 10개의 아미노산): Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2; 뉴로메딘 B: Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2; 뉴로메딘 C: Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2; 리토린: pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Met-NH2; 인간 GRP (마지막 10개의 아미노산): Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2.
본 발명에 사용하기 적합한 유사체는 다음의 문헌에 소개된 것들을 포함한다: U.S. 특허출원 제502,438호 (1990년 3월 30일); U.S. 특허출원 제 397,169호 (1989년 8월 21일); U.S. 특허출원 제376,555호 (1989년 7월 7일); U.S. 특허출원 제394,727호 (1989년 8월 16일); U.S. 특허출원 제317,941호 (1989년 3월 2일); U.S. 특허출원 제282,328호 (1988년 12월 9일); U.S. 특허출원 제257,998호 (1988년 10월 14일), U.S. 특허출원 제248,771호 (1988년 9월 23일), U.S. 특허출원 제207,759호 (1988년 6월 16일), U.S. 특허출원 제204,171호 (1988년 6월 8일), U.S. 특허출원 제173,311호 (1988년 3월 25일), U.S. 특허출원 제100,571호 (1987년 9월 24일); 또한 U.S. 특허출원 제520,225호 (1990년 5월 9일), U.S. 특허출원 제440,039호 (1989년 11월 21일) 등으로서, 이들 문헌의 내용을 본원에 참고로서 수록한다. 또한 봄베신 유사체는 다음의 문헌에 소개되어 있다: Zachary et al., Proc. Nat. Aca. Sci. 82:7616 (1985); Heimbrook et al., "합성 펩티드: 생물학적 문제에 대한 해결방안", UCLA Symposium on Mol. and Cell. Biol. New Series, Vol. 86, ed. Tarn and Kaiser; Heinz-Erian et al., Am. J. Physiol. G439 (1986); Martinez et al., J. Med. Chem. 28:1874 (1985); Gargosky et al., Biochem. J. 247:427 (1987); Dubreuil et al. , Drug Design and Delivery, Vol 2:49, Harwood Academic Publishers, GB (1987); Heikkila et al., J. Biol. Chem. 262:16456 (1987); Caranikas et al. , J. Med. Chem. 25:1313 (1982); Saeed et al., Peptides 10:597 (1989); Rosell et al., Trends in Pharmacological Sciences 3:211 (1982); Lundberg et al., Proc. Nat. Aca. Sci. 80:1120, (1983); Engberg et al., Nature 293:222 (1984); Mizrahi et al., Euro. J. Pharma. 82:101 (1982); Leander et al., Nature 294:467 (1981); Woll et al., Biochem. Biophys. Res. Comm. 155:359 (1988); Rivier et al., Biochem. 17:1766 (1978); Cuttitta et al., Cancer Surveys 4:707 (1985); Aumelas et al., Int. J. Peptide Res. 30:596 (1987), 등으로서 이들 문헌의 내용을 본원에 참고로서 수록한다.
상술한 유사체를 WO 92/20363 및 EP 0737691 에 개시된 바와 같이 종래 기술에 따라 제조할 수 있다.
본 발명에서 사용하기에 적합한 또다른 봄베신 유사체는 다음과 같다: D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-jjsi-Tac-NH2; D-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-Łsi-Tac-NH2; D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-si-DMTac-NH2; Hca-Gln-Trp-Ala-Val-Gly-His-Leu-jβsi-Tac-NH2; D-Trp-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Leu-NH2; D-Trp-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Phe-NH2; D-Trp-Glu(MeNH)-Trp-Ala-Val-Gly-His-Leu-psi-Phe-NH2; D-Trp-Gin-Trp-Ala-Val-Gly-His-Leu-psi-Trp-NH2; D-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Leu-NH2; D-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Phe-NH2; D-Tpi-GIn-Trp-Ala-Val-Gly-His-Leu-psi-Trp-NH2; D-pGlu-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2.; D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2; D-Trp-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2; Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2; NH2CO-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2 and ACY-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2 (여기서 ACY 는 아세틸, 옥타노일 혹은 3-히드록시-2-나프토일); D-Tpi-Gln-Trp-Ala-Val-Gly His-Leu-psi-Tpi-NH2; D-Trp-Glu(MeO)-Trp-Ala-Val-Gly-His-Leu-psi-Tpi-NH2; D-Trp-Glu(MeNH)-Trp-Ala-VaI-Gly-His-Leu-psi-Tpi-NH2; D-Trp-His(Bz)-Trp-Ala-Val Gly-His-Leu-psi-Tpi-NH2; Phe-Glu-Trp-Ala-Val-Gly His-Leu-psi-Tpi-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Nal-Cys-Thr-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Nal-Cys-Nal-NH2; H2-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Nal-NH2; H2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Nal-NH2; H2-D-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Val-D-Cys-Nal-NH2; H2-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Phe-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Nal-Lys-Val-Cys-Nal-NH2; H2-D-Phe-Cys-Tyr-D-Trp-Lys-Nal-Cys-Thr-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Orn-Val-Cys-Nal-NH2; H2-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Nal-NH2; H2-D-Phe-Cys-Tyr-D-Trp-Lys(iPr)-Thr-Cys-Nal-NH2; H2-D-Phe-Cys-Tyr-D-Trp-Lys(diEt)-Thr-Cys-Nal-NH2 H2-D-Phe-Cys-Tyr-D-Trp-Lys-Ser-Cys-Thr-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Nal-NH2; H2-D-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Nal-NH2; or H2-D-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Nal-NH2; H2-D-Nal-Cys-Tyr-D-Trp-Dab-Val-Cys-Nal-NH2, H2-D-Nal-Cys-Tyr-D-Trp-Orn-Val-Cys-Nal-NH2, H2-D-Nal-Cys-Tyr-D-Trp-Arg-Val-Cys-Nal-NH2; pGlu-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, D-Cpa-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2, D-Cpa-Gln-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2, pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Met-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Leu-Nle-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Phe-Nle-NH2, D-Phe-Gln-Trp-Ala-Val-D-Ala-His-Phe-Nle-NH2, D-p-Cl-Phe-Gln-Trp-Ala-Val-Gly-His-Leuc[CH2NH]Phe-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-프로필아미드, Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Leu-NH2, D-Phe-Gln-Trp-Ala-Val-Gly-His-CHx-Ala-Leu-NH2, cyclo-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu, D-Cys-Asn-Trp-Ala-Val-Gly-His-Leu-Cys-NH2, 시클로-His-Trp-Ala-Val-Gly-His-Leu-Met, Cys-Trp-Ala-Val-Gly-His-Leu-Cys-NH2, 시클로-D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Met, 시클로-D-Phe-His-Trp-Ala-Val-Gly-His-Leu-Met, cyclo-Trp-Ala-Val-Gly-His-Leu-Met.
그밖의 또다른 봄베신 유사체는, WO 89/02897, WO 91/17181, WO 90/03980 및 WO 91/02746 등에 개시되어 있으며 이들 문헌을 본원에 참고로서 수록한다.
본 발명의 TM에 사용하기 적합한 그렐린 유사체의 예를 들면 다음과 같다: Tyr-DTrp-DLys-Trp-DPhe-NH2, Tyr-DTrp-Lys-Trp-DPhe-NH2, His-DTrp-DLys-Trp-DPhe-NH2, His-DTrp-DLys-Phe-DTrp-NH2, His-DTrp-DArg-Trp-DPhe-NH2, His-DTrp-DLys-Trp-DPhe-Lys-NH2, DesaminoTyr-DTrp-AIa-Trp-DPhe-NH2, DesaminoTyr-DTrp-DLys-Trp-DPhe-NH2, DeaminoTyr-DTrp-Ser-Trp-DPhe-Lys-NH2, DesaminoTyr-DTrp-Ser-Trp-DPhe-NH2, His-DTrp-DTrp-Phe-Met-NH2, Tyr-DTrp-DTrp-Phe-Phe-NH2, GlyΨ[CH2NH]-DβNal-Ala-Trp-DPhe-Lys-NH2, GlyΨ[CH2NH]-DbetaNaI-DLyS-TrP-DPhe-Lys-NH2, DAIa-DbetaNaI-DLys-DTrp-Phe-Lys-NH2, His-DbetaNaI-DLys-Trp-DPhe-Lys-NH2, AIa-His-DTrp-DLys-Trp-DPhe-Lys-NH2, AIaΨ[CH2NH]-DbetaNaI-AIa-Trp-DPhe-Lys-NH2, DbetaNaI-AIa-Trp-DPhe-AIa-NH2, DAIa-DcyclohexylAIa-AIa-Phe-DPhe-Nle-NH2, DcyclohexylAla-Ala-Phe-DTrp-Lys-NH2, DAla-DbetaAla-Thr-DThr-Lys-NH2, DcyclohexylAla-Ala-Trp-DPhe-NH2, DAIa-DbetaNaI-AIa-AIa-DAIa-Lys-NH2, DbetaNaI-Ala-Trp-DPhe-Leu-NH2, His-DTrp-Phe-Trp-DPhe-Lys-NH2, DAla-DbetaNal-DAla-DTrp-Phe-Lys-NH2, pAla-Trp-DAla-DTrp-Phe-NH2, His-Trp-DAla-DTrp-Phe-LysNH2, DLys-DβNal-Ala-Trp-DPhe-Lys-NH2, DAla-DbetaNal-DLys-DTrp-Phe-Lys-NH2, Tyr-DAla-Phe-Aib-NH2, Tyr-DAla-Sar-NMePhe-NH2, αβAbu-DTrp-DTrp-Ser-NH2, αβAbu-DTrp-DTrρ-Lys-NH2, αβAbu-DTrp-DTrρ-Orn-NH2, αAbu-DTrp-DTrp-Orn-NH2, DThr-Dα'Nal-DTrp-DPro-Arg-NH2, DAla-Ala-DAla-DTrp-Phe-Lys-NH2, AlaΨ[CH2NH]His-DTrp-Ala-Trp-DPhe-Lys-NH2, Lys-DHis-DTrp-Phe-NH2, γAbu-DTrp-DTrp-Orn-NH2, inip-Trp-Trp-Phe-NH2, Ac-DTrp-Phe-DTrp-Leu-NH2, Ac-DTrp-Phe-DTrp-Lys-NH2, Ac-DTrp-DTrp-Lys-NH2, DLys-Tyr-DTrp-DTrp-Phe-Lys-NH2, Ac-DbetaNal-Leu-Pro-NH2, pAla-Trp-DTrp-DTrp-Orn-NH2, DVaI-DαNal-DTrp-Phe-Arg-NH2, DLeu-DαNal-DTrp-Phe-Arg-NH2, CyclohexylAla-DαNal-DTrp-Phe-Arg-NH2, DTp-DαNal-DTrp-Phe-Arg-NH2, DAla-DαNal-DPro-Phe-Arg-NH2, Ac-DαNal-DTrp-Phe-Arg-NH2, DαNal-DTrp-Phe-Arg-NH2, His-DTrp-DTrp-Lys-NH2, Ac-DpNal-DTrp-NH2, αAib-DTrp-DcyclohexylAla-NH2, αAib-DTrp-DAla-cyclohexylAla-NH2, DAIa-DcyclohexylAIa-AIa-AIa-Phe-DPhe-NIe-NH2, DPhe-AIa-Phe-DPaI-NH2, DPhe-AIa-Phe-DPhe-Lys-NH2, DLys-Tyr-DTrp-DTrp-Phe-NH2, Ac-DLys-Tyr-DTrp-DTrp-Phe-NH2, Arg-DTrp-Leu-Tyr-Trp-Pro(cyclic Arg-Pro), Ac-DβNal-PicLys-ILys-DPhe-NH2, DPal-Phe-DTrp-Phe-Met-NH2, DPhe-Trp-DPhe-Phe-Met-NH2, DPal-Trp-DPhe-Phe-Met-NH2, pAla-Pal-DTrp-DTrp-Orn-NH2, αγAbu-Trp-DTrp-DTrp-Orn-NH2, βAla-Trp-DTrp-DTrp-Lys-NH2, γAbu-Trp-DTrp-DTrp-Orn-NH2, Ava-Trp-DTrp-DTrp-Orn-NH2, DLys-Tyr-DTrp-Ala-Trp-DPhe-NH2, His-DTrp-DArg-Trp-DPhe-NH2, <Glu-His-Trp-DSer-DArg-NH2, DPhe-DPhe-DTrp-Met-DLys-NH2, 0-(2-메틸알릴)벤조포논 옥심, (R)-2-아미노-3-(lH-인돌-3-일)-l-(4-페닐피페리딘-1-일)프로판-1-온, N-((R)-1-((R)-1-((S)-3-(lH-인돌-3-일)-1-옥소-1-(4-페닐리페리딘-1-일)프로판-2-일 아미노)-6-아미노-1-옥소헥산-2-일 아미노)-3-히드록시-1-옥소프로판-2-일)벤즈아미드, (S)-N-((S)-3-(1H-인돌-3-일)-1-옥소-1-(4-페닐피페리딘-1-일)프로판-2-일)-6-아세트아미도-2-((S)-2-아미노-3-(벤질옥시)프로판아미도)헥산아미드, (S)-N-((R)-3-(1H-인돌-3-일)-1-옥소-1-(4-페닐피페리딘-1-일)프로판-2-일)-2-((S)-2-아세트아미도-3-(벤질옥시)프로판아미도)-6-아미노헥산아미드, (R)-N-(3-(1H-인돌-3-일)-1-(4-(2-메톡시페닐)피페리딘-1-일)-1-옥소프로판-2-일)-4-아미노부탄아미드, (R)-N-(3-(1H-인돌-3-일)-1-(4-(2-메톡시페닐)피페리딘-1-일)-1-옥소프로판-2-일)-2-아미노-2-메틸프로판아미드, 메틸 3-(p-톨일카르바모일)-2-나프토에이트, 에틸 3-(4-(2-메톡시페닐)피페리딘-1-카르보닐)-2-나프토에이트, 3-(2-메톡시페닐아르바모일)-2-나프토에이트, (S)-2,4-디아미노-N-((R)-3-(나프탈렌-2-일메톡시)-1-옥소-1-(4-페닐피페리딘-1-일)프로판-2-일)부탄아미드, 나프탈렌-2,3-디일비스((4-(2-메톡시페닐)피페라진-1-일)메타논), (R)-2-아미노-N-(3-(벤지옥시)-1-옥소-1-(4-페닐피페라진-1-일)프로판-2-일)-2-메틸 프로판아미드, 또는 (R)-2-아미노-3-(벤질옥시)-1-(4-페닐피페라진-1-일)프로판-1-온 등이 있다.
본 발명의 TM에 사용하기 적합한 GnRH 유사체의 예는 EP171477, WO 96/033729, WO 92/022322, WO 92/013883 및 WO 91/05563 등에 개시된 것을 포함하며 이들 문헌을 본원에 참고로서 수록한다. 이의 구체적인 예를 다음과 같이 포함한다:
(NAcDQal1,DPtf2,DPAI3,cjsPzACAIa5,DPicLys6,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,cjsPzACAIa5,DNicLys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,Thr4,PicLys5,DPicLys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,PicLys5,DPicLys6,Thr7,ILys8,DAIa10)LHRH;
(NapDThr1,DpCIPhe2,DPal3, PicLys5,DPicLys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,NicLys5,DNicLys6,Thr7,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,Thr4NicLys5,DNicLys6,Thr7,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,PicLys5,D(PicSar)Lys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,D(PicSar)Lys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,PicLys5,D(6ANic)Lys6,ILys8,DAIa10)LHRH;
(NAcDNal1,DpCIPhe2,DPal3,PicLys5,D(6ANic)0rn6,ILys8,DAIa10)LHRH;
(NAcDQal1,DCpa2,DPal3,cisPzACAIa5,DPicLys6,NLeu7,ILys8,DAIa10)LHRH;
(NAcDNal1,DCpa2,DPal3 .DPicLys5,DAPhe(PicSar)β,ILys8,DAIal0)LHRH;
NAcDQal1,DCpa2,DPal3,PicLys5,DPal6,ILys8,DAIa10)LHRH;
(NAcDNal1,DCpa2,DPal3,PicLys5,DOrn(ACyp)6,ILys8,DAIa10)LHRH; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(시클로-펜틸)-Phe-Arg-Pro-D-Ala-NH2; N-아세틸-D-θ-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(시클로펜틸)-Phe-Lys(시클로펜틸)-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-(이소프로필)D-Lys-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(벤질)-Phe-Arg-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(Cl-벤질)-Phe-Arg-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(헵틸)-Phe-Arg-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Lys-(t-부틸메틸)-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Lys-(4-메틸-벤질)-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Lys-(벤질)-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-p-Cl-Phe-D-Trp-Ser-Tyr-D-p-NH2-Phe-Phe-(이소프로필)Lys-Pro-D-Ala-NH2; N-아세틸-D-베타-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(헵틸)-Phe-Lys-(헵틸)-Pro-D-Ala-NH2; N-아세틸-D-3-Nal-D-Phe-D-Phe-Ser-Tyr-D-Lys(1-부틸펜틸)-Phe-Lys(1-부틸펜틸)-Arg-Pro-D-Ala-NH2 등이 있다.
본 발명의 TM에 사용하기 적합한 우로텐신 유사체는 예를 들어, Cpa-c [D-Cys-Phe-Trp-Lys-Thr-Cys]-Val-NH2; 및 Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH 을 포함한다.
본 발명의 폴리펩티드는 클로스트리듐 신경독소의 기능성 HC 도메인이 결핍되어 있다. 따라서 이들 폴리펩티드는, 공지 문헌 (Shone et al . (1985) Eur. J. Biochem. 151, 75-82)에 개시된 바와 같은 결합 분석시험에 따르면, (클류스트리듐 HC 성분을 경유하여) 래트의 시냅토솜막에 결합할 수 없다. 바람직한 구현예에서, 폴리펩티드는 클로스트리듐 신경독소 홀로톡신의 마지막 50개의 C-말단 아미노산을 갖지 않는 것이 바람직하다. 또다른 구현예에서, 폴리펩티드는 클로스트리듐 신경독소 홀로톡신의 마지막 100개, 바람직하게는 마지막 150개, 더 바람직하게는 마지막 200개, 특히 바람직하게는 마지막 250개, 또한 가장 바람직하게는 마지막 300개의 C-말단 아미노산 잔기를 보유하지 않는다. 이와 별도로, HC 결합활성은 돌연변이에 의해 무효능화/감소될 수 있다- 예를 들어, 편의상 BoNT/A의 경우, 강글리오사이드 결합 포켓에 들어있는 1개 또는 2개의 아미노산 잔기 돌연변이를 변형시키면 (W1266을 L로 또한 Y1267을 F로) HC 영역이 수용체 결합기능을 잃게된다. A군 비-혈청형 클로스트리듐 펩티드 성분, 예컨대, 돌연변이 함유 보튤리늄 B 혹은 보틀리눔 E에 기초한 구조체에 유사체 돌연변이를 형성할 수 있다 (보틀리눔 B의 경우, W1262를 L로 또한 Y1263를 F로; 보틀리눔 E의 경우, W1224를 L로 또한 Y1225를 F로). 활성부위에 대한 돌연변이도 마찬가지로 HC 수용체 결합활성을 없앨 수 있으며, 예컨대, 보튤리늄 A형 독소의 Y1267S 및 이에 상응하는 클로스트리듐 신경독소의 잔기가 여기에 속한다. 이들 및 기타의 돌연변이는 공지 문헌, Rummel et al (2004) (Molecular Microbiol. 51:631-634)에 기술되어 있으며 이 문헌을 본원에 참고로서 수록한다.
또다른 구현예에서, 본 발명의 폴리펩티드는 클로스트륨 신경독소의 기능성 HC 도메인 및 이와 동등한 기능의 TM이 결핍되어 있다. 따라서, 상술한 폴리펩티드는 클로스트리듐 신경독소의 고유 결합기능이 없으며, 공지문헌 (Shone et al. (1985) Eur. J. Biochem. 151, 75-82)에 개시된 바와 같은 결합 분석시험에 따르면, (클로스트리듐 HC 성분이나 이와 동등한 기능의 TM을 통하여) 래트 시냅토솜막에 결합할 수 없다.
자연형 클로스트리듐 신경독소의 HC 펩티드는 약 400 내지 440개의 아미노산 잔기를 포함하고, 또한 기능적으로 구별되는 2개의 도메인, 즉, N-말단영역 (통상 HCN 펩티드나 도메인이라 함) 및 C-말단영역 (통상 HCC 펩티드나 도메인이라 함)으로 구성된다. 이들 도메인은 각각의 크기가 약 25 kDa 정도이다. 이와 같은 사실은 다음과 같은 공지 문헌에서 확인할 수 있으며 이들을 본원에 참고로서 수록한다: Umland Tc(1997) Nat. Struct. Biol. 4: 788-792; Herreros J (2000) Biochem. J. 347: 199-204; Halpern J (1993) J. Biol. Chem. 268: 15, pp. 11188-11192; Rummel A (2007) PNAS 104: 359-364; Lacey DB (1998) Nat. Struct. Biol. 5: 898-902; Knapp (1998) Am. Cryst. Assoc. Abstract Papers 25: 90; Swaminathan and Eswaramoorthy (2000) Nat. Struct. Biol. 7: 1751-1759; and Rummel A (2004) Mol. Microbiol. 51(3), 631-643. 또한, C-말단의 160개 내지 200개의 아미노산 잔기를 구성하는 C-말단영역(Hcc)은 이것의 자연 세포 수용체, 즉, 신경근육 접합부에 있는 신경 말단에 대한 클로스트리듐 신경독소의 결합에 대응할 수 있다. 이러한 사실 역시 상술한 문헌으로부터 확인할 수 있다. 그러므로 본원의 상세한 설명에 있어서, 클로스트리듐 중사슬에 기능성 중사슬 HC 펩티드 (또는 도메인)가 결핍된 탓에, 자연형 클로스트리듐 신경독소가 결합되어 있는 세포 표면 수용체에 중사슬이 결합할 수 없다는 것은 간단히 말하면 클로스트리듐 중사슬에 기능성 HCC가 존재하지 않는다는 뜻이다. 다시 말하면, HCC 펩티드 영역 전체 혹은 일부가 제거되었거나 아니면 변형되어 (예, 종래의 화학적 처리 혹은 단백질분해 처리에 따라) 신경근육 접합부에 있는 신경 말단에 대해 본래의 결합능력을 발휘하지 못한다.
그러므로 한 구현예에서, 본 발명의 크로스트리듐 HN 펩티드에는 클로스트리듐 신경독소의 C-말단 펩티드 부분(HCC)이 존재하지 않으며 따라서 자연형 클로스트리듐 신경독소의 HC 결합기능을 갖지 않는다. 예를 들어 한 구현예에서, C-말단 연장된 클로스트리듐 HN 펩티드는 클로스트리듐 신경독소 중사슬의 C-말단의 40개 아미노산 잔기, C-말단의 60개 아미노산 잔기, C-말단의 80개 아미노산 잔기, C-말단의 100개 아미노산 잔기, C-말단의 120개 아미노산 잔기, C-말단의 140개 아미노산 잔기, C-말단의 150개 아미노산 잔기 혹은 C-말단의 160개 아미노산 잔기를 보유하지 않는다. 또다른 구현예에서, 본 발명의 클로스트리듐 HN 펩티드는 클로스트리듐 신경독소의 전체 C-말단 펩티드 부분(HCC)이 결핍되어 있으며 따라서 자연형 클로스트리듐 신경독소의 HC 결합기능을 갖지 않는다. 예를 들어 한 구현예에서, 클로스트리듐 HN 펩티드는 클로스트리듐 신경독소 중사슬의 C-말단 165개 아미노산 잔기, C-말단의 170개 아미노산 잔기, C-말단의 175개 아미노산 잔기, C-말단의 180개 아미노산 잔기, C-말단의 185개 아미노산 잔기, C-말단의 190개 아미노산 잔기 혹은 C-말단의 195개 아미노산 잔기를 보유하지 않는다. 또다른 예로서, 본 발명의 클로스트리듐 HN 펩티드에는 다음으로 이루어진 군에서 선택된 클로스트리듐 HCC 기준서열이 결핍되어 있다:
보툴리눔 A형 신경독소 - 아미노산 잔기 (Y1111-L1296)
보툴리눔 B형 신경독소 - 아미노산 잔기 (Y1098-E1291)
보툴리눔 C형 신경독소 - 아미노산 잔기 (Y1112-E1291)
보툴리눔 D형 신경독소 - 아미노산 잔기 (Y1099-E1276)
보툴리눔 E형 신경독소 - 아미노산 잔기 (Y1086-K1252)
보툴리눔 F형 신경독소 - 아미노산 잔기 (Y1106-E1274)
보툴리눔 G형 신경독소 - 아미노산 잔기 (Y1106-E1297)
테타누스 신경독소 - 아미노산 잔기 (Y1128-D1315).
위와 같이 동정된 기준서열을 가이드로 하며, 혈청아형(sub-serotype)에 따라 소폭의 변화가 있을 수 있다.
본 발명의 프로테아제는 진핵세포에 함유된 세포외배출성 융합체의 하나 이상의 단백질을 절단할 수 있는 모든 비-세포독성 프로테아제를 포함한다.
본 발명의 프로테아제는 바람직하게는 박테리아형 프로테아제 (혹은 그의 절편)이다. 더욱 바람직하게, 이 박테리아형 프로테아제는 클로스트리듐이나 네이세리아 / 스트렙토코쿠스 (예, 클로스트리듐 L-사슬, 혹은 N. 고노로에아에 또는 S. 뉴모니아에로부터 유래된 네이세리아 IgA 프로테아제) 중에서 선택된다.
프로테아제 변이체가 여전히 소정의 프로테아제 활성을 나타낸다면, 본 발명은 이들 비-세포독성 프로테아제 변이체 (즉, 자연발생형 프로테아제 분자의 변이체)도 포함한다. 예를 들어, 변이체는 기준 프로테아제 서열에 대해 적어도 70%, 바람직하게는 적어도 80%, 더 바람직하게는 적어도 90%, 및 가장 바람직하게는 적어도 95%나 적어도 98%의 아미노산 서열 상동성을 나타낼 수 있다. 따라서, 상기의 변이체란 용어에는 개선된 (혹은 저하된) 엔도펩티다제 (펩티드내부 가수분해효소) 활성을 가진 비-세포독성 프로테아제도 포함되며- 특히 본 명세서에서는 높은 Kcat/Km을 갖는 BoNT/A 돌연변이체 Q161A, E54A 및 K165L 등을 말한다 (본원에 참고로서 수록된 문헌, Ahmed, S.A. (2008), Protein J. DOI 10.1007/s10930-007-9118-8 을 참조한다). 프로테아제에 있어서 절편이란, 기준 프로테아제에 있는 적어도 150개, 바람직하게는 적어도 200개, 더 바람직하게는 적어도 250개, 또한 가장 바람직하게는 적어도 300개의 아미노산 잔기를 가진 펩티드를 말한다. TM '절편' 성분(상기 참조)에 있어서, 본 발명의 프로테아제 '절편'은 기준서열을 기초로 하는 변이체의 절편도 포함한다.
본 발명의 프로테아제는 바람직하게 세린이나 금속단백질 분해효소의 활성을 나타낸다 (예, 엔도펩티다제 활성). 프로테아제는 바람직하게는, SNARE 단백질(예, SNAP-25, 시냅토브레빈/VAMP, 신탁신 등)에 특이적이다.
이제 신경독소의 프로테아제 도메인, 예를 들어, 박테리아성 신경독소의 프로테아제 도메인에 대해 구체적으로 설명한다. 따라서, 본 발명은 자연발생적인 신경독소 도메인뿐만 아니라 이러한 자연발생형 신경독소의 재조합 조제물의 용도도 포함한다.
전형적인 신경독소는 클로스트리듐에 의해 생성되며, 여기서 클로스트리듐 신경독소는 C. 테타니 (TeNT) 및 C. 보툴리눔 (BoNT) 혈청형 (A군 내지 G군 혈청형)에 의해 생성되는 신경독소를 지칭할뿐만 아니라, 이와 밀접한 관계가 있는 것으로서 C. 바라티 및 C. 부티리쿰에 의해 생성되는 BoNT-유사 신경독소도 포함한다. 상술한 약어를 본 명세서에서 일관되게 사용한다. 예를 들어, BoNT/A는 신경독소의 공급원이 BoNT (A군 혈청형)임을 나타낸다. 기타의 BoNT 혈청형에 대해서도 이에 상응하는 명칭을 부여한다.
BoNTs는 가장 강력한 독소로 알려져 있으며, 생쥐의 경우, 혈청형에 따라 중간치사량(LD50) 값이 0.5 내지 5ng/kg의 범위에 이른다. BoNTs는 위장관에 흡착 및 전신순환에 유입된 후, 콜린성 신경말단의 시냅스전 세포막에 결합하여 신경전달물질 아세틸콜린의 방출을 방해한다. BoNT/B, BoNT/D, BoNT/F 및 BoNT/G은 시냅토브레빈/소포체-결합 막단백질(VAMP)을 절단하고; BoNT/C, BoNT/A 및 BoNT/E는 크기가 25 kDa인 시냅토솜-결합 단백질(SNAP-25)을 절단하며; 또한 BoNT/C는 신탁신을 절단한다.
BoNTs 들은 공통의 구조를 공유하며, 이는 단일 디설파이드 결합에 의해 최고 50 kDa의 경사슬 (L-사슬)에 공유접합된 최고 100 kDa의 중사슬 (H-사슬)로 이루어진 최고 150 kDa의 2-사슬 단백질이다. H-사슬은 2개의 도메인으로 구성되며 이 각각의 도메인의 크기가 최고 50 kDa이다. C-말단 도메인(HC)은 고친화성 신경결합에 필요한 반면, N-말단 도메인(HN)은 막 전위에 수반된다. L-사슬은 기질 SNARE 단백질의 절단에 대응하는 아연의존성 금속단백 분해효소이다.
L-사슬 절편이란 신경독소의 L-사슬의 한 성분을 말하며, 금속단백 분해효소 활성을 나타내고, 또한 단백질 분해작용에 따라 세포형 세포외방출(exocytosis)에 수반되는 소포체 및/또는 혈장막 결합단백질을 절단할 수 있다. 적절한 프로테아제 (기준)서열의 예는 다음과 같다:
보툴리눔 A형 신경독소 -아미노산 잔기 (1-448)
보툴리눔 B형 신경독소 -아미노산 잔기 (1-440)
보툴리눔 C형 신경독소 -아미노산 잔기 (1-441)
보툴리눔 D형 신경독소 -아미노산 잔기 (1-445)
보툴리눔 E형 신경독소 -아미노산 잔기 (1-422)
보툴리눔 F형 신경독소 -아미노산 잔기 (1-439)
보툴리눔 G형 신경독소 -아미노산 잔기 (1-441)
테타누스 신경독소 -아미노산 잔기 (1-457)
IgA 프로테아제 -아미노산 잔기 (1-959)*
* Pohlner, J. et al. (1987). Nature 325, pp. 458-462, (본원에 참고로서 수록됨).
위와 같이 동정된 기준서열을 가이드로 하며, 혈청아형에 따라 소폭의 변화가 있을 수 있다. 예를 들어, US 2007/0166332 (본원에 참고로서 수록됨)는 다음과 같이 다소 상이한 클로스트리듐 서열을 개시한다:
보툴리눔 A형 신경독소 -아미노산 잔기 (M1-K448)
보툴리눔 B형 신경독소 -아미노산 잔기 (M1-K441)
보툴리눔 C형 신경독소 -아미노산 잔기 (M1-K449)
보툴리눔 D형 신경독소 -아미노산 잔기 (M1-R445)
보툴리눔 E형 신경독소 -아미노산 잔기 (M1-R422)
보툴리눔 F형 신경독소 -아미노산 잔기 (M1-K439)
보툴리눔 G형 신경독소 -아미노산 잔기 (M1-K446)
테타누스 신경독소 -아미노산 잔기 (M1-A457)
경사슬 절편이 특별히 신경전달물질 방출체의 코어 성분을 표적으로 삼아 전체 세포기전에 참여할 수 있고 그 결과로서 클로스트리듐 독소가 단백질 분해작용에 따라 기질을 절단할 수 있을 경우, 이러한 경사슬을 함유하는 각종 클로스트리듐 독소 절편을 본 발명에 효과적으로 사용할 수 있다. 클로스트리듐 독소의 경사슬은 약 420 내지 460개의 아미노산 길이로 이루어지며 효소 도메인을 보유한다. 연구 결과, 클로스트리듐 독소 경사슬의 전체 길이는 효소 도메인의 효소활성에 필요불가결한 것은 아님이 확인되었다. 비제한적인 예로서, BoNT/A 경사슬의 처음 8개의 아미노산은 효소활성에 필요치 않다. 또다른 비제한적인 예로서, TeNT 경사슬의 처음 8개의 아미노산은 효소활성에 필요치 않다. 마찬가지로, 경사슬의 카르복실기 말단은 활성작용에 필요하지 않다. 또한 비제한적인 예로서, 상기 BoNT/A 경사슬의 마지막 32개의 아미노산 (잔기 417-448)은 효소활성에 필요하지 않다. 또다른 비제한적이 예로서, TeNT 경사슬의 마지막 31개의 아미노산 (잔기 427-457)는 효소활성에 필요하지 않다. 그러므로 상기 구현예의 측면에 따르면, 예를 들어, 적어도 350개의 아미노산, 적어도 375개의 아미노산, 적어도 400개의 아미노산, 적어도 425개의 아미노산 및 적어도 450개의 아미노산으로 된 길이를 갖는 효소 도메인이 포함된 클로스트리듐 독소 경사슬을 제공할 수 있다. 상기 구현예의 또다른 측면에 따르면, 예를 들어, 최대 350개의 아미노산, 최대 375개의 아미노산, 최대 400개의 아미노산, 최대 425개의 아미노산 및 최대 450개의 아미노산으로 된 길이를 갖는 효소 도메인이 포함된 클로스트리듐 독소 경사슬을 제공할 수 있다.
본 발명의 비-세포독성 프로테아제 성분은 바람직하게 BoNT/A, BoNT/B 또는 BoNT/D 혈청형 L-사슬 (또는 이의 절편이나 변이체)를 포함한다.
본 발명의 폴리펩티드, 특히 폴리펩티드의 프로테아제 성분은 PEG화 될 수 있으며, 이 물질은 안정성 개선, 예를 들어, 프로테아제 성분의 지속적인 작용에 도움이 된다. PEG화 반응은 프로테아제가 BoNT/A, B 또는 C1 프로테아제일 때 특히 바람직하다. PEG화 반응은 프로테아제 성분의 N-말단에 PEG를 첨가하는 것을 포함한다. 예를 들어, 프로테아제의 N-말단은 서로 동일하거나 상이한 하나 이상의 아미노산 잔기(예, 시스테인)를 이용하여 연장할 수 있다. 상술한 하나 이상의 아미노산 잔기는 자신의 PEG 분자가 여기에 부착 (예, 공유결합)될 수도 있다. 이러한 기술의 예는 WO 2007/104567에 개시되어 있으며 이 문헌을 본원에 참고로서 수록한다.
전위 도메인은, 표적세포의 사이토졸 내에서 프로테아제 활성을 기능적 발현하도록, 프로테아제를 표적세포로 전위시킬 수 있는 분자다. 분자(예, 단백질이나 펩티드)가 본 발명에 따른 필수 전위 기능을 갖는지의 여부는 다양한 종래의 분석법중 어느 하나를 이용하여 확인할 수 있다.
예를들어, Shone C. (1987)는 시험분자를 이용하여 챌린지(유발시험)한 리포좀이 이용되는 체외 분석법에 대해 개시한다. 필수 전위 기능을 보유하고 있는지의 여부는 리포좀으로부터 K+ 및/또는 표지화된 NAD의 방출로 확인할 수 있으며, 이는 쉽게 관측된다 (Shoe C., (1987) Eur. J. Biochem; vol. 167(1): pp. 175-180 참조).
또다른 예는 Blaustein R. (1987)에 따른 것으로 이 문헌에서는 편평한 인지질 2중막을 이용한 간단한 체외 분석법을 개시한다. 즉, 시험분자를 이용하여 이 막을 챌린지하며 필수 전위 기능은 상기 막을 통한 컨덕턴스의 증가에 따라 확인된다 (Blaustein (1987) FEBS Letts; vol. 226, no. 1: pp. 115-120 참조).
막융합을 평가하고 또한 본 발명에서 이용하기에 적절한 전위 도메인을 정동할 수 있는 또다른 방법이 문헌상에 공지되어 있다 (Methods in Enzymology Vol 220 and 221, Membrane Fusion Techniques, Parts A and B, Academic Press 1993).
변이체 도메인이 필수 전위 활성을 나타낸다면 본 발명은 또한 이러한 변이체 전위 도메인도 포함할 수 있다. 예를 들어 변이체는, 기준 전위 도메인에 대해 적어도 70%, 바람직하게 적어도 80%, 더 바람직하게 적어도 80%, 가장 바람직하게 적어도 95% 혹은 적어도 98%의 아미노산 서열 상동성을 가질 수 있다. 전위 도메인에 관련하여 지칭하는 절편이란, 기준 전위 도메인의 적어도 20개, 바람직하게는 적어도 40개, 더 바람직하게는 적어도 80개, 또한 가장 바람직하게는 적어도 100개의 아미노산 잔기를 보유한 펩티드를 말한다. 클로스트리듐 전위 도메인의 경우, 절편은 기준 전위 도메인 (예, HN 도메인)의 적어도 100개, 바람직하게는 적어도 150개, 더 바람직하게는 적어도 200개, 및 가장 바람직하게는 적어도 250개의 아미노산 잔기를 갖는다. 'TM' 절편성분(상기 참조)에 있어서, 본 발명의 전위 '절편'은 기준서열에 기초한 변이체 전위 도메인의 절편도 포함한다.
전위 도메인은 바람직하게는 저 pH 조건하에 지질막에 이온투과 기공을 형성할 수 있는 것이 바람직하다. 바람직하게는, 엔도솜막 내에서 기공을 형성할 수 있는 단백질 분자의 상기 부분만 사용하는 것으로 확인되었다.
전위 도메인은 항균성 단백질원 특히, 박테리아성이나 바이러스성 단백질원으로부터 수득할 수 있다. 그러므로 본 발명의 한 구현예에서, 전위 도메인은 박테리아 독소나 바이러스 단백질 같은 효소의 전위 도메인이다.
박테리아 독소 분자의 도메인에서 상기와 같은 기공을 형성할 수 있음은 널리 공지되어 있다. 또한 바이러스 발현된 막융합단백질의 전위 도메인에서 이러한 기공을 형성할 수 있음도 공지되어 있다. 이러한 도메인을 본 발명에서 사용할 수 있다.
전위 도메인은, HN 도메인 (혹은 이의 기능적 성분)처럼, 클로스트리듐에서 기원한다. HN 는 H-사슬 중 아미노-말단 하프(절반)과 거의 동등한 클로스트리듐 신경독소의 H-사슬의 일부나 혹은 그의 절편, 혹은 (손상되지 않은) 원형의 H-사슬에 존재하는 절편에 상응하는 도메인을 말한다. H-사슬에는, H-사슬의 HC 성분이 보유한 자연결합 기능이 결핍되어 있다. 이 경우, HC 아미노산 서열을 제거함으로써 (DNA 합성 수준, 혹은 뉴클레아제나 프로테아제 처리에 따른 합성후 수준으로) 상기의 HC 기능을 없앨 수 있다. 이와 또다르게, 화학적 혹은 생물학적 처리에 따라 HC 기능을 비활성화 할 수도 있다. 따라서 H-사슬은 클로스트리듐 신경독소(즉, 홀로톡신)가 결합될 표적세포의 결합부위에 결합할 수 없게 된다.
적절한 (기준) 전위 도메인의 예로서 다음의 것들을 포함한다:
보툴리눔 A형 신경독소 -아미노산 잔기 (449-871)
보툴리눔 B형 신경독소 -아미노산 잔기 (441-858)
보툴리눔 C형 신경독소 -아미노산 잔기 (442-866)
보툴리눔 D형 신경독소 -아미노산 잔기 (446-862)
보툴리눔 E형 신경독소 -아미노산 잔기 (423-845)
보툴리눔 F형 신경독소 -아미노산 잔기 (440-864)
보툴리눔 G형 신경독소 -아미노산 잔기 (442-863)
테타누스 신경독소 -아미노산 잔기 (458-879)
위와 같이 동정된 기준서열을 가이드로 하며, 혈청아형에 따라 소폭의 변화가 있을 수 있다. 예를 들어, US 2007/0166332 (본원에 참고로서 수록됨)는 다음과 같이 다소 상이한 클로스트리듐 서열을 개시한다:
보툴리눔 A형 신경독소 -아미노산 잔기 (A449-K871)
보툴리눔 B형 신경독소 -아미노산 잔기 (A442-S858)
보툴리눔 C형 신경독소 -아미노산 잔기 (T450-N866)
보툴리눔 D형 신경독소 -아미노산 잔기 (D446-N862)
보툴리눔 E형 신경독소 -아미노산 잔기 (K423-K845)
보툴리눔 F형 신경독소 -아미노산 잔기 (A440-K864)
보툴리눔 G형 신경독소 -아미노산 잔기 (S447-S863)
테타누스 신경독소 -아미노산 잔기 (S458-V879)
전위 도메인을 포함하는 다양한 클로스트리듐 독소 HN 영역을 본 발명에 이용할 수 있다. 단 이것은, 활성 절편이 표적세포의 사이토졸의 세포내 소포체로부터 비-세포독성 프로테아제(예, 클로스트리듐 L-사슬)의 외부 방출을 촉진하여 전반적인 세포기전에 참여할 수 있고 그 결과로 클로스트리듐 독소가 단백질 분해작용에 따라 기질을 절단할 수 있다는 것을 전제로 한다. 클로스트리듐 독소의 중사슬에서 HN 영역은 약 410 내지 430개 아미노산 길이로 이루어지고 또한 전위 도메인을 갖는다. 연구 결과, 클로스트리듐 독소 중사슬의 HN 영역의 전체 길이는 전위 도메인의 전위 작용에 필요불가결한 것은 아님이 확인되었다. 상기 구현예는, 예를 들어, 적어도 350개의 아미노산, 적어도 375개의 아미노산, 적어도 400개의 아미노산 및 적어도 425개의 아미노산으로 된 길이를 갖는 전위 도메인이 포함된 클로스트리듐 독소 HN 영역을 포함할 수 있다. 상기 구현예의 또다른 측면은, 예를 들어, 최대 350개의 아미노산, 최대 375개의 아미노산, 최대 400개의 아미노산 및 최대 425개의 아미노산으로 된 길이를 갖는 전위 도메인이 포함된 클로스트리듐 독소 HN 영역을 포함할 수 있다.
클로스트리듐 보툴리눔(보톡스) 및 C. 테타니(파상풍균)의 독소 생산에 관한 유전학적 근거에 대해서는 공지문헌인 Henderson et al (1997) in The clostridia : Molecular Biology and Pathogenesis , Academic press을 인용한다.
HN 이란 용어는 자연발생적인 신경독소 HN 부분 및 아미노산 서열을 가진 변형 HN 부분 모두에 대해 적용되며, 단, 이 변형 HN 부분이 상술한 전위 기능을 나타내는 경우에 한한다.
이와 또다르게, 전위 도메인은 클로스트리듐 이외의 기원에서 유래될 수도 있다. 비-클로스트리듐 (기준) 전위 도메인 기원은 특별히 한정되지는 않으나, 예를 들면: 디프테리아 독소의 전위 도메인 [O'Keefe et al ., Proc. Natl. Acad. Sci. USA (1992) 89, 6202-6206; Silverman et al ., J. Biol. Chem. (1993) 269, 22524-22532; and London, E. (1992) Biochem. Biophys . Acta ., 1112, pp .25-51]; 쉐도모나스 비독소 A형의 전위 도메인 [Prior et al . Biochemistry (1992) 31, 3555-3559]; 탄저병 독소의 전위 도메인 [Blanke et al . Proc. Natl. Acad. Sci. USA (1996) 93, 8437-8442]; 전위 기능을 가진 다양한 종의 융합형 혹은 소수성 펩티드 [Plank et al . J. Biol. Chem. (1994) 269, 12918-12924; and Wagner et al (1992) PNAS , 89, pp .7934-7938]; 또한 양쪽친화성 펩티드류 [Murata et al (1992) Biochem ., 31, pp .1986-1992] 등을 포함한다. 상기의 전위 도메인은 자연발생형 단백질에 존재하는 전위 도메인과 거울 대칭이거나 또는 아미노산 변이물도 포함할 수 있으나, 이때의 변이물이 전위 도메인의 전위 능력을 손상하지 않는 것을 전제로 한다.
본 발명에서 사용하기에 적절한 바이러스성 (기준) 전위 도메인의 구체적인 예로서, 바이러스 발현된 막융합 단백질의 소정의 전위 영역이 있다. 예를 들어, Wagner et al . (1992) 및 Murata et al. (1992) 는 인플루엔자 바이러스 헤마글루티닌의 N-말단 영역에서 유래된 다수의 융합성 및 양쪽친화성 펩티드의 전위 기능 (예, 막융합 및 소낭형성)에 대해 기술한다. 소정의 전위 활성을 갖는 것으로 알려진 또다른 바이러스 발현된 막융합 단백질은, 셈리키 포레스트 바이러스(SFV)의 전위 도메인, 소낭성-구내염 바이러스(VSV) 당단백질 G의 전위 도메인 및 거품성 바이러스 엔벌로프 당단백질의 전위 도메인 등이다. 바이러스 암호화된 스파이크 단백질은 본 발명에 있어서 특별한 용도, 예컨대, SFV의 E1 및 VSV의 G 단백질 등으로 이용된다.
하기의 표에 열거된 (기준) 전위 도메인의 용도는 이들의 서열변이체의 용도도 포함한다. 변이체는 하나 이상의 보존성 핵산 치환체 및/또는 핵산 결손물 혹은 삽입물을 포함할 수 있으며, 단, 이때의 변이체는 필수 전위 기능을 갖는 것을 전제로 한다. 또한 변이체가 필수 전위 기능을 갖는다는 조건하에, 상기의 변이체는 하나 이상의 아미노산 치환체 및/또는 아미노산 결손이나 삽입물을 포함할 수 있다.
전위 도메인 공급원 | 아미노산 잔기 | 참고 문헌 |
디프테리아 독소 | 194-380 | Silverman et al ., 1994, J. Biol. Chem. 269, 22524-22532 London E., 1992, Biochem. Biophys. Acta., 1113, 25-51 |
셰도모나스 엑소톡신의 II형 도메인 | 405-613 | Prior et al ., 1992, Biochemistry 31, 3555-3559 Kihara & Pastan, 1994, Bioconj Chem. 5, 532-538 |
인플루엔자 바이러스 해마글루티닌 | GLFGAIAGFIENGWEGMIDGWYG, 및 이의 변이체 | Plank et al ., 1994, J. Biol. Chem. 269, 12918-12924 Wagner et al ., 1992, PNAS, 89, 7934-7938 Murata et al ., 1992, Biochemistry 31, 1986-1992 |
셈리키 포레스트 바이러스 융합유도성(fusogenic) 단백질 | 전위 도메인 | Kielian et al ., 1996, J Cell Biol. 134(4), 863-872 |
소낭성 구내염 바이러스 당단백질 G | 118-139 | Yao et al ., 2003, Virology 310(2), 319-332 |
SER 바이러스 F 단백질 | 전위 도메인 | Seth et al ., 2003, J Virol 77(11) 6520-6527 |
거품형 바이러스 엔벌로프 당단백질 | 전위 도메인 | Picard - Maureau et al ., 2003, J Virol. 77(8), 4722-473 |
본 발명의 폴리펩티드는 또한 전위 촉진 도메인을 더 포함할 수 있다. 이러한 도메인은 비-세포독성 프로테아제가 표적세포의 사이토졸에 전달되는 것을 촉진하며, 이에 대한 내용은 WO 08/008803 및 WO 08/008805에 개시되어 있다. 이들 문헌을 본원에 참고로서 수록한다.
예를 들어, 적절한 전위 촉진 도메인은 외피를 가진 바이러스 융합성 펩티드 도메인을 포함하며 이러한 융합성 펩티드 도메인은 또한, 예를 들어, 인플루엔자 바이러스 융합성 펩티드 도메인 (예, 23개의 아미노산으로 이루어진 인플루엔자 A 바이러스 융합성 펩티드 도메인), 알파바이러스 융합성 펩티드 도메인 (예, 26개의 아미노산으로 이루어진 셈리키 포레스트 바이러스 융합성 펩티드 도메인), 소낭성 바이러스 융합성 펩티드 도메인 (예, 21개의 아미노산으로 이루어진 소낭성-구내염 바이러스 융합성 펩티드 도메인), 레스피로바이러스 융합성 펩티드 도메인 (예, 25개의 아미노산으로 이루어진 센다이 바이러스 융합성 펩티드 도메인), 모르빌리바이러스 융합성 펩티드 도메인 (예, 25개의 아미노산으로 이루어진 개홍역 바이러스 융합성 펩티드 도메인), 애볼라바이러스 융합성 펩티드 도메인 (예, 25개의 아미노산으로 이루어진 뉴캐슬병 바이러스 융합성 펩티드 도메인), 헤니파 바이러스 융합성 펩티드 도메인 (예, 25개의 아미노산으로 이루어진 헨드라 바이러스 융합성 펩티드 도메인), 메타뉴모 바이러스 융합성 펩티드 도메인 (예, 25개의 아미노산으로 이루어진 인간 메타뉴모 바이러스 융합성 펩티드 도메인) 혹은 시미안 포미 바이러스 융합성 펩티드 같은 거품 바이러스 융합성 펩티드 도메인, 또는 이들의 절편이나 변이체 등이 있다.
또다른 예로서, 전위 촉진 도메인은 클로스트리듐 독소 HCN 도메인이나 이의 절편 혹은 변이체를 포함할 수 있다. 보다 상세하게, 클로스트리듐 독소 HCN 전위 촉진 도메인은 적어도 200개의 아미노산, 적어도 225개의 아미노산, 적어도 250개의 아미노산, 혹은 적어도 275개의 아미노산으로 된 길이를 가질 수 있다. 이 경우, 클로스트리듐 독소 HCN 전위 촉진 도메인은 바람직하게는 최대 200개의 아미노산, 최대 225개의 아미노산, 최대 250개의 아미노산 혹은 최대 275개의 아미노산으로 된 길이를 갖는다. 구체적인 (기준서열의) 예를 들면 다음과 같다:
보틀리눔 A형 신경독소-아미노산 잔기 (872-1110)
보틀리눔 B형 신경독소 -아미노산 잔기 (859-1097)
보틀리눔 C형 신경독소 -아미노산 잔기 (867-1111)
보틀리눔 D형 신경독소 -아미노산 잔기 (863-1098)
보틀리눔 E형 신경독소 -아미노산 잔기 (846-1085)
보틀리눔 F형 신경독소 -아미노산 잔기 (865-1105)
보틀리눔 G형 신경독소 -아미노산 잔기 (864-1105)
테타누스 신경독소 -아미노산 잔기 (880-1127)
상기의 서열위치는 혈청형/혈청아형에 따라 약간 변할 수도 있으며, 적절한 (기준) 클로스트리듐 독소 HCN 도메인의 예를 들면 다음과 같다:
보틀리눔 A형 신경독소 -아미노산 잔기 (874-1110)
보틀리눔 B형 신경독소 -아미노산 잔기 (861-1097)
보틀리눔 C형 신경독소 -아미노산 잔기 (869-1111)
보틀리눔 D형 신경독소 -아미노산 잔기 (865-1098)
보틀리눔 E형 신경독소 -아미노산 잔기 (848-1085)
보틀리눔 F형 신경독소 -아미노산 잔기 (867-1105)
보틀리눔 G형 신경독소 -아미노산 잔기 (866-1105)
테타누스 신경독소 -아미노산 잔기 (882-1127)
상기의 촉진 도메인을 본 발명의 용도에 적합한 전술한 전위 도메인 펩티드들 중 임의의 것과 조합할 수도 있다. 따라서 예를 들어, 비-클로스트리듐성 촉진 도메인은 비-클로스트리듐성 전위 도메인 펩티드 또는 클로스트리듐 전위 도메인 펩티드와 조합 가능하다. 이와 별도로, 클로스트리듐 독소 HCN 전위 촉진 도메인을 비-클로스트리듐성 전위 도메인 펩티드와 조합할 수 있다. 이와 또다르게, 클로스트리듐 독소 HCN 촉진 도메인은 클로스트리듐 전위 도메인 펩티드와 조합이 가능하며 이러한 예를 들면 다음과 같다:
보틀리눔 A형 신경독소 -아미노산 잔기 (449-1110)
보틀리눔 B형 신경독소 -아미노산 잔기 (442-1097)
보틀리눔 C형 신경독소 -아미노산 잔기 (450-1111)
보틀리눔 D형 신경독소 -아미노산 잔기 (446-1098)
보틀리눔 E형 신경독소 -아미노산 잔기 (423-1085)
보틀리눔 F형 신경독소 -아미노산 잔기 (440-1105)
보틀리눔 G형 신경독소 -아미노산 잔기 (447-1105)
테타누스 신경독소 -아미노산 잔기(458-1127)
서열
상동성
:
각종 서열 정렬법을 이용하여 백분율 단위로 서열 동일성을 측정할 수 있으며, 비제한적인 예로서, 광역법, 국소법, 및 시그먼트 어프로치법 (segment approach method) 등의 혼성법이 여기에 속한다. 백분율 단위의 서열 동일성을 결정하는 프로토콜은 당해 분야의 범위에서 상용적으로 행하는 절차이다. 광역법은, 분자의 시작에서 마지막까지에 이르는 서열을 정렬하고, 각 잔기쌍 숫자를 더하고 틈새 벌점을 부과하여 최적의 배열을 결정하는 것이다. 이 방법의 비제한적인 예는 다음과 같은 다수의 문헌에 공지되어 있다: CLUSTAL W. 의 문헌, 예컨대, Julie D. Thompson et al., CLUSTAL W: "Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting," Position-Specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); 및 미세조정 방법에 관련하여 예컨대, Osamu Gotoh, "Significant Improvement in Accuracy of Multiple Protein" 또는 Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. MoI. Biol. 823-838 (1996) 등을 참조한다. 국소법은 입력 서열이 모두 공유하는 하나 이상의 보존된 모티프를 확인함으로써 서열을 정렬하는 것이다. 이 방법의 비제한적인 예를 들면 다음과 같다: 매치박스법(Match-box), 예컨대, Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501-509 (1992); 깁스 샘플링법(Gibbs sampling), 예컨대, C. E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262(5131) Science 208-214 (1993); M-정렬법(Align-M), 예컨대, Ivo Van WaIIe et al., Align-M-A New Algorithm for Multiple Alignment of Highly Divergent Sequences, 20(9) Bioinformatics: 1428-1435 (2004) 등을 참조한다.
따라서 백분율 단위의 서열 동일성은 종래의 방법에 따라 결정된다. 이에 관련하여, 다음의 문헌을 참조한다: Altschul et al., Bull . Math . Bio . 48: 603-16, 1986, 또한 Henikoff and Henikoff, Proc . Natl . Acad . Sci. USA 89:10915-19, 1992. 요약하면, 틈새 개방 벌점으로 10, 틈새 연장 벌점으로 1, 및 하기와 같은 헤니코프 앤 헤니코프 (Henikoff and Henikoff, ibid.)의 "블로섬(blosum) 62" 스코어 결정 행렬을 이용하여 정렬 스코어를 최적화할 수 있도록, 2개의 아미노산 서열을 정렬한다 (아미노산은 표준 단일문자 코드로 나타낸다).
서열 동일성을 결정하는 정렬 스코어
백분율 단위의 서열 동일성은 다음과 같이 계산한다:
상동 폴리펩티드는 사실상 하나 이상의 아미노산 치환물, 결손물 혹은 부가물을 갖는 것을 특징으로 한다. 이러한 변화는 부수적인 특징으로서, 즉, 보존성 아미노산 치환물 (하기 참조) 및 기타의 치환물, 예컨대, 폴리펩티드의 접힘이나 활성에 큰 영향을 미치지 않는 치환물; 통상 1개 내지 30개의 아미노산으로 된 소량의 결손물; 및 짧은 길이의 아미노-말단 혹은 카르복실-말단 연장물, 예컨대, 최대 20 내지 25개 잔기로 된 짧은 길이 링커 펩티드나 친화성 태그 등에 따른 것이다.
보존성 아미노산
치환물
염기성: 아르기닌
리신
히스티딘
산성: 글루탐산
아스파탐산
극성: 글루타민
아스파라긴
소수성: 류신
이소류신
발린
방향족: 페닐알라닌
트립토판
티로신
소형: 글리신
알라닌
세린
트레오닌
메티오닌
20개의 표준 아미노산 이외에도, 비-표준 아미노산 (4-히드록시프로릴, 6-N-메틸리신, 2-아미노이소부티르산, 이소발린 및 α-메틸세린 등)으로 본 발명에 따른 폴리펩티드의 아미노산 잔기를 치환할 수도 있다. 한정된 수의 비-보존성 아미노산, 유전자 코드에 따라 암호화 되지 않은 아미노산, 및 합성 아미노산 등으로 클로스트리듐 폴리펩티드 아미노산 잔기를 대체할 수 있다. 본 발명의 폴리펩티드는 또한 비-자연발생형 아미노산 잔기도 포함할 수 있다.
비-자연발생형 아미노산은 특별히 제한되지는 않지만, 예를 들어, 트랜스-3-메틸프롤린, 2,4-메타노-프롤린, 시스-4-히드록시프롤린, 트랜스-4-히드록시-프롤린, N-메틸글리신, 알로-트레오닌, 메틸-트레오닌, 히드록시-에틸시스테인, 히드록시에틸호모-시스테인, 니트로-글루타민, 호모글루타민, 피페콜린산, tert-류신, 노르발린, 2-아자페닐알라닌, 3-아자페닐알라닌, 4-아자페닐알라닌 및 4-플루오로페닐알라닌 등이 있다. 비-자연발생형 아미노산 잔기를 단백질에 삽입하는 다수의 방법이 공지되어 있다. 예를 들어, 체외 시스템을 이용할 수 있는데, 화학적 아미노아실화 억제자 tRNAs 를 이용하여 넌센스(nonsense) 돌연변이를 억제한다. 아미노산 및 아미노아실화 tRNA를 합성하는 방법은 공지되어 있다. 대장균 S30 추출물, 상용의 효소 및 기타 시약을 함유하는 무세포계에서 넌센스 돌연변이를 함유하는 플라스미드의 전사 및 번역을 시행한다. 단백질은 크로마토그래피로 정제한다. 이에 관련하여 다음의 문헌을 참조한다: 즉, Robertson et al., J. Am . Chem . Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-9, 1993; and Chung et al., Proc . Natl . Acad . Sci . USA 90:10145-9, 1993) 등을 참조한다. 두번째 방법에서, 돌연변이된 mRNA 및 화학적으로 아미노아실화된 억제자 tRNA를 미세주입하여 제노푸스 오오사이트(Xenopus oocyte)에서 번역을 실행한다 (Turcatti et al., J. Biol . Chem. 271:19991-8, 1996). 세번째 방법에서, 대장균 세포는 치환될 자연형 아미노산 (예, 페닐알라닌)의 결핍하에 또한 원하는 비-자연발생형 아미노산 (예, 2-아자페닐알라닌, 3-아자페닐알라닌, 4-아자페닐알라닌, 4-플루오로페닐알라닌 등)의 존재하에 배양한다. 상기 비-자연발생형 아미노산은 이것의 자연형 대응체(counterpart)를 대신하여 폴리펩티드에 삽입된다 (Koide et al., Biochem. 33:7470-6, 1994 참조). 자연발생형 아미노산 잔기는 체외 화학변형을 통해 비-자연발생형 아미노산 종류로 전환될 수 있다. 화학변형과 부위별 돌연변이를 조합하면 치환물의 범위를 더 확대할 수 있다 (Wynn and Richards, Protein Sci. 2:395-403, 1993 참조).
한정된 수의 비-보존성 아미노산, 유전자 코드에 의해 암호화 되지 않은 아미노산, 비-자연발생형 아미노산, 및 합성 아미노산 등을 본 발명에 따른 폴리펩티드의 아미노산 잔기 대신 사용할 수 있다.
본 발명에 따른 폴리펩티드의 필수 아미노산은 부위-지정 돌연변이나 알라닌-주사형 돌연변이 등의 공지 방법에 따라 정동할 수 있다 (Cunningham and Wells, Science 244: 1081-5, 1989). 생물학적 상호작용 부위는 또한 물리적 구조 분석법, 예컨대, 핵자기공명, 결정학적 방법, 전자회절 또는 광친화성 표지화 등의 기술을 추정 접촉부위 아미노산의 돌연변이와 함께 응용함으로써 결정할 수 있다. 이에 관하여 다음과 같은 문헌을 참조한다: de Vos et al., Science 255:306-12, 1992; Smith et al., J. Mol . Biol . 224:899-904, 1992; Wlodaver et al., FEBS Lett . 309:59-64, 1992. 필수 아미노산의 동일성은 또한, 본 발명에 따른 폴리펩티드의 관련 성분 (예, 전위 성분이나 프로테아제 성분)과의 상동성 분석에 따라서도 추측할 수 있다.
하기의 문헌에 기술된 바와 같이, 공지의 돌연변이 방법 및 스크리닝을 통해 다수의 아미노산 치환체를 제조 및 시험할 수 있다: Reidhaar-Olson and Sauer (Science 241:53-7, 1988) 또는 Bowie and Sauer (Proc. Natl . Acad . Sci . USA 86:2152-6, 1989). 요약하면, 상기의 저자들은 폴리펩티드 내의 2개 이상의 위치를 기능성 폴리펩티드를 위해 동시적으로 또한 무작위적으로 선택한 다음, 돌연변이된 폴리펩티드를 서열화하여 각 위치에 고정될 치환체의 범위를 결정하는 방법에 대해 소개하고 있다. 그 외에도 사용가능한 다른 방법으로서, 파지 디스플레이 (예, Lowman et al., Biochem . 30:10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) 및 영역-지정 돌연변이 (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988) 등이 있다.
본 발명의 측면 및/또는 구현예를 예시하는 도면의 간단한 설명은 아래와 같다.
도 1- LH N /D- CT - CST28 융합단백질의 정제
실시예 5에 개략적으로 기술한 방법에 따라, 대장균 BL21(DE3) 세포로부터 LHN/D-CT-CST28 융합단백질을 정제했다. 즉, 세포 파열로 얻은 가용성 산물을 니켈충전된 친화성 포집컬럼에 가했다. 결합 단백질을 200mM 이미다졸에 용리하여 엔테로키나제로 처리함으로써 융합단백질을 활성화시키고, 이를 두번째의 니켈충전된 친화성 포집컬럼에 다시 가했다. 정제법에 따라 얻은 시료를 SDS-PAGE 로 분석했다. 레인 1: 1차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 2: 비환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 3: 환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 및 레인 4: 분자량 마커 (kDa)
도 2- LH N /A- CT - SST14 융합단백질의 정제
실시예 6에 개략적으로 기술한 방법에 따라, 대장균 BL21(DE3) 세포로부터 LHN/A-CT-SST14 융합단백질을 정제했다. 즉, 세포 파열로 얻은 가용성 산물을 니켈충전된 친화성 포집컬럼에 가했다. 결합 단백질을 200mM 이미다졸에 용리하여 Xa 인자로 처리함으로써 융합단백질을 활성화시키고, 이를 두번째의 니켈충전된 친화성 포집컬럼에 다시 가했다. 정제법에 따라 얻은 시료를 SDS-PAGE 로 분석했다. 레인 1: 1차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 2: 분자량 마커 (kDa), 레인 3-4: 비환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 및 레인 5-6: 환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액.
도 3-배양된 내분비 세포( AtT20 )에서 발현되는 SST - LH N /A의 활성
도 3a는 SST-LHN/A에 의한 ACTH 분비 억제효과를 도시하고, 도 3b는 SST-LHN/A에 의한 SNAP-25 절단 형태를 도시한다.
도 4-배양된 내분비 세포( GH3 )에서 발현되는 SST - LH N /D의 활성
도 4는 GH3 세포로부터의 성장호르몬 분비 억제효과를 도시한다. SST-LH/D의 투약량이 증가할수록 성장호르몬 분비 억제효과도 상승한다.
도 5- 래트의 체내 IGF -1 농도에 대한 CP - GHRH - LHD 활성
도 5는 치료후 제5일의 래트 IGF-1 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독과 비교하여 도시한다.
도 6- 래트의 체내 IGF -1 농도에 대한 CP - GHRH - LHD 활성
도 6은 치료 후 제1일 내지 제8일의 래트 IGF-1 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독과 비교하여 도시한다. 캐뉼러 차단 탓에 제9일 및 제10일에는 'n'이 너무 작은 것으로 판단된다.
도 7- 래트의 체내 성장 호르몬 농도에 대한 CP - GHRH - LHD 활성
도 7b은 치료 후 제5일의 래트 성장호르몬 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독(도 7a) 및 옥트레오티드 주입액(도 7c)과 비교하여 도시한다.
도 1- LH N /D- CT - CST28 융합단백질의 정제
실시예 5에 개략적으로 기술한 방법에 따라, 대장균 BL21(DE3) 세포로부터 LHN/D-CT-CST28 융합단백질을 정제했다. 즉, 세포 파열로 얻은 가용성 산물을 니켈충전된 친화성 포집컬럼에 가했다. 결합 단백질을 200mM 이미다졸에 용리하여 엔테로키나제로 처리함으로써 융합단백질을 활성화시키고, 이를 두번째의 니켈충전된 친화성 포집컬럼에 다시 가했다. 정제법에 따라 얻은 시료를 SDS-PAGE 로 분석했다. 레인 1: 1차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 2: 비환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 3: 환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 및 레인 4: 분자량 마커 (kDa)
도 2- LH N /A- CT - SST14 융합단백질의 정제
실시예 6에 개략적으로 기술한 방법에 따라, 대장균 BL21(DE3) 세포로부터 LHN/A-CT-SST14 융합단백질을 정제했다. 즉, 세포 파열로 얻은 가용성 산물을 니켈충전된 친화성 포집컬럼에 가했다. 결합 단백질을 200mM 이미다졸에 용리하여 Xa 인자로 처리함으로써 융합단백질을 활성화시키고, 이를 두번째의 니켈충전된 친화성 포집컬럼에 다시 가했다. 정제법에 따라 얻은 시료를 SDS-PAGE 로 분석했다. 레인 1: 1차 니켈 킬레이트화 세파로스 컬럼 용리액, 레인 2: 분자량 마커 (kDa), 레인 3-4: 비환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액, 및 레인 5-6: 환원성 조건하의 2차 니켈 킬레이트화 세파로스 컬럼 용리액.
도 3-배양된 내분비 세포( AtT20 )에서 발현되는 SST - LH N /A의 활성
도 3a는 SST-LHN/A에 의한 ACTH 분비 억제효과를 도시하고, 도 3b는 SST-LHN/A에 의한 SNAP-25 절단 형태를 도시한다.
도 4-배양된 내분비 세포( GH3 )에서 발현되는 SST - LH N /D의 활성
도 4는 GH3 세포로부터의 성장호르몬 분비 억제효과를 도시한다. SST-LH/D의 투약량이 증가할수록 성장호르몬 분비 억제효과도 상승한다.
도 5- 래트의 체내 IGF -1 농도에 대한 CP - GHRH - LHD 활성
도 5는 치료후 제5일의 래트 IGF-1 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독과 비교하여 도시한다.
도 6- 래트의 체내 IGF -1 농도에 대한 CP - GHRH - LHD 활성
도 6은 치료 후 제1일 내지 제8일의 래트 IGF-1 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독과 비교하여 도시한다. 캐뉼러 차단 탓에 제9일 및 제10일에는 'n'이 너무 작은 것으로 판단된다.
도 7- 래트의 체내 성장 호르몬 농도에 대한 CP - GHRH - LHD 활성
도 7b은 치료 후 제5일의 래트 성장호르몬 농도에 대한 CP-GHRH-LHD (SXN 101000)의 정맥주사 투여의 효과를, 대조군으로 사용된 전색제 단독(도 7a) 및 옥트레오티드 주입액(도 7c)과 비교하여 도시한다.
실시예의
요약
실시예 1 LHA 골격 구조체의 제조
실시예 2 LHA-CP-SST28의 제작
실시예 3 LHA-CP-SST28 융합단백질의 발현 및 정제
실시예 4 LHD-CT-CST28의 제작
실시예 5 LHD-CT-CST28 융합단백질의 발현 및 정제
실시예 6 SST TM에 대한 LHN/A의 화학적 접합
실시예 7 배양된 내분비 세포(AtT20) 내에서의 SST-LHA의 활성
실시예 8 배양된 신경내분비계 세포(GH3) 내에서의 SST-LHD의 활성
실시예 9 뇌하수체 선종으로 인해 증가된 GH 및 IGF-1 농도를 감소시켜 말단비대증 증세를 경감하는 방법
실시예 10 뇌하수체 선종으로 인해 증가된 GH 및 IGF-1 농도를 감소시켜 손가락의 부종 및 다모증을 정상화 하는 방법
실시예 11 성장호르몬 분비성 뇌하수체 선종의 재발을 완화하는 방법
실시예 12 소마토스타틴 유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
실시예 13 소마토스타틴 유사체에 대한 내성이 없는 환자의 쿠싱병 치료방법
실시예 14 프로락틴 분비종 치료에 따른 여성 성기능 부진의 회복방법
실시예 15 인슐린 종양의 치료로 체중감소를 달성하는 방법
실시예 16 글루카곤종 치료방법
실시예 17 장폴리펩티드 분비종에 의한 설사 및 작열감을 치료하는 방법
실시예 18 가스트린종 치료방법
실시예 19 티로트로피노마에 의한 갑상선중독증의 치료방법
실시예 20 말단비대증으로 인한 재발성 연부조직 부종의 치료방법
실시예 21 쿠싱병으로 인한 과다 안면 다모증의 치료방법
실시예 22 프로락틴 분비종으로 인한 남성의 프로락틴 분비 증세를 치료하는 방법
실시예 23 인슐린 종양으로 인한 다발성 증세의 치료방법
실시예 24 소마토스타틴 유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
실시예 25 소마토스타틴 유사체에 대한 내성이 없는 환자의 쿠싱병 치료방법
실시예 26 프로락틴 분비종의 치료에 따른 여성 성기능 부진의 회복방법
실시예 27 쿠싱병 치료방법
실시예 28 가스트린종 치료방법
실시예 29 뇌하수체 선종으로 인해 증가한 GH 및 IGF-1 농도를 감소시켜 말단비대증의 증세를 완화하는 방법
실시예 30 소마토스타틴 유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
실시예 31 말단비대증 치료방법
실시예 32 래트의 체내 IGF-1 농도에 대한 CP-GHRH-LHD 활성
실시예 33 래트의 체내 IGF-1 농도에 대한 CP-GHRH-LHD 활성
실시예 34 래트의 체내 성장 호르몬 농도에 대한 CP-GHRH-LHD 활성
실시예
1
LH
N
/A
골격 구조체의 제조
다음의 절차에 따라, 다중 도메인 단백질 발현을 위해 발현 골격으로 이용할 클론을 제작한다. 이 실시예는 A군 혈청형 클론(서열번호 1)의 제조에 기초하나, 합성 용도에 적절한 공개 서열(서열번호 32)을 이용함으로써 동일한 절차와 방법을 B군 혈청형(서열번호 2), C군 혈청형(서열번호 3), D군 혈청형(서열번호 4) 등의 모든 LHN 혈청형 및 기타의 프로테아제나 전위 도메인, 예컨대, IgA 및 테타누스 HN 등에도 적용할 수 있다.
클로닝
및 발현 벡터의 제조
pCR4(Invitrogen)은 구조체 확인에 용이한 벡터 및 이의 인접 서열 프라이머 부위 내에 제한서열이 없기 때문에 표준 클로닝 벡터로서 선택된다. 이 발현벡터는, 구조체를 삽입하기 위해 다중 클로닝 부위 NdeI- BamHI- SalI- PstI-XbaI-HindIII를 포함하도록 변형된 pET(Novagen) 발현벡터에 기초한다. 상기 발현벡터의 절편을 분리하여 비-이동성 플라스미드를 생성하고, 다양한 융합 태그를 삽입하여 정제 옵션을 늘리고, 또한 벡터 골격에 있는 기존의 XbaI 부위를 제거하여 서브클로닝을 단순화하였다.
LC
/A 제조
다양한 역번역(back translation) 소프트웨어 툴 중 하나 (예, 백트랜슬레이션 툴 v2.0 (Entelechon))을 응용하여 LC/A 아미노산 서열 (GenBank 등의 무료 이용 데이터베이스 공급처에서 받음; 수탁번호 P10845)을 역번역함으로써 DNA 서열을 설계한다. BamHI/SalI 인지서열은 올바른 해독프레임을 유지하는 서열의 5' 및 3' 말단에 각각 삽입된다. 상기 DNA 서열은 역번역 과정에서 삽입된 제한효소 분절서열에 관하여 스크리닝 처리한다 (SeqBuilder, DNASTAR Inc. 등의 소프트웨어를 이용함). 백트랜슬레이션 툴을 이용하여, 클로닝 시스템에 필요한 서열과 공통이 되는 분절서열을 문제의 암호화 서열로부터 제거하면 일반 대장균 코돈을 계속 사용할 수 있다. 대장균 코돈의 사용빈도를 그래픽 코돈 사용빈도 분석기(Geneart) 등의 소프트웨어 프로그램에 따라 평가하며, 또한 공개된 코돈 사용표 (예, GenBank Release 143, 2004년 9월 13일)에 근거하여 GC% 함량 및 코돈 사용비율을 평가한다. 상기의 LC/A 개방 해독프레임(ORF)을 구비한 최적화된 DNA 서열을 다시 상용 합성하여 (예, Entelechon 이용, Geneart 또는 Sigma-Genosys) pCR 4 벡터에 제공한다.
H
N
/A 삽입물의 제조
다양한 역번역(back translation) 소프트웨어 툴 중 하나 (예, 백트랜슬레이션 툴 v2.0 (Entelechon))를 응용하여 HN/A 아미노산 서열 (GenBank 등의 무료 이용 데이터베이스 공급처에서 받음; 수탁번호 P10845)를 역번역함으로써 DNA 서열을 설계한다. PstI 제한서열을 N-말단에 또한 XbaI-종결 코돈-HindIII을 C-말단에 각각 부가하여 올바른 해독프레임을 유지한다. 상기 DNA 서열은 역번역 과정에서 삽입된 제한효소 분절서열에 관하여 스크리닝 처리한다 (SeqBuilder, DNASTAR Inc. 등의 소프트웨어를 이용함). 백트랜슬레이션 툴을 이용하여, 클로닝 시스템에 필요한 서열과 공통이 되는 분절서열을 문제의 암호화 서열로부터 제거하면 일반 대장균 코돈을 계속 사용할 수 있다. 대장균 코돈의 사용빈도를 그래픽 코돈 사용빈도 분석기(Geneart) 등의 소프트웨어 프로그램에 따라 평가하며, 또한 공개된 코돈 사용표 (예, GenBank Release 143, 2004년 9월 13일)에 근거하여 GC% 함량 및 코돈 사용비율을 평가한다. 상기의 최적화된 DNA 서열을 다시 상용 합성하여 (예, Entelechon 이용, Geneart 또는 Sigma-Genosys) pCR 4 벡터에 제공한다.
인터도메인
(
LC
-
H
N
링커)의 제조
LC-HN 링커는 주형(template)인 링커에 관한 기존의 서열정보를 이용하여 제1 원리에 따라 설계할 수 있다. 예를 들어, A군 혈청형 링커 (여기서는 LC와 HN간 디설파이드 브릿지의 시스테인들 사이에 존재하는 도메인간 폴리펩티드 영역으로 정의함)는 'VRGIIPFKTKSLDEGYNKALNDL' 서열을 갖는다. 이 서열정보는 GenBank 등의 상용 데이터베이스 공급처로부터 무료로 이용할 수 있다 (수탁번호 P10845). 특이적 프로테아제 분절부위의 형성에 있어서, Xa 인자의 자연형 인지서열을 'VDGIITSKTKSLIEGR' 변형서열에서 사용할 수 있거나 또는 엔테로키나제 인지서열을 활성화 고리에 삽입하여 'VDGIITSKTKSDDDDKNKALNLQ' 서열을 형성한다. 각종 역번역 소프트웨어 툴 중 하나를 이용하여(예, 백트랜슬레이션 툴 v2.0 (Entelechon)), 상기 링커 영역을 암호화할 DNA 서열을 결정한다. BamHI/SalI 및 PstI/XbaI-종결 코돈-HindIII 제한효소 서열을 올바른 해독프레임의 각 말단에 삽입한다. 역번역 과정에서 삽입된 제한효소 분절서열에 대해 DNA 서열을 스크리닝 처리한다 (Seqbuilder 등의 소프트웨어 사용, DNASTAR Inc.). 백트랜슬레이션 툴을 이용하여, 클로닝 시스템에 필요한 서열과 공통이 되는 분절서열을 문제의 암호화 서열로부터 제거하면 일반 대장균 코돈을 계속 사용할 수 있다. 대장균 코돈의 사용빈도를 그래픽 코돈 사용빈도 분석기(Geneart) 등의 소프트웨어 프로그램에 따라 평가하며, 또한 공개된 코돈 사용표 (예, GenBank Release 143, 2004년 9월 13일)에 근거하여 GC% 함량 및 코돈 사용비율을 평가한다. 상기의 최적화된 DNA 서열을 다시 상용 합성하여 (예, Entelechon 이용, Geneart 또는 Sigma-Genosys) pCR 4 벡터에 제공한다.
골격 클론의 조립 및 확인
크기가 작은 탓에, 활성화 링커는 2단계 과정을 거쳐 전달해야 한다. 즉, pCR-4 링커 벡터는 BamHI + SalI 조합형 제한효소로 절단하며, 이 절단된 링커 벡터는 또한 BamHI + SalI 제한효소 절단 LC DNA를 위한 수령체 역할을 한다. LC 암호화 DNA가 링커 DNA 상류에 삽입되면 전체 LC-링커 DNA 절편이 분리 및 pET 발현 벡터 MCS에 전달될 수 있다. BamHI/PstI 제한효소 소화작용을 통해 LC-링커가 pCR-4 클로닝 벡터로부터 절단된다. 동일한 효소로 pET 발현벡터를 소화하고 또한, 재순환을 방지하기 위한 추가 조치로서, 이 벡터를 남극 인산 가수분해 효소로 처리한다. LC-링커와 pET 벡터 골격을 겔-정제하고 또한, T4 DNA 리가제를 이용하여, 상기의 정제된 삽입물과 벡터 골격을 서로 접합시킨다. 결과로 나온 산물은 TOP10 세포를 이용하여 형질전환한 다음, BamHI/PstI 제한효소 소화작용을 통해 LC-링커에 대해 스크리닝 처리한다. 상기의 과정을 반복함으로써 pET-LC-링커 구조체의 PstI/HindIII 제한위치에 HN 를 삽입한다.
합성 과정에서 모든 성분들이 이미 서열화 되어 있으므로, 최종 골격이 올바른지 여부는 제한효소를 이용한 스크리닝 처리로 충분하다. 그러나, 성분 중 일부를 골격에 서브클로닝 하는 과정에서 유사한 크기의 절편이 제거 및 삽입될 경우, 올바른 삽입 여부를 확인하기 위해서는 소영역의 서열 형성작업이 필요하다.
실시예
2
LH
N
/
AA
-
CP
-
GS15
-
SST28
제작
표적화 성분(TM)이 프로테아제와 전위 도메인 사이의 중심에 존재할 경우, 다중도메인 융합발현을 위한 발현 구조체로 이용될 클론을 다음의 절차에 따라 제작한다. 이 실시예는 LHN/A-CP-GS15-SST28 융합물(서열번호 25)의 제조에 기초하나, TM이 전위 도메인쪽의 N-말단에 있다면 그 밖의 다른 프로테아제, 전위 성분 및 TM 융합물 등을 생성하는데도 상기와 동일한 절차와 방법을 적용할 수 있다. 이 실시예에서, 측부(flanking) 15-아미노산 글리신-세린 스페이서(G4S)3를 인터도메인 서열 속에 도입함으로써 수용체의 리간드 수용력을 확보한다. 그러나 다른 스페이서도 적용할 수 있다.
스페이서
-인간
SST28
삽입체의
제조
LC-HN 인터도메인 폴리펩티드 링커 영역은 LC와 HN간의 디설파이드 브릿지의 시스테인들 사이에 존재한다. 프로테아제 분절위치, 스페이서 및 표적화 성분(TM) 영역을 활성화 고리에 삽입하기 위하여, 다양한 역번역 소프트웨어 툴 (예, 백트랜슬레이션 툴 v2.0 (Entelechon))을 이용하여 링커 영역 암호화를 위한 DNA 서열을 결정한다. HN 도메인의 N-말단에 SST28 서열을 제공하기 위하여, GS 스페이서 및 표적화 성분(TM) 영역을 위한 DNA 서열을 설계하고 이것을 골격 클론(서열번호 1) 속에 삽입할 수 있다. 상기 DNA 서열은 BamHI-SalI-스페이서-프로테아제 활성부위-SST28-스페이서-PstI-XbaI-종결 코돈-HindIII (서열번호 5) 형태로 정리배열될 수 있다. TM DNA를 설계한 후, 스페이서를 암호화 하는데 필요한 또다른 DNA를 Silico 실험에서 제작한다. 스페이서, SST28 및 제한서열에 관련한 올바른 해독프레임을 확보하는 것과 또한, XbaI 서열에서, DAM 메틸화 반응을 유도하는 염기 TC가 선행하지 않는다는 점이 중요하다. DNA 서열은 삽입된 제한서열에 관하여 스크리닝 처리하고 또다른 부위는 나머지 서열로부터 수작업으로 제거함으로써, 일반적인 대장균 코돈의 사용빈도를 지속 유지한다. 대장균 코돈의 사용빈도를 그래픽 코돈 사용빈도 분석기(Geneart) 등의 소프트웨어 프로그램에 따라 평가하며, 또한 공개된 코돈 사용표 (예, GenBank Release 143, 2004년 9월 13일)에 근거하여 GC% 함량 및 코돈 사용비율을 평가한다. 상기의 최적화된 DNA 서열을 다시 상용 합성하여 (예, Entelechon 이용, Geneart 또는 Sigma-Genosys) pCR 4 벡터에 제공한다.
골격 클론의 조립 및 확인
골격 구조체(서열번호 1) 및, SST28 TM(서열번호 5)를 암호화하는, 신규합성된 pCR 4-스페이서-활성부위-TM-스페이서 벡터를 이용하여, LC-스페이서-활성부위-SST28-스페이서-HN 구조체(서열번호 25)를 제작하기 위하여, 1단계 혹은 2단계 방법을 이용할 수 있다: 통상, 2단계 방법은 TM DNA가 100 염기쌍 미만일 때 이용한다. 1단계 방법을 이용할 경우, 먼저 pCR 4-스페이서-활성부위-TM-스페이서 벡터를 Sall 및 PstI 제한효소로 절단한 다음 TM 암호화 DNA 절편을 상기와 유사한 pET 골격 구조체편 속에 삽입함으로써, SST28 링커 영역을 직접 골격 구조체에 삽입할 수 있다. 한편 2단계 방법의 경우, BamHI 및 SalI 제한효소를 이용하여 LC 도메인을 골격 클론에서 제거한 다음 이 제거물을 소화처리된 유사한 pCR 4-스페이서-활성부위-TM-스페이서 벡터에 접합시키는 것이다. 상기 방법에 따라 pCR 4의 내부에 LC-스페이서-활성부위-SST28-스페이서 ORF를 형성하며, 이 형성물은 BamHI 및 SalI 제한효소를 이용하여 벡터로부터 제거하여 유사한 pET 발현 구조체에 추후 접합시킬 수 있다. 최종 구조체는 LC-스페이서-활성부위-SST28-스페이서-HN DNA(서열번호 25)을 함유하며, 결과적으로 서열번호 26에 예시된 서열을 함유하는 융합단백질을 얻는다.
실시예
3
LH
N
/A-
CP
-
SST28
융합단백질의
발현 및 정제
본 실시예는 SST28 TM 폴리펩티드를 인터도메인 링커 영역(서열번호 26)에 삽입하는 LHN/A 단백질의 제조방법에 근거하며, 상기 영역에서 pET 발현 벡터 ORF는 히스티딘 정제 태그를 암호화 한다. 이러한 절차와 방법은 서열번호 7-14, 42-48, 57 및 60-91에서 보는 바와 같은 기타의 융합단백질에도 마찬가지로 적용될 수 있다. 바람직하게는, 각 서열에서 프로테아제 활성부위와 융화성이 있는 활성효소를 선택한다.
LH
N
/A-
CP
-
SST28
발현
LHN/A-CP-SST28 단백질의 발현은 다음과 같은 프로토콜에 따라 달성된다. 0.2% 글루코사민이 함유된 100ml의 TB 변형물 및 30 ㎍/ml의 카나마이신을 250ml 플라스크에 담고, 여기에 LHA-CP-SST28 발현균주로부터 얻은 단일 콜로니를 접종한다. 배양물을 37℃ 및 225rpm 하에 16시간 동안 성장시킨다. 0.2% 글루코사민이 함유된 1 L TB 변형물 및 30 ㎍/ml의 카나마이신을 2L 플라스크에 담고, 여기에 하룻밤 배양한 배양액을 10ml의 양으로 가하여 접종한다. 약 0.5 OD600nm에 도달할 때까지 배양물을 37℃에서 성장시키고 상기 농도에 도달하면 온도를 16℃으로 낮춘다. 1시간 후 1mM IPTG로 배양을 촉진하고 16℃에서 다시 16시간 동안 성장시킨다.
LH
N
/A-
CP
-
SST28
단백질의 정제
35ml의 50mM HEPES pH 7.2 200mM NaCl 및 약 10g의 대장균 BL21(DE3) 세포 페이스트가 담긴 디프로스트 팰컨 튜브을 준비한다. 상기 세포 페이스트를 균질화하고(20psi) 시료를 냉각 상태로 유지한다. 용균 세포를 4℃에서 18000rpm으로 30분간 스핀 교반한다. 50 mM HEPES pH 7.2 200 mM NaCl로 평형화 처리한 0.1M NiSO4 충전 킬레이트 컬럼 (20 내지 30ml 용량의 컬럼이면 충분함)에 상청액을 주입한다. 10, 40 및 100mM 이미다졸을 단계적으로 사용하여 비-특이적 결합단백질을 세척제거한 뒤 200mM 이미다졸로 융합단백질을 용리한다. 용리된 융합단백질을 4℃에서 하룻밤동안 5L의 50mM HEPES pH7.2 200mM NaCl에 투석시키고 OD280nm 값을 측정하여 단백질 농도를 확정한다. 융합단백질 1mg당 3.2㎕ 엔테로키나제 (뉴잉글랜드 바이오랩)을 첨가하고 25℃에서 하룻밤동안 정치배양한다. 50 mM HEPES pH 7.2 200 mM NaCl로 평형화 처리한 0.1M NiSO4 충전 킬레이트화 컬럼 (20 내지 30ml 용량의 컬럼이면 충분함)에 상기 용액을 주입한다. 50 mM HEPES pH 7.2 200 mM NaCl로 컬럼을 기준선까지 세척한다. 10, 40 및 100mM 이미다졸을 단계적으로 사용하여 비-특이적 결합단백질을 세척제거한 뒤 200mM 이미다졸로 융합단백질을 용리한다. 용리된 융합단백질을 4℃에서 하룻밤동안 5L의 50mM HEPES pH7.2 200mM NaCl에 투석시키고 이 융합물을 약 2mg/ml까지 농축하며, 시료를 분취하여 -20℃로 냉동시킨다. 정제 단백질을 OD280, BCA 및 순도 분석법에 따라 시험한다.
실시예
4
LH
N
/D-
CT
-
GS20
-
CST28
제작
표적화 성분(TM)이 전위 도메인 방향의 C-말단측에 존재하는 경우, 다중도메인 융합발현을 위한 발현 구조체로 이용될 클론을 다음의 절차에 따라 제작한다. 본 실시예는 LHN/D-CT-GS20-CST28 융합물(서열번호 17)의 제조에 기초하나, TM이 전위 도메인 측의 C-말단에 있는 경우라면 다른 프로테아제, 전위 성분 및 TM 융합물의 제조에도 위와 동일한 절차와 방법을 적용할 수 있다. 이 실시예에서 측부 20개 아미노산 글리신-세린 스페이서(G4S)3를 인터도메인 서열 속에 도입함으로써 수용체의 리간드 수용력을 확보한다. 그러나 다른 스페이서도 적용할 수 있다.
스페이서
-인간
CST28
삽입체의
제조
HN 도메인의 C-말단에 CST28 서열을 제공함에 있어서, 골격 클론(서열번호 4)에 삽입할 수 있도록 스페이서 및 표적화 성분(TM) 영역에 측부 접합되는 형태로 DNA 서열을 설계한다. DNA 서열은 BamHI-SalI-PstI-XbaI-스페이서-CST28-종결 코돈-HindIII (서열번호 6) 형태로 정리배열될 수 있다. 다양한 역번역 소프트웨어 툴 중 하나 (예, EditSeq 베스트 대장균 역번역기(DNASTAR Inc.) 혹은 백트랜슬레이션 툴 v2.0(Enterlechon))을 이용하여 DNA 서열을 설계할 수 있다. TM DNA를 설계한 후, 적당한 스페이서를 암호화 하는데 필요한 또다른 DNA를 Silico 실험에서 제작한다. 스페이서, SST28 및 제한서열에 관련한 올바른 해독프레임을 확보하는 것과 또한, XbaI 서열에서, DAM 메틸화 반응을 유도하는 염기 TC가 선행하지 않는다는 점이 중요하다. DNA 서열은 삽입된 제한서열에 관하여 스크리닝 처리하고 또다른 서열은 나머지 서열로부터 수작업으로 제거함으로써, 일반적인 대장균 코돈을 계속 사용한다. 대장균 코돈의 사용빈도를 그래픽 코돈 사용빈도 분석기(Geneart) 등의 소프트웨어 프로그램에 따라 평가하며, 또한 공개된 코돈 사용표 (예, GenBank Release 143, 2004년 9월 13일)에 근거하여 GC% 함량 및 코돈 사용비율을 평가한다. 상기의 최적화된 DNA 서열을 다시 상용 합성하여 (예, Entelechon 이용, Geneart 또는 Sigma-Genosys) pCR 4 벡터에 제공한다.
골격 클론의 조립과 확인
골격 구조체(서열번호 4)와 또한, CST28 TM(서열번호 6)를 암호화하는, 신규합성된 pCR 4-스페이서-TM 벡터를 이용하여 LHN/D-GS20-CST28 구조체(서열번호 17)를 제작하기 위해서, 1단계 혹은 2단계식 방법을 이용할 수 있다: 통상, 2단계 방법은 TM DNA가 100 염기쌍 미만일 때 이용한다. 1단계 방법을 이용할 경우, 먼저 pCR 4-스페이서-TM 벡터를 Xbal 및 HindIII 제한효소로 절단한 다음 TM 암호화 DNA 절편을 유사하게 절단된 pET 골격 구조체편 속에 삽입함으로써, CST28을 직접 골격 구조체에 삽입할 수 있다. 한편 2단계 방법의 경우, BamHI 및 XbaI 제한효소를 이용하여 LHN 도메인을 골격 클론에서 제거한 다음 이 제거물을 소화처리된 유사한 pCR 4-스페이서-CST28 벡터에 접합시키는 것이다. 상기 방법에 따라 pCR 4의 내부에 LHN-스페이서-CST28 ORF를 형성하며, 이 형성물은 BamHI 및 HindIII 제한효소를 이용하여 벡터로부터 제거하여 유사하게 절단된 pET 발현 구조체에 추후 접합시킬 수 있다. 최종 구조체는 LC-링커-HN-스페이서-CST28 DNA(서열번호 17)을 함유하며, 결과적으로 서열번호 18에 예시된 서열을 함유하는 융합단백질을 얻는다.
실시예
5
LH
N
/D-
CT
-
CST28
융합단백질의
발현 및 정제
본 실시예는 CST28 TM 폴리펩티드를 HN 도메인(서열번호 18)의 카르복실기 말단에 삽입한 LHN/D 단백질의 제조방법에 근거하며, 상기 영역에서 pET 발현 벡터 ORF는 히스티딘 정제 태그를 암호화 한다. 이러한 절차와 방법은 서열번호 15, 16, 18-24, 27-31, 33-41, 58-59 및 93-94에서 보는 바와 같은 기타의 융합단백질에도 마찬가지로 적용될 수 있다. 바람직하게는, 각 서열에서 프로테아제 활성부위와 융화성이 있는 활성효소를 선택한다.
LH
N
/D-
CT
-
CST28
발현
LHN/D-CT-CST28 단백질의 발현은 다음과 같은 프로토콜에 따라 달성된다. 0.2% 글루코사민이 함유된 100ml의 TB 변형물 및 30 ㎍/ml의 카나마이신을 250ml 플라스크에 담고, 여기에 LHN/D-CT-CST28 발현균주로부터 얻은 단일 콜로니를 접종한다. 배양물을 37℃ 및 225rpm에서 16시간 동안 성장시킨다. 0.2% 글루코사민이 함유된 1L TB 변형물 및 30 ㎍/ml의 카나마이신을 2L 플라스크에 담고, 여기에 하룻밤 배양한 배양액을 10ml의 양으로 가하여 접종한다. 약 0.5 OD600nm에 도달할 때까지 배양물을 37℃ 서 성장시키고 상기 농도에 도달하면 온도를 16℃으로 낮춘다. 1시간 후 1mM IPTG로 배양을 촉진하고 16℃에서 다시 16시간 동안 성장시킨다.
단백질
LH
N
/D-
CT
-
CST28
정제
35ml의 50mM HEPES pH 7.2 200mM NaCl 및 약 10g의 대장균 BL21(DE3) 세포 페이스트가 담긴 디프로스트 팰컨 튜브을 준비한다. 상기 세포 페이스트를 균질화하고(20psi) 시료를 냉각 상태로 유지한다. 용균 세포를 4℃에서 18000rpm으로 30분간 스핀 교반한다. 50 mM HEPES pH 7.2 200 mM NaCl로 평형화 처리한 0.1M NiSO4 충전 킬레이트 컬럼 (20 내지 30ml 용량의 컬럼이면 충분함)에 상청액을 주입한다. 10, 40 및 100mM 이미다졸을 단계적으로 사용하여 비-특이적 결합단백질을 세척제거한 뒤 200mM 이미다졸로 융합단백질을 용리한다. 용리된 융합단백질을 4℃에서 하룻밤동안 5L의 50mM HEPES pH7.2 200mM NaCl에 투석시키고 OD280nm 값을 측정하여 단백질 농도를 확정한다. 융합단백질 1mg당 3.2㎕ 엔테로키나제 (뉴잉글랜드 바이오랩)을 첨가하고 25℃에서 하룻밤동안 정치배양한다. 50 mM HEPES pH 7.2 200 mM NaCl로 평형화 처리한 0.1M NiSO4 충전 킬레이트화 컬럼 (20 내지 30ml 용량의 컬럼이면 충분함)에 상기 용액을 주입한다. 50 mM HEPES pH 7.2 200 mM NaCl로 컬럼을 기준선까지 세척한다. 10, 40 및 100mM 이미다졸을 단계적으로 사용하여 비-특이적 결합단백질을 세척제거한 뒤 200mM 이미다졸로 융합단백질을 용리한다. 용리된 융합단백질을 4℃에서 하룻밤동안 5L의 50mM HEPES pH7.2 200mM NaCl에 투석시키고 이 융합물을 약 2mg/ml까지 농축한 뒤, 시료를 분취하여 -20℃로 냉동시킨다. 정제 단백질을 OD280, BCA 및 순도 분석법에 따라 시험한다. 도 1 및 2는 SDS-PAGE로 분석한 융합단백질의 정제 상태를 도시한다.
실시예
6
SST
TM
에 대한
LH
N
/
A 의
화학 접합
실시예 3에 개시된 제조방법에 따라 서열번호 1으로부터 얻은 LHN/A 아미노산 서열(서열번호 49)을 보유하는 화학접합된 분자 및 화학합성된 SST 옥트레오티드 펩티드(서열번호 54)를 다음과 같은 절차로 제작한다. 그러나, 아미노산 서열(서열번호 50, 51, 52, 53 등)을 함유하는 프로테아제/전위 도메인 단백질에 대하여 서열번호 55 및 서열번호 56 등의 다른 펩티드를 접합하는 경우에도 위와 동일한 절차 및 방법을 적용할 수 있다.
LHN/A 단백질에 대하여, Bio-rad PD10 컬럼을 통해 50 mM Hepes 150 Mm염을 PBSE (100mM 14.2g NA2HPO4, 100mM 5.85g NaCl, 1mM EDTANa2 pH 7.5 with 1M HCl)으로 완충액 교환했다. 상기 작업은 컬럼 1개에 해당하는 부피의 PBSE를 PD10 컬럼에 부어 세척함으로써 달성하였다. 다음, PD10 컬럼의 말단 밖으로 흘러나오지 않을 때까지 단백질을 컬럼에 채웠다. 여기에 8ml의 PBSE를 가하여 0.5ml 분획물을 수거했다. 수거한 분획물은 A280 판독법을 이용하여 측정하고 단백질 함유 분획물을 수집한다. 완충액 교환 단계에서 수득한 LHN/A의 농도는 1.55mg/ml이었으며 이것을 이용하여 다음과 같은 반응 조건을 설정하였다:
LHN/A 1.55 mg/ml | 20 mM SPDP 또는 술포-LC-SPDP |
A 200 ㎕ | 0 |
B 200 ㎕ | 4배 증가, 0.62 ㎕ |
C 200 ㎕ | 8배 증가, 1.24 ㎕ |
시료를 뒤섞으며 실온(RT)에서 3시간 동안 놓아둔 후 또다른 PD10 컬럼에 통과시켜 PBSE로 완충액 교환처리 했다. 단백질이 함유된 분획물을 수집했다. 최종 농도 25mM의 DTT를 상기와 같이 유도된 단백질에 가한 후 이 시료를 10분간 실온에 두었다. A280 및 A343 판독치를 구하여 SPDP:LHN/A의 상호반응비를 산출하고, 그 결과로 얻은 1 내지 3의 유도반응비를 펩티드 접합반응에 이용했다. SPDP 시약은 N-히드록시숙신이미드(NHS) 에스테르를 통해 LHN/A의 1차 아민에 결합하고, 이 결과로 나온 술프히드릴-반응성 부분은 합성 펩티드에서 유리된 시스테인의 SH 유리기와 디설파이드 결합을 형성한다. 여기서의 펩티드 서열은 N-말단에서 유리 시스테인과 합성된 옥트레오티드이다 (서열번호 91). SPDP-유도화된 LHN/A를 4배 초과량의 옥트레오티드 리간드와 혼합하고 이 반응물은 RT에서 90분간 교반 유지하였다. LHN/A-옥트레오티드 접합(혹은 공액)분자를 잔류시키는 상기 두 PD10 컬럼 중 어느 하나를 이용하여 초과량의 옥트레오티드를 제거했다.
실시예
7 배양된 내분비 세포(
AtT20
)에서의
SST
-
LH
N
/A의 활성
래트 뇌하수체 종양 세포주 AtT20는 내분비계 세포주의 한 예이다. 따라서 이것이 소정 약제의 방출 억제효과 모델 연구에 이용되는 대표적인 모델 세포주가 된다.
AtT20 세포는 SST-LHN/A의 결합 및 '내부화'를 가능하게 하는 표면수용체를 보유한다. 반면에, AtT20 세포는 클로스트리듐 신경독소를 위한 적절한 수용체는 갖고 있지 않으므로 보툴리눔 신경독소(BoNTs)의 침입에 취약하지 않다.
도 3a는 SST-LHN/A를 이용한 사전배양 후 AtT20 세포로부터 ACTH의 방출이 억제되는 효과를 보여준다. 즉 약량의존성 억제효과가 뚜렷이 관찰되며, 이는 SST-LHN/A가 내분비계 세포 모델에서 ACTH 방출을 억제할 수 있음을 입증하는 것이다. ACTH 방출 억제는 SNARE 단백질인 SNAP25의 절단과 상호관련이 있는 것으로 확인되었다 (도 3a 및 b). 그러므로 화학 메신저의 방출 억제는, SNARE-단백질 절단에 대한 클로스트리듐 엔도펩티다제-매개의 영향에 기인한 것이다.
재료와 방법
ACTH 효소 면역분석 키트는 바켐 리서치사(CA, USA)의 제품이었다. 웨스턴 블롯 시약은 인비트로겐 시그마 (Invitrogen and Sigma)사 제품이었다. AtT20 세포는 12웰 플레이트에 분주하여 10% 태아소 혈청 및 4mM 글루타막스가 함유된 DMEM에서 배양했다. 1일 후 SST-LHN/A 를 72시간에 걸쳐 가한 다음 세포를 세척하여 결합되지 않은 SST-LHN/A를 제거했다. 30분 동안 세포외칼륨(60mM KCI) 및 세포외칼슘 (5mM CaCl2)의 농도를 증가시켜 ACTH 분비를 자극했다. 세포로부터 배지를 수득하여, 제조사의 사용설명에 따라 면역분석 키트로 ACTH 함량을 분석하기 전까지 -20℃ 에서 보관했다. 1x LDS 전기영동 환원형 시료 완충액에 세포를 용해시켜 90℃로 10분간 열처리한 후 웨스턴 블롯 전까지 -20℃에서 보관했다. 자극 조건하의 총 방출에서 기저방출량을 제하여 자극에 따른 분비량을 계산했다. 용해된 세포 시료는 SDS-PAGE로 분리하여 니트로셀룰로오스막에 전달했다. SNAP-25, 주요 신경분비 성분, 및 BoNT/A의 아연의존성 엔도펩티다제 활성에 이용되는 기질 등의 단백질 분해작용은, 원형 및 절단 형태의 SNAP-25를 모두 인지하는 항체를 이용하여 탐침함으로서 검출하였다. 특수 영상장치 (Synoptics Syngene GeneGnome imaging system)를 이용한 영상분석법과 유전자툴(GeneTool) 소프트웨어에 따라 상기의 단백질 분해작용을 정량분석하였다.
실시예
8 배양된 내분비 세포(
GH3
)에서의
SST
-
LH
N
/D의 활성
래트 뇌하수체 종양 세포주 GH3은 내분비계 세포주의 한 예이다. 따라서 이것이 특정 약제의 방출 억제효과 모델 연구에 이용되는 대표적인 모델 세포주가 된다.
GH3 세포는 SST-LHN/D의 결합 및 내부화를 가능하게 하는 표면수용체를 보유한다. 반면에, GH3 세포는 클로스트리듐 신경독소에 적합한 수용체는 갖고 있지 않으므로 보툴리눔 신경독소(BoNTs)의 침입에 취약하지 않다.
도 4는 SST-LHN/D를 이용한 사전배양 후 GH3 세포로부터 성장호르몬(GH)의 방출이 억제되는 효과를 보여준다. 즉 약량의존성 억제효과가 뚜렷이 관찰되며, 이는 SST-LHN/D가 내분비계 세포 모델에서 GH 방출을 억제할 수 있음을 입증하는 것이다.
접합체 및 표적화되지 않은 LHN/D에서 관찰된 억제효과를 비교하면, 표적화 성분(TM)이 신경전달물질의 방출을 효과적으로 억제하는데 공헌함을 확인할 수 있다.
재료 및 방법
GH 효소 면역분석 키트는 밀리포어사 (MA, USA) 제품이었다. GH3 세포는, 15% 말혈청, 2.5% FBS 및 2mM L-글루타민을 보충한 F-10 영양혼합액(Ham)에 넣어 24웰 플레이트에서 배양했다. SST-LHN/D 또는 LHN/D 로 세포를 72시간 처리한 다음 세척하여 결합되지 않은 SST-LHN/D을 제거했다. 세포를 10μM의 테트라데카노일 포볼 아세테이트(TPA, PMA)에 30분 정도 노출시켜 분비를 자극했다. 세포로부터 배지를 수득하여, 제조사의 사용설명에 따라 면역분석 키트로 GH 함량을 분석하기 전까지 -20℃ 에서 보관했다. 자극 조건하의 총 방출에서 기저방출량을 제하여 자극에 따른 분비량을 계산했다.
실시예
9 뇌하수체 선종에 의해 증가한
GH
및
IGF
-1 농도를 감소시켜 말단비대증 증세를 경감하는 방법
배드민턴 지역팀의 35세 남성 회원이 하복부 통증으로 척수 X-선 검사를 받았다. 상담의사가 비정상적인 골성장을 주목했고 질문에 대해 피검사자는 수면 무호흡에 빠지는 경우가 늘고 피부의 유분이 증가하고 있음을 전달했다.
의사의 권고에 따라 순환 IGF-1의 상태를 측정한 결과 그 농도가 상승한 것으로 확인되었다. 후속 검사에서 정상치보다 높은 순환 GH 농도가 확인되어 뇌 자기공명(MRI) 스캔 검사를 실시하였다. 검사 결과 9mm 직경크기의 뇌하수체 종양이 발견되었다. 환자에게 코르티스타틴이나 소마토스타틴 펩티드 TM 융합단백질(예, 서열번호 7-16, 18-24, 26-31) 을 정맥주사하여 치료하였다.
그 후 1주일 간격으로 순환 IGF-1 농도를 측정했을 때, 최초 측정시 그 농도가 감소했고 또한 후속의 6주일에 걸쳐 정상치보다 15% 상회하는 수준까지 계속 감소하는 것으로 나타났다. 이 시기의 순환 GH 농도는 정상이었다. 그 뒤, 2주일 간격으로 IGF-1를 측정하면서 약제를 투여하자 이 호르몬이 정상범위의 상한치로 안정화되는 것을 확인할 수 있다. 2차 치료뒤 6주일후, 뇌 MRI 스캔에서 종양이 6mm로 축소한 것으로 나타났다. 2주일 간격 및 투약량을 줄여 계속 치료하면서 제7주에 IGF-1 및 GH 농도를 측정했다. 이들 농도는 모두 정상범위로 안정한 상태이며 이제 수면 무호흡이나 피부 유분 등도 사라졌다. 처음 치료 뒤 1년 후의 척수 X-선 검사에서, 최초 관찰했을 때의 골격 크기가 더 이상 증가하지 않은 것으로 확인되었다.
실시예
10 뇌하수체 선종으로 인해
증가된
GH
및
IGF
-1 농도를 감소시켜 손가락의 부종 및 다모증을
정상화 하는
방법
한 50세 여성 제과사는 결혼반지를 빼기 어려운 상태가 심화되어 주치의를 찾았다. 의사는 환자의 손가락에 예상보다 많은 체모가 있음에 주목하여 질문했고 이에 환자는 이러한 병리상태가 점차 진행되고 있음을 인정했다. 후속의 임상검사에서, 고혈당 음료를 섭취한 뒤에도 순환 GH 농도에 변화가 없고 평균보다 높은 수준인 것으로 나타났다. 말단비대증 증세가 의심되어 뇌 CT 스캔한 결과 작은 뇌하수체 종양이 확인되었다.
외과수술은 부적절한 것으로 판단되어 환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM 융합단백질 (예, 서열번호 7-16, 18-24, 26-31)을 정맥주사하여 치료했다. 4주 이내에 내당능검사에서 GH 농도 및 IGF-1 농도가 정상에 가까운 반응을 보이는 것으로 확인되었다. 6주일 간격으로 치료를 계속한 결과 제18주의 끝에 환자는 결혼반지를 쉽게 뺄 수 있었으며 다모증도 사라졌다.
실시예
11 성장호르몬 분비성 뇌하수체 선종의 재발을 완화하는 방법
52세 남성 스쿠버다이버가 뚜렷한 말단비대증 증세와 함께 연조직 부종 및 사지 확장 현상을 나타내었다. 정밀 검사에서 12mm 뇌하수체 선종이 발견되었다. 소마토스타틴 유사체에 대한 내성이 낮아 종양을 절제한 후 2년간 정기 검사를 시행한 결과, 순환 GH 및 IGF-1 농도가 정상 범위 중 상위 수준이었으며 따라서 추가의 약제는 투여하지 않았다. 18개월 후, 다한증 및 약간의 고혈압 증세를 보이는 한편 GH 및 IGF-1 농도가 정상치보다 높은 것으로 확인되었고 CT 스캔 결과 뇌하수체 선종이 다시 성장한 것으로 나타났다. 재수술은 바람직하지 않은 것으로 판단되었다.
이 환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM 융합단백질 (예, 서열번호 7-16, 18-24, 26-31)을 정맥주사하여 치료하였다. 이와 함께 방사선치료도 병용한 결과 4주후, GH 및 IGF-1 농도와 더불어 다한증 및 고혈압이 거의 정상에 근접하였다. 추후 3년 동안 증세는 재발하지 않았으며 치료후 5년간 종양의 재성장도 발견되지 않았다.
실시예
12
소마토스타틴
유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
축제마당의 타로카드 점술사인 60세의 말단비대증 환자의 경우, 지난 6년간 소마토스타틴 유사체를 이용하여 순환 GH 및 IGF-1 농도를 성공적으로 제어했으나, 현재 피부의 유지 분비가 증가하고 있으며 다한증 탓에 체취가 심하다. 이 환자는 내당능 장애 상태에 있으며 순환 IGF-1 농도가 상승하는 추세이고 또한 SSA 투약량을 늘려도 이러한 증세를 억제하지 못하였다.
환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM 융합단백질 (예, 서열번호 7-16, 18-24, 26-31)을 국소주사하여 치료하였다. 환자는 14일이 지나지 않아 땀 분비량이 현저히 감소하였음을 알려왔다. 후속월에는 번들거리는 피부가 정상으로 회복되었고 같은 시기에 환자의 GH 및 IGF-1 농도가 모두 정상 범위에 들어왔다. 이러한 상태가 추후 5년간 지속되었다.
실시예
13
소마토스타틴
유사체에 대한 내성이 없는 환자의 쿠싱병 치료방법
학생인 30세의 여성이 의사를 방문하여 우울 및 불안증 치료를 요청했다. 관찰 결과 의사는 여성이 둥근 얼굴로 목 주변에 지방이 많고 정상인보다 팔과 다리가 가늘다고 판단했다. 질문을 통해 여성의 생리주기가 불규칙한 것을 확인했다. 24시간 동안의 소변내 유리 코르티솔의 농도가 150㎍ 으로 측정되어 쿠싱병을 의심했다. 복부 MRI 스캔에서 부신피질 종양은 나타나지 않았으나 뇌 MRI 스캔 결과 작은 뇌하수체 종양이 발견되었다.
이 환자는 수술을 시행하기에 부적절하다고 판단하여 소마토스타틴이나 코르티스타틴 펩티드 TM 융합단백질 (예, 서열번호 7-16, 18-24, 26-31)로 치료했다.
실시예
14 프로락틴
분비종
치료에 따른 여성 성기능 부진의 회복방법
36세 여성이 의사를 방문하여, 임신검사에서 음성이었음에도 불구하고 현재 젖이 분비되고 있다는 걱정을 털어놓았다. 또한 검사에서 질건조증이 진찰되었고 환자 스스로 성욕이 사라졌다고 전했다. 임상검사 결과, 대체적으로는 정상이었으나 고프로락틴혈증이 다소 나타났다. 뇌 MRI 스캔에서 뇌하수체 선종이 발견되었으며 이는 프로락틴 농도의 증가와 일관하는 것이다.
환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM 융합단백질 (예, 서열번호 7-16, 18-24, 26-31)의 조제약을 경구 투여하여 치료했다. 8일후, 더 이상 유즙 분비가 나타나지 않았으며 질의 수분 농도도 크게 개선되었다. 7주후에는 건조증이 다시 나타나기 시작했으나 2차 치료에 의해 거의 즉시 회복되었다. 6주간 성질환 진료소를 방문하면서 치료를 계속한 결과, 이 여성은 성적 활력이 정상으로 돌아왔다고 전했다.
실시예
15 인슐린 종양을 치료하여 체중감소를 달성하는 방법
64세, BMI값이 35인 여성이 수술 불가한 인슐린 종양을 가진 것으로 진단되었다. 지속적인 식욕감소 및 체중감소를 달성하고자 에어로빅에 적극적인 관심을 기울이고 있는 환자에게, 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단배질을 전신투여하여 치료했다. 치료후 10일 내지 14일 이내에 체중이 안정 상태로 접어들고 30일째에는 체중감소가 이루어졌다. 24주간에 걸친 일련의 주사로 약물을 지속 투여함으로써 환자의 체중이 대폭 감소하였다.
실시예
16
글루카곤종
치료방법
둔부, 서혜부 및 하지에 발진이 생긴 63세 여성이 의사를 방문하여 신체의 불편을 호소했다. 혈액검사에서 빈혈과 당뇨가 확인되었으며 또한 잦은 설사도 겪고 있었다. 글루카곤종으로 의심되었으며 CT 스캔으로 췌장끝에 종양이 있음을 확인했다.
환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)을 함유한 융합단백질을 투여하여 치료했다. 4주후 설사 증세가 가라앉고 발진도 크게 줄어 깨끗해졌다. 적혈구 수치도 정상에 가까운 상태로 회복되었다. 6주간격으로 이 치료를 반복하자 모든 증세가 대부분 제어 가능한 상태로 유지되었다.
실시예
17
장폴리펩티드
분비종에
의한 설사 및 작열감을 치료하는 방법
49세 남성이 만성 작열감과 함께 분비성 설사로 고통받고 있다. 임상검사에서 대사성 산혈증이 확인되었고 CT 스캔시 종양 -VIPoma (장폴리펩티드 분비종)이 거의 확정적- 이 췌장 근처에서 나타났다.
외과적 수술은 적용할 수 없으므로 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질로 환자를 치료했다. 3주 이내에 작열감이 중단되고 설사 횟수도 크게 감소했다. 치료후 7주가 되자 모든 증세가 사라졌으며 이 상태를 유지하기 위해 약 8주 간격으로 치료를 반복했다.
실시예
18
가스트린종
치료방법
47세 남성이 심각한 소화궤양으로 급성 복통을 호소했다. 또한 원인불명의 설사증을 경험하여, 결국 혈액검사 및 복부 초음파 검사에서 췌장내 가스트린종으로 진단받았다.
환자에게 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질 또는 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유한 융합물로 이루어진 약제를 종양내 주사로 투여하여 치료했다. 1주일 내에 고통스런 위장 증세가 개선되기 시작했다. 고가스트린혈증이 진정되고 설사증도 그 심각도와 횟수가 감소했다. 이러한 상태가 7주간 지속되었으나 그 후부터 혈중 가스트린 농도가 상승하기 시작했다. 치료를 7주 간격으로 반복했고 이에 따라 혈중 가스트린 농도가 정상 수준을 유지하며 다른 증세들은 재발하지 않았다.
실시예
19
티로트로피노마에
의한 갑상선중독증의 치료방법
39세 여성 항공기 승무원이 과다 발한 및 원인불명의 신경과민으로 일 수행시 능력에 영향을 받기 시작하자 의사를 찾았다. 진찰 과정에서 미세한 종양이 발견되었고 의사는 갑상선중독증으로 감지했다. 여성에게 내분비학 전문가를 소개하여 수차례 혈액검사를 받게 했다. 검출된 주요 이상징후는 티록신 농도 증가뿐만 아니라 TSH (티로트로핀) 농도의 증가로서, 이는 티로트로피노마를 가리키는 지표이다. 뇌의 MRI 스캔 결과 뇌하수체 종양이 확인되었다.
여성에겐 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질으로 이루어진 약제를 투여하여 치료했다. 발한 및 신경과민이 2주에 걸쳐 감소하였다. 2주후 혈액검사에서 티록신 및 티로트로핀의 농도가 하강하는 것으로 나타났으며 6주일이 지나자 정상 수준에 도달하였다. 환자는 근무활력을 완전히 되찾을 수 있었다.
실시예
20 말단비대증으로 인한 재발성 연부조직 부종의 치료방법
뇌하수체 거대선종 제거를 위해 (경접형동) 수술을 받은 72세 여성이 말단비대증 증세의 재발 (1차로 손가락과 혀의 부종이 있고 피로감 및 무기력감이 증가함)을 보였다. 뇌 MRI 스캔에서 뇌하수체 미세선종으로 추측되는 종양이 발견되고 후속의 혈액검사에서 순환 GH 및 IGF-1 농도의 상승을 확인하였다.
수술은 이미 존재하는 의료 조건과 병용하기 부적합하다고 판단하여 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질로 이루어진 약제로 치료한다. 1주후 환자는 훨씬 활력이 있으며 손가락과 혀의 부종도 크게 감소했다고 알려왔다. 3주가 지나자 재발성 증세도 완전히 회복되었으며 내분비학적 검사에서 GH 및 IGF-1 농도가 정상화 한 것을 확인했다. 환자를 월 단위로 모니터하고 10주 간격으로 반복치료를 시행했다. 이 투약 처방에 따라 호르몬 농도를 정상 수준으로 유지하고 증세 재발을 방지했다.
실시예
21 쿠싱병으로 인한 과다 안면 다모증의 치료방법
27세 미용 컨설턴트로서 안면의 체모가 현저히 성장하기 시작한 환자이다. 일반적인 제모법으로는 적절히 치유되지 않았으며 직업 및 사생활에 있어서 심각한 정신적 문제를 일으켰다 (우울, 불안 등). 주치의는 쿠싱증후군임을 감지하고 내분비 전문의를 찾도록 했다. 혈액검사 및 소변검사 결과 코르티솔 및 ACTH 농도가 증가하고 CRH 자극 시험에서 양성으로 나타나, ACTH-분비성 뇌하수체 종양의 가능성이 높은 것으로 확인되었다. 부신 및 뇌하수체 CT-스캔에서 뇌하수체 종양의 존재가 확인되었으나 부신이상은 보이지 않았다.
상담의사와 의논한 후 환자는 의료적 조치를 받기로 했으며, 이에따라 소마소스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질 또는 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유한 융합물로 이루어진 약제로 환자를 치료했다. 10일 이내에 여성의 컨디션이 좋아지기 시작하고 2주후부터 체모 표백이나 제모 용도의 크림을 사용하는 횟수가 현저히 감소했다. 이 증세는 10 내지 12주 즈음에 다시 나타나기 시작하였으므로 2차 치료를 시행했다. 증세 완화, 점진적 재현 및 치료라는 패턴이 유사하게 일어난다. 3차 치료 도중, 환자는 뇌하수체 종양을 절제하는 수술을 선택했다. 그 후 2년간의 지속적인 관찰에서 위와 같은 증세나 종양이 재발하지 않는 것으로 나타났다.
실시예
22 프로락틴
분비종으로
인한 남성의
유루증을
치료하는 방법
40세 남성 럭비선수는 훈련 탓으로 보기에 지나칠 정도로 가슴이 커지는 것을 걱정하였다. 특히 왼쪽 가슴에서 젖이 조금씩 새어나올 때가 있어 큰 스트레스를 받고 있다. 주치의는 즉시 뇌하수체의 프로락틴 분비종을 의심하여 환자를 방사선과 전문의 및 내분비계 전문의에게 보냈다. 혈액검사에서 고프로락티네미아로 나타났으나 갑상선 기능은 정상이었다. 뇌 MRI 스캔 결과 뇌하수체 종양이 존재하는 것으로 확인되었다.
종양 덩어리에 의한 영향은 없으므로 소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)을 함유한 융합단백질로 이루어진 약제를 이용하여 환자를 치료했다. 4일만에 유즙 분비가 멈추었고 6주 후에는 비근육성 가슴 조직이 뚜렷하게 감소했다. 이 시기 동안 혈중 프로락틴 농도를 격주 측정했고 4주간의 치료에 따라 이 농도는 정상으로 회복했다. 12주 간격으로 치료를 반복했고 이 동안 증세 재발이나 종양 성장 등의 징후는 나타나지 않았다. 상술한 조건이 유지되는 한 수술 혹은 기타의 종양 축소 치료는 불필요하다고 판단되었다.
실시예
23 인슐린 종양으로 인한 다발성 증세의 치료방법
침침한 시야, 두근거림, 쇠약, 불면 등 최근에 다양한 병리상태를 겪고 또한 3개월 동안 두번 기절한 경험도 있는 51세 남성이 의사를 찾아 인슐린 종양으로 진단받았다. 이 진단결과는 내분비계 및 방사선 검사로 확진 판정을 받았다.
소마토스타틴이나 코르티스타틴 펩티드 TM (예, 서열번호 7-16, 18-24, 26-31)를 함유한 융합단백질 혹은 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유한 융합물로 이루어진 약제로 환자를 치료했다. 1주일 이내에 시력과 원기를 정상 수준으로 회복했으며 추후 2주일에 걸쳐 지속적으로 개선되었다. 4주일째부터 저혈당이 더 지속되지 않으며 이 시점에서 췌장 두부의 종양에 대한 복강경 적출 수술을 실시했다. 환자를 후속 모니터한 결과 종양 덩어리나 증세가 더 이상 나타나지 않았고 3년후에도 여전히 건강을 유지했다.
실시예
24
소마토스타틴
유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
말단비대증 환자인 54세 여성 사무원은 지난 3년간 소마토스타틴 유사체로 순환 GH 및 IGF-1을 성공적으로 제어하였으나, 최근 피부 유분이 눈에 띄게 증가하고 다한증으로 인해 체취가 심해졌다. 환자에게서 내당능 장애 및 순환 IGF-1 농도 증가가 확인되었고 SSA 투약량을 늘려도 이 상태는 제어되지 않았다.
환자에게 성장호르몬 분비 호르몬 펩티드 TM (예, 서열번호 34, 42-47, 60-92)을 함유한 융합단백질을 정맥주사하여 치료하였다. 14일 이내에 환자의 발한증세가 크게 감소한 것으로 기록되었다. 후속 월에는 번들거리는 피부가 정상으로 회복되고 이 시점에서 GH 및 IGF-1 농도 모두가 정상 범위에 들어왔다. 이러한 상태는 후속 5년 동안 계속 유지되었다.
실시예
25
소마토스타틴
유사체에 대한 내성이 없는 환자의 쿠싱병 치료방법
리셉션 담당자인 37세 여성이 주치의를 방문하여 불안과 우울증 치료를 요청했다. 의사의 관찰에 따르면 여성은 둥근 얼굴로서 목 주변에 지방이 많고 팔과 다리는 정상인보다 가늘었다. 질문을 통해 여성의 생리주기가 불규칙한 것을 확인했다. 24시간 동안 소변내 유리 코르티솔의 농도가 150㎍ 으로 측정되어 쿠싱 증후군을 의심했다. 복부 MRI 스캔에서 부신피질 종양은 나타나지 않았으나 뇌 MRI 스캔 결과 작은 뇌하수체 종양이 발견되었다.
이 환자는 수술을 시행하기에 부적절하다고 판단하여 우로텐신 펩티드 TM (예, 서열번호 48)를 함유한 융합단백질을 정맥주사하여 치료했다.
실시예
26 프로락틴
분비종의
치료에 따른 여성 성기능 부진의 회복방법
28세 여성이 의사를 방문하여, 임신검사에서 음성이었음에도 불구하고 현재 젖이 분비되고 있다는 걱정을 털어놓았다. 또한 검사에서 질건조증이 진찰되었고 환자 스스로 성욕이 사라졌다고 전했다. 임상검사 결과, 대체적으로는 정상이었으나 고프로락틴혈증이 다소 나타났다. 뇌 MRI 스캔에서 뇌하수체 선종이 발견되었으며 이는 프로락틴 농도의 증가와 일치하는 것이다.
그렐린 펩티드(GHRP) TM (예, 서열번호 33, 35, 38)을 함유한 융합단백질 혹은 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유한 융합물을 정맥주사하여 치료했다. 4일후, 더 이상 유즙 분비가 나타나지 않았으며 질의 수분 농도도 크게 개선되었다. 13주후에는 건조증이 다시 나타나기 시작했으나 2차 치료에 의해 거의 즉시 회복되었다. 12주간 성질환 진료소를 방문하면서 치료를 계속한 결과, 이 여성은 성적 활력이 정상으로 돌아왔다고 전했다.
실시예
27 쿠싱병 치료방법
30세 여성 타이피스트가 주치의를 방문하여 불안과 우울증 치료를 요청했다. 의사의 관찰에 따르면 여성은 둥근 얼굴로서 목 주변에 지방이 많고 팔과 다리는 정상인보다 가늘었다. 질문을 통해 여성의 생리주기가 불규칙한 것을 확인했다. 24시간 동안 소변내 유리 코르티솔의 농도가 200㎍ 으로 측정되어 쿠싱 증후군을 의심했다. 복부 MRI 스캔에서 부신피질 종양은 나타나지 않았으나 뇌 MRI 스캔 결과 작은 뇌하수체 종양이 발견되었다.
이 환자는 수술을 시행하기에 부적절하다고 판단하여 봄베신 펩티드(GRP) TM (예, 서열번호 40-41)를 함유한 융합단백질 혹은 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유하는 융합물을 이용하여 치료했다.
실시예
28
가스트린종
치료방법
63세 남성이 심한 소화궤양으로 급성 복통을 호소했다. 또한 원인불명의 설사증을 겪은 적도 있었다. 결국 혈액검사 및 복부 초음파 검사에서 췌장내 가스트린종으로 진단받았다.
프로테아제-전위 단백질 (예, 서열번호 49-53)에 화학접합된 소마토스타틴이나 코르티스타틴 펩티드 TM 유사체 (옥트레오티드 - 서열번호 54)를 함유한 융합단백질로 이루어진 약제를 종양내 주사로 투여하여 환자를 치료했다. 1주일 내에 고통스런 위장 증세가 개선되기 시작했다. 고가스트린혈증이 진정되고 설사증도 그 심각도와 횟수가 감소했다. 이러한 상태가 8주간 지속되었으나 그 후 혈중 가스트린 농도가 상승하기 시작했다. 치료를 8주 간격으로 반복했고 이에 의해 혈중 가스트린 농도가 정상 수준을 유지하며 다른 증세들은 재발하지 않았다.
실시예
29 뇌하수체 선종으로 인해 증가한
GH
및
IGF
-1 농도를 감소시켜 말단비대증의 증세를 완화하는 방법
50세 여성이 수면 무호흡에 빠지는 경우가 늘고 또한 피부의 유분이 증가하고 있음을 담당의사에게 전했고, 의사는 관찰을 통해 환자의 비정상적인 골성장을 확인했다.
의사의 권고에 따라 순환 IGF-1의 상태를 측정한 결과 그 농도가 상승한 것으로 확인되었다. 또한 후속 검사에서 정상치보다 높은 순환 GH 농도가 확인되어 뇌 MRI 스캔을 실시하였다. 검사 결과 5mm 직경크기의 뇌하수체 종양이 발견되었다. 환자에게 MCH 융합단백질 (예, 서열번호 57)을 정맥주사하여 치료하였다.
그 후 1주일 간격으로 순환 IGF-1 농도를 측정했을 때, 최초 측정시 그 농도가 감소했고 또한 후속의 8주일에 걸쳐 정상치보다 5% 상회하는 수준까지 계속 감소하는 것으로 나타났다. 이 시기의 순환 GH 농도는 정상이었다. 그 뒤, 2주일 간격으로 IGF-1를 측정하면서 약제를 투여하자 이 호르몬이 정상범위의 상한치에서 안정화되는 것을 확인할 수 있다. 2차 치료뒤 6주일후, 뇌 MRI 스캔에서 종양이 3mm로 축소한 것으로 나타났다. 2주일 간격 및 투약량을 줄여 계속 치료하면서 제7주에 IGF-1 및 GH 농도를 측정했다. 이들 농도는 모두 정상범위에서 안정한 상태이며 이제 수면 무호흡이나 피부 유분 등도 사라졌다.
실시예
30
소마토스타틴
유사체에 대한 내성이 있는 말단비대증 환자의 치료방법
말단비대증 환자인 40세 굴착기 운전사는 지난 1년간 소마토스타틴 유사체로 순환 GH 및 IGF-1을 성공적으로 제어하였으나, 최근 피부 유분이 눈에 띄게 증가하고 다한증으로 인해 체취가 심해졌다. 환자에게서 내당능 장애 및 순환 IGF-1 농도 증가가 확인되었고 SSA 투약량을 늘려도 이 상태는 제어되지 않았다.
이 환자에게 KISS1R 결합펩티드 TM (예, 서열번호 58)를 함유한 융합단백질 혹은 GnRH 펩티드 TM (예, 서열번호 93-94)를 함유한 융합물을 정맥주사하여 치료하였다. 14일 이내에 환자의 발한증세가 크게 감소한 것으로 기록되었다. 후속월에는 번들거리는 피부가 정상으로 회복되고 이 시점에서 GH 및 IGF-1 농도 모두가 정상 범위에 들어왔다. 이러한 상태는 후속 5년 동안 계속 유지되었다.
실시예
31 말단비대증 치료방법
지난 25년간 신어왔던 8호 사이즈 구두가 더 이상 맞지않고 더불어 결혼반지도 낄 수 없게된 환자가 담당의사를 찾았다. 비만 가능성을 배제한 후, 담당의는 위와 같은 증세가 뇌하수체 질환의 결과일 수도 있다고 판단하여 검사를 받게 했다. 검사 결과 IGF-1 및 GH 농도가 현저히 증가한 것을 확인하였다. 이에 뇌 MRI 검사에서 뇌하수체 선종이 존재함을 확인하였다.
프로락틴 분비 호르몬 수용체 결합단백질 TM (예, 서열번호 59)를 함유한 융합단백질을 환자에게 정맥주사하여 치료했다. 후속의 수개월에 걸쳐 GH 및 IGF-1 농도가 정상치로 회복하였으며 이 상태는 상기의 융합단백질을 분기별 주사함으로써 계속 유지했다.
실시예
32
래트의
체내
IGF
-1 농도에 대한
CP
-
GHRH
-
LHD
활성
목표
치료 5일후 래트의 IGF-1 농도에 미치는 CP-GHRH-LHD 융합물의 정맥주사의 효능을, 전색제 단독으로 치료한 대조군과 비교하여 평가했다.
재료 및 방법
동물: 아침 5시에 조명을 켜고 (14L:10D) 먹이와 물을 자유공급(ad libitum)하면서 표준 사육 환경하에 유지한 어른 수컷 스프라그-다울리 래트로서, 수술전 최소 1주일간 이 환경에서 사육하였다.
수술: 실험 제1일에 래트(200-250g 체중)를 하이프놈(Hypnorm) (0.32mg/kg의 펜타닐시트레이트 및 10mg/kg의 플루아니손, 근육주사) 및 디아제팜 (2.6mg/kg, 복강주사)의 복합투여로 마취시킨다. 우측 목정맥을 노출시켜 실라스틱 팁 (내경 0.5mm, 외경 0.93mm)이 부착된 폴리텐 캐뉼러를(Portex, UK)를 우심방 입구에 근접할 때까지 혈관 내로 삽입한다. 헤파린 첨가된 등장염수(10IU/ml)를 캐뉼러에 미리 충전한다. 두피를 절제하여 캐뉼러의 자유 말단을 몸 밖으로 꺼내고 다시, 2개의 스텐레스강 나사와 치과용 즉시경화형 아크릴 수지를 이용하여 두개골에 고정한 보호 스프링에 관통시켜 터널을 만들었다. 원상 복구한 동물을 자동 혈액채취실에 설치된 각각의 우리에 넣었다. 보호 스프링의 말단을 기계식 회전기에 부착하여 동물이 가능한 자유롭게 움직일 수 있도록 했다. 캐뉼러는 헤파린 첨가 염수로 매일 세척하여 개방성을 유지했다.
치료: 실험 제2일 오전 9시, 래트에게 CP-GHRH-LHD 또는 전색제 단독의 대조군을 각각 정맥주사했다.
시료 채취: 자동 혈액채취 장치(ABS)는 전술한 바와 같다 (Clark et al., 1986; Windle et al., 1997). 수술뒤 3일 내지 4일 후에, 각 동물의 목정맥 캐뉼러를 자동 혈액채취 장치에 연결한다. 실험 제6일 오전 7시에 시료 채취를 개시한다. 혈액 시료는 24시간 동안 자동 혈액채취 장치를 이용하여 10분 간격으로 수집한다. 각 동물에 대해 총 144개의 시료를 수집하며 전혈의 양을 기준으로 38㎕을 넘지 않도록 한다.
결과
IGF-1 ELISA 키트로 IGF-1 농도를 측정했다. 도 5는, 불과 5일후의 t-검사 P 값이 0.0416인 전색제 단독의 대조군과 비교시, 융합물로 치료한 래트의 IGF-1 농도가 통계학적 측면에서 현저히 감소한 것을 보여준다.
실시예
33
래트의
체내
IGF
-1 농도에 대한
CP
-
GHRH
-
LHD
활성
목표
이 실험은 CP-GHRH-LHD 융합물에 대한 경시적 활성 변화를 조사함으로써, 화합물의 투여 및 이 화합물이 IGF-1 농도에 미치는 초기 효과 간의 지체시간을 확인하기 위한 것이다.
재료 및 방법
동물: 아침 5시에 조명을 켜고 (14L:10D) 먹이와 물을 자유공급하면서 표준 사육 환경하에 유지한 어른 수컷 스프라그-다울리 래트로서, 수술전 최소 1주일간 이 환경에서 사육하였다.
수술: 실험 제1일에 래트(260-280g 체중)를 하이프놈 및 디아제팜의 복합투여로 마취시킨다. 우측 목정맥을 노출시켜 실라스틱 팁 (내경 0.5mm, 외경 0.93mm)이 부착된 폴리텐 캐뉼러 (Portex, UK)를 우심방 입구에 근접할 때까지 혈관 내로 삽입한다. 헤파린 첨가된 등장염수(10IU/ml)를 캐뉼러에 미리 충전한다. 두피를 절제하여 캐뉼러의 자유 말단을 몸 밖으로 꺼내고 다시, 스텐레스강 나사와 치과용 시멘트를 이용하여 두개골에 고정한 보호 스프링에 관통시켰다. 원상 복구한 동물을 ABS실에 설치된 각각의 우리에 넣었다. 스프링을 회전기에 부착하여 동물이 가능한 자유롭게 움직일 수 있도록 했다. 캐뉼러는 헤파린 첨가 염수로 매일 세척하여 개방성을 유지했다.
치료: 실험 제5일 오전 10시, 래트에게 CP-GHRH-LHD 또는 전색제 (멸균 염수) 대조군을 각각 정맥주사했다
시료 채취: 캐뉼러를 세척한 후 오전 9시30분에 각 래트에게서 수작업으로 혈액시료(100㎕)를 채취한다. 실험 제5일 내지 제18일까지 (혹은 캐뉼러가 막힐 때까지) 시료를 채취한다. 혈액 시료중 혈장만 -20℃에서 보관하여 추후 ELISA 키트로 IGF-1 함량을 분석하는데 이용했다.
결과
도 6은, 치료 후 제4일부터 전색제 단독의 대조군과 비교시 융합물로 치료한 래트의 IGF-1 농도가 통계학적 측면에서 현저히 감소한 것을 보여준다.
실시예
34
래트의
체내 성장 호르몬 농도에 대한
CP
-
GHRH
-
LHD
활성
목표
치료 5일후 래트의 성장호르몬 농도에 미치는 CP-GHRH-LHD 융합물의 정맥주사의 효능을, 전색제 단독의 대조군 및 옥트레오티드 주사액 대조군과 비교하여 평가했다.
재료 및 방법
동물: 아침 5시에 조명을 켜고 (14L:10D) 먹이와 물을 자유공급하면서 표준 사육 환경하에 유지한 어른 수컷 스프라그-다울리 래트로서, 수술전 최소 1주일간 이 환경에서 사육하였다.
수술: 실험 제1일에 래트(200-250g 체중)를 하이프놈(0.32mg/kg의 펜타닐시트레이트 및 10mg/kg의 플루아니손, 근육주사) 및 디아제팜 (2.6mg/kg, 복강주사)의 복합투여로 마취시킨다. 우측 목정맥을 노출시켜 실라스틱 팁 (내경 0.5mm, 외경 0.93mm)이 부착된 폴리텐 캐뉼러 (Portex, UK)를 우심방 입구에 근접할 때까지 혈관 내로 삽입한다. 헤파린 첨가된 등장염수(10IU/ml)를 캐뉼러에 미리 충전한다. 두피를 절제하여 캐뉼러의 자유 말단을 몸 밖으로 꺼내고 다시, 2개의 스텐레스강 나사와 치과용 즉시경화형 아크릴 수지를 이용하여 두개골에 고정한 보호 스프링에 관통시켜 터널을 만들었다. 원상 복구한 동물을 자동 혈액채취실에 설치된 각각의 우리에 넣었다. 보호 스프링의 말단을 기계식 회전기에 부착하여 동물이 가능한 자유롭게 움직일 수 있도록 했다. 캐뉼러는 헤파린 첨가 염수로 매일 세척하여 개방성을 유지했다.
치료: 실험 제2일 오전 9시, 래트에게 신탁신 활성 화합물 혹은 전색제를 각각 정맥주사했다. 시료채취 개시부터 6시간 지난 후에 (2개의 캐뉼러 관 중 하나를 통해 투여한) 소마토스타틴 (혹은 그 유사체)를 정확하게 12시간 동안 주입한다. [위와 같이 주입시간을 설정하면 최저 분비수준을 나타내고 또한 이를 억제하여 신속한 회복/복원을 달성하므로, GH 분석 제어 효과가 탁월하다]
시료 채취: 자동 혈액채취 장치(ABS)는 전술한 바와 같다 (Clark et al., 1986; Windle et al., 1997). 수술뒤 3일 내지 4일 후에, 각 동물의 목정맥 캐뉼러를 자동 혈액채취 장치에 연결한다. 실험 제6일 오전 7시에 시료 채취를 개시한다. 혈액 시료는 24시간 동안 자동 혈액채취 장치를 이용하여 10분 간격으로 수거한다. 각 동물에 대해 총 144개의 시료를 수거하며 전혈의 양을 기준으로 38㎕을 넘지 않도록 한다.
결과
성장 호르몬 농도를 RIA 분석법으로 측정했다. 도 7a는 전색제 치료 동물에 있어서 성장호르몬이 박동식으로 방출하는 일반적인 양상을 도시하고, 도 7b는 GHRH-LHD 키메라로 치료한 후 이와 같은 박동식 성장호르몬 방출이 완전히 사라진 것을 나타내며, 또한 도 7c는 박동식 성장호르몬 차단 및 옥트레오티드 주입이 중단되었을 때의 후속 회복상태를 도시한다.
서열번호
1. LHN/A의 DNA 서열
2. LHN/B의 DNA 서열
3. LHN/C의 DNA 서열
4. LHN/D의 DNA 서열
5. 인간 CP-EN-GS15-SST28 링커의 DNA 서열
6. 인간 CT-GS20-CST28 링커의 DNA 서열
7. CP-CST14-GS20-LHD 융합물의 단백질 서열
8. CP-CST14-GS30-LHD 융합물의 단백질 서열
9. CP-CST28-GS20-LHD 융합물의 단백질 서열
10. CP-CST28-GS30-LHD 융합물의 단백질 서열
11. CP-SST14-GS20-LHD 융합물의 단백질 서열
12. CP-SST14-GS30-LHD 융합물의 단백질 서열
13. CP-SST28-GS20-LHD 융합물의 단백질 서열
14. CP-SST28-GS30-LHD 융합물의 단백질 서열
15. CT-CST14-GS20-LHD 융합물의 단백질 서열
16. CT-CST14-GS30-LHD 융합물의 단백질 서열
17. CT-CST28-GS20-LHD 융합물의 DNA 서열
18. CT-CST28-GS20-LHD 융합물의 단백질 서열
19. CT-CST28-GS30-LHD 융합물의 단백질 서열
20. CT-SST14-GS15-L(#Fxa)HD 융합물의 단백질 서열
21. CT-SST14-GS30-LHD 융합물의 단백질 서열
22. CT-SST28-GS20-LHD 융합물의 단백질 서열
23. CT-SST28-GS30-LHD 융합물의 단백질 서열
24. CT-SST14-GS35-LHC 융합물의 단백질 서열
25. CP-GS15-SST28-LHA 융합물의 DNA 서열
26. CP-GS15-SST28-LHA 융합물의 단백질 서열
27. CT-SST28-GS15-LHB 융합물의 단백질 서열
28. CT-CST14-GS20-LHC 융합물의 단백질 서열
29. CT-CST17-GS25-LHC 융합물의 단백질 서열
30. CT-CST29-GS15-LHA 융합물의 단백질 서열
31. CT-CST29-GS30-LHB 융합물의 단백질 서열
32. IgA-HNtet의 DNA 서열
33. CT-GHRP-LHC 융합물의 단백질 서열
34. CT-GHRH-LHD 융합물의 단백질 서열
35. CT-GHRP-LHD 융합물의 단백질 서열
36. CT-그렐린-LHA 융합물의 단백질 서열
37. IgA-HNtet-CT-SST14 융합물의 단백질 서열
38. IgA-HNtet-CT-GHRP 융합물의 단백질 서열
39. CT-그렐린 S3W-LHA 융합물의 단백질 서열
40. CT-GRP-LHD 융합물의 단백질 서열
41. CT-GRP-LHB 융합물의 단백질 서열
42. CP-qGHRH29-LHD 융합물의 단백질 서열
43. CP-qGHRH-LHA 융합물의 단백질 서열
44. CP-qGHRH-LHC 융합물의 단백질 서열
45. CP-qGHRH-LHD 융합물의 단백질 서열
46. CP-qGHRH-LHD N10-PL5 융합물의 단백질 서열
47. CP-qGHRH-LHD N10-HX12 융합물의 단백질 서열
48. CP-UTS-LHA 융합물의 단백질 서열
49. LHN/A의 단백질 서열
50. LHN/B의 단백질 서열
51. LHN/C의 단백질 서열
52. LHN/D의 단백질 서열
53. IgA-HNtet의 단백질 서열
54. 합성 옥트레오티드 펩티드
55. 합성 GHRH 길항근 펩티드
56. 합성 GHRH 길항제 펩티드
57. CP-MCH-LHD 융합물의 단백질 서열
58. CT-KISS-LHD 융합물의 단백질 서열
59. CT-PrRP-LHA 융합물의 단백질 서열
60. CP-HS_GHRH_1-27-LHD 융합물의 단백질 서열
61. CP-HS_GHRH_1-28-LHD 융합물의 단백질 서열
62. CP-HS_GHRH_1-29-LHD 융합물의 단백질 서열
63. CP-HS_GHRH_1-44-LHD 융합물의 단백질 서열
64. CP-HS_GHRH_1-40-LHD 융합물의 단백질 서열
65. CP-HS_GHRH_Ala9-LHD 융합물의 단백질 서열
66. CP-HS_GHRH_Ala22-LHD 융합물의 단백질 서열
67. CP-HS_GHRH_Ala8_Lys11_1-29-LHD 융합물의 단백질 서열
68. CP-HS_GHRH_Ala8_Lys11_Arg12_1-29-LHD 융합물의 단백질 서열
69. CP-HS_GHRH_Ala8_Asn11_1-29-LHD 융합물의 단백질 서열
70. CP-HS_GHRH_Ala8_Lys20_1-29-LHD 융합물의 단백질 서열
71. CP-HS_GHRH_Ala8_Lys11_Lys20_1-29-LHD 융합물의 단백질 서열
72. CP-HS_GHRH_Ala8_Asn20_1-29-LHD 융합물의 단백질 서열
73. CP-HS_GHRH_Ala8_Asn12_1-29-LHD 융합물의 단백질 서열
74. CP-HS_GHRH_Ala8_Asn21_1-29-LHD 융합물의 단백질 서열
75. CP-HS_GHRH_Ala8_Glu_7_1-29-LHD 융합물의 단백질 서열
76. CP-HS_GHRH_Ala8_Glu_10_1-29LHD 융합물의 단백질 서열
77. CP-HS_GHRH_Ala8_Glu_13_1-29-LHD 융합물의 단백질 서열
78. CP-HS_GHRH_Ala8-LHD 융합물의 단백질 서열
79. CP-HS_GHRH_Glu8_1-29-LHD 융합물의 단백질 서열
80. CP-HS_GHRH_Ala15_1-27-LHD 융합물의 단백질 서열
81. CP-HS_GHRH_Ala15-LHD 융합물의 단백질 서열
82. CP-HS_GHRH_Ala8_Ala15_1-29-LHD 융합물의 단백질 서열
83. CP-HS_GHRH_Ala8_9_15_22_27-LHD 융합물의 단백질 서열
84. CP-HS_GHRH_Ala8_9_15_22-LHD 융합물의 단백질 서열
85. CP-HS_GHRH_HVQAL_1-32-LHD 융합물의 단백질 서열
86. CP-HS_GHRH_HVSAL_1-29-LHD 융합물의 단백질 서열
87. CP-HS_GHRH_HVTAL_1-29-LHD 융합물의 단백질 서열
88. CP-HS_GHRH_QALN-LHD 융합물의 단백질 서열
89. CP-HS_GHRH_QAL-LHD 융합물의 단백질 서열
90. CP-hGHRH29 N8A M27L-LHD 융합물의 단백질 서열
91. CP-hGHRH29 N8A K12N M27L-LHD 융합물의 단백질 서열
92. N-말단-hGHRH29 N8A M27L-LHD 융합물의 단백질 서열
93. 인간 GnRH-C 융합물의 단백질 서열
94. 인간 GnRH -D GS 20 융합물의 단백질 서열
서열번호
1. DNA sequence of LHN/A
ggatccATGGAGTTCGTTAACAAACAGTTCAACTATAAAGACCCAGTTAACGGTGTTGACATTGCTTACATCAAAATCCCGAACGCTGGCCAGATGCAGCCGGTAAAGGCATTCAAAATCCACAACAAAATCTGGGTTATCCCGGAACGTGATACCTTTACTAACCCGGAAGAAGGTGACCTGAACCCGCCACCGGAAGCGAAACAGGTGCCGGTATCTTACTATGACTCCACCTACCTGTCTACCGATAACGAAAAGGACAACTACCTGAAAGGTGTTACTAAACTGTTCGAGCGTATTTACTCCACCGACCTGGGCCGTATGCTGCTGACTAGCATCGTTCGCGGTATCCCGTTCTGGGGCGGTTCTACCATCGATACCGAACTGAAAGTAATCGACACTAACTGCATCAACGTTATTCAGCCGGACGGTTCCTATCGTTCCGAAGAACTGAACCTGGTGATCATCGGCCCGTCTGCTGATATCATCCAGTTCGAGTGTCTGAGCTTTGGTCACGAAGTTCTGAACCTCACCCGTAACGGCTACGGTTCCACTCAGTACATCCGTTTCTCTCCGGACTTCACCTTCGGTTTTGAAGAATCCCTGGAAGTAGACACGAACCCACTGCTGGGCGCTGGTAAATTCGCAACTGATCCTGCGGTTACCCTGGCTCACGAACTGATTCATGCAGGCCACCGCCTGTACGGTATCGCCATCAATCCGAACCGTGTCTTCAAAGTTAACACCAACGCGTATTACGAGATGTCCGGTCTGGAAGTTAGCTTCGAAGAACTGCGTACTTTTGGCGGTCACGACGCTAAATTCATCGACTCTCTGCAAGAAAACGAGTTCCGTCTGTACTACTATAACAAGTTCAAAGATATCGCATCCACCCTGAACAAAGCGAAATCCATCGTGGGTACCACTGCTTCTCTCCAGTACATGAAGAACGTTTTTAAAGAAAAATACCTGCTCAGCGAAGACACCTCCGGCAAATTCTCTGTAGACAAGTTGAAATTCGATAAACTTTACAAAATGCTGACTGAAATTTACACCGAAGACAACTTCGTTAAGTTCTTTAAAGTTCTGAACCGCAAAACCTATCTGAACTTCGACAAGGCAGTATTCAAAATCAACATCGTGCCGAAAGTTAACTACACTATCTACGATGGTTTCAACCTGCGTAACACCAACCTGGCTGCTAATTTTAACGGCCAGAACACGGAAATCAACAACATGAACTTCACAAAACTGAAAAACTTCACTGGTCTGTTCGAGTTTTACAAGCTGCTGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAACAAAGCGCTGAACCTGCAGTGTATCAAGGTTAACAACTGGGATTTATTCTTCAGCCCGAGTGAAGACAACTTCACCAACGACCTGAACAAAGGTGAAGAAATCACCTCAGATACTAACATCGAAGCAGCCGAAGAAAACATCTCGCTGGACCTGATCCAGCAGTACTACCTGACCTTTAATTTCGACAACGAGCCGGAAAACATTTCTATCGAAAACCTGAGCTCTGATATCATCGGCCAGCTGGAACTGATGCCGAACATCGAACGTTTCCCAAACGGTAAAAAGTACGAGCTGGACAAATATACCATGTTCCACTACCTGCGCGCGCAGGAATTTGAACACGGCAAATCCCGTATCGCACTGACTAACTCCGTTAACGAAGCTCTGCTCAACCCGTCCCGTGTATACACCTTCTTCTCTAGCGACTACGTGAAAAAGGTCAACAAAGCGACTGAAGCTGCAATGTTCTTGGGTTGGGTTGAACAGCTTGTTTATGATTTTACCGACGAGACGTCCGAAGTATCTACTACCGACAAAATTGCGGATATCACTATCATCATCCCGTACATCGGTCCGGCTCTGAACATTGGCAACATGCTGTACAAAGACGACTTCGTTGGCGCACTGATCTTCTCCGGTGCGGTGATCCTGCTGGAGTTCATCCCGGAAATCGCCATCCCGGTACTGGGCACCTTTGCTCTGGTTTCTTACATTGCAAACAAGGTTCTGACTGTACAAACCATCGACAACGCGCTGAGCAAACGTAACGAAAAATGGGATGAAGTTTACAAATATATCGTGACCAACTGGCTGGCTAAGGTTAATACTCAGATCGACCTCATCCGCAAAAAAATGAAAGAAGCACTGGAAAACCAGGCGGAAGCTACCAAGGCAATCATTAACTACCAGTACAACCAGTACACCGAGGAAGAAAAAAACAACATCAACTTCAACATCGACGATCTGTCCTCTAAACTGAACGAATCCATCAACAAAGCTATGATCAACATCAACAAGTTCCTGAACCAGTGCTCTGTAAGCTATCTGATGAACTCCATGATCCCGTACGGTGTTAAACGTCTGGAGGACTTCGATGCGTCTCTGAAAGACGCCCTGCTGAAATACATTTACGACAACCGTGGCACTCTGATCGGTCAGGTTGATCGTCTGAAGGACAAAGTGAACAATACCTTATCGACCGACATCCCTTTTCAGCTCAGTAAATATGTCGATAACCAACGCCTTTTGTCCACTtaataagctt
2. DNA sequence of LHN/B
GGATCCATGCCGGTTACCATCAACAACTTCAACTACAACGACCCGATCGACAACAACAACATCATTATGATGGAACCGCCGTTCGCACGTGGTACCGGACGTTACTACAAGGCTTTTAAGATCACCGACCGTATCTGGATCATCCCGGAACGTTACACCTTCGGTTACAAACCTGAGGACTTCAACAAGAGTAGCGGGATTTTCAATCGTGACGTCTGCGAGTACTATGATCCAGATTATCTGAATACCAACGATAAGAAGAACATATTCCTTCAGACTATGATTAAACTCTTCAACCGTATCAAAAGCAAACCGCTCGGTGAAAAACTCCTCGAAATGATTATCAACGGTATCCCGTACCTCGGTGACCGTCGTGTCCCGCTTGAAGAGTTCAACACCAACATCGCAAGCGTCACCGTCAACAAACTCATCAGCAACCCAGGTGAAGTCGAACGTAAAAAAGGTATCTTCGCAAACCTCATCATCTTCGGTCCGGGTCCGGTCCTCAACGAAAACGAAACCATCGACATCGGTATCCAGAACCACTTCGCAAGCCGTGAAGGTTTCGGTGGTATCATGCAGATGAAATTCTGCCCGGAATACGTCAGTGTCTTCAACAACGTCCAGGAAAACAAAGGTGCAAGCATCTTCAACCGTCGTGGTTACTTCAGCGACCCGGCACTCATCCTCATGCATGAACTCATCCACGTCCTCCACGGTCTCTACGGTATCAAAGTTGACGACCTCCCGATCGTCCCGAACGAGAAGAAATTCTTCATGCAGAGCACCGACGCAATCCAGGCTGAGGAACTCTACACCTTCGGTGGCCAAGACCCAAGTATCATAACCCCGTCCACCGACAAAAGCATCTACGACAAAGTCCTCCAGAACTTCAGGGGTATCGTGGACAGACTCAACAAAGTCCTCGTCTGCATCAGCGACCCGAACATCAATATCAACATATACAAGAACAAGTTCAAAGACAAGTACAAATTCGTCGAGGACAGCGAAGGCAAATACAGCATCGACGTAGAAAGTTTCGACAAGCTCTACAAAAGCCTCATGTTCGGTTTCACCGAAACCAACATCGCCGAGAACTACAAGATCAAGACAAGGGCAAGTTACTTCAGCGACAGCCTCCCGCCTGTCAAAATCAAGAACCTCTTAGACAACGAGATTTACACAATTGAAGAGGGCTTCAACATCAGTGACAAAGACATGGAGAAGGAATACAGAGGTCAGAACAAGGCTATCAACAAACAGGCATACGAGGAGATCAGCAAAGAACACCTCGCAGTCTACAAGATCCAGATGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAACAAAGCGCTGAACCTGCAGTGCATCGACGTTGACAACGAAGACCTGTTCTTCATCGCTGACAAAAACAGCTTCAGTGACGACCTGAGCAAAAACGAACGTATCGAATACAACACCCAGAGCAACTACATCGAAAACGACTTCCCGATCAACGAACTGATCCTGGACACCGACCTGATAAGTAAAATCGAACTGCCGAGCGAAAACACCGAAAGTCTGACCGACTTCAACGTTGACGTTCCGGTTTACGAAAAACAGCCGGCTATCAAGAAAATCTTCACCGACGAAAACACCATCTTCCAGTACCTGTACAGCCAGACCTTCCCGCTGGACATCCGTGACATCAGTCTGACCAGCAGTTTCGACGACGCTCTGCTGTTCAGCAACAAAGTTTACAGTTTCTTCAGCATGGACTACATCAAAACCGCTAACAAAGTTGTTGAAGCAGGGCTGTTCGCTGGTTGGGTTAAACAGATCGTTAACGACTTCGTTATCGAAGCTAACAAAAGCAACACTATGGACAAAATCGCTGACATCAGTCTGATCGTTCCGTACATCGGTCTGGCTCTGAACGTTGGTAACGAAACCGCTAAAGGTAACTTTGAAAACGCTTTCGAGATCGCTGGTGCAAGCATCCTGCTGGAGTTCATCCCGGAACTGCTGATCCCGGTTGTTGGTGCTTTCCTGCTGGAAAGTTACATCGACAACAAAAACAAGATCATCAAAACCATCGACAACGCTCTGACCAAACGTAACGAAAAATGGAGTGATATGTACGGTCTGATCGTTGCTCAGTGGCTGAGCACCGTCAACACCCAGTTCTACACCATCAAAGAAGGTATGTACAAAGCTCTGAACTACCAGGCTCAGGCTCTGGAAGAGATCATCAAATACCGTTACAACATCTACAGTGAGAAGGAAAAGAGTAACATCAACATCGACTTCAACGACATCAACAGCAAACTGAACGAAGGTATCAACCAGGCTATCGACAACATCAACAACTTCATCAACGGTTGCAGTGTTAGCTACCTGATGAAGAAGATGATCCCGCTGGCTGTTGAAAAACTGCTGGACTTCGACAACACCCTGAAAAAGAACCTGCTGAACTACATCGACGAAAACAAGCTGTACCTGATCGGTAGTGCTGAATACGAAAAAAGTAAAGTGAACAAATACCTGAAGACCATCATGCCGTTCGACCTGAGTATCTACACCAACGACACCATCCTGATCGAAATGTTCAACAAATACAACTCTtaataagctt
3. DNA sequence of LHN/C
ggatccATGCCGATCACCATCAACAACTTCAACTACAGCGATCCGGTGGATAACAAAAACATCCTGTACCTGGATACCCATCTGAATACCCTGGCGAACGAACCGGAAAAAGCGTTTCGTATCACCGGCAACATTTGGGTTATTCCGGATCGTTTTAGCCGTAACAGCAACCCGAATCTGAATAAACCGCCGCGTGTTACCAGCCCGAAAAGCGGTTATTACGATCCGAACTATCTGAGCACCGATAGCGATAAAGATACCTTCCTGAAAGAAATCATCAAACTGTTCAAACGCATCAACAGCCGTGAAATTGGCGAAGAACTGATCTATCGCCTGAGCACCGATATTCCGTTTCCGGGCAACAACAACACCCCGATCAACACCTTTGATTTCGATGTGGATTTCAACAGCGTTGATGTTAAAACCCGCCAGGGTAACAATTGGGTGAAAACCGGCAGCATTAACCCGAGCGTGATTATTACCGGTCCGCGCGAAAACATTATTGATCCGGAAACCAGCACCTTTAAACTGACCAACAACACCTTTGCGGCGCAGGAAGGTTTTGGCGCGCTGAGCATTATTAGCATTAGCCCGCGCTTTATGCTGACCTATAGCAACGCGACCAACGATGTTGGTGAAGGCCGTTTCAGCAAAAGCGAATTTTGCATGGACCCGATCCTGATCCTGATGCATGAACTGAACCATGCGATGCATAACCTGTATGGCATCGCGATTCCGAACGATCAGACCATTAGCAGCGTGACCAGCAACATCTTTTACAGCCAGTACAACGTGAAACTGGAATATGCGGAAATCTATGCGTTTGGCGGTCCGACCATTGATCTGATTCCGAAAAGCGCGCGCAAATACTTCGAAGAAAAAGCGCTGGATTACTATCGCAGCATTGCGAAACGTCTGAACAGCATTACCACCGCGAATCCGAGCAGCTTCAACAAATATATCGGCGAATATAAACAGAAACTGATCCGCAAATATCGCTTTGTGGTGGAAAGCAGCGGCGAAGTTACCGTTAACCGCAATAAATTCGTGGAACTGTACAACGAACTGACCCAGATCTTCACCGAATTTAACTATGCGAAAATCTATAACGTGCAGAACCGTAAAATCTACCTGAGCAACGTGTATACCCCGGTGACCGCGAATATTCTGGATGATAACGTGTACGATATCCAGAACGGCTTTAACATCCCGAAAAGCAACCTGAACGTTCTGTTTATGGGCCAGAACCTGAGCCGTAATCCGGCGCTGCGTAAAGTGAACCCGGAAAACATGCTGTACCTGTTCACCAAATTTTGCGTCGACGCGATTGATGGTCGTAGCCTGTACAACAAAACCCTGCAGTGTCGTGAACTGCTGGTGAAAAACACCGATCTGCCGTTTATTGGCGATATCAGCGATGTGAAAACCGATATCTTCCTGCGCAAAGATATCAACGAAGAAACCGAAGTGATCTACTACCCGGATAACGTGAGCGTTGATCAGGTGATCCTGAGCAAAAACACCAGCGAACATGGTCAGCTGGATCTGCTGTATCCGAGCATTGATAGCGAAAGCGAAATTCTGCCGGGCGAAAACCAGGTGTTTTACGATAACCGTACCCAGAACGTGGATTACCTGAACAGCTATTACTACCTGGAAAGCCAGAAACTGAGCGATAACGTGGAAGATTTTACCTTTACCCGCAGCATTGAAGAAGCGCTGGATAACAGCGCGAAAGTTTACACCTATTTTCCGACCCTGGCGAACAAAGTTAATGCGGGTGTTCAGGGCGGTCTGTTTCTGATGTGGGCGAACGATGTGGTGGAAGATTTCACCACCAACATCCTGCGTAAAGATACCCTGGATAAAATCAGCGATGTTAGCGCGATTATTCCGTATATTGGTCCGGCGCTGAACATTAGCAATAGCGTGCGTCGTGGCAATTTTACCGAAGCGTTTGCGGTTACCGGTGTGACCATTCTGCTGGAAGCGTTTCCGGAATTTACCATTCCGGCGCTGGGTGCGTTTGTGATCTATAGCAAAGTGCAGGAACGCAACGAAATCATCAAAACCATCGATAACTGCCTGGAACAGCGTATTAAACGCTGGAAAGATAGCTATGAATGGATGATGGGCACCTGGCTGAGCCGTATTATCACCCAGTTCAACAACATCAGCTACCAGATGTACGATAGCCTGAACTATCAGGCGGGTGCGATTAAAGCGAAAATCGATCTGGAATACAAAAAATACAGCGGCAGCGATAAAGAAAACATCAAAAGCCAGGTTGAAAACCTGAAAAACAGCCTGGATGTGAAAATTAGCGAAGCGATGAATAACATCAACAAATTCATCCGCGAATGCAGCGTGACCTACCTGTTCAAAAACATGCTGCCGAAAGTGATCGATGAACTGAACGAATTTGATCGCAACACCAAAGCGAAACTGATCAACCTGATCGATAGCCACAACATTATTCTGGTGGGCGAAGTGGATAAACTGAAAGCGAAAGTTAACAACAGCTTCCAGAACACCATCCCGTTTAACATCTTCAGCTATACCAACAACAGCCTGCTGAAAGATATCATCAACGAATACTTCAATtaataagctt
4. DNA sequence of LHN/D
ggatccATGACGTGGCCAGTTAAGGATTTCAACTACTCAGATCCTGTAAATGACAACGATATTCTGTACCTTCGCATTCCACAAAATAAACTGATCACCACACCAGTCAAAGCATTCATGATTACTCAAAACATTTGGGTCATTCCAGAACGCTTTTCTAGTGACACAAATCCGAGTTTATCTAAACCTCCGCGTCCGACGTCCAAATATCAGAGCTATTACGATCCCTCATATCTCAGTACGGACGAACAAAAAGATACTTTCCTTAAAGGTATCATTAAACTGTTTAAGCGTATTAATGAGCGCGATATCGGGAAAAAGTTGATTAATTATCTTGTTGTGGGTTCCCCGTTCATGGGCGATAGCTCTACCCCCGAAGACACTTTTGATTTTACCCGTCATACGACAAACATCGCGGTAGAGAAGTTTGAGAACGGATCGTGGAAAGTCACAAACATCATTACACCTAGCGTCTTAATTTTTGGTCCGCTGCCAAACATCTTAGATTATACAGCCAGCCTGACTTTGCAGGGGCAACAGTCGAATCCGAGTTTCGAAGGTTTTGGTACCCTGAGCATTCTGAAAGTTGCCCCGGAATTTCTGCTCACTTTTTCAGATGTCACCAGCAACCAGAGCTCAGCAGTATTAGGAAAGTCAATTTTTTGCATGGACCCGGTTATTGCACTGATGCACGAACTGACGCACTCTCTGCATCAACTGTATGGGATCAACATCCCCAGTGACAAACGTATTCGTCCCCAGGTGTCTGAAGGATTTTTCTCACAGGATGGGCCGAACGTCCAGTTCGAAGAGTTGTATACTTTCGGAGGCCTGGACGTAGAGATCATTCCCCAGATTGAGCGCAGTCAGCTGCGTGAGAAGGCATTGGGCCATTATAAGGATATTGCAAAACGCCTGAATAACATTAACAAAACGATTCCATCTTCGTGGATCTCGAATATTGATAAATATAAGAAAATTTTTAGCGAGAAATATAATTTTGATAAAGATAATACAGGTAACTTTGTGGTTAACATTGACAAATTCAACTCCCTTTACAGTGATTTGACGAATGTAATGAGCGAAGTTGTGTATAGTTCCCAATACAACGTTAAGAATCGTACCCATTACTTCTCTCGTCACTACCTGCCGGTTTTCGCGAACATCCTTGACGATAATATTTACACTATTCGTGACGGCTTTAACTTGACCAACAAGGGCTTCAATATTGAAAATTCAGGCCAGAACATTGAACGCAACCCGGCCTTGCAGAAACTGTCGAGTGAATCCGTGGTTGACCTGTTTACCAAAGTCTGCGTCGACAAAAGCGAAGAGAAGCTGTACGATGACGATGACAAAGATCGTTGGGGATCGTCCCTGCAGTGTATTAAAGTGAAAAACAATCGGCTGCCTTATGTAGCAGATAAAGATAGCATTAGTCAGGAGATTTTCGAAAATAAAATTATCACTGACGAAACCAATGTTCAGAATTATTCAGATAAATTTTCACTGGACGAAAGCATCTTAGATGGCCAAGTTCCGATTAACCCGGAAATTGTTGATCCGTTACTGCCGAACGTGAATATGGAACCGTTAAACCTCCCTGGCGAAGAGATCGTATTTTATGATGACATTACGAAATATGTGGACTACCTTAATTCTTATTACTATTTGGAAAGCCAGAAACTGTCCAATAACGTGGAAAACATTACTCTGACCACAAGCGTGGAAGAGGCTTTAGGCTACTCAAATAAGATTTATACCTTCCTCCCGTCGCTGGCGGAAAAAGTAAATAAAGGTGTGCAGGCTGGTCTGTTCCTCAACTGGGCGAATGAAGTTGTCGAAGACTTTACCACGAATATTATGAAAAAGGATACCCTGGATAAAATCTCCGACGTCTCGGTTATTATCCCATATATTGGCCCTGCGTTAAATATCGGTAATAGTGCGCTGCGGGGGAATTTTAACCAGGCCTTTGCTACCGCGGGCGTCGCGTTCCTCCTGGAGGGCTTTCCTGAATTTACTATCCCGGCGCTCGGTGTTTTTACATTTTACTCTTCCATCCAGGAGCGTGAGAAAATTATCAAAACCATCGAAAACTGCCTGGAGCAGCGGGTGAAACGCTGGAAAGATTCTTATCAATGGATGGTGTCAAACTGGTTATCTCGCATCACGACCCAATTCAACCATATTAATTACCAGATGTATGATAGTCTGTCGTACCAAGCTGACGCCATTAAAGCCAAAATTGATCTGGAATATAAAAAGTACTCTGGTAGCGATAAGGAGAACATCAAAAGCCAGGTGGAGAACCTTAAGAATAGTCTGGATGTGAAAATCTCTGAAGCTATGAATAACATTAACAAATTCATTCGTGAATGTTCGGTGACGTACCTGTTCAAGAATATGCTGCCAAAAGTTATTGATGAACTGAATAAATTTGATCTGCGTACCAAAACCGAACTTATCAACCTCATCGACTCCCACAACATTATCCTTGTGGGCGAAGTGGATCGTCTGAAGGCCAAAGTAAACGAGAGCTTTGAAAATACGATGCCGTTTAATATTTTTTCATATACCAATAACTCCTTGCTGAAAGATATCATCAATGAATATTTCAATtaataagctt
5. DNA sequence of the human CP-EN-GS15-SST28 linker
CATATGGGATCCGGTTTAAACGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAGCGCCAATTCAAATCCTGCAATGGCGCCACGCGAACGCAAAGCTGGTTGCAAAAACTTCTTCTGGAAAACCTTCACCTCTTGCGCGCTAGCGGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCTGCAGCTAGAATAATGAAAGCTT
6. DNA sequence of the Human CT-GS20-CST28 linker
GGATCCGTCGACCTGCAGGGTCTAGAAGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCAGGAAAGACCTCCATTACAACAACCTCCACATCGCGATAAGAAACCATGTAAGAATTTCTTTTGGAAAACATTTAGCAGTTGCAAATGATAAAAGCTT
7. Protein sequence of the CP-CST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
8. Protein sequence of the CP-CST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
9. Protein sequence of the CP-CST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKQERPPLQQPPHRDKKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
10. Protein sequence of the CP-CST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKQERPPLQQPPHRDKKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
11. Protein sequence of the CP-SST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
12. Protein sequence of the CP-SST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
13. Protein sequence of the CP-SST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
14. Protein sequence of the CP-SST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
15. Protein sequence of the CT-CST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVPCKNFFWKTFSSCK
16. Protein sequence of the CT-CST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVPCKNFFWKTFSSCK
17. DNA sequence of the CT-CST28-GS20-LHD fusion
GGATCCATGACGTGGCCAGTTAAGGATTTCAACTACTCAGATCCTGTAAATGACAACGATATTCTGTACCTTCGCATTCCACAAAATAAACTGATCACCACACCAGTCAAAGCATTCATGATTACTCAAAACATTTGGGTCATTCCAGAACGCTTTTCTAGTGACACAAATCCGAGTTTATCTAAACCTCCGCGTCCGACGTCCAAATATCAGAGCTATTACGATCCCTCATATCTCAGTACGGACGAACAAAAAGATACTTTCCTTAAAGGTATCATTAAACTGTTTAAGCGTATTAATGAGCGCGATATCGGGAAAAAGTTGATTAATTATCTTGTTGTGGGTTCCCCGTTCATGGGCGATAGCTCTACCCCCGAAGACACTTTTGATTTTACCCGTCATACGACAAACATCGCGGTAGAGAAGTTTGAGAACGGATCGTGGAAAGTCACAAACATCATTACACCTAGCGTCTTAATTTTTGGTCCGCTGCCAAACATCTTAGATTATACAGCCAGCCTGACTTTGCAGGGGCAACAGTCGAATCCGAGTTTCGAAGGTTTTGGTACCCTGAGCATTCTGAAAGTTGCCCCGGAATTTCTGCTCACTTTTTCAGATGTCACCAGCAACCAGAGCTCAGCAGTATTAGGAAAGTCAATTTTTTGCATGGACCCGGTTATTGCACTGATGCACGAACTGACGCACTCTCTGCATCAACTGTATGGGATCAACATCCCCAGTGACAAACGTATTCGTCCCCAGGTGTCTGAAGGATTTTTCTCACAGGATGGGCCGAACGTCCAGTTCGAAGAGTTGTATACTTTCGGAGGCCTGGACGTAGAGATCATTCCCCAGATTGAGCGCAGTCAGCTGCGTGAGAAGGCATTGGGCCATTATAAGGATATTGCAAAACGCCTGAATAACATTAACAAAACGATTCCATCTTCGTGGATCTCGAATATTGATAAATATAAGAAAATTTTTAGCGAGAAATATAATTTTGATAAAGATAATACAGGTAACTTTGTGGTTAACATTGACAAATTCAACTCCCTTTACAGTGATTTGACGAATGTAATGAGCGAAGTTGTGTATAGTTCCCAATACAACGTTAAGAATCGTACCCATTACTTCTCTCGTCACTACCTGCCGGTTTTCGCGAACATCCTTGACGATAATATTTACACTATTCGTGACGGCTTTAACTTGACCAACAAGGGCTTCAATATTGAAAATTCAGGCCAGAACATTGAACGCAACCCGGCCTTGCAGAAACTGTCGAGTGAATCCGTGGTTGACCTGTTTACCAAAGTCTGCGTCGACAAAAGCGAAGAGAAGCTGTACGATGACGATGACAAAGATCGTTGGGGATCGTCCCTGCAGTGTATTAAAGTGAAAAACAATCGGCTGCCTTATGTAGCAGATAAAGATAGCATTAGTCAGGAGATTTTCGAAAATAAAATTATCACTGACGAAACCAATGTTCAGAATTATTCAGATAAATTTTCACTGGACGAAAGCATCTTAGATGGCCAAGTTCCGATTAACCCGGAAATTGTTGATCCGTTACTGCCGAACGTGAATATGGAACCGTTAAACCTCCCTGGCGAAGAGATCGTATTTTATGATGACATTACGAAATATGTGGACTACCTTAATTCTTATTACTATTTGGAAAGCCAGAAACTGTCCAATAACGTGGAAAACATTACTCTGACCACAAGCGTGGAAGAGGCTTTAGGCTACTCAAATAAGATTTATACCTTCCTCCCGTCGCTGGCGGAAAAAGTAAATAAAGGTGTGCAGGCTGGTCTGTTCCTCAACTGGGCGAATGAAGTTGTCGAAGACTTTACCACGAATATTATGAAAAAGGATACCCTGGATAAAATCTCCGACGTCTCGGTTATTATCCCATATATTGGCCCTGCGTTAAATATCGGTAATAGTGCGCTGCGGGGGAATTTTAACCAGGCCTTTGCTACCGCGGGCGTCGCGTTCCTCCTGGAGGGCTTTCCTGAATTTACTATCCCGGCGCTCGGTGTTTTTACATTTTACTCTTCCATCCAGGAGCGTGAGAAAATTATCAAAACCATCGAAAACTGCCTGGAGCAGCGGGTGAAACGCTGGAAAGATTCTTATCAATGGATGGTGTCAAACTGGTTATCTCGCATCACGACCCAATTCAACCATATTAATTACCAGATGTATGATAGTCTGTCGTACCAAGCTGACGCCATTAAAGCCAAAATTGATCTGGAATATAAAAAGTACTCTGGTAGCGATAAGGAGAACATCAAAAGCCAGGTGGAGAACCTTAAGAATAGTCTGGATGTGAAAATCTCTGAAGCTATGAATAACATTAACAAATTCATTCGTGAATGTTCGGTGACGTACCTGTTCAAGAATATGCTGCCAAAAGTTATTGATGAACTGAATAAATTTGATCTGCGTACCAAAACCGAACTTATCAACCTCATCGACTCCCACAACATTATCCTTGTGGGCGAAGTGGATCGTCTGAAGGCCAAAGTAAACGAGAGCTTTGAAAATACGATGCCGTTTAATATTTTTTCATATACCAATAACTCCTTGCTGAAAGATATCATCAATGAATATTTCAATCTAGAAGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCAGGAAAGACCTCCATTACAACAACCTCCACATCGCGATAAGAAACCATGTAAGAATTTCTTTTGGAAAACATTTAGCAGTTGCAAAtaataagctt
18. Protein sequence of the CT-CST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVQERPPLQQPPHRDKKPCKNFFWKTFSSCK
19. Protein sequence of the CT-CST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVQERPPLQQPPHRDKKPCKNFFWKTFSSCK
20. Protein sequence of the CT-SST14-GS15-L(#Fxa)HD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSIDGRNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYIDGRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
21. Protein sequence of the CT-SST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
22. Protein sequence of the CT-SST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVSANSNPAMAPRERKAGCKNFFWKTFTSC
23. Protein sequence of the CT-SST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVSANSNPAMAPRERKAGCKNFFWKTFTSC
24. Protein sequence of the CT-SST14-GS35-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
25. DNA sequence of the CP-SST28-GS15-LHA fusion
ggatccATGGAGTTCGTTAACAAACAGTTCAACTATAAAGACCCAGTTAACGGTGTTGACATTGCTTACATCAAAATCCCGAACGCTGGCCAGATGCAGCCGGTAAAGGCATTCAAAATCCACAACAAAATCTGGGTTATCCCGGAACGTGATACCTTTACTAACCCGGAAGAAGGTGACCTGAACCCGCCACCGGAAGCGAAACAGGTGCCGGTATCTTACTATGACTCCACCTACCTGTCTACCGATAACGAAAAGGACAACTACCTGAAAGGTGTTACTAAACTGTTCGAGCGTATTTACTCCACCGACCTGGGCCGTATGCTGCTGACTAGCATCGTTCGCGGTATCCCGTTCTGGGGCGGTTCTACCATCGATACCGAACTGAAAGTAATCGACACTAACTGCATCAACGTTATTCAGCCGGACGGTTCCTATCGTTCCGAAGAACTGAACCTGGTGATCATCGGCCCGTCTGCTGATATCATCCAGTTCGAGTGTCTGAGCTTTGGTCACGAAGTTCTGAACCTCACCCGTAACGGCTACGGTTCCACTCAGTACATCCGTTTCTCTCCGGACTTCACCTTCGGTTTTGAAGAATCCCTGGAAGTAGACACGAACCCACTGCTGGGCGCTGGTAAATTCGCAACTGATCCTGCGGTTACCCTGGCTCACGAACTGATTCATGCAGGCCACCGCCTGTACGGTATCGCCATCAATCCGAACCGTGTCTTCAAAGTTAACACCAACGCGTATTACGAGATGTCCGGTCTGGAAGTTAGCTTCGAAGAACTGCGTACTTTTGGCGGTCACGACGCTAAATTCATCGACTCTCTGCAAGAAAACGAGTTCCGTCTGTACTACTATAACAAGTTCAAAGATATCGCATCCACCCTGAACAAAGCGAAATCCATCGTGGGTACCACTGCTTCTCTCCAGTACATGAAGAACGTTTTTAAAGAAAAATACCTGCTCAGCGAAGACACCTCCGGCAAATTCTCTGTAGACAAGTTGAAATTCGATAAACTTTACAAAATGCTGACTGAAATTTACACCGAAGACAACTTCGTTAAGTTCTTTAAAGTTCTGAACCGCAAAACCTATCTGAACTTCGACAAGGCAGTATTCAAAATCAACATCGTGCCGAAAGTTAACTACACTATCTACGATGGTTTCAACCTGCGTAACACCAACCTGGCTGCTAATTTTAACGGCCAGAACACGGAAATCAACAACATGAACTTCACAAAACTGAAAAACTTCACTGGTCTGTTCGAGTTTTACAAGCTGCTGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAGCGCCAATTCAAATCCTGCAATGGCGCCACGCGAACGCAAAGCTGGATGCAAAAACTTCTTTTGGAAGACATTTACTAGTTGTGCGCTAGCGGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCTGCAGTGTATCAAGGTTAACAACTGGGATTTATTCTTCAGCCCGAGTGAAGACAACTTCACCAACGACCTGAACAAAGGTGAAGAAATCACCTCAGATACTAACATCGAAGCAGCCGAAGAAAACATCTCGCTGGACCTGATCCAGCAGTACTACCTGACCTTTAATTTCGACAACGAGCCGGAAAACATTTCTATCGAAAACCTGAGCTCTGATATCATCGGCCAGCTGGAACTGATGCCGAACATCGAACGTTTCCCAAACGGTAAAAAGTACGAGCTGGACAAATATACCATGTTCCACTACCTGCGCGCGCAGGAATTTGAACACGGCAAATCCCGTATCGCACTGACTAACTCCGTTAACGAAGCTCTGCTCAACCCGTCCCGTGTATACACCTTCTTCTCTAGCGACTACGTGAAAAAGGTCAACAAAGCGACTGAAGCTGCAATGTTCTTGGGTTGGGTTGAACAGCTTGTTTATGATTTTACCGACGAGACGTCCGAAGTATCTACTACCGACAAAATTGCGGATATCACTATCATCATCCCGTACATCGGTCCGGCTCTGAACATTGGCAACATGCTGTACAAAGACGACTTCGTTGGCGCACTGATCTTCTCCGGTGCGGTGATCCTGCTGGAGTTCATCCCGGAAATCGCCATCCCGGTACTGGGCACCTTTGCTCTGGTTTCTTACATTGCAAACAAGGTTCTGACTGTACAAACCATCGACAACGCGCTGAGCAAACGTAACGAAAAATGGGATGAAGTTTACAAATATATCGTGACCAACTGGCTGGCTAAGGTTAATACTCAGATCGACCTCATCCGCAAAAAAATGAAAGAAGCACTGGAAAACCAGGCGGAAGCTACCAAGGCAATCATTAACTACCAGTACAACCAGTACACCGAGGAAGAAAAAAACAACATCAACTTCAACATCGACGATCTGTCCTCTAAACTGAACGAATCCATCAACAAAGCTATGATCAACATCAACAAGTTCCTGAACCAGTGCTCTGTAAGCTATCTGATGAACTCCATGATCCCGTACGGTGTTAAACGTCTGGAGGACTTCGATGCGTCTCTGAAAGACGCCCTGCTGAAATACATTTACGACAACCGTGGCACTCTGATCGGTCAGGTTGATCGTCTGAAGGACAAAGTGAACAATACCTTATCGACCGACATCCCTTTTCAGCTCAGTAAATATGTCGATAACCAACGCCTTTTGTCCACTtaataagctt
26. Protein sequence of the CP-SST28-GS15-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECLSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
27. Protein sequence of the CT-SST28-GS15-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDGIITSKTKSDDDDKNKALNLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSALDSANSNPAMAPRERKAGCKNFFWKTFTSC
28. Protein sequence of the CT-CST14-GS20-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
29. Protein sequence of the CT-CST17-GS25-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVDRMPCRNFFWKTFSSCK
30. Protein sequence of the CT-CST29-GS15-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECLSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVQEGAPPQQSARRDRMPCRNFFWKTFSSCK
31. Protein sequence of the CT-CST29-GS30-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDGIITSKTKSDDDDKNKALNLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSALDQEGAPPQQSARRDRMPCRNFFWKTFSSCK
32. DNA sequence of IgA-HNtet
ggatccATGGAGTCCAATCAGCCGGAAAAAAATGGAACCGCGACTAAACCCGAGAATTCGGGGAACACTACGTCGGAAAACGGCCAGACGGAACCTGAGAAGAAACTGGAACTACGAAATGTGTCCGATATCGAGCTATACTCTCAAACCAATGGAACCTATAGGCAGCATGTTTCATTGGACGGAATCCCAGAAAATACGGATACATATTTCGTCAAAGTGAAGTCTAGCGCATTCAAGGATGTATATATCCCCGTTGCGAGTATTACAGAAGAGAAGCGGAACGGTCAAAGCGTTTATAAGATTACAGCAAAGGCCGAAAAGTTACAACAGGAGTTAGAAAACAAATACGTTGACAATTTCACTTTTTATCTCGATAAAAAGGCTAAAGAGGAAAACACGAACTTCACGTCATTTAGTAATCTGGTCAAAGCCATAAATCAAAATCCATCTGGTACATACCATCTCGCGGCAAGTCTAAACGCGAATGAAGTAGAACTTGGCCCGGACGAGCGTTCATACATTAAGGATACCTTTACTGGCAGACTCATAGGGGAAAAAGACGGTAAGAACTATGCTATATACAATTTGAAAAAGCCTTTATTTGAGAACCTGTCGGGCGCCACCGTCGAGAAATTGTCCCTTAAAAACGTAGCTATAAGCGGAAAGAATGACATCGGTAGTCTTGCAAACGAGGCTACTAACGGGACAAAGATTAAACAAGTGCACGTAGATGGGtgtgtcgacggcatcattacctccaaaactaaatctgacgatgacgataaaaacaaagcgctgaacctgcagtgcattaaaataaagaatgaggatttgacattcatcgcagaaaaaaatagcttcagcgaagagccgttccaagatgagatagtaagctacaacaccaagaacaagccgcttaattttaattactcgttagataaaatcatagttgactacaaccttcaatcgaagatcacgttaccgaatgacagaacaactcctgtcacaaaaggaattccctatgcacctgagtataagtcaaatgccgcgtcaacaatagagattcataatatagatgacaacaccatctatcaatatctgtacgctcagaaaagtccaacaactcttcagcgtataacaatgaccaatagtgtcgatgacgcattgataaattctaccaagatatactcttatttcccgagcgtcatctccaaagttaatcaaggtgctcaaggcattctatttttgcaatgggtccgagacatcatagatgacttcactaatgagtcgtctcagaaaaccacgattgataaaatatcagatgtttccaccatcgtcccctacatcggacctgcgcttaacattgtgaagcaggggtatgaggggaattttatcggagcgttagaaactacgggggttgtgctattacttgaatacataccagagataacattgcccgttatagcggccctcagtatcgcagaatcaagtacacaaaaagaaaagataatcaaaacaatcgacaacttcctagaaaagaggtacgaaaaatggatagaggtttataaactcgtgaaagcgaaatggttaggcactgttaatacgcagttccaaaagagatcctatcaaatgtatagatcactggagtaccaggtggatgccataaagaaaattatcgactatgaatataaaatatattcaggtccagataaggagcagatagctgatgaaataaacaatttaaaaaacaaacttgaagagaaggcgaataaggccatgatcaatatcaatatttttatgcgagaatcttcacgatcttttttggtaaatcagatgattaacgaagccaaaaagcagctgcttgagttcgacacacagtccaaaaacatactaatgcaatatatcaaagcaaactcaaaattcattggaattactgagctgaagaaactggaatccaaaataaataaagtattctctaccccgatcccgttctcttactctaaaaaccttgactgctgggtagataacgaagaagatattgacgttctagagtaataagctt
33. Protein sequence of the CT-GHRP-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
34. Protein sequence of the CT-GHRH-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA
35. Protein sequence of the CT-GHRP-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
36. Protein sequence of the CT-ghrelin-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
37. Protein sequence of the IgA-HNtet-CT-SST14 Fusion
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVLEGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
38. Protein sequence of the IgA-HNtet-CT-GHRP Fusion
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
39. Protein sequence of the CT-ghrelin S3W-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEIYALVGSWFLSPEHQRVQQRKESKKPPAKLQPR
40. Protein sequence of the CT-GRP-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGNHWAVGHLM
41. Protein sequence of the CT-GRP-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDEEKLYDDDDKDRWGSSLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDAIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSALVGNHWAVGHLM
42. Protein sequence of the CP-qGHRH29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRAEAAAKEAAAKALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
43. Protein sequence of the CP-qGHRH-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSLIEGRHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
44. Protein sequence of the CP-qGHRH-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGALAGGGGSGGGGSGGGGSALVLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFN
45. Protein sequence of the CP-qGHRH-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
46. Protein sequence of the CP-qGHRH-LHD N10-PL5 fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAPAPAPLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
47. Protein sequence of the CP-qGHRH-LHD N10-HX12 fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAEAAAKEAAAKALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
48. Protein sequence of the CP-UTS-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGGGGSADDDDKNDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEVALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
49. Protein sequence of LHN/A
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
50. Protein sequence of LHN/B
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDEEKLYDDDDKDRWGSSLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDAIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNS
51. Protein sequence of LHN/C
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFN
52. Protein sequence of LHN/D
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
53. Protein sequence of IgA-HNtet
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDV
54. Synthesised Octreotide peptide
Cys-Dphe-Cys-Phe-Dtrp-Lys-Thr-Cys-Thr-ol
55. Synthesised GHRH agonist peptide
HIS-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-NLE-SER-ARG-CYS
56. Synthesised GHRH antagonist peptide
PhAc-Tyr-D-Arg-Asp-Ala-Ile-Phe(4-Cl)-Thr-Ala-Har-Tyr(Me)-His-Lys-Val-Leu-Abu-Gln-Leu-Ser-Ala-His-Lys-Leu-Leu-Gln-Asp-Ile-Nle-D-Arg-Har-CYS
57. Protein sequence of CP-MCH-LHD
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKDFDMLRCMLGRVYRPCWQVALAKRLVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
58. Protein sequence of CT-KISS-LHD
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVYNWNSFGLRFG
59. Protein sequence of CT-PrRP-LHA
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVTPDINPAWYASRGIRPVGRFG
60. Protein sequence of CP-HS_GHRH_1-27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
61. Protein sequence of the CP-HS_GHRH_1-28-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
62. Protein sequence of the CP-HS_GHRH_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
63. Protein sequence of the CP-HS_GHRH_1-44-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
64. Protein sequence of the CP-HS_GHRH_1-40-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
65. Protein sequence of the CP-HS_GHRH_Ala9-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNAYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
66. Protein sequence of the CP-HS_GHRH_Ala22-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKALQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
67. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
68. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_Arg12_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKRVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
69. Protein sequence of the CP-HS_GHRH_Ala8_Asn11_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYNKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
70. Protein sequence of the CP-HS_GHRH_Ala8_Lys20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSAKKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
71. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_Lys20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKKVLGQLSAKKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
72. Protein sequence of the CP-HS_GHRH_Ala8_Asn20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSANKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
73. Protein sequence of the CP-HS_GHRH_Ala8_Asn12_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRNVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
74. Protein sequence of the CP-HS_GHRH_Ala8_Asn21_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSARNLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
75. Protein sequence of the CP-HS_GHRH_Ala8_Glu_7_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFEASYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
76. Protein sequence of the CP-HS_GHRH_Ala8_Glu_10_1-29LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASERKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
77. Protein sequence of the CP-HS_GHRH_Ala8_Glu_13_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKELGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
78. Protein sequence of the CP-HS_GHRH_Ala8-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
79. Protein sequence of the CP-HS_GHRH_Glu8_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTESYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
80. Protein sequence of the CP-HS_GHRH_Ala15_1-27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLAQLSARKLLQDIMALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
81. Protein sequence of the CP-HS_GHRH_Ala15-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLAQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
82. Protein sequence of the CP- HS_GHRH_Ala8_Ala15_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLAQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
83. Protein sequence of the CP-HS_GHRH_Ala8_9_15_22_27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTAAYRKVLAQLSARKALQDIASRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
84. Protein sequence of the CP-HS_GHRH_Ala8_9_15_22-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTAAYRKVLAQLSARKALQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
85. Protein sequence of the CP-HS_GHRH_HVQAL_1-32-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTQSYRKVLAQLSARKALQDILSRQQGALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
86. Protein sequence of the CP-HS_GHRH_HVSAL_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTSSYRKVLAQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
87. Protein sequence of the CP-HS_GHRH_HVTAL_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTTSYRKVLAQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
88. Protein sequence of the CP-HS_GHRH_QALN-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTQSYRKVLAQLSARKALQDILNRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
89. Protein sequence of the CP-HS_GHRH_QAL-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTQSYRKVLAQLSARKALQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
90. Protein sequence of the CP-hGHRH29 N8A M27L -LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSIEGRYADAIFTASYRKVLGQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
91. Protein sequence of the CP-hGHRH29 N8A K12N M27L -LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSIEGR YADAIFTASYRNVLGQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
92. Protein sequence of the N-termianal-hGHRH29 N8A M27L -LHD fusion
HVDAIFTQSYRKVLAQLSARKLLQDILNRNNNNNNNNNNTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
SEQ ID93 GnRH-C fusion protein
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVMKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI
SEQ ID94 GnRH-D fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSALVMKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI
1. LHN/A의 DNA 서열
2. LHN/B의 DNA 서열
3. LHN/C의 DNA 서열
4. LHN/D의 DNA 서열
5. 인간 CP-EN-GS15-SST28 링커의 DNA 서열
6. 인간 CT-GS20-CST28 링커의 DNA 서열
7. CP-CST14-GS20-LHD 융합물의 단백질 서열
8. CP-CST14-GS30-LHD 융합물의 단백질 서열
9. CP-CST28-GS20-LHD 융합물의 단백질 서열
10. CP-CST28-GS30-LHD 융합물의 단백질 서열
11. CP-SST14-GS20-LHD 융합물의 단백질 서열
12. CP-SST14-GS30-LHD 융합물의 단백질 서열
13. CP-SST28-GS20-LHD 융합물의 단백질 서열
14. CP-SST28-GS30-LHD 융합물의 단백질 서열
15. CT-CST14-GS20-LHD 융합물의 단백질 서열
16. CT-CST14-GS30-LHD 융합물의 단백질 서열
17. CT-CST28-GS20-LHD 융합물의 DNA 서열
18. CT-CST28-GS20-LHD 융합물의 단백질 서열
19. CT-CST28-GS30-LHD 융합물의 단백질 서열
20. CT-SST14-GS15-L(#Fxa)HD 융합물의 단백질 서열
21. CT-SST14-GS30-LHD 융합물의 단백질 서열
22. CT-SST28-GS20-LHD 융합물의 단백질 서열
23. CT-SST28-GS30-LHD 융합물의 단백질 서열
24. CT-SST14-GS35-LHC 융합물의 단백질 서열
25. CP-GS15-SST28-LHA 융합물의 DNA 서열
26. CP-GS15-SST28-LHA 융합물의 단백질 서열
27. CT-SST28-GS15-LHB 융합물의 단백질 서열
28. CT-CST14-GS20-LHC 융합물의 단백질 서열
29. CT-CST17-GS25-LHC 융합물의 단백질 서열
30. CT-CST29-GS15-LHA 융합물의 단백질 서열
31. CT-CST29-GS30-LHB 융합물의 단백질 서열
32. IgA-HNtet의 DNA 서열
33. CT-GHRP-LHC 융합물의 단백질 서열
34. CT-GHRH-LHD 융합물의 단백질 서열
35. CT-GHRP-LHD 융합물의 단백질 서열
36. CT-그렐린-LHA 융합물의 단백질 서열
37. IgA-HNtet-CT-SST14 융합물의 단백질 서열
38. IgA-HNtet-CT-GHRP 융합물의 단백질 서열
39. CT-그렐린 S3W-LHA 융합물의 단백질 서열
40. CT-GRP-LHD 융합물의 단백질 서열
41. CT-GRP-LHB 융합물의 단백질 서열
42. CP-qGHRH29-LHD 융합물의 단백질 서열
43. CP-qGHRH-LHA 융합물의 단백질 서열
44. CP-qGHRH-LHC 융합물의 단백질 서열
45. CP-qGHRH-LHD 융합물의 단백질 서열
46. CP-qGHRH-LHD N10-PL5 융합물의 단백질 서열
47. CP-qGHRH-LHD N10-HX12 융합물의 단백질 서열
48. CP-UTS-LHA 융합물의 단백질 서열
49. LHN/A의 단백질 서열
50. LHN/B의 단백질 서열
51. LHN/C의 단백질 서열
52. LHN/D의 단백질 서열
53. IgA-HNtet의 단백질 서열
54. 합성 옥트레오티드 펩티드
55. 합성 GHRH 길항근 펩티드
56. 합성 GHRH 길항제 펩티드
57. CP-MCH-LHD 융합물의 단백질 서열
58. CT-KISS-LHD 융합물의 단백질 서열
59. CT-PrRP-LHA 융합물의 단백질 서열
60. CP-HS_GHRH_1-27-LHD 융합물의 단백질 서열
61. CP-HS_GHRH_1-28-LHD 융합물의 단백질 서열
62. CP-HS_GHRH_1-29-LHD 융합물의 단백질 서열
63. CP-HS_GHRH_1-44-LHD 융합물의 단백질 서열
64. CP-HS_GHRH_1-40-LHD 융합물의 단백질 서열
65. CP-HS_GHRH_Ala9-LHD 융합물의 단백질 서열
66. CP-HS_GHRH_Ala22-LHD 융합물의 단백질 서열
67. CP-HS_GHRH_Ala8_Lys11_1-29-LHD 융합물의 단백질 서열
68. CP-HS_GHRH_Ala8_Lys11_Arg12_1-29-LHD 융합물의 단백질 서열
69. CP-HS_GHRH_Ala8_Asn11_1-29-LHD 융합물의 단백질 서열
70. CP-HS_GHRH_Ala8_Lys20_1-29-LHD 융합물의 단백질 서열
71. CP-HS_GHRH_Ala8_Lys11_Lys20_1-29-LHD 융합물의 단백질 서열
72. CP-HS_GHRH_Ala8_Asn20_1-29-LHD 융합물의 단백질 서열
73. CP-HS_GHRH_Ala8_Asn12_1-29-LHD 융합물의 단백질 서열
74. CP-HS_GHRH_Ala8_Asn21_1-29-LHD 융합물의 단백질 서열
75. CP-HS_GHRH_Ala8_Glu_7_1-29-LHD 융합물의 단백질 서열
76. CP-HS_GHRH_Ala8_Glu_10_1-29LHD 융합물의 단백질 서열
77. CP-HS_GHRH_Ala8_Glu_13_1-29-LHD 융합물의 단백질 서열
78. CP-HS_GHRH_Ala8-LHD 융합물의 단백질 서열
79. CP-HS_GHRH_Glu8_1-29-LHD 융합물의 단백질 서열
80. CP-HS_GHRH_Ala15_1-27-LHD 융합물의 단백질 서열
81. CP-HS_GHRH_Ala15-LHD 융합물의 단백질 서열
82. CP-HS_GHRH_Ala8_Ala15_1-29-LHD 융합물의 단백질 서열
83. CP-HS_GHRH_Ala8_9_15_22_27-LHD 융합물의 단백질 서열
84. CP-HS_GHRH_Ala8_9_15_22-LHD 융합물의 단백질 서열
85. CP-HS_GHRH_HVQAL_1-32-LHD 융합물의 단백질 서열
86. CP-HS_GHRH_HVSAL_1-29-LHD 융합물의 단백질 서열
87. CP-HS_GHRH_HVTAL_1-29-LHD 융합물의 단백질 서열
88. CP-HS_GHRH_QALN-LHD 융합물의 단백질 서열
89. CP-HS_GHRH_QAL-LHD 융합물의 단백질 서열
90. CP-hGHRH29 N8A M27L-LHD 융합물의 단백질 서열
91. CP-hGHRH29 N8A K12N M27L-LHD 융합물의 단백질 서열
92. N-말단-hGHRH29 N8A M27L-LHD 융합물의 단백질 서열
93. 인간 GnRH-C 융합물의 단백질 서열
94. 인간 GnRH -D GS 20 융합물의 단백질 서열
서열번호
1. DNA sequence of LHN/A
ggatccATGGAGTTCGTTAACAAACAGTTCAACTATAAAGACCCAGTTAACGGTGTTGACATTGCTTACATCAAAATCCCGAACGCTGGCCAGATGCAGCCGGTAAAGGCATTCAAAATCCACAACAAAATCTGGGTTATCCCGGAACGTGATACCTTTACTAACCCGGAAGAAGGTGACCTGAACCCGCCACCGGAAGCGAAACAGGTGCCGGTATCTTACTATGACTCCACCTACCTGTCTACCGATAACGAAAAGGACAACTACCTGAAAGGTGTTACTAAACTGTTCGAGCGTATTTACTCCACCGACCTGGGCCGTATGCTGCTGACTAGCATCGTTCGCGGTATCCCGTTCTGGGGCGGTTCTACCATCGATACCGAACTGAAAGTAATCGACACTAACTGCATCAACGTTATTCAGCCGGACGGTTCCTATCGTTCCGAAGAACTGAACCTGGTGATCATCGGCCCGTCTGCTGATATCATCCAGTTCGAGTGTCTGAGCTTTGGTCACGAAGTTCTGAACCTCACCCGTAACGGCTACGGTTCCACTCAGTACATCCGTTTCTCTCCGGACTTCACCTTCGGTTTTGAAGAATCCCTGGAAGTAGACACGAACCCACTGCTGGGCGCTGGTAAATTCGCAACTGATCCTGCGGTTACCCTGGCTCACGAACTGATTCATGCAGGCCACCGCCTGTACGGTATCGCCATCAATCCGAACCGTGTCTTCAAAGTTAACACCAACGCGTATTACGAGATGTCCGGTCTGGAAGTTAGCTTCGAAGAACTGCGTACTTTTGGCGGTCACGACGCTAAATTCATCGACTCTCTGCAAGAAAACGAGTTCCGTCTGTACTACTATAACAAGTTCAAAGATATCGCATCCACCCTGAACAAAGCGAAATCCATCGTGGGTACCACTGCTTCTCTCCAGTACATGAAGAACGTTTTTAAAGAAAAATACCTGCTCAGCGAAGACACCTCCGGCAAATTCTCTGTAGACAAGTTGAAATTCGATAAACTTTACAAAATGCTGACTGAAATTTACACCGAAGACAACTTCGTTAAGTTCTTTAAAGTTCTGAACCGCAAAACCTATCTGAACTTCGACAAGGCAGTATTCAAAATCAACATCGTGCCGAAAGTTAACTACACTATCTACGATGGTTTCAACCTGCGTAACACCAACCTGGCTGCTAATTTTAACGGCCAGAACACGGAAATCAACAACATGAACTTCACAAAACTGAAAAACTTCACTGGTCTGTTCGAGTTTTACAAGCTGCTGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAACAAAGCGCTGAACCTGCAGTGTATCAAGGTTAACAACTGGGATTTATTCTTCAGCCCGAGTGAAGACAACTTCACCAACGACCTGAACAAAGGTGAAGAAATCACCTCAGATACTAACATCGAAGCAGCCGAAGAAAACATCTCGCTGGACCTGATCCAGCAGTACTACCTGACCTTTAATTTCGACAACGAGCCGGAAAACATTTCTATCGAAAACCTGAGCTCTGATATCATCGGCCAGCTGGAACTGATGCCGAACATCGAACGTTTCCCAAACGGTAAAAAGTACGAGCTGGACAAATATACCATGTTCCACTACCTGCGCGCGCAGGAATTTGAACACGGCAAATCCCGTATCGCACTGACTAACTCCGTTAACGAAGCTCTGCTCAACCCGTCCCGTGTATACACCTTCTTCTCTAGCGACTACGTGAAAAAGGTCAACAAAGCGACTGAAGCTGCAATGTTCTTGGGTTGGGTTGAACAGCTTGTTTATGATTTTACCGACGAGACGTCCGAAGTATCTACTACCGACAAAATTGCGGATATCACTATCATCATCCCGTACATCGGTCCGGCTCTGAACATTGGCAACATGCTGTACAAAGACGACTTCGTTGGCGCACTGATCTTCTCCGGTGCGGTGATCCTGCTGGAGTTCATCCCGGAAATCGCCATCCCGGTACTGGGCACCTTTGCTCTGGTTTCTTACATTGCAAACAAGGTTCTGACTGTACAAACCATCGACAACGCGCTGAGCAAACGTAACGAAAAATGGGATGAAGTTTACAAATATATCGTGACCAACTGGCTGGCTAAGGTTAATACTCAGATCGACCTCATCCGCAAAAAAATGAAAGAAGCACTGGAAAACCAGGCGGAAGCTACCAAGGCAATCATTAACTACCAGTACAACCAGTACACCGAGGAAGAAAAAAACAACATCAACTTCAACATCGACGATCTGTCCTCTAAACTGAACGAATCCATCAACAAAGCTATGATCAACATCAACAAGTTCCTGAACCAGTGCTCTGTAAGCTATCTGATGAACTCCATGATCCCGTACGGTGTTAAACGTCTGGAGGACTTCGATGCGTCTCTGAAAGACGCCCTGCTGAAATACATTTACGACAACCGTGGCACTCTGATCGGTCAGGTTGATCGTCTGAAGGACAAAGTGAACAATACCTTATCGACCGACATCCCTTTTCAGCTCAGTAAATATGTCGATAACCAACGCCTTTTGTCCACTtaataagctt
2. DNA sequence of LHN/B
GGATCCATGCCGGTTACCATCAACAACTTCAACTACAACGACCCGATCGACAACAACAACATCATTATGATGGAACCGCCGTTCGCACGTGGTACCGGACGTTACTACAAGGCTTTTAAGATCACCGACCGTATCTGGATCATCCCGGAACGTTACACCTTCGGTTACAAACCTGAGGACTTCAACAAGAGTAGCGGGATTTTCAATCGTGACGTCTGCGAGTACTATGATCCAGATTATCTGAATACCAACGATAAGAAGAACATATTCCTTCAGACTATGATTAAACTCTTCAACCGTATCAAAAGCAAACCGCTCGGTGAAAAACTCCTCGAAATGATTATCAACGGTATCCCGTACCTCGGTGACCGTCGTGTCCCGCTTGAAGAGTTCAACACCAACATCGCAAGCGTCACCGTCAACAAACTCATCAGCAACCCAGGTGAAGTCGAACGTAAAAAAGGTATCTTCGCAAACCTCATCATCTTCGGTCCGGGTCCGGTCCTCAACGAAAACGAAACCATCGACATCGGTATCCAGAACCACTTCGCAAGCCGTGAAGGTTTCGGTGGTATCATGCAGATGAAATTCTGCCCGGAATACGTCAGTGTCTTCAACAACGTCCAGGAAAACAAAGGTGCAAGCATCTTCAACCGTCGTGGTTACTTCAGCGACCCGGCACTCATCCTCATGCATGAACTCATCCACGTCCTCCACGGTCTCTACGGTATCAAAGTTGACGACCTCCCGATCGTCCCGAACGAGAAGAAATTCTTCATGCAGAGCACCGACGCAATCCAGGCTGAGGAACTCTACACCTTCGGTGGCCAAGACCCAAGTATCATAACCCCGTCCACCGACAAAAGCATCTACGACAAAGTCCTCCAGAACTTCAGGGGTATCGTGGACAGACTCAACAAAGTCCTCGTCTGCATCAGCGACCCGAACATCAATATCAACATATACAAGAACAAGTTCAAAGACAAGTACAAATTCGTCGAGGACAGCGAAGGCAAATACAGCATCGACGTAGAAAGTTTCGACAAGCTCTACAAAAGCCTCATGTTCGGTTTCACCGAAACCAACATCGCCGAGAACTACAAGATCAAGACAAGGGCAAGTTACTTCAGCGACAGCCTCCCGCCTGTCAAAATCAAGAACCTCTTAGACAACGAGATTTACACAATTGAAGAGGGCTTCAACATCAGTGACAAAGACATGGAGAAGGAATACAGAGGTCAGAACAAGGCTATCAACAAACAGGCATACGAGGAGATCAGCAAAGAACACCTCGCAGTCTACAAGATCCAGATGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAACAAAGCGCTGAACCTGCAGTGCATCGACGTTGACAACGAAGACCTGTTCTTCATCGCTGACAAAAACAGCTTCAGTGACGACCTGAGCAAAAACGAACGTATCGAATACAACACCCAGAGCAACTACATCGAAAACGACTTCCCGATCAACGAACTGATCCTGGACACCGACCTGATAAGTAAAATCGAACTGCCGAGCGAAAACACCGAAAGTCTGACCGACTTCAACGTTGACGTTCCGGTTTACGAAAAACAGCCGGCTATCAAGAAAATCTTCACCGACGAAAACACCATCTTCCAGTACCTGTACAGCCAGACCTTCCCGCTGGACATCCGTGACATCAGTCTGACCAGCAGTTTCGACGACGCTCTGCTGTTCAGCAACAAAGTTTACAGTTTCTTCAGCATGGACTACATCAAAACCGCTAACAAAGTTGTTGAAGCAGGGCTGTTCGCTGGTTGGGTTAAACAGATCGTTAACGACTTCGTTATCGAAGCTAACAAAAGCAACACTATGGACAAAATCGCTGACATCAGTCTGATCGTTCCGTACATCGGTCTGGCTCTGAACGTTGGTAACGAAACCGCTAAAGGTAACTTTGAAAACGCTTTCGAGATCGCTGGTGCAAGCATCCTGCTGGAGTTCATCCCGGAACTGCTGATCCCGGTTGTTGGTGCTTTCCTGCTGGAAAGTTACATCGACAACAAAAACAAGATCATCAAAACCATCGACAACGCTCTGACCAAACGTAACGAAAAATGGAGTGATATGTACGGTCTGATCGTTGCTCAGTGGCTGAGCACCGTCAACACCCAGTTCTACACCATCAAAGAAGGTATGTACAAAGCTCTGAACTACCAGGCTCAGGCTCTGGAAGAGATCATCAAATACCGTTACAACATCTACAGTGAGAAGGAAAAGAGTAACATCAACATCGACTTCAACGACATCAACAGCAAACTGAACGAAGGTATCAACCAGGCTATCGACAACATCAACAACTTCATCAACGGTTGCAGTGTTAGCTACCTGATGAAGAAGATGATCCCGCTGGCTGTTGAAAAACTGCTGGACTTCGACAACACCCTGAAAAAGAACCTGCTGAACTACATCGACGAAAACAAGCTGTACCTGATCGGTAGTGCTGAATACGAAAAAAGTAAAGTGAACAAATACCTGAAGACCATCATGCCGTTCGACCTGAGTATCTACACCAACGACACCATCCTGATCGAAATGTTCAACAAATACAACTCTtaataagctt
3. DNA sequence of LHN/C
ggatccATGCCGATCACCATCAACAACTTCAACTACAGCGATCCGGTGGATAACAAAAACATCCTGTACCTGGATACCCATCTGAATACCCTGGCGAACGAACCGGAAAAAGCGTTTCGTATCACCGGCAACATTTGGGTTATTCCGGATCGTTTTAGCCGTAACAGCAACCCGAATCTGAATAAACCGCCGCGTGTTACCAGCCCGAAAAGCGGTTATTACGATCCGAACTATCTGAGCACCGATAGCGATAAAGATACCTTCCTGAAAGAAATCATCAAACTGTTCAAACGCATCAACAGCCGTGAAATTGGCGAAGAACTGATCTATCGCCTGAGCACCGATATTCCGTTTCCGGGCAACAACAACACCCCGATCAACACCTTTGATTTCGATGTGGATTTCAACAGCGTTGATGTTAAAACCCGCCAGGGTAACAATTGGGTGAAAACCGGCAGCATTAACCCGAGCGTGATTATTACCGGTCCGCGCGAAAACATTATTGATCCGGAAACCAGCACCTTTAAACTGACCAACAACACCTTTGCGGCGCAGGAAGGTTTTGGCGCGCTGAGCATTATTAGCATTAGCCCGCGCTTTATGCTGACCTATAGCAACGCGACCAACGATGTTGGTGAAGGCCGTTTCAGCAAAAGCGAATTTTGCATGGACCCGATCCTGATCCTGATGCATGAACTGAACCATGCGATGCATAACCTGTATGGCATCGCGATTCCGAACGATCAGACCATTAGCAGCGTGACCAGCAACATCTTTTACAGCCAGTACAACGTGAAACTGGAATATGCGGAAATCTATGCGTTTGGCGGTCCGACCATTGATCTGATTCCGAAAAGCGCGCGCAAATACTTCGAAGAAAAAGCGCTGGATTACTATCGCAGCATTGCGAAACGTCTGAACAGCATTACCACCGCGAATCCGAGCAGCTTCAACAAATATATCGGCGAATATAAACAGAAACTGATCCGCAAATATCGCTTTGTGGTGGAAAGCAGCGGCGAAGTTACCGTTAACCGCAATAAATTCGTGGAACTGTACAACGAACTGACCCAGATCTTCACCGAATTTAACTATGCGAAAATCTATAACGTGCAGAACCGTAAAATCTACCTGAGCAACGTGTATACCCCGGTGACCGCGAATATTCTGGATGATAACGTGTACGATATCCAGAACGGCTTTAACATCCCGAAAAGCAACCTGAACGTTCTGTTTATGGGCCAGAACCTGAGCCGTAATCCGGCGCTGCGTAAAGTGAACCCGGAAAACATGCTGTACCTGTTCACCAAATTTTGCGTCGACGCGATTGATGGTCGTAGCCTGTACAACAAAACCCTGCAGTGTCGTGAACTGCTGGTGAAAAACACCGATCTGCCGTTTATTGGCGATATCAGCGATGTGAAAACCGATATCTTCCTGCGCAAAGATATCAACGAAGAAACCGAAGTGATCTACTACCCGGATAACGTGAGCGTTGATCAGGTGATCCTGAGCAAAAACACCAGCGAACATGGTCAGCTGGATCTGCTGTATCCGAGCATTGATAGCGAAAGCGAAATTCTGCCGGGCGAAAACCAGGTGTTTTACGATAACCGTACCCAGAACGTGGATTACCTGAACAGCTATTACTACCTGGAAAGCCAGAAACTGAGCGATAACGTGGAAGATTTTACCTTTACCCGCAGCATTGAAGAAGCGCTGGATAACAGCGCGAAAGTTTACACCTATTTTCCGACCCTGGCGAACAAAGTTAATGCGGGTGTTCAGGGCGGTCTGTTTCTGATGTGGGCGAACGATGTGGTGGAAGATTTCACCACCAACATCCTGCGTAAAGATACCCTGGATAAAATCAGCGATGTTAGCGCGATTATTCCGTATATTGGTCCGGCGCTGAACATTAGCAATAGCGTGCGTCGTGGCAATTTTACCGAAGCGTTTGCGGTTACCGGTGTGACCATTCTGCTGGAAGCGTTTCCGGAATTTACCATTCCGGCGCTGGGTGCGTTTGTGATCTATAGCAAAGTGCAGGAACGCAACGAAATCATCAAAACCATCGATAACTGCCTGGAACAGCGTATTAAACGCTGGAAAGATAGCTATGAATGGATGATGGGCACCTGGCTGAGCCGTATTATCACCCAGTTCAACAACATCAGCTACCAGATGTACGATAGCCTGAACTATCAGGCGGGTGCGATTAAAGCGAAAATCGATCTGGAATACAAAAAATACAGCGGCAGCGATAAAGAAAACATCAAAAGCCAGGTTGAAAACCTGAAAAACAGCCTGGATGTGAAAATTAGCGAAGCGATGAATAACATCAACAAATTCATCCGCGAATGCAGCGTGACCTACCTGTTCAAAAACATGCTGCCGAAAGTGATCGATGAACTGAACGAATTTGATCGCAACACCAAAGCGAAACTGATCAACCTGATCGATAGCCACAACATTATTCTGGTGGGCGAAGTGGATAAACTGAAAGCGAAAGTTAACAACAGCTTCCAGAACACCATCCCGTTTAACATCTTCAGCTATACCAACAACAGCCTGCTGAAAGATATCATCAACGAATACTTCAATtaataagctt
4. DNA sequence of LHN/D
ggatccATGACGTGGCCAGTTAAGGATTTCAACTACTCAGATCCTGTAAATGACAACGATATTCTGTACCTTCGCATTCCACAAAATAAACTGATCACCACACCAGTCAAAGCATTCATGATTACTCAAAACATTTGGGTCATTCCAGAACGCTTTTCTAGTGACACAAATCCGAGTTTATCTAAACCTCCGCGTCCGACGTCCAAATATCAGAGCTATTACGATCCCTCATATCTCAGTACGGACGAACAAAAAGATACTTTCCTTAAAGGTATCATTAAACTGTTTAAGCGTATTAATGAGCGCGATATCGGGAAAAAGTTGATTAATTATCTTGTTGTGGGTTCCCCGTTCATGGGCGATAGCTCTACCCCCGAAGACACTTTTGATTTTACCCGTCATACGACAAACATCGCGGTAGAGAAGTTTGAGAACGGATCGTGGAAAGTCACAAACATCATTACACCTAGCGTCTTAATTTTTGGTCCGCTGCCAAACATCTTAGATTATACAGCCAGCCTGACTTTGCAGGGGCAACAGTCGAATCCGAGTTTCGAAGGTTTTGGTACCCTGAGCATTCTGAAAGTTGCCCCGGAATTTCTGCTCACTTTTTCAGATGTCACCAGCAACCAGAGCTCAGCAGTATTAGGAAAGTCAATTTTTTGCATGGACCCGGTTATTGCACTGATGCACGAACTGACGCACTCTCTGCATCAACTGTATGGGATCAACATCCCCAGTGACAAACGTATTCGTCCCCAGGTGTCTGAAGGATTTTTCTCACAGGATGGGCCGAACGTCCAGTTCGAAGAGTTGTATACTTTCGGAGGCCTGGACGTAGAGATCATTCCCCAGATTGAGCGCAGTCAGCTGCGTGAGAAGGCATTGGGCCATTATAAGGATATTGCAAAACGCCTGAATAACATTAACAAAACGATTCCATCTTCGTGGATCTCGAATATTGATAAATATAAGAAAATTTTTAGCGAGAAATATAATTTTGATAAAGATAATACAGGTAACTTTGTGGTTAACATTGACAAATTCAACTCCCTTTACAGTGATTTGACGAATGTAATGAGCGAAGTTGTGTATAGTTCCCAATACAACGTTAAGAATCGTACCCATTACTTCTCTCGTCACTACCTGCCGGTTTTCGCGAACATCCTTGACGATAATATTTACACTATTCGTGACGGCTTTAACTTGACCAACAAGGGCTTCAATATTGAAAATTCAGGCCAGAACATTGAACGCAACCCGGCCTTGCAGAAACTGTCGAGTGAATCCGTGGTTGACCTGTTTACCAAAGTCTGCGTCGACAAAAGCGAAGAGAAGCTGTACGATGACGATGACAAAGATCGTTGGGGATCGTCCCTGCAGTGTATTAAAGTGAAAAACAATCGGCTGCCTTATGTAGCAGATAAAGATAGCATTAGTCAGGAGATTTTCGAAAATAAAATTATCACTGACGAAACCAATGTTCAGAATTATTCAGATAAATTTTCACTGGACGAAAGCATCTTAGATGGCCAAGTTCCGATTAACCCGGAAATTGTTGATCCGTTACTGCCGAACGTGAATATGGAACCGTTAAACCTCCCTGGCGAAGAGATCGTATTTTATGATGACATTACGAAATATGTGGACTACCTTAATTCTTATTACTATTTGGAAAGCCAGAAACTGTCCAATAACGTGGAAAACATTACTCTGACCACAAGCGTGGAAGAGGCTTTAGGCTACTCAAATAAGATTTATACCTTCCTCCCGTCGCTGGCGGAAAAAGTAAATAAAGGTGTGCAGGCTGGTCTGTTCCTCAACTGGGCGAATGAAGTTGTCGAAGACTTTACCACGAATATTATGAAAAAGGATACCCTGGATAAAATCTCCGACGTCTCGGTTATTATCCCATATATTGGCCCTGCGTTAAATATCGGTAATAGTGCGCTGCGGGGGAATTTTAACCAGGCCTTTGCTACCGCGGGCGTCGCGTTCCTCCTGGAGGGCTTTCCTGAATTTACTATCCCGGCGCTCGGTGTTTTTACATTTTACTCTTCCATCCAGGAGCGTGAGAAAATTATCAAAACCATCGAAAACTGCCTGGAGCAGCGGGTGAAACGCTGGAAAGATTCTTATCAATGGATGGTGTCAAACTGGTTATCTCGCATCACGACCCAATTCAACCATATTAATTACCAGATGTATGATAGTCTGTCGTACCAAGCTGACGCCATTAAAGCCAAAATTGATCTGGAATATAAAAAGTACTCTGGTAGCGATAAGGAGAACATCAAAAGCCAGGTGGAGAACCTTAAGAATAGTCTGGATGTGAAAATCTCTGAAGCTATGAATAACATTAACAAATTCATTCGTGAATGTTCGGTGACGTACCTGTTCAAGAATATGCTGCCAAAAGTTATTGATGAACTGAATAAATTTGATCTGCGTACCAAAACCGAACTTATCAACCTCATCGACTCCCACAACATTATCCTTGTGGGCGAAGTGGATCGTCTGAAGGCCAAAGTAAACGAGAGCTTTGAAAATACGATGCCGTTTAATATTTTTTCATATACCAATAACTCCTTGCTGAAAGATATCATCAATGAATATTTCAATtaataagctt
5. DNA sequence of the human CP-EN-GS15-SST28 linker
CATATGGGATCCGGTTTAAACGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAGCGCCAATTCAAATCCTGCAATGGCGCCACGCGAACGCAAAGCTGGTTGCAAAAACTTCTTCTGGAAAACCTTCACCTCTTGCGCGCTAGCGGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCTGCAGCTAGAATAATGAAAGCTT
6. DNA sequence of the Human CT-GS20-CST28 linker
GGATCCGTCGACCTGCAGGGTCTAGAAGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCAGGAAAGACCTCCATTACAACAACCTCCACATCGCGATAAGAAACCATGTAAGAATTTCTTTTGGAAAACATTTAGCAGTTGCAAATGATAAAAGCTT
7. Protein sequence of the CP-CST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
8. Protein sequence of the CP-CST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
9. Protein sequence of the CP-CST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKQERPPLQQPPHRDKKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
10. Protein sequence of the CP-CST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKQERPPLQQPPHRDKKPCKNFFWKTFSSCKALAGGGGSGGGGSGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
11. Protein sequence of the CP-SST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
12. Protein sequence of the CP-SST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
13. Protein sequence of the CP-SST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
14. Protein sequence of the CP-SST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
15. Protein sequence of the CT-CST14-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVPCKNFFWKTFSSCK
16. Protein sequence of the CT-CST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVPCKNFFWKTFSSCK
17. DNA sequence of the CT-CST28-GS20-LHD fusion
GGATCCATGACGTGGCCAGTTAAGGATTTCAACTACTCAGATCCTGTAAATGACAACGATATTCTGTACCTTCGCATTCCACAAAATAAACTGATCACCACACCAGTCAAAGCATTCATGATTACTCAAAACATTTGGGTCATTCCAGAACGCTTTTCTAGTGACACAAATCCGAGTTTATCTAAACCTCCGCGTCCGACGTCCAAATATCAGAGCTATTACGATCCCTCATATCTCAGTACGGACGAACAAAAAGATACTTTCCTTAAAGGTATCATTAAACTGTTTAAGCGTATTAATGAGCGCGATATCGGGAAAAAGTTGATTAATTATCTTGTTGTGGGTTCCCCGTTCATGGGCGATAGCTCTACCCCCGAAGACACTTTTGATTTTACCCGTCATACGACAAACATCGCGGTAGAGAAGTTTGAGAACGGATCGTGGAAAGTCACAAACATCATTACACCTAGCGTCTTAATTTTTGGTCCGCTGCCAAACATCTTAGATTATACAGCCAGCCTGACTTTGCAGGGGCAACAGTCGAATCCGAGTTTCGAAGGTTTTGGTACCCTGAGCATTCTGAAAGTTGCCCCGGAATTTCTGCTCACTTTTTCAGATGTCACCAGCAACCAGAGCTCAGCAGTATTAGGAAAGTCAATTTTTTGCATGGACCCGGTTATTGCACTGATGCACGAACTGACGCACTCTCTGCATCAACTGTATGGGATCAACATCCCCAGTGACAAACGTATTCGTCCCCAGGTGTCTGAAGGATTTTTCTCACAGGATGGGCCGAACGTCCAGTTCGAAGAGTTGTATACTTTCGGAGGCCTGGACGTAGAGATCATTCCCCAGATTGAGCGCAGTCAGCTGCGTGAGAAGGCATTGGGCCATTATAAGGATATTGCAAAACGCCTGAATAACATTAACAAAACGATTCCATCTTCGTGGATCTCGAATATTGATAAATATAAGAAAATTTTTAGCGAGAAATATAATTTTGATAAAGATAATACAGGTAACTTTGTGGTTAACATTGACAAATTCAACTCCCTTTACAGTGATTTGACGAATGTAATGAGCGAAGTTGTGTATAGTTCCCAATACAACGTTAAGAATCGTACCCATTACTTCTCTCGTCACTACCTGCCGGTTTTCGCGAACATCCTTGACGATAATATTTACACTATTCGTGACGGCTTTAACTTGACCAACAAGGGCTTCAATATTGAAAATTCAGGCCAGAACATTGAACGCAACCCGGCCTTGCAGAAACTGTCGAGTGAATCCGTGGTTGACCTGTTTACCAAAGTCTGCGTCGACAAAAGCGAAGAGAAGCTGTACGATGACGATGACAAAGATCGTTGGGGATCGTCCCTGCAGTGTATTAAAGTGAAAAACAATCGGCTGCCTTATGTAGCAGATAAAGATAGCATTAGTCAGGAGATTTTCGAAAATAAAATTATCACTGACGAAACCAATGTTCAGAATTATTCAGATAAATTTTCACTGGACGAAAGCATCTTAGATGGCCAAGTTCCGATTAACCCGGAAATTGTTGATCCGTTACTGCCGAACGTGAATATGGAACCGTTAAACCTCCCTGGCGAAGAGATCGTATTTTATGATGACATTACGAAATATGTGGACTACCTTAATTCTTATTACTATTTGGAAAGCCAGAAACTGTCCAATAACGTGGAAAACATTACTCTGACCACAAGCGTGGAAGAGGCTTTAGGCTACTCAAATAAGATTTATACCTTCCTCCCGTCGCTGGCGGAAAAAGTAAATAAAGGTGTGCAGGCTGGTCTGTTCCTCAACTGGGCGAATGAAGTTGTCGAAGACTTTACCACGAATATTATGAAAAAGGATACCCTGGATAAAATCTCCGACGTCTCGGTTATTATCCCATATATTGGCCCTGCGTTAAATATCGGTAATAGTGCGCTGCGGGGGAATTTTAACCAGGCCTTTGCTACCGCGGGCGTCGCGTTCCTCCTGGAGGGCTTTCCTGAATTTACTATCCCGGCGCTCGGTGTTTTTACATTTTACTCTTCCATCCAGGAGCGTGAGAAAATTATCAAAACCATCGAAAACTGCCTGGAGCAGCGGGTGAAACGCTGGAAAGATTCTTATCAATGGATGGTGTCAAACTGGTTATCTCGCATCACGACCCAATTCAACCATATTAATTACCAGATGTATGATAGTCTGTCGTACCAAGCTGACGCCATTAAAGCCAAAATTGATCTGGAATATAAAAAGTACTCTGGTAGCGATAAGGAGAACATCAAAAGCCAGGTGGAGAACCTTAAGAATAGTCTGGATGTGAAAATCTCTGAAGCTATGAATAACATTAACAAATTCATTCGTGAATGTTCGGTGACGTACCTGTTCAAGAATATGCTGCCAAAAGTTATTGATGAACTGAATAAATTTGATCTGCGTACCAAAACCGAACTTATCAACCTCATCGACTCCCACAACATTATCCTTGTGGGCGAAGTGGATCGTCTGAAGGCCAAAGTAAACGAGAGCTTTGAAAATACGATGCCGTTTAATATTTTTTCATATACCAATAACTCCTTGCTGAAAGATATCATCAATGAATATTTCAATCTAGAAGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCAGGAAAGACCTCCATTACAACAACCTCCACATCGCGATAAGAAACCATGTAAGAATTTCTTTTGGAAAACATTTAGCAGTTGCAAAtaataagctt
18. Protein sequence of the CT-CST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVQERPPLQQPPHRDKKPCKNFFWKTFSSCK
19. Protein sequence of the CT-CST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVQERPPLQQPPHRDKKPCKNFFWKTFSSCK
20. Protein sequence of the CT-SST14-GS15-L(#Fxa)HD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSIDGRNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYIDGRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
21. Protein sequence of the CT-SST14-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
22. Protein sequence of the CT-SST28-GS20-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVSANSNPAMAPRERKAGCKNFFWKTFTSC
23. Protein sequence of the CT-SST28-GS30-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVSANSNPAMAPRERKAGCKNFFWKTFTSC
24. Protein sequence of the CT-SST14-GS35-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
25. DNA sequence of the CP-SST28-GS15-LHA fusion
ggatccATGGAGTTCGTTAACAAACAGTTCAACTATAAAGACCCAGTTAACGGTGTTGACATTGCTTACATCAAAATCCCGAACGCTGGCCAGATGCAGCCGGTAAAGGCATTCAAAATCCACAACAAAATCTGGGTTATCCCGGAACGTGATACCTTTACTAACCCGGAAGAAGGTGACCTGAACCCGCCACCGGAAGCGAAACAGGTGCCGGTATCTTACTATGACTCCACCTACCTGTCTACCGATAACGAAAAGGACAACTACCTGAAAGGTGTTACTAAACTGTTCGAGCGTATTTACTCCACCGACCTGGGCCGTATGCTGCTGACTAGCATCGTTCGCGGTATCCCGTTCTGGGGCGGTTCTACCATCGATACCGAACTGAAAGTAATCGACACTAACTGCATCAACGTTATTCAGCCGGACGGTTCCTATCGTTCCGAAGAACTGAACCTGGTGATCATCGGCCCGTCTGCTGATATCATCCAGTTCGAGTGTCTGAGCTTTGGTCACGAAGTTCTGAACCTCACCCGTAACGGCTACGGTTCCACTCAGTACATCCGTTTCTCTCCGGACTTCACCTTCGGTTTTGAAGAATCCCTGGAAGTAGACACGAACCCACTGCTGGGCGCTGGTAAATTCGCAACTGATCCTGCGGTTACCCTGGCTCACGAACTGATTCATGCAGGCCACCGCCTGTACGGTATCGCCATCAATCCGAACCGTGTCTTCAAAGTTAACACCAACGCGTATTACGAGATGTCCGGTCTGGAAGTTAGCTTCGAAGAACTGCGTACTTTTGGCGGTCACGACGCTAAATTCATCGACTCTCTGCAAGAAAACGAGTTCCGTCTGTACTACTATAACAAGTTCAAAGATATCGCATCCACCCTGAACAAAGCGAAATCCATCGTGGGTACCACTGCTTCTCTCCAGTACATGAAGAACGTTTTTAAAGAAAAATACCTGCTCAGCGAAGACACCTCCGGCAAATTCTCTGTAGACAAGTTGAAATTCGATAAACTTTACAAAATGCTGACTGAAATTTACACCGAAGACAACTTCGTTAAGTTCTTTAAAGTTCTGAACCGCAAAACCTATCTGAACTTCGACAAGGCAGTATTCAAAATCAACATCGTGCCGAAAGTTAACTACACTATCTACGATGGTTTCAACCTGCGTAACACCAACCTGGCTGCTAATTTTAACGGCCAGAACACGGAAATCAACAACATGAACTTCACAAAACTGAAAAACTTCACTGGTCTGTTCGAGTTTTACAAGCTGCTGTGCGTCGACGGCATCATTACCTCCAAAACTAAATCTGACGATGACGATAAAAGCGCCAATTCAAATCCTGCAATGGCGCCACGCGAACGCAAAGCTGGATGCAAAAACTTCTTTTGGAAGACATTTACTAGTTGTGCGCTAGCGGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGGCGGTGGCGGTAGCGCACTAGTGCTGCAGTGTATCAAGGTTAACAACTGGGATTTATTCTTCAGCCCGAGTGAAGACAACTTCACCAACGACCTGAACAAAGGTGAAGAAATCACCTCAGATACTAACATCGAAGCAGCCGAAGAAAACATCTCGCTGGACCTGATCCAGCAGTACTACCTGACCTTTAATTTCGACAACGAGCCGGAAAACATTTCTATCGAAAACCTGAGCTCTGATATCATCGGCCAGCTGGAACTGATGCCGAACATCGAACGTTTCCCAAACGGTAAAAAGTACGAGCTGGACAAATATACCATGTTCCACTACCTGCGCGCGCAGGAATTTGAACACGGCAAATCCCGTATCGCACTGACTAACTCCGTTAACGAAGCTCTGCTCAACCCGTCCCGTGTATACACCTTCTTCTCTAGCGACTACGTGAAAAAGGTCAACAAAGCGACTGAAGCTGCAATGTTCTTGGGTTGGGTTGAACAGCTTGTTTATGATTTTACCGACGAGACGTCCGAAGTATCTACTACCGACAAAATTGCGGATATCACTATCATCATCCCGTACATCGGTCCGGCTCTGAACATTGGCAACATGCTGTACAAAGACGACTTCGTTGGCGCACTGATCTTCTCCGGTGCGGTGATCCTGCTGGAGTTCATCCCGGAAATCGCCATCCCGGTACTGGGCACCTTTGCTCTGGTTTCTTACATTGCAAACAAGGTTCTGACTGTACAAACCATCGACAACGCGCTGAGCAAACGTAACGAAAAATGGGATGAAGTTTACAAATATATCGTGACCAACTGGCTGGCTAAGGTTAATACTCAGATCGACCTCATCCGCAAAAAAATGAAAGAAGCACTGGAAAACCAGGCGGAAGCTACCAAGGCAATCATTAACTACCAGTACAACCAGTACACCGAGGAAGAAAAAAACAACATCAACTTCAACATCGACGATCTGTCCTCTAAACTGAACGAATCCATCAACAAAGCTATGATCAACATCAACAAGTTCCTGAACCAGTGCTCTGTAAGCTATCTGATGAACTCCATGATCCCGTACGGTGTTAAACGTCTGGAGGACTTCGATGCGTCTCTGAAAGACGCCCTGCTGAAATACATTTACGACAACCGTGGCACTCTGATCGGTCAGGTTGATCGTCTGAAGGACAAAGTGAACAATACCTTATCGACCGACATCCCTTTTCAGCTCAGTAAATATGTCGATAACCAACGCCTTTTGTCCACTtaataagctt
26. Protein sequence of the CP-SST28-GS15-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECLSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKSANSNPAMAPRERKAGCKNFFWKTFTSCALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
27. Protein sequence of the CT-SST28-GS15-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDGIITSKTKSDDDDKNKALNLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSALDSANSNPAMAPRERKAGCKNFFWKTFTSC
28. Protein sequence of the CT-CST14-GS20-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
29. Protein sequence of the CT-CST17-GS25-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSGGGGSALVDRMPCRNFFWKTFSSCK
30. Protein sequence of the CT-CST29-GS15-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECLSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVQEGAPPQQSARRDRMPCRNFFWKTFSSCK
31. Protein sequence of the CT-CST29-GS30-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDGIITSKTKSDDDDKNKALNLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSALDQEGAPPQQSARRDRMPCRNFFWKTFSSCK
32. DNA sequence of IgA-HNtet
ggatccATGGAGTCCAATCAGCCGGAAAAAAATGGAACCGCGACTAAACCCGAGAATTCGGGGAACACTACGTCGGAAAACGGCCAGACGGAACCTGAGAAGAAACTGGAACTACGAAATGTGTCCGATATCGAGCTATACTCTCAAACCAATGGAACCTATAGGCAGCATGTTTCATTGGACGGAATCCCAGAAAATACGGATACATATTTCGTCAAAGTGAAGTCTAGCGCATTCAAGGATGTATATATCCCCGTTGCGAGTATTACAGAAGAGAAGCGGAACGGTCAAAGCGTTTATAAGATTACAGCAAAGGCCGAAAAGTTACAACAGGAGTTAGAAAACAAATACGTTGACAATTTCACTTTTTATCTCGATAAAAAGGCTAAAGAGGAAAACACGAACTTCACGTCATTTAGTAATCTGGTCAAAGCCATAAATCAAAATCCATCTGGTACATACCATCTCGCGGCAAGTCTAAACGCGAATGAAGTAGAACTTGGCCCGGACGAGCGTTCATACATTAAGGATACCTTTACTGGCAGACTCATAGGGGAAAAAGACGGTAAGAACTATGCTATATACAATTTGAAAAAGCCTTTATTTGAGAACCTGTCGGGCGCCACCGTCGAGAAATTGTCCCTTAAAAACGTAGCTATAAGCGGAAAGAATGACATCGGTAGTCTTGCAAACGAGGCTACTAACGGGACAAAGATTAAACAAGTGCACGTAGATGGGtgtgtcgacggcatcattacctccaaaactaaatctgacgatgacgataaaaacaaagcgctgaacctgcagtgcattaaaataaagaatgaggatttgacattcatcgcagaaaaaaatagcttcagcgaagagccgttccaagatgagatagtaagctacaacaccaagaacaagccgcttaattttaattactcgttagataaaatcatagttgactacaaccttcaatcgaagatcacgttaccgaatgacagaacaactcctgtcacaaaaggaattccctatgcacctgagtataagtcaaatgccgcgtcaacaatagagattcataatatagatgacaacaccatctatcaatatctgtacgctcagaaaagtccaacaactcttcagcgtataacaatgaccaatagtgtcgatgacgcattgataaattctaccaagatatactcttatttcccgagcgtcatctccaaagttaatcaaggtgctcaaggcattctatttttgcaatgggtccgagacatcatagatgacttcactaatgagtcgtctcagaaaaccacgattgataaaatatcagatgtttccaccatcgtcccctacatcggacctgcgcttaacattgtgaagcaggggtatgaggggaattttatcggagcgttagaaactacgggggttgtgctattacttgaatacataccagagataacattgcccgttatagcggccctcagtatcgcagaatcaagtacacaaaaagaaaagataatcaaaacaatcgacaacttcctagaaaagaggtacgaaaaatggatagaggtttataaactcgtgaaagcgaaatggttaggcactgttaatacgcagttccaaaagagatcctatcaaatgtatagatcactggagtaccaggtggatgccataaagaaaattatcgactatgaatataaaatatattcaggtccagataaggagcagatagctgatgaaataaacaatttaaaaaacaaacttgaagagaaggcgaataaggccatgatcaatatcaatatttttatgcgagaatcttcacgatcttttttggtaaatcagatgattaacgaagccaaaaagcagctgcttgagttcgacacacagtccaaaaacatactaatgcaatatatcaaagcaaactcaaaattcattggaattactgagctgaagaaactggaatccaaaataaataaagtattctctaccccgatcccgttctcttactctaaaaaccttgactgctgggtagataacgaagaagatattgacgttctagagtaataagctt
33. Protein sequence of the CT-GHRP-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
34. Protein sequence of the CT-GHRH-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA
35. Protein sequence of the CT-GHRP-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
36. Protein sequence of the CT-ghrelin-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
37. Protein sequence of the IgA-HNtet-CT-SST14 Fusion
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVLEGGGGSGGGGSGGGGSALVAGCKNFFWKTFTSC
38. Protein sequence of the IgA-HNtet-CT-GHRP Fusion
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDVLEGGGGSGGGGSGGGGSALVGSSFLSPEHQRVQQRKESKKPPAKLQPR
39. Protein sequence of the CT-ghrelin S3W-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEIYALVGSWFLSPEHQRVQQRKESKKPPAKLQPR
40. Protein sequence of the CT-GRP-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVGNHWAVGHLM
41. Protein sequence of the CT-GRP-LHB fusion
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDEEKLYDDDDKDRWGSSLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDAIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSLEGGGGSGGGGSGGGGSALVGNHWAVGHLM
42. Protein sequence of the CP-qGHRH29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRAEAAAKEAAAKALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
43. Protein sequence of the CP-qGHRH-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSLIEGRHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
44. Protein sequence of the CP-qGHRH-LHC fusion
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGALAGGGGSGGGGSGGGGSALVLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFN
45. Protein sequence of the CP-qGHRH-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
46. Protein sequence of the CP-qGHRH-LHD N10-PL5 fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAPAPAPLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
47. Protein sequence of the CP-qGHRH-LHD N10-HX12 fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDNNNNNNNNNNDDDDKHVDAIFTQSYRKVLAQLSARKLLQDILNRQQGERNQEQGAEAAAKEAAAKALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
48. Protein sequence of the CP-UTS-LHA fusion
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGGGGSADDDDKNDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEVALAGGGGSGGGGSGGGGSALVLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
49. Protein sequence of LHN/A
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLST
50. Protein sequence of LHN/B
PVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCVDEEKLYDDDDKDRWGSSLQCIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDAIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNS
51. Protein sequence of LHN/C
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFN
52. Protein sequence of LHN/D
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
53. Protein sequence of IgA-HNtet
ESNQPEKNGTATKPENSGNTTSENGQTEPEKKLELRNVSDIELYSQTNGTYRQHVSLDGIPENTDTYFVKVKSSAFKDVYIPVASITEEKRNGQSVYKITAKAEKLQQELENKYVDNFTFYLDKKAKEENTNFTSFSNLVKAINQNPSGTYHLAASLNANEVELGPDERSYIKDTFTGRLIGEKDGKNYAIYNLKKPLFENLSGATVEKLSLKNVAISGKNDIGSLANEATNGTKIKQVHVDGCVDGIITSKTKSDDDDKNKALNLQCIKIKNEDLTFIAEKNSFSEEPFQDEIVSYNTKNKPLNFNYSLDKIIVDYNLQSKITLPNDRTTPVTKGIPYAPEYKSNAASTIEIHNIDDNTIYQYLYAQKSPTTLQRITMTNSVDDALINSTKIYSYFPSVISKVNQGAQGILFLQWVRDIIDDFTNESSQKTTIDKISDVSTIVPYIGPALNIVKQGYEGNFIGALETTGVVLLLEYIPEITLPVIAALSIAESSTQKEKIIKTIDNFLEKRYEKWIEVYKLVKAKWLGTVNTQFQKRSYQMYRSLEYQVDAIKKIIDYEYKIYSGPDKEQIADEINNLKNKLEEKANKAMININIFMRESSRSFLVNQMINEAKKQLLEFDTQSKNILMQYIKANSKFIGITELKKLESKINKVFSTPIPFSYSKNLDCWVDNEEDIDV
54. Synthesised Octreotide peptide
Cys-Dphe-Cys-Phe-Dtrp-Lys-Thr-Cys-Thr-ol
55. Synthesised GHRH agonist peptide
HIS-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-NLE-SER-ARG-CYS
56. Synthesised GHRH antagonist peptide
PhAc-Tyr-D-Arg-Asp-Ala-Ile-Phe(4-Cl)-Thr-Ala-Har-Tyr(Me)-His-Lys-Val-Leu-Abu-Gln-Leu-Ser-Ala-His-Lys-Leu-Leu-Gln-Asp-Ile-Nle-D-Arg-Har-CYS
57. Protein sequence of CP-MCH-LHD
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKDFDMLRCMLGRVYRPCWQVALAKRLVLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
58. Protein sequence of CT-KISS-LHD
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVYNWNSFGLRFG
59. Protein sequence of CT-PrRP-LHA
EFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKTKSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEGGGGSGGGGSGGGGSALVTPDINPAWYASRGIRPVGRFG
60. Protein sequence of CP-HS_GHRH_1-27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
61. Protein sequence of the CP-HS_GHRH_1-28-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
62. Protein sequence of the CP-HS_GHRH_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
63. Protein sequence of the CP-HS_GHRH_1-44-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
64. Protein sequence of the CP-HS_GHRH_1-40-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
65. Protein sequence of the CP-HS_GHRH_Ala9-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNAYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
66. Protein sequence of the CP-HS_GHRH_Ala22-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLGQLSARKALQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
67. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
68. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_Arg12_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKRVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
69. Protein sequence of the CP-HS_GHRH_Ala8_Asn11_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYNKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
70. Protein sequence of the CP-HS_GHRH_Ala8_Lys20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSAKKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
71. Protein sequence of the CP-HS_GHRH_Ala8_Lys11_Lys20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYKKVLGQLSAKKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
72. Protein sequence of the CP-HS_GHRH_Ala8_Asn20_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSANKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
73. Protein sequence of the CP-HS_GHRH_Ala8_Asn12_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRNVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
74. Protein sequence of the CP-HS_GHRH_Ala8_Asn21_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSARNLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
75. Protein sequence of the CP-HS_GHRH_Ala8_Glu_7_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFEASYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
76. Protein sequence of the CP-HS_GHRH_Ala8_Glu_10_1-29LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASERKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
77. Protein sequence of the CP-HS_GHRH_Ala8_Glu_13_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKELGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
78. Protein sequence of the CP-HS_GHRH_Ala8-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
79. Protein sequence of the CP-HS_GHRH_Glu8_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTESYRKVLGQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
80. Protein sequence of the CP-HS_GHRH_Ala15_1-27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLAQLSARKLLQDIMALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
81. Protein sequence of the CP-HS_GHRH_Ala15-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTNSYRKVLAQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
82. Protein sequence of the CP- HS_GHRH_Ala8_Ala15_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTASYRKVLAQLSARKLLQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
83. Protein sequence of the CP-HS_GHRH_Ala8_9_15_22_27-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTAAYRKVLAQLSARKALQDIASRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
84. Protein sequence of the CP-HS_GHRH_Ala8_9_15_22-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTAAYRKVLAQLSARKALQDIMSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
85. Protein sequence of the CP-HS_GHRH_HVQAL_1-32-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTQSYRKVLAQLSARKALQDILSRQQGALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
86. Protein sequence of the CP-HS_GHRH_HVSAL_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTSSYRKVLAQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
87. Protein sequence of the CP-HS_GHRH_HVTAL_1-29-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKHVDAIFTTSYRKVLAQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
88. Protein sequence of the CP-HS_GHRH_QALN-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTQSYRKVLAQLSARKALQDILNRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
89. Protein sequence of the CP-HS_GHRH_QAL-LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSDDDDKYADAIFTQSYRKVLAQLSARKALQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
90. Protein sequence of the CP-hGHRH29 N8A M27L -LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSIEGRYADAIFTASYRKVLGQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
91. Protein sequence of the CP-hGHRH29 N8A K12N M27L -LHD fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDGIITSKTKSIEGR YADAIFTASYRNVLGQLSARKLLQDILSRALAGGGGSGGGGSGGGGSALALQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
92. Protein sequence of the N-termianal-hGHRH29 N8A M27L -LHD fusion
HVDAIFTQSYRKVLAQLSARKLLQDILNRNNNNNNNNNNTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFN
SEQ ID93 GnRH-C fusion protein
PITINNFNYSDPVDNKNILYLDTHLNTLANEPEKAFRITGNIWVIPDRFSRNSNPNLNKPPRVTSPKSGYYDPNYLSTDSDKDTFLKEIIKLFKRINSREIGEELIYRLSTDIPFPGNNNTPINTFDFDVDFNSVDVKTRQGNNWVKTGSINPSVIITGPRENIIDPETSTFKLTNNTFAAQEGFGALSIISISPRFMLTYSNATNDVGEGRFSKSEFCMDPILILMHELNHAMHNLYGIAIPNDQTISSVTSNIFYSQYNVKLEYAEIYAFGGPTIDLIPKSARKYFEEKALDYYRSIAKRLNSITTANPSSFNKYIGEYKQKLIRKYRFVVESSGEVTVNRNKFVELYNELTQIFTEFNYAKIYNVQNRKIYLSNVYTPVTANILDDNVYDIQNGFNIPKSNLNVLFMGQNLSRNPALRKVNPENMLYLFTKFCVDAIDGRSLYNKTLQCRELLVKNTDLPFIGDISDVKTDIFLRKDINEETEVIYYPDNVSVDQVILSKNTSEHGQLDLLYPSIDSESEILPGENQVFYDNRTQNVDYLNSYYYLESQKLSDNVEDFTFTRSIEEALDNSAKVYTYFPTLANKVNAGVQGGLFLMWANDVVEDFTTNILRKDTLDKISDVSAIIPYIGPALNISNSVRRGNFTEAFAVTGVTILLEAFPEFTIPALGAFVIYSKVQERNEIIKTIDNCLEQRIKRWKDSYEWMMGTWLSRIITQFNNISYQMYDSLNYQAGAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNEFDRNTKAKLINLIDSHNIILVGEVDKLKAKVNNSFQNTIPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSALVMKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI
SEQ ID94 GnRH-D fusion
TWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCVDKSEEKLYDDDDKDRWGSSLQCIKVKNNRLPYVADKDSISQEIFENKIITDETNVQNYSDKFSLDESILDGQVPINPEIVDPLLPNVNMEPLNLPGEEIVFYDDITKYVDYLNSYYYLESQKLSNNVENITLTTSVEEALGYSNKIYTFLPSLAEKVNKGVQAGLFLNWANEVVEDFTTNIMKKDTLDKISDVSVIIPYIGPALNIGNSALRGNFNQAFATAGVAFLLEGFPEFTIPALGVFTFYSSIQEREKIIKTIENCLEQRVKRWKDSYQWMVSNWLSRITTQFNHINYQMYDSLSYQADAIKAKIDLEYKKYSGSDKENIKSQVENLKNSLDVKISEAMNNINKFIRECSVTYLFKNMLPKVIDELNKFDLRTKTELINLIDSHNIILVGEVDRLKAKVNESFENTMPFNIFSYTNNSLLKDIINEYFNLEGGGGSGGGGSGGGGSGGGGSALVMKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI
SEQUENCE LISTING
<110> SYNTAXIN LIMITED
<120> SUPPRESSION OF NEUROENDOCRINE DISEASES
<130> P30900WO
<140> PCT/GB2009/050665
<141> 2009-06-11
<150> GB 0810785.6
<151> 2008-06-12
<150> GB 0810782.3
<151> 2008-06-12
<160> 94
<170> PatentIn version 3.5
<210> 1
<211> 2611
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 1
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg tctgagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctg acgatgacga taaaaacaaa gcgctgaacc tgcagtgtat caaggttaac 1380
aactgggatt tattcttcag cccgagtgaa gacaacttca ccaacgacct gaacaaaggt 1440
gaagaaatca cctcagatac taacatcgaa gcagccgaag aaaacatctc gctggacctg 1500
atccagcagt actacctgac ctttaatttc gacaacgagc cggaaaacat ttctatcgaa 1560
aacctgagct ctgatatcat cggccagctg gaactgatgc cgaacatcga acgtttccca 1620
aacggtaaaa agtacgagct ggacaaatat accatgttcc actacctgcg cgcgcaggaa 1680
tttgaacacg gcaaatcccg tatcgcactg actaactccg ttaacgaagc tctgctcaac 1740
ccgtcccgtg tatacacctt cttctctagc gactacgtga aaaaggtcaa caaagcgact 1800
gaagctgcaa tgttcttggg ttgggttgaa cagcttgttt atgattttac cgacgagacg 1860
tccgaagtat ctactaccga caaaattgcg gatatcacta tcatcatccc gtacatcggt 1920
ccggctctga acattggcaa catgctgtac aaagacgact tcgttggcgc actgatcttc 1980
tccggtgcgg tgatcctgct ggagttcatc ccggaaatcg ccatcccggt actgggcacc 2040
tttgctctgg tttcttacat tgcaaacaag gttctgactg tacaaaccat cgacaacgcg 2100
ctgagcaaac gtaacgaaaa atgggatgaa gtttacaaat atatcgtgac caactggctg 2160
gctaaggtta atactcagat cgacctcatc cgcaaaaaaa tgaaagaagc actggaaaac 2220
caggcggaag ctaccaaggc aatcattaac taccagtaca accagtacac cgaggaagaa 2280
aaaaacaaca tcaacttcaa catcgacgat ctgtcctcta aactgaacga atccatcaac 2340
aaagctatga tcaacatcaa caagttcctg aaccagtgct ctgtaagcta tctgatgaac 2400
tccatgatcc cgtacggtgt taaacgtctg gaggacttcg atgcgtctct gaaagacgcc 2460
ctgctgaaat acatttacga caaccgtggc actctgatcg gtcaggttga tcgtctgaag 2520
gacaaagtga acaatacctt atcgaccgac atcccttttc agctcagtaa atatgtcgat 2580
aaccaacgcc ttttgtccac ttaataagct t 2611
<210> 2
<211> 2635
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 2
ggatccatgc cggttaccat caacaacttc aactacaacg acccgatcga caacaacaac 60
atcattatga tggaaccgcc gttcgcacgt ggtaccggac gttactacaa ggcttttaag 120
atcaccgacc gtatctggat catcccggaa cgttacacct tcggttacaa acctgaggac 180
ttcaacaaga gtagcgggat tttcaatcgt gacgtctgcg agtactatga tccagattat 240
ctgaatacca acgataagaa gaacatattc cttcagacta tgattaaact cttcaaccgt 300
atcaaaagca aaccgctcgg tgaaaaactc ctcgaaatga ttatcaacgg tatcccgtac 360
ctcggtgacc gtcgtgtccc gcttgaagag ttcaacacca acatcgcaag cgtcaccgtc 420
aacaaactca tcagcaaccc aggtgaagtc gaacgtaaaa aaggtatctt cgcaaacctc 480
atcatcttcg gtccgggtcc ggtcctcaac gaaaacgaaa ccatcgacat cggtatccag 540
aaccacttcg caagccgtga aggtttcggt ggtatcatgc agatgaaatt ctgcccggaa 600
tacgtcagtg tcttcaacaa cgtccaggaa aacaaaggtg caagcatctt caaccgtcgt 660
ggttacttca gcgacccggc actcatcctc atgcatgaac tcatccacgt cctccacggt 720
ctctacggta tcaaagttga cgacctcccg atcgtcccga acgagaagaa attcttcatg 780
cagagcaccg acgcaatcca ggctgaggaa ctctacacct tcggtggcca agacccaagt 840
atcataaccc cgtccaccga caaaagcatc tacgacaaag tcctccagaa cttcaggggt 900
atcgtggaca gactcaacaa agtcctcgtc tgcatcagcg acccgaacat caatatcaac 960
atatacaaga acaagttcaa agacaagtac aaattcgtcg aggacagcga aggcaaatac 1020
agcatcgacg tagaaagttt cgacaagctc tacaaaagcc tcatgttcgg tttcaccgaa 1080
accaacatcg ccgagaacta caagatcaag acaagggcaa gttacttcag cgacagcctc 1140
ccgcctgtca aaatcaagaa cctcttagac aacgagattt acacaattga agagggcttc 1200
aacatcagtg acaaagacat ggagaaggaa tacagaggtc agaacaaggc tatcaacaaa 1260
caggcatacg aggagatcag caaagaacac ctcgcagtct acaagatcca gatgtgcgtc 1320
gacggcatca ttacctccaa aactaaatct gacgatgacg ataaaaacaa agcgctgaac 1380
ctgcagtgca tcgacgttga caacgaagac ctgttcttca tcgctgacaa aaacagcttc 1440
agtgacgacc tgagcaaaaa cgaacgtatc gaatacaaca cccagagcaa ctacatcgaa 1500
aacgacttcc cgatcaacga actgatcctg gacaccgacc tgataagtaa aatcgaactg 1560
ccgagcgaaa acaccgaaag tctgaccgac ttcaacgttg acgttccggt ttacgaaaaa 1620
cagccggcta tcaagaaaat cttcaccgac gaaaacacca tcttccagta cctgtacagc 1680
cagaccttcc cgctggacat ccgtgacatc agtctgacca gcagtttcga cgacgctctg 1740
ctgttcagca acaaagttta cagtttcttc agcatggact acatcaaaac cgctaacaaa 1800
gttgttgaag cagggctgtt cgctggttgg gttaaacaga tcgttaacga cttcgttatc 1860
gaagctaaca aaagcaacac tatggacaaa atcgctgaca tcagtctgat cgttccgtac 1920
atcggtctgg ctctgaacgt tggtaacgaa accgctaaag gtaactttga aaacgctttc 1980
gagatcgctg gtgcaagcat cctgctggag ttcatcccgg aactgctgat cccggttgtt 2040
ggtgctttcc tgctggaaag ttacatcgac aacaaaaaca agatcatcaa aaccatcgac 2100
aacgctctga ccaaacgtaa cgaaaaatgg agtgatatgt acggtctgat cgttgctcag 2160
tggctgagca ccgtcaacac ccagttctac accatcaaag aaggtatgta caaagctctg 2220
aactaccagg ctcaggctct ggaagagatc atcaaatacc gttacaacat ctacagtgag 2280
aaggaaaaga gtaacatcaa catcgacttc aacgacatca acagcaaact gaacgaaggt 2340
atcaaccagg ctatcgacaa catcaacaac ttcatcaacg gttgcagtgt tagctacctg 2400
atgaagaaga tgatcccgct ggctgttgaa aaactgctgg acttcgacaa caccctgaaa 2460
aagaacctgc tgaactacat cgacgaaaac aagctgtacc tgatcggtag tgctgaatac 2520
gaaaaaagta aagtgaacaa atacctgaag accatcatgc cgttcgacct gagtatctac 2580
accaacgaca ccatcctgat cgaaatgttc aacaaataca actcttaata agctt 2635
<210> 3
<211> 2614
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 3
ggatccatgc cgatcaccat caacaacttc aactacagcg atccggtgga taacaaaaac 60
atcctgtacc tggataccca tctgaatacc ctggcgaacg aaccggaaaa agcgtttcgt 120
atcaccggca acatttgggt tattccggat cgttttagcc gtaacagcaa cccgaatctg 180
aataaaccgc cgcgtgttac cagcccgaaa agcggttatt acgatccgaa ctatctgagc 240
accgatagcg ataaagatac cttcctgaaa gaaatcatca aactgttcaa acgcatcaac 300
agccgtgaaa ttggcgaaga actgatctat cgcctgagca ccgatattcc gtttccgggc 360
aacaacaaca ccccgatcaa cacctttgat ttcgatgtgg atttcaacag cgttgatgtt 420
aaaacccgcc agggtaacaa ttgggtgaaa accggcagca ttaacccgag cgtgattatt 480
accggtccgc gcgaaaacat tattgatccg gaaaccagca cctttaaact gaccaacaac 540
acctttgcgg cgcaggaagg ttttggcgcg ctgagcatta ttagcattag cccgcgcttt 600
atgctgacct atagcaacgc gaccaacgat gttggtgaag gccgtttcag caaaagcgaa 660
ttttgcatgg acccgatcct gatcctgatg catgaactga accatgcgat gcataacctg 720
tatggcatcg cgattccgaa cgatcagacc attagcagcg tgaccagcaa catcttttac 780
agccagtaca acgtgaaact ggaatatgcg gaaatctatg cgtttggcgg tccgaccatt 840
gatctgattc cgaaaagcgc gcgcaaatac ttcgaagaaa aagcgctgga ttactatcgc 900
agcattgcga aacgtctgaa cagcattacc accgcgaatc cgagcagctt caacaaatat 960
atcggcgaat ataaacagaa actgatccgc aaatatcgct ttgtggtgga aagcagcggc 1020
gaagttaccg ttaaccgcaa taaattcgtg gaactgtaca acgaactgac ccagatcttc 1080
accgaattta actatgcgaa aatctataac gtgcagaacc gtaaaatcta cctgagcaac 1140
gtgtataccc cggtgaccgc gaatattctg gatgataacg tgtacgatat ccagaacggc 1200
tttaacatcc cgaaaagcaa cctgaacgtt ctgtttatgg gccagaacct gagccgtaat 1260
ccggcgctgc gtaaagtgaa cccggaaaac atgctgtacc tgttcaccaa attttgcgtc 1320
gacgcgattg atggtcgtag cctgtacaac aaaaccctgc agtgtcgtga actgctggtg 1380
aaaaacaccg atctgccgtt tattggcgat atcagcgatg tgaaaaccga tatcttcctg 1440
cgcaaagata tcaacgaaga aaccgaagtg atctactacc cggataacgt gagcgttgat 1500
caggtgatcc tgagcaaaaa caccagcgaa catggtcagc tggatctgct gtatccgagc 1560
attgatagcg aaagcgaaat tctgccgggc gaaaaccagg tgttttacga taaccgtacc 1620
cagaacgtgg attacctgaa cagctattac tacctggaaa gccagaaact gagcgataac 1680
gtggaagatt ttacctttac ccgcagcatt gaagaagcgc tggataacag cgcgaaagtt 1740
tacacctatt ttccgaccct ggcgaacaaa gttaatgcgg gtgttcaggg cggtctgttt 1800
ctgatgtggg cgaacgatgt ggtggaagat ttcaccacca acatcctgcg taaagatacc 1860
ctggataaaa tcagcgatgt tagcgcgatt attccgtata ttggtccggc gctgaacatt 1920
agcaatagcg tgcgtcgtgg caattttacc gaagcgtttg cggttaccgg tgtgaccatt 1980
ctgctggaag cgtttccgga atttaccatt ccggcgctgg gtgcgtttgt gatctatagc 2040
aaagtgcagg aacgcaacga aatcatcaaa accatcgata actgcctgga acagcgtatt 2100
aaacgctgga aagatagcta tgaatggatg atgggcacct ggctgagccg tattatcacc 2160
cagttcaaca acatcagcta ccagatgtac gatagcctga actatcaggc gggtgcgatt 2220
aaagcgaaaa tcgatctgga atacaaaaaa tacagcggca gcgataaaga aaacatcaaa 2280
agccaggttg aaaacctgaa aaacagcctg gatgtgaaaa ttagcgaagc gatgaataac 2340
atcaacaaat tcatccgcga atgcagcgtg acctacctgt tcaaaaacat gctgccgaaa 2400
gtgatcgatg aactgaacga atttgatcgc aacaccaaag cgaaactgat caacctgatc 2460
gatagccaca acattattct ggtgggcgaa gtggataaac tgaaagcgaa agttaacaac 2520
agcttccaga acaccatccc gtttaacatc ttcagctata ccaacaacag cctgctgaaa 2580
gatatcatca acgaatactt caattaataa gctt 2614
<210> 4
<211> 2632
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 4
ggatccatga cgtggccagt taaggatttc aactactcag atcctgtaaa tgacaacgat 60
attctgtacc ttcgcattcc acaaaataaa ctgatcacca caccagtcaa agcattcatg 120
attactcaaa acatttgggt cattccagaa cgcttttcta gtgacacaaa tccgagttta 180
tctaaacctc cgcgtccgac gtccaaatat cagagctatt acgatccctc atatctcagt 240
acggacgaac aaaaagatac tttccttaaa ggtatcatta aactgtttaa gcgtattaat 300
gagcgcgata tcgggaaaaa gttgattaat tatcttgttg tgggttcccc gttcatgggc 360
gatagctcta cccccgaaga cacttttgat tttacccgtc atacgacaaa catcgcggta 420
gagaagtttg agaacggatc gtggaaagtc acaaacatca ttacacctag cgtcttaatt 480
tttggtccgc tgccaaacat cttagattat acagccagcc tgactttgca ggggcaacag 540
tcgaatccga gtttcgaagg ttttggtacc ctgagcattc tgaaagttgc cccggaattt 600
ctgctcactt tttcagatgt caccagcaac cagagctcag cagtattagg aaagtcaatt 660
ttttgcatgg acccggttat tgcactgatg cacgaactga cgcactctct gcatcaactg 720
tatgggatca acatccccag tgacaaacgt attcgtcccc aggtgtctga aggatttttc 780
tcacaggatg ggccgaacgt ccagttcgaa gagttgtata ctttcggagg cctggacgta 840
gagatcattc cccagattga gcgcagtcag ctgcgtgaga aggcattggg ccattataag 900
gatattgcaa aacgcctgaa taacattaac aaaacgattc catcttcgtg gatctcgaat 960
attgataaat ataagaaaat ttttagcgag aaatataatt ttgataaaga taatacaggt 1020
aactttgtgg ttaacattga caaattcaac tccctttaca gtgatttgac gaatgtaatg 1080
agcgaagttg tgtatagttc ccaatacaac gttaagaatc gtacccatta cttctctcgt 1140
cactacctgc cggttttcgc gaacatcctt gacgataata tttacactat tcgtgacggc 1200
tttaacttga ccaacaaggg cttcaatatt gaaaattcag gccagaacat tgaacgcaac 1260
ccggccttgc agaaactgtc gagtgaatcc gtggttgacc tgtttaccaa agtctgcgtc 1320
gacaaaagcg aagagaagct gtacgatgac gatgacaaag atcgttgggg atcgtccctg 1380
cagtgtatta aagtgaaaaa caatcggctg ccttatgtag cagataaaga tagcattagt 1440
caggagattt tcgaaaataa aattatcact gacgaaacca atgttcagaa ttattcagat 1500
aaattttcac tggacgaaag catcttagat ggccaagttc cgattaaccc ggaaattgtt 1560
gatccgttac tgccgaacgt gaatatggaa ccgttaaacc tccctggcga agagatcgta 1620
ttttatgatg acattacgaa atatgtggac taccttaatt cttattacta tttggaaagc 1680
cagaaactgt ccaataacgt ggaaaacatt actctgacca caagcgtgga agaggcttta 1740
ggctactcaa ataagattta taccttcctc ccgtcgctgg cggaaaaagt aaataaaggt 1800
gtgcaggctg gtctgttcct caactgggcg aatgaagttg tcgaagactt taccacgaat 1860
attatgaaaa aggataccct ggataaaatc tccgacgtct cggttattat cccatatatt 1920
ggccctgcgt taaatatcgg taatagtgcg ctgcggggga attttaacca ggcctttgct 1980
accgcgggcg tcgcgttcct cctggagggc tttcctgaat ttactatccc ggcgctcggt 2040
gtttttacat tttactcttc catccaggag cgtgagaaaa ttatcaaaac catcgaaaac 2100
tgcctggagc agcgggtgaa acgctggaaa gattcttatc aatggatggt gtcaaactgg 2160
ttatctcgca tcacgaccca attcaaccat attaattacc agatgtatga tagtctgtcg 2220
taccaagctg acgccattaa agccaaaatt gatctggaat ataaaaagta ctctggtagc 2280
gataaggaga acatcaaaag ccaggtggag aaccttaaga atagtctgga tgtgaaaatc 2340
tctgaagcta tgaataacat taacaaattc attcgtgaat gttcggtgac gtacctgttc 2400
aagaatatgc tgccaaaagt tattgatgaa ctgaataaat ttgatctgcg taccaaaacc 2460
gaacttatca acctcatcga ctcccacaac attatccttg tgggcgaagt ggatcgtctg 2520
aaggccaaag taaacgagag ctttgaaaat acgatgccgt ttaatatttt ttcatatacc 2580
aataactcct tgctgaaaga tatcatcaat gaatatttca attaataagc tt 2632
<210> 5
<211> 240
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 5
catatgggat ccggtttaaa cgtcgacggc atcattacct ccaaaactaa atctgacgat 60
gacgataaaa gcgccaattc aaatcctgca atggcgccac gcgaacgcaa agctggttgc 120
aaaaacttct tctggaaaac cttcacctct tgcgcgctag cgggcggtgg cggtagcggc 180
ggtggcggta gcggcggtgg cggtagcgca ctagtgctgc agctagaata atgaaagctt 240
<210> 6
<211> 195
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 6
ggatccgtcg acctgcaggg tctagaaggc ggtggcggta gcggcggtgg cggtagcggc 60
ggtggcggta gcggcggtgg cggtagcgca ctagtgcagg aaagacctcc attacaacaa 120
cctccacatc gcgataagaa accatgtaag aatttctttt ggaaaacatt tagcagttgc 180
aaatgataaa agctt 195
<210> 7
<211> 902
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 7
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser
450 455 460
Cys Lys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
465 470 475 480
Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Lys Asn Asn
485 490 495
Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe
500 505 510
Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp
515 520 525
Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn
530 535 540
Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu
545 550 555 560
Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr
565 570 575
Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser
580 585 590
Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu
595 600 605
Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys
610 615 620
Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu
625 630 635 640
Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp
645 650 655
Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu
660 665 670
Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala
675 680 685
Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile
690 695 700
Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu
705 710 715 720
Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg
725 730 735
Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile
740 745 750
Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser
755 760 765
Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys
770 775 780
Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu
785 790 795 800
Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn
805 810 815
Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu
820 825 830
Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr
835 840 845
Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu
850 855 860
Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met
865 870 875 880
Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile
885 890 895
Ile Asn Glu Tyr Phe Asn
900
<210> 8
<211> 912
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 8
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser
450 455 460
Cys Lys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
465 470 475 480
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu
485 490 495
Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala
500 505 510
Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr
515 520 525
Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu
530 535 540
Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro
545 550 555 560
Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu
565 570 575
Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser
580 585 590
Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile
595 600 605
Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile
610 615 620
Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln
625 630 635 640
Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr
645 650 655
Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser
660 665 670
Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala
675 680 685
Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe
690 695 700
Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe
705 710 715 720
Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile
725 730 735
Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln
740 745 750
Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His
755 760 765
Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile
770 775 780
Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys
785 790 795 800
Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val
805 810 815
Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys
820 825 830
Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu
835 840 845
Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile
850 855 860
Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala
865 870 875 880
Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser
885 890 895
Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
900 905 910
<210> 9
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 9
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Gln Glu Arg Pro Pro Leu Gln Gln Pro Pro His Arg
450 455 460
Asp Lys Lys Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
465 470 475 480
Lys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 10
<211> 927
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 10
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Gln Glu Arg Pro Pro Leu Gln Gln Pro Pro His Arg
450 455 460
Asp Lys Lys Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
465 470 475 480
Lys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val
500 505 510
Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp
515 520 525
Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp
530 535 540
Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser
545 550 555 560
Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu
565 570 575
Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile
580 585 590
Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr
595 600 605
Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr
610 615 620
Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr
625 630 635 640
Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala
645 650 655
Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr
660 665 670
Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val
675 680 685
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu
690 695 700
Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu
705 710 715 720
Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr
725 730 735
Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu
740 745 750
Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp
755 760 765
Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile
770 775 780
Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys
785 790 795 800
Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu
805 810 815
Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys
820 825 830
Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser
835 840 845
Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu
850 855 860
Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp
865 870 875 880
Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys
885 890 895
Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr
900 905 910
Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
915 920 925
<210> 11
<211> 902
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 11
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr
450 455 460
Ser Cys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
465 470 475 480
Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Lys Asn Asn
485 490 495
Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe
500 505 510
Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp
515 520 525
Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn
530 535 540
Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu
545 550 555 560
Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr
565 570 575
Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser
580 585 590
Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu
595 600 605
Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys
610 615 620
Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu
625 630 635 640
Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp
645 650 655
Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu
660 665 670
Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala
675 680 685
Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile
690 695 700
Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu
705 710 715 720
Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg
725 730 735
Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile
740 745 750
Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser
755 760 765
Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys
770 775 780
Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu
785 790 795 800
Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn
805 810 815
Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu
820 825 830
Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr
835 840 845
Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu
850 855 860
Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met
865 870 875 880
Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile
885 890 895
Ile Asn Glu Tyr Phe Asn
900
<210> 12
<211> 912
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 12
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr
450 455 460
Ser Cys Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
465 470 475 480
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu
485 490 495
Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala
500 505 510
Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr
515 520 525
Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu
530 535 540
Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro
545 550 555 560
Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu
565 570 575
Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser
580 585 590
Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile
595 600 605
Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile
610 615 620
Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln
625 630 635 640
Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr
645 650 655
Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser
660 665 670
Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala
675 680 685
Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe
690 695 700
Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe
705 710 715 720
Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile
725 730 735
Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln
740 745 750
Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His
755 760 765
Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile
770 775 780
Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys
785 790 795 800
Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val
805 810 815
Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys
820 825 830
Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu
835 840 845
Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile
850 855 860
Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala
865 870 875 880
Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser
885 890 895
Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
900 905 910
<210> 13
<211> 916
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 13
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu
450 455 460
Arg Lys Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
465 470 475 480
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
485 490 495
Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
500 505 510
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
515 520 525
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
530 535 540
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
545 550 555 560
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
565 570 575
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
580 585 590
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
595 600 605
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
610 615 620
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
625 630 635 640
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
645 650 655
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
660 665 670
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
675 680 685
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
690 695 700
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
705 710 715 720
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
725 730 735
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
740 745 750
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
755 760 765
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
770 775 780
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
785 790 795 800
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
805 810 815
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
820 825 830
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
835 840 845
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
850 855 860
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
865 870 875 880
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
885 890 895
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
900 905 910
Glu Tyr Phe Asn
915
<210> 14
<211> 926
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 14
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu
450 455 460
Arg Lys Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
465 470 475 480
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
485 490 495
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Ala Leu
500 505 510
Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys
515 520 525
Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu
530 535 540
Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile
545 550 555 560
Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu Leu
565 570 575
Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val
580 585 590
Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr
595 600 605
Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu
610 615 620
Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr
625 630 635 640
Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly
645 650 655
Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn
660 665 670
Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val Ile
675 680 685
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg
690 695 700
Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu
705 710 715 720
Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe
725 730 735
Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn
740 745 750
Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met
755 760 765
Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile Asn
770 775 780
Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala
785 790 795 800
Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn
805 810 815
Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile
820 825 830
Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val
835 840 845
Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn
850 855 860
Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser
865 870 875 880
His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val
885 890 895
Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr
900 905 910
Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
915 920 925
<210> 15
<211> 905
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 15
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Pro Cys Lys Asn Phe
885 890 895
Phe Trp Lys Thr Phe Ser Ser Cys Lys
900 905
<210> 16
<211> 915
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 16
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
885 890 895
Gly Ser Ala Leu Val Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser
900 905 910
Ser Cys Lys
915
<210> 17
<211> 2779
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 17
ggatccatga cgtggccagt taaggatttc aactactcag atcctgtaaa tgacaacgat 60
attctgtacc ttcgcattcc acaaaataaa ctgatcacca caccagtcaa agcattcatg 120
attactcaaa acatttgggt cattccagaa cgcttttcta gtgacacaaa tccgagttta 180
tctaaacctc cgcgtccgac gtccaaatat cagagctatt acgatccctc atatctcagt 240
acggacgaac aaaaagatac tttccttaaa ggtatcatta aactgtttaa gcgtattaat 300
gagcgcgata tcgggaaaaa gttgattaat tatcttgttg tgggttcccc gttcatgggc 360
gatagctcta cccccgaaga cacttttgat tttacccgtc atacgacaaa catcgcggta 420
gagaagtttg agaacggatc gtggaaagtc acaaacatca ttacacctag cgtcttaatt 480
tttggtccgc tgccaaacat cttagattat acagccagcc tgactttgca ggggcaacag 540
tcgaatccga gtttcgaagg ttttggtacc ctgagcattc tgaaagttgc cccggaattt 600
ctgctcactt tttcagatgt caccagcaac cagagctcag cagtattagg aaagtcaatt 660
ttttgcatgg acccggttat tgcactgatg cacgaactga cgcactctct gcatcaactg 720
tatgggatca acatccccag tgacaaacgt attcgtcccc aggtgtctga aggatttttc 780
tcacaggatg ggccgaacgt ccagttcgaa gagttgtata ctttcggagg cctggacgta 840
gagatcattc cccagattga gcgcagtcag ctgcgtgaga aggcattggg ccattataag 900
gatattgcaa aacgcctgaa taacattaac aaaacgattc catcttcgtg gatctcgaat 960
attgataaat ataagaaaat ttttagcgag aaatataatt ttgataaaga taatacaggt 1020
aactttgtgg ttaacattga caaattcaac tccctttaca gtgatttgac gaatgtaatg 1080
agcgaagttg tgtatagttc ccaatacaac gttaagaatc gtacccatta cttctctcgt 1140
cactacctgc cggttttcgc gaacatcctt gacgataata tttacactat tcgtgacggc 1200
tttaacttga ccaacaaggg cttcaatatt gaaaattcag gccagaacat tgaacgcaac 1260
ccggccttgc agaaactgtc gagtgaatcc gtggttgacc tgtttaccaa agtctgcgtc 1320
gacaaaagcg aagagaagct gtacgatgac gatgacaaag atcgttgggg atcgtccctg 1380
cagtgtatta aagtgaaaaa caatcggctg ccttatgtag cagataaaga tagcattagt 1440
caggagattt tcgaaaataa aattatcact gacgaaacca atgttcagaa ttattcagat 1500
aaattttcac tggacgaaag catcttagat ggccaagttc cgattaaccc ggaaattgtt 1560
gatccgttac tgccgaacgt gaatatggaa ccgttaaacc tccctggcga agagatcgta 1620
ttttatgatg acattacgaa atatgtggac taccttaatt cttattacta tttggaaagc 1680
cagaaactgt ccaataacgt ggaaaacatt actctgacca caagcgtgga agaggcttta 1740
ggctactcaa ataagattta taccttcctc ccgtcgctgg cggaaaaagt aaataaaggt 1800
gtgcaggctg gtctgttcct caactgggcg aatgaagttg tcgaagactt taccacgaat 1860
attatgaaaa aggataccct ggataaaatc tccgacgtct cggttattat cccatatatt 1920
ggccctgcgt taaatatcgg taatagtgcg ctgcggggga attttaacca ggcctttgct 1980
accgcgggcg tcgcgttcct cctggagggc tttcctgaat ttactatccc ggcgctcggt 2040
gtttttacat tttactcttc catccaggag cgtgagaaaa ttatcaaaac catcgaaaac 2100
tgcctggagc agcgggtgaa acgctggaaa gattcttatc aatggatggt gtcaaactgg 2160
ttatctcgca tcacgaccca attcaaccat attaattacc agatgtatga tagtctgtcg 2220
taccaagctg acgccattaa agccaaaatt gatctggaat ataaaaagta ctctggtagc 2280
gataaggaga acatcaaaag ccaggtggag aaccttaaga atagtctgga tgtgaaaatc 2340
tctgaagcta tgaataacat taacaaattc attcgtgaat gttcggtgac gtacctgttc 2400
aagaatatgc tgccaaaagt tattgatgaa ctgaataaat ttgatctgcg taccaaaacc 2460
gaacttatca acctcatcga ctcccacaac attatccttg tgggcgaagt ggatcgtctg 2520
aaggccaaag taaacgagag ctttgaaaat acgatgccgt ttaatatttt ttcatatacc 2580
aataactcct tgctgaaaga tatcatcaat gaatatttca atctagaagg cggtggcggt 2640
agcggcggtg gcggtagcgg cggtggcggt agcgcactag tgcaggaaag acctccatta 2700
caacaacctc cacatcgcga taagaaacca tgtaagaatt tcttttggaa aacatttagc 2760
agttgcaaat aataagctt 2779
<210> 18
<211> 920
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 18
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Gln Glu Arg Pro Pro
885 890 895
Leu Gln Gln Pro Pro His Arg Asp Lys Lys Pro Cys Lys Asn Phe Phe
900 905 910
Trp Lys Thr Phe Ser Ser Cys Lys
915 920
<210> 19
<211> 930
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 19
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
885 890 895
Gly Ser Ala Leu Val Gln Glu Arg Pro Pro Leu Gln Gln Pro Pro His
900 905 910
Arg Asp Lys Lys Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser
915 920 925
Cys Lys
930
<210> 20
<211> 902
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 20
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Ile Asp Gly Arg Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Ile Asp Gly
435 440 445
Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
450 455 460
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
465 470 475 480
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
485 490 495
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
500 505 510
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
515 520 525
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
530 535 540
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
545 550 555 560
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
565 570 575
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
580 585 590
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
595 600 605
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
610 615 620
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
625 630 635 640
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
645 650 655
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
660 665 670
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
675 680 685
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
690 695 700
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
705 710 715 720
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
725 730 735
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
740 745 750
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
755 760 765
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
770 775 780
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
785 790 795 800
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
805 810 815
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
820 825 830
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
835 840 845
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
850 855 860
Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
865 870 875 880
Gly Gly Gly Gly Ser Ala Leu Val Ala Gly Cys Lys Asn Phe Phe Trp
885 890 895
Lys Thr Phe Thr Ser Cys
900
<210> 21
<211> 915
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 21
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
885 890 895
Gly Ser Ala Leu Val Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe
900 905 910
Thr Ser Cys
915
<210> 22
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 22
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Ser Ala Asn Ser Asn
885 890 895
Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn Phe Phe
900 905 910
Trp Lys Thr Phe Thr Ser Cys
915
<210> 23
<211> 929
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 23
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
885 890 895
Gly Ser Ala Leu Val Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg
900 905 910
Glu Arg Lys Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser
915 920 925
Cys
<210> 24
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 24
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
865 870 875 880
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
885 890 895
Ser Gly Gly Gly Gly Ser Ala Leu Val Ala Gly Cys Lys Asn Phe Phe
900 905 910
Trp Lys Thr Phe Thr Ser Cys
915
<210> 25
<211> 2743
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 25
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg tctgagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctg acgatgacga taaaagcgcc aattcaaatc ctgcaatggc gccacgcgaa 1380
cgcaaagctg gatgcaaaaa cttcttttgg aagacattta ctagttgtgc gctagcgggc 1440
ggtggcggta gcggcggtgg cggtagcggc ggtggcggta gcgcactagt gctgcagtgt 1500
atcaaggtta acaactggga tttattcttc agcccgagtg aagacaactt caccaacgac 1560
ctgaacaaag gtgaagaaat cacctcagat actaacatcg aagcagccga agaaaacatc 1620
tcgctggacc tgatccagca gtactacctg acctttaatt tcgacaacga gccggaaaac 1680
atttctatcg aaaacctgag ctctgatatc atcggccagc tggaactgat gccgaacatc 1740
gaacgtttcc caaacggtaa aaagtacgag ctggacaaat ataccatgtt ccactacctg 1800
cgcgcgcagg aatttgaaca cggcaaatcc cgtatcgcac tgactaactc cgttaacgaa 1860
gctctgctca acccgtcccg tgtatacacc ttcttctcta gcgactacgt gaaaaaggtc 1920
aacaaagcga ctgaagctgc aatgttcttg ggttgggttg aacagcttgt ttatgatttt 1980
accgacgaga cgtccgaagt atctactacc gacaaaattg cggatatcac tatcatcatc 2040
ccgtacatcg gtccggctct gaacattggc aacatgctgt acaaagacga cttcgttggc 2100
gcactgatct tctccggtgc ggtgatcctg ctggagttca tcccggaaat cgccatcccg 2160
gtactgggca cctttgctct ggtttcttac attgcaaaca aggttctgac tgtacaaacc 2220
atcgacaacg cgctgagcaa acgtaacgaa aaatgggatg aagtttacaa atatatcgtg 2280
accaactggc tggctaaggt taatactcag atcgacctca tccgcaaaaa aatgaaagaa 2340
gcactggaaa accaggcgga agctaccaag gcaatcatta actaccagta caaccagtac 2400
accgaggaag aaaaaaacaa catcaacttc aacatcgacg atctgtcctc taaactgaac 2460
gaatccatca acaaagctat gatcaacatc aacaagttcc tgaaccagtg ctctgtaagc 2520
tatctgatga actccatgat cccgtacggt gttaaacgtc tggaggactt cgatgcgtct 2580
ctgaaagacg ccctgctgaa atacatttac gacaaccgtg gcactctgat cggtcaggtt 2640
gatcgtctga aggacaaagt gaacaatacc ttatcgaccg acatcccttt tcagctcagt 2700
aaatatgtcg ataaccaacg ccttttgtcc acttaataag ctt 2743
<210> 26
<211> 908
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 26
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Leu Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Ser Ala Asn
435 440 445
Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn
450 455 460
Phe Phe Trp Lys Thr Phe Thr Ser Cys Ala Leu Ala Gly Gly Gly Gly
465 470 475 480
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln
485 490 495
Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp
500 505 510
Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr
515 520 525
Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln
530 535 540
Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile
545 550 555 560
Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn
565 570 575
Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr
580 585 590
Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg
595 600 605
Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg
610 615 620
Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala
625 630 635 640
Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp
645 650 655
Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp
660 665 670
Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn
675 680 685
Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala
690 695 700
Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly
705 710 715 720
Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln
725 730 735
Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val
740 745 750
Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile
755 760 765
Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu
770 775 780
Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu
785 790 795 800
Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu
805 810 815
Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn
820 825 830
Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val
835 840 845
Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys
850 855 860
Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu
865 870 875 880
Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu
885 890 895
Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
900 905
<210> 27
<211> 920
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 27
Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asn
1 5 10 15
Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr
20 25 30
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg
35 40 45
Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile
50 55 60
Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn Thr
65 70 75 80
Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe Asn
85 90 95
Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile Ile
100 105 110
Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu Phe
115 120 125
Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn Pro
130 135 140
Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile Phe
145 150 155 160
Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile
165 170 175
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met
180 185 190
Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu Asn
195 200 205
Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro Ala
210 215 220
Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr Gly
225 230 235 240
Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe Phe
245 250 255
Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly
260 265 270
Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile Tyr
275 280 285
Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys
290 295 300
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys
305 310 315 320
Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly Lys
325 330 335
Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys Thr
355 360 365
Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys Asn
370 375 380
Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser
385 390 395 400
Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn
405 410 415
Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys
420 425 430
Ile Gln Met Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Asn Lys Ala Leu Asn Leu Gln Cys Ile Asp Val Asp
450 455 460
Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser Asp Asp
465 470 475 480
Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn Tyr Ile
485 490 495
Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp Leu Ile
500 505 510
Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr Asp Phe
515 520 525
Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys Lys Ile
530 535 540
Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln Thr Phe
545 550 555 560
Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp Asp Ala
565 570 575
Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp Tyr Ile
580 585 590
Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val
595 600 605
Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr
610 615 620
Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu
625 630 635 640
Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala
645 650 655
Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro Glu Leu
660 665 670
Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn
675 680 685
Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn
690 695 700
Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser
705 710 715 720
Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala
725 730 735
Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr Arg Tyr
740 745 750
Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn
755 760 765
Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn
770 775 780
Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys
785 790 795 800
Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn Thr Leu
805 810 815
Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr Leu Ile
820 825 830
Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu Lys Thr
835 840 845
Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile Leu Ile
850 855 860
Glu Met Phe Asn Lys Tyr Asn Ser Leu Glu Gly Gly Gly Gly Ser Gly
865 870 875 880
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Asp Ser Ala Asn Ser
885 890 895
Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn Phe
900 905 910
Phe Trp Lys Thr Phe Thr Ser Cys
915 920
<210> 28
<211> 904
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 28
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
865 870 875 880
Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Ala Gly Cys Lys Asn Phe
885 890 895
Phe Trp Lys Thr Phe Thr Ser Cys
900
<210> 29
<211> 912
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 29
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
865 870 875 880
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Asp
885 890 895
Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
900 905 910
<210> 30
<211> 913
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 30
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Leu Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Asn Lys Ala
435 440 445
Leu Asn Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
450 455 460
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
465 470 475 480
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
485 490 495
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
500 505 510
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
515 520 525
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
530 535 540
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
545 550 555 560
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
565 570 575
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
580 585 590
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
595 600 605
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
610 615 620
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
625 630 635 640
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
645 650 655
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
660 665 670
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
675 680 685
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
690 695 700
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
705 710 715 720
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
725 730 735
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
740 745 750
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
755 760 765
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
770 775 780
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
785 790 795 800
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
805 810 815
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
820 825 830
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
835 840 845
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
850 855 860
Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
865 870 875 880
Ser Ala Leu Val Gln Glu Gly Ala Pro Pro Gln Gln Ser Ala Arg Arg
885 890 895
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
900 905 910
Lys
<210> 31
<211> 936
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 31
Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asn
1 5 10 15
Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr
20 25 30
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg
35 40 45
Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile
50 55 60
Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn Thr
65 70 75 80
Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe Asn
85 90 95
Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile Ile
100 105 110
Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu Phe
115 120 125
Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn Pro
130 135 140
Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile Phe
145 150 155 160
Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile
165 170 175
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met
180 185 190
Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu Asn
195 200 205
Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro Ala
210 215 220
Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr Gly
225 230 235 240
Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe Phe
245 250 255
Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly
260 265 270
Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile Tyr
275 280 285
Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys
290 295 300
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys
305 310 315 320
Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly Lys
325 330 335
Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys Thr
355 360 365
Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys Asn
370 375 380
Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser
385 390 395 400
Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn
405 410 415
Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys
420 425 430
Ile Gln Met Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Asn Lys Ala Leu Asn Leu Gln Cys Ile Asp Val Asp
450 455 460
Asn Glu Asp Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser Asp Asp
465 470 475 480
Leu Ser Lys Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn Tyr Ile
485 490 495
Glu Asn Asp Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp Leu Ile
500 505 510
Ser Lys Ile Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr Asp Phe
515 520 525
Asn Val Asp Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys Lys Ile
530 535 540
Phe Thr Asp Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln Thr Phe
545 550 555 560
Pro Leu Asp Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp Asp Ala
565 570 575
Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp Tyr Ile
580 585 590
Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val
595 600 605
Lys Gln Ile Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr
610 615 620
Met Asp Lys Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu
625 630 635 640
Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala
645 650 655
Phe Glu Ile Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro Glu Leu
660 665 670
Leu Ile Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn
675 680 685
Lys Asn Lys Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn
690 695 700
Glu Lys Trp Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser
705 710 715 720
Thr Val Asn Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala
725 730 735
Leu Asn Tyr Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr Arg Tyr
740 745 750
Asn Ile Tyr Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn
755 760 765
Asp Ile Asn Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn
770 775 780
Ile Asn Asn Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys
785 790 795 800
Met Ile Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn Thr Leu
805 810 815
Lys Lys Asn Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr Leu Ile
820 825 830
Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu Lys Thr
835 840 845
Ile Met Pro Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile Leu Ile
850 855 860
Glu Met Phe Asn Lys Tyr Asn Ser Leu Glu Gly Gly Gly Gly Ser Gly
865 870 875 880
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
885 890 895
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Asp Gln Glu Gly Ala Pro
900 905 910
Pro Gln Gln Ser Ala Arg Arg Asp Arg Met Pro Cys Arg Asn Phe Phe
915 920 925
Trp Lys Thr Phe Ser Ser Cys Lys
930 935
<210> 32
<211> 2065
<212> DNA
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"
<400> 32
ggatccatgg agtccaatca gccggaaaaa aatggaaccg cgactaaacc cgagaattcg 60
gggaacacta cgtcggaaaa cggccagacg gaacctgaga agaaactgga actacgaaat 120
gtgtccgata tcgagctata ctctcaaacc aatggaacct ataggcagca tgtttcattg 180
gacggaatcc cagaaaatac ggatacatat ttcgtcaaag tgaagtctag cgcattcaag 240
gatgtatata tccccgttgc gagtattaca gaagagaagc ggaacggtca aagcgtttat 300
aagattacag caaaggccga aaagttacaa caggagttag aaaacaaata cgttgacaat 360
ttcacttttt atctcgataa aaaggctaaa gaggaaaaca cgaacttcac gtcatttagt 420
aatctggtca aagccataaa tcaaaatcca tctggtacat accatctcgc ggcaagtcta 480
aacgcgaatg aagtagaact tggcccggac gagcgttcat acattaagga tacctttact 540
ggcagactca taggggaaaa agacggtaag aactatgcta tatacaattt gaaaaagcct 600
ttatttgaga acctgtcggg cgccaccgtc gagaaattgt cccttaaaaa cgtagctata 660
agcggaaaga atgacatcgg tagtcttgca aacgaggcta ctaacgggac aaagattaaa 720
caagtgcacg tagatgggtg tgtcgacggc atcattacct ccaaaactaa atctgacgat 780
gacgataaaa acaaagcgct gaacctgcag tgcattaaaa taaagaatga ggatttgaca 840
ttcatcgcag aaaaaaatag cttcagcgaa gagccgttcc aagatgagat agtaagctac 900
aacaccaaga acaagccgct taattttaat tactcgttag ataaaatcat agttgactac 960
aaccttcaat cgaagatcac gttaccgaat gacagaacaa ctcctgtcac aaaaggaatt 1020
ccctatgcac ctgagtataa gtcaaatgcc gcgtcaacaa tagagattca taatatagat 1080
gacaacacca tctatcaata tctgtacgct cagaaaagtc caacaactct tcagcgtata 1140
acaatgacca atagtgtcga tgacgcattg ataaattcta ccaagatata ctcttatttc 1200
ccgagcgtca tctccaaagt taatcaaggt gctcaaggca ttctattttt gcaatgggtc 1260
cgagacatca tagatgactt cactaatgag tcgtctcaga aaaccacgat tgataaaata 1320
tcagatgttt ccaccatcgt cccctacatc ggacctgcgc ttaacattgt gaagcagggg 1380
tatgagggga attttatcgg agcgttagaa actacggggg ttgtgctatt acttgaatac 1440
ataccagaga taacattgcc cgttatagcg gccctcagta tcgcagaatc aagtacacaa 1500
aaagaaaaga taatcaaaac aatcgacaac ttcctagaaa agaggtacga aaaatggata 1560
gaggtttata aactcgtgaa agcgaaatgg ttaggcactg ttaatacgca gttccaaaag 1620
agatcctatc aaatgtatag atcactggag taccaggtgg atgccataaa gaaaattatc 1680
gactatgaat ataaaatata ttcaggtcca gataaggagc agatagctga tgaaataaac 1740
aatttaaaaa acaaacttga agagaaggcg aataaggcca tgatcaatat caatattttt 1800
atgcgagaat cttcacgatc ttttttggta aatcagatga ttaacgaagc caaaaagcag 1860
ctgcttgagt tcgacacaca gtccaaaaac atactaatgc aatatatcaa agcaaactca 1920
aaattcattg gaattactga gctgaagaaa ctggaatcca aaataaataa agtattctct 1980
accccgatcc cgttctctta ctctaaaaac cttgactgct gggtagataa cgaagaagat 2040
attgacgttc tagagtaata agctt 2065
<210> 33
<211> 913
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 33
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
865 870 875 880
Gly Ser Ala Leu Val Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg
885 890 895
Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro
900 905 910
Arg
<210> 34
<211> 931
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 34
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Tyr Ala Asp Ala Ile
885 890 895
Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln Leu Ser Ala Arg Lys
900 905 910
Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly Glu Ser Asn Gln Glu
915 920 925
Arg Gly Ala
930
<210> 35
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 35
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Gly Ser Ser Phe Leu
885 890 895
Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro
900 905 910
Pro Ala Lys Leu Gln Pro Arg
915
<210> 36
<211> 912
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 36
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Asn Lys Ala
435 440 445
Leu Asn Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
450 455 460
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
465 470 475 480
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
485 490 495
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
500 505 510
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
515 520 525
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
530 535 540
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
545 550 555 560
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
565 570 575
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
580 585 590
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
595 600 605
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
610 615 620
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
625 630 635 640
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
645 650 655
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
660 665 670
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
675 680 685
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
690 695 700
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
705 710 715 720
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
725 730 735
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
740 745 750
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
755 760 765
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
770 775 780
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
785 790 795 800
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
805 810 815
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
820 825 830
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
835 840 845
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
850 855 860
Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
865 870 875 880
Ser Ala Leu Val Gly Ser Ser Phe Leu Ser Pro Glu His Gln Arg Val
885 890 895
Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu Gln Pro Arg
900 905 910
<210> 37
<211> 714
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 37
Glu Ser Asn Gln Pro Glu Lys Asn Gly Thr Ala Thr Lys Pro Glu Asn
1 5 10 15
Ser Gly Asn Thr Thr Ser Glu Asn Gly Gln Thr Glu Pro Glu Lys Lys
20 25 30
Leu Glu Leu Arg Asn Val Ser Asp Ile Glu Leu Tyr Ser Gln Thr Asn
35 40 45
Gly Thr Tyr Arg Gln His Val Ser Leu Asp Gly Ile Pro Glu Asn Thr
50 55 60
Asp Thr Tyr Phe Val Lys Val Lys Ser Ser Ala Phe Lys Asp Val Tyr
65 70 75 80
Ile Pro Val Ala Ser Ile Thr Glu Glu Lys Arg Asn Gly Gln Ser Val
85 90 95
Tyr Lys Ile Thr Ala Lys Ala Glu Lys Leu Gln Gln Glu Leu Glu Asn
100 105 110
Lys Tyr Val Asp Asn Phe Thr Phe Tyr Leu Asp Lys Lys Ala Lys Glu
115 120 125
Glu Asn Thr Asn Phe Thr Ser Phe Ser Asn Leu Val Lys Ala Ile Asn
130 135 140
Gln Asn Pro Ser Gly Thr Tyr His Leu Ala Ala Ser Leu Asn Ala Asn
145 150 155 160
Glu Val Glu Leu Gly Pro Asp Glu Arg Ser Tyr Ile Lys Asp Thr Phe
165 170 175
Thr Gly Arg Leu Ile Gly Glu Lys Asp Gly Lys Asn Tyr Ala Ile Tyr
180 185 190
Asn Leu Lys Lys Pro Leu Phe Glu Asn Leu Ser Gly Ala Thr Val Glu
195 200 205
Lys Leu Ser Leu Lys Asn Val Ala Ile Ser Gly Lys Asn Asp Ile Gly
210 215 220
Ser Leu Ala Asn Glu Ala Thr Asn Gly Thr Lys Ile Lys Gln Val His
225 230 235 240
Val Asp Gly Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
245 250 255
Asp Asp Asp Lys Asn Lys Ala Leu Asn Leu Gln Cys Ile Lys Ile Lys
260 265 270
Asn Glu Asp Leu Thr Phe Ile Ala Glu Lys Asn Ser Phe Ser Glu Glu
275 280 285
Pro Phe Gln Asp Glu Ile Val Ser Tyr Asn Thr Lys Asn Lys Pro Leu
290 295 300
Asn Phe Asn Tyr Ser Leu Asp Lys Ile Ile Val Asp Tyr Asn Leu Gln
305 310 315 320
Ser Lys Ile Thr Leu Pro Asn Asp Arg Thr Thr Pro Val Thr Lys Gly
325 330 335
Ile Pro Tyr Ala Pro Glu Tyr Lys Ser Asn Ala Ala Ser Thr Ile Glu
340 345 350
Ile His Asn Ile Asp Asp Asn Thr Ile Tyr Gln Tyr Leu Tyr Ala Gln
355 360 365
Lys Ser Pro Thr Thr Leu Gln Arg Ile Thr Met Thr Asn Ser Val Asp
370 375 380
Asp Ala Leu Ile Asn Ser Thr Lys Ile Tyr Ser Tyr Phe Pro Ser Val
385 390 395 400
Ile Ser Lys Val Asn Gln Gly Ala Gln Gly Ile Leu Phe Leu Gln Trp
405 410 415
Val Arg Asp Ile Ile Asp Asp Phe Thr Asn Glu Ser Ser Gln Lys Thr
420 425 430
Thr Ile Asp Lys Ile Ser Asp Val Ser Thr Ile Val Pro Tyr Ile Gly
435 440 445
Pro Ala Leu Asn Ile Val Lys Gln Gly Tyr Glu Gly Asn Phe Ile Gly
450 455 460
Ala Leu Glu Thr Thr Gly Val Val Leu Leu Leu Glu Tyr Ile Pro Glu
465 470 475 480
Ile Thr Leu Pro Val Ile Ala Ala Leu Ser Ile Ala Glu Ser Ser Thr
485 490 495
Gln Lys Glu Lys Ile Ile Lys Thr Ile Asp Asn Phe Leu Glu Lys Arg
500 505 510
Tyr Glu Lys Trp Ile Glu Val Tyr Lys Leu Val Lys Ala Lys Trp Leu
515 520 525
Gly Thr Val Asn Thr Gln Phe Gln Lys Arg Ser Tyr Gln Met Tyr Arg
530 535 540
Ser Leu Glu Tyr Gln Val Asp Ala Ile Lys Lys Ile Ile Asp Tyr Glu
545 550 555 560
Tyr Lys Ile Tyr Ser Gly Pro Asp Lys Glu Gln Ile Ala Asp Glu Ile
565 570 575
Asn Asn Leu Lys Asn Lys Leu Glu Glu Lys Ala Asn Lys Ala Met Ile
580 585 590
Asn Ile Asn Ile Phe Met Arg Glu Ser Ser Arg Ser Phe Leu Val Asn
595 600 605
Gln Met Ile Asn Glu Ala Lys Lys Gln Leu Leu Glu Phe Asp Thr Gln
610 615 620
Ser Lys Asn Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile
625 630 635 640
Gly Ile Thr Glu Leu Lys Lys Leu Glu Ser Lys Ile Asn Lys Val Phe
645 650 655
Ser Thr Pro Ile Pro Phe Ser Tyr Ser Lys Asn Leu Asp Cys Trp Val
660 665 670
Asp Asn Glu Glu Asp Ile Asp Val Leu Glu Gly Gly Gly Gly Ser Gly
675 680 685
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Ala Gly Cys Lys
690 695 700
Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
705 710
<210> 38
<211> 728
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 38
Glu Ser Asn Gln Pro Glu Lys Asn Gly Thr Ala Thr Lys Pro Glu Asn
1 5 10 15
Ser Gly Asn Thr Thr Ser Glu Asn Gly Gln Thr Glu Pro Glu Lys Lys
20 25 30
Leu Glu Leu Arg Asn Val Ser Asp Ile Glu Leu Tyr Ser Gln Thr Asn
35 40 45
Gly Thr Tyr Arg Gln His Val Ser Leu Asp Gly Ile Pro Glu Asn Thr
50 55 60
Asp Thr Tyr Phe Val Lys Val Lys Ser Ser Ala Phe Lys Asp Val Tyr
65 70 75 80
Ile Pro Val Ala Ser Ile Thr Glu Glu Lys Arg Asn Gly Gln Ser Val
85 90 95
Tyr Lys Ile Thr Ala Lys Ala Glu Lys Leu Gln Gln Glu Leu Glu Asn
100 105 110
Lys Tyr Val Asp Asn Phe Thr Phe Tyr Leu Asp Lys Lys Ala Lys Glu
115 120 125
Glu Asn Thr Asn Phe Thr Ser Phe Ser Asn Leu Val Lys Ala Ile Asn
130 135 140
Gln Asn Pro Ser Gly Thr Tyr His Leu Ala Ala Ser Leu Asn Ala Asn
145 150 155 160
Glu Val Glu Leu Gly Pro Asp Glu Arg Ser Tyr Ile Lys Asp Thr Phe
165 170 175
Thr Gly Arg Leu Ile Gly Glu Lys Asp Gly Lys Asn Tyr Ala Ile Tyr
180 185 190
Asn Leu Lys Lys Pro Leu Phe Glu Asn Leu Ser Gly Ala Thr Val Glu
195 200 205
Lys Leu Ser Leu Lys Asn Val Ala Ile Ser Gly Lys Asn Asp Ile Gly
210 215 220
Ser Leu Ala Asn Glu Ala Thr Asn Gly Thr Lys Ile Lys Gln Val His
225 230 235 240
Val Asp Gly Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
245 250 255
Asp Asp Asp Lys Asn Lys Ala Leu Asn Leu Gln Cys Ile Lys Ile Lys
260 265 270
Asn Glu Asp Leu Thr Phe Ile Ala Glu Lys Asn Ser Phe Ser Glu Glu
275 280 285
Pro Phe Gln Asp Glu Ile Val Ser Tyr Asn Thr Lys Asn Lys Pro Leu
290 295 300
Asn Phe Asn Tyr Ser Leu Asp Lys Ile Ile Val Asp Tyr Asn Leu Gln
305 310 315 320
Ser Lys Ile Thr Leu Pro Asn Asp Arg Thr Thr Pro Val Thr Lys Gly
325 330 335
Ile Pro Tyr Ala Pro Glu Tyr Lys Ser Asn Ala Ala Ser Thr Ile Glu
340 345 350
Ile His Asn Ile Asp Asp Asn Thr Ile Tyr Gln Tyr Leu Tyr Ala Gln
355 360 365
Lys Ser Pro Thr Thr Leu Gln Arg Ile Thr Met Thr Asn Ser Val Asp
370 375 380
Asp Ala Leu Ile Asn Ser Thr Lys Ile Tyr Ser Tyr Phe Pro Ser Val
385 390 395 400
Ile Ser Lys Val Asn Gln Gly Ala Gln Gly Ile Leu Phe Leu Gln Trp
405 410 415
Val Arg Asp Ile Ile Asp Asp Phe Thr Asn Glu Ser Ser Gln Lys Thr
420 425 430
Thr Ile Asp Lys Ile Ser Asp Val Ser Thr Ile Val Pro Tyr Ile Gly
435 440 445
Pro Ala Leu Asn Ile Val Lys Gln Gly Tyr Glu Gly Asn Phe Ile Gly
450 455 460
Ala Leu Glu Thr Thr Gly Val Val Leu Leu Leu Glu Tyr Ile Pro Glu
465 470 475 480
Ile Thr Leu Pro Val Ile Ala Ala Leu Ser Ile Ala Glu Ser Ser Thr
485 490 495
Gln Lys Glu Lys Ile Ile Lys Thr Ile Asp Asn Phe Leu Glu Lys Arg
500 505 510
Tyr Glu Lys Trp Ile Glu Val Tyr Lys Leu Val Lys Ala Lys Trp Leu
515 520 525
Gly Thr Val Asn Thr Gln Phe Gln Lys Arg Ser Tyr Gln Met Tyr Arg
530 535 540
Ser Leu Glu Tyr Gln Val Asp Ala Ile Lys Lys Ile Ile Asp Tyr Glu
545 550 555 560
Tyr Lys Ile Tyr Ser Gly Pro Asp Lys Glu Gln Ile Ala Asp Glu Ile
565 570 575
Asn Asn Leu Lys Asn Lys Leu Glu Glu Lys Ala Asn Lys Ala Met Ile
580 585 590
Asn Ile Asn Ile Phe Met Arg Glu Ser Ser Arg Ser Phe Leu Val Asn
595 600 605
Gln Met Ile Asn Glu Ala Lys Lys Gln Leu Leu Glu Phe Asp Thr Gln
610 615 620
Ser Lys Asn Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile
625 630 635 640
Gly Ile Thr Glu Leu Lys Lys Leu Glu Ser Lys Ile Asn Lys Val Phe
645 650 655
Ser Thr Pro Ile Pro Phe Ser Tyr Ser Lys Asn Leu Asp Cys Trp Val
660 665 670
Asp Asn Glu Glu Asp Ile Asp Val Leu Glu Gly Gly Gly Gly Ser Gly
675 680 685
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Gly Ser Ser Phe
690 695 700
Leu Ser Pro Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys
705 710 715 720
Pro Pro Ala Lys Leu Gln Pro Arg
725
<210> 39
<211> 899
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 39
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Asn Lys Ala
435 440 445
Leu Asn Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
450 455 460
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
465 470 475 480
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
485 490 495
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
500 505 510
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
515 520 525
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
530 535 540
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
545 550 555 560
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
565 570 575
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
580 585 590
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
595 600 605
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
610 615 620
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
625 630 635 640
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
645 650 655
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
660 665 670
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
675 680 685
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
690 695 700
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
705 710 715 720
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
725 730 735
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
740 745 750
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
755 760 765
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
770 775 780
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
785 790 795 800
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
805 810 815
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
820 825 830
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
835 840 845
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
850 855 860
Leu Glu Ile Tyr Ala Leu Val Gly Ser Trp Phe Leu Ser Pro Glu His
865 870 875 880
Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro Ala Lys Leu
885 890 895
Gln Pro Arg
<210> 40
<211> 901
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 40
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Gly Asn His Trp Ala
885 890 895
Val Gly His Leu Met
900
<210> 41
<211> 899
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 41
Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asn
1 5 10 15
Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr
20 25 30
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg
35 40 45
Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile
50 55 60
Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn Thr
65 70 75 80
Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe Asn
85 90 95
Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile Ile
100 105 110
Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu Phe
115 120 125
Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn Pro
130 135 140
Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile Phe
145 150 155 160
Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile
165 170 175
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met
180 185 190
Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu Asn
195 200 205
Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro Ala
210 215 220
Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr Gly
225 230 235 240
Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe Phe
245 250 255
Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly
260 265 270
Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile Tyr
275 280 285
Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys
290 295 300
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys
305 310 315 320
Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly Lys
325 330 335
Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys Thr
355 360 365
Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys Asn
370 375 380
Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser
385 390 395 400
Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn
405 410 415
Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys
420 425 430
Ile Gln Met Cys Val Asp Glu Glu Lys Leu Tyr Asp Asp Asp Asp Lys
435 440 445
Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Asp Val Asp Asn Glu Asp
450 455 460
Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser Asp Asp Leu Ser Lys
465 470 475 480
Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn Tyr Ile Glu Asn Asp
485 490 495
Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp Leu Ile Ser Lys Ile
500 505 510
Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr Asp Phe Asn Val Asp
515 520 525
Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys Lys Ile Phe Thr Asp
530 535 540
Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln Thr Phe Pro Leu Asp
545 550 555 560
Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp Asp Ala Leu Leu Phe
565 570 575
Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp Tyr Ile Lys Thr Ala
580 585 590
Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val Lys Gln Ile
595 600 605
Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr Met Asp Ala
610 615 620
Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu Ala Leu Asn
625 630 635 640
Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala Phe Glu Ile
645 650 655
Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro Glu Leu Leu Ile Pro
660 665 670
Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn Lys Asn Lys
675 680 685
Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn Glu Lys Trp
690 695 700
Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser Thr Val Asn
705 710 715 720
Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala Leu Asn Tyr
725 730 735
Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr Arg Tyr Asn Ile Tyr
740 745 750
Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn Asp Ile Asn
755 760 765
Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn Ile Asn Asn
770 775 780
Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys Met Ile Pro
785 790 795 800
Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn Thr Leu Lys Lys Asn
805 810 815
Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr Leu Ile Gly Ser Ala
820 825 830
Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu Lys Thr Ile Met Pro
835 840 845
Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile Leu Ile Glu Met Phe
850 855 860
Asn Lys Tyr Asn Ser Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly
865 870 875 880
Ser Gly Gly Gly Gly Ser Ala Leu Val Gly Asn His Trp Ala Val Gly
885 890 895
His Leu Met
<210> 42
<211> 909
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 42
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn
435 440 445
Asp Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg
450 455 460
Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu
465 470 475 480
Asn Arg Ala Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Ala Leu Gln
485 490 495
Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp
500 505 510
Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr
515 520 525
Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu
530 535 540
Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu Leu Pro
545 550 555 560
Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val Phe
565 570 575
Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr
580 585 590
Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu Thr
595 600 605
Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe
610 615 620
Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly Leu
625 630 635 640
Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn Ile
645 650 655
Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val Ile Ile
660 665 670
Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly
675 680 685
Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu Glu
690 695 700
Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr
705 710 715 720
Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys
725 730 735
Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met Val
740 745 750
Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile Asn Tyr
755 760 765
Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys
770 775 780
Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile
785 790 795 800
Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile Ser
805 810 815
Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val Thr
820 825 830
Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn Lys
835 840 845
Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser His
850 855 860
Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val Asn
865 870 875 880
Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn
885 890 895
Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
900 905
<210> 43
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 43
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg His Val Asp
435 440 445
Ala Ile Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln Leu Ser Ala
450 455 460
Arg Lys Leu Leu Gln Asp Ile Leu Asn Arg Gln Gln Gly Glu Arg Asn
465 470 475 480
Gln Glu Gln Gly Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly
485 490 495
Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn
500 505 510
Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp
515 520 525
Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala
530 535 540
Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe
545 550 555 560
Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser
565 570 575
Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro
580 585 590
Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu
595 600 605
Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn
610 615 620
Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe
625 630 635 640
Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met
645 650 655
Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr
660 665 670
Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile
675 680 685
Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp
690 695 700
Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu
705 710 715 720
Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val
725 730 735
Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala
740 745 750
Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val
755 760 765
Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys
770 775 780
Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile
785 790 795 800
Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile
805 810 815
Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn
820 825 830
Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser
835 840 845
Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp
850 855 860
Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn
865 870 875 880
Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn
885 890 895
Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp
900 905 910
Asn Gln Arg Leu Leu Ser Thr
915
<210> 44
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 44
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg His Val Asp Ala Ile
435 440 445
Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln Leu Ser Ala Arg Lys
450 455 460
Leu Leu Gln Asp Ile Leu Asn Arg Gln Gln Gly Glu Arg Asn Gln Glu
465 470 475 480
Gln Gly Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
485 490 495
Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Arg Glu Leu Leu Val Lys
500 505 510
Asn Thr Asp Leu Pro Phe Ile Gly Asp Ile Ser Asp Val Lys Thr Asp
515 520 525
Ile Phe Leu Arg Lys Asp Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr
530 535 540
Pro Asp Asn Val Ser Val Asp Gln Val Ile Leu Ser Lys Asn Thr Ser
545 550 555 560
Glu His Gly Gln Leu Asp Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser
565 570 575
Glu Ile Leu Pro Gly Glu Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln
580 585 590
Asn Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
595 600 605
Ser Asp Asn Val Glu Asp Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala
610 615 620
Leu Asp Asn Ser Ala Lys Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn
625 630 635 640
Lys Val Asn Ala Gly Val Gln Gly Gly Leu Phe Leu Met Trp Ala Asn
645 650 655
Asp Val Val Glu Asp Phe Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu
660 665 670
Asp Lys Ile Ser Asp Val Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala
675 680 685
Leu Asn Ile Ser Asn Ser Val Arg Arg Gly Asn Phe Thr Glu Ala Phe
690 695 700
Ala Val Thr Gly Val Thr Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr
705 710 715 720
Ile Pro Ala Leu Gly Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg
725 730 735
Asn Glu Ile Ile Lys Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys
740 745 750
Arg Trp Lys Asp Ser Tyr Glu Trp Met Met Gly Thr Trp Leu Ser Arg
755 760 765
Ile Ile Thr Gln Phe Asn Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu
770 775 780
Asn Tyr Gln Ala Gly Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
785 790 795 800
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
805 810 815
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
820 825 830
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
835 840 845
Leu Pro Lys Val Ile Asp Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys
850 855 860
Ala Lys Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
865 870 875 880
Glu Val Asp Lys Leu Lys Ala Lys Val Asn Asn Ser Phe Gln Asn Thr
885 890 895
Ile Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
900 905 910
Ile Ile Asn Glu Tyr Phe Asn
915
<210> 45
<211> 928
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 45
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Asn
465 470 475 480
Arg Gln Gln Gly Glu Arg Asn Gln Glu Gln Gly Ala Ala Leu Ala Gly
485 490 495
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu
500 505 510
Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala
515 520 525
Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr
530 535 540
Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu
545 550 555 560
Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro
565 570 575
Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu
580 585 590
Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser
595 600 605
Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile
610 615 620
Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile
625 630 635 640
Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln
645 650 655
Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr
660 665 670
Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser
675 680 685
Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala
690 695 700
Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe
705 710 715 720
Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe
725 730 735
Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile
740 745 750
Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln
755 760 765
Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His
770 775 780
Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile
785 790 795 800
Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys
805 810 815
Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val
820 825 830
Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys
835 840 845
Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu
850 855 860
Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile
865 870 875 880
Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala
885 890 895
Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser
900 905 910
Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
915 920 925
<210> 46
<211> 913
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 46
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn
435 440 445
Asp Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg
450 455 460
Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu
465 470 475 480
Asn Arg Gln Gln Gly Glu Arg Asn Gln Glu Gln Gly Ala Pro Ala Pro
485 490 495
Ala Pro Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val
500 505 510
Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile
515 520 525
Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp
530 535 540
Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp
545 550 555 560
Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu
565 570 575
Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn
580 585 590
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn
595 600 605
Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys
610 615 620
Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val
625 630 635 640
Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe
645 650 655
Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
660 665 670
Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser
675 680 685
Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala
690 695 700
Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val
705 710 715 720
Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr
725 730 735
Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr
740 745 750
Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn
755 760 765
His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala
770 775 780
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
785 790 795 800
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
805 810 815
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
820 825 830
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
835 840 845
Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu
850 855 860
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys
865 870 875 880
Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe
885 890 895
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
900 905 910
Asn
<210> 47
<211> 919
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 47
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn
435 440 445
Asp Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg
450 455 460
Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu
465 470 475 480
Asn Arg Gln Gln Gly Glu Arg Asn Gln Glu Gln Gly Ala Glu Ala Ala
485 490 495
Ala Lys Glu Ala Ala Ala Lys Ala Leu Gln Cys Ile Lys Val Lys Asn
500 505 510
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
515 520 525
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
530 535 540
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
545 550 555 560
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
565 570 575
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
580 585 590
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
595 600 605
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
610 615 620
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
625 630 635 640
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
645 650 655
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
660 665 670
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
675 680 685
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
690 695 700
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
705 710 715 720
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
725 730 735
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
740 745 750
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
755 760 765
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
770 775 780
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
785 790 795 800
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
805 810 815
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
820 825 830
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
835 840 845
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
850 855 860
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
865 870 875 880
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
885 890 895
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
900 905 910
Ile Ile Asn Glu Tyr Phe Asn
915
<210> 48
<211> 918
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 48
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Gly Gly Gly Ser Ala Asp Asp Asp Asp Lys Asn Asp Asp Pro Pro Ile
435 440 445
Ser Ile Asp Leu Thr Phe His Leu Leu Arg Asn Met Ile Glu Met Ala
450 455 460
Arg Ile Glu Asn Glu Arg Glu Gln Ala Gly Leu Asn Arg Lys Tyr Leu
465 470 475 480
Asp Glu Val Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
485 490 495
Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn
500 505 510
Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu
515 520 525
Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu
530 535 540
Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn
545 550 555 560
Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp
565 570 575
Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn
580 585 590
Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg
595 600 605
Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser
610 615 620
Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser
625 630 635 640
Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe
645 650 655
Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser
660 665 670
Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro
675 680 685
Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp
690 695 700
Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe
705 710 715 720
Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser
725 730 735
Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu
740 745 750
Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr
755 760 765
Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys
770 775 780
Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile
785 790 795 800
Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn
805 810 815
Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys
820 825 830
Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr
835 840 845
Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe
850 855 860
Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg
865 870 875 880
Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn
885 890 895
Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn
900 905 910
Gln Arg Leu Leu Ser Thr
915
<210> 49
<211> 864
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 49
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Asn Lys Ala
435 440 445
Leu Asn Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
450 455 460
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
465 470 475 480
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
485 490 495
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
500 505 510
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
515 520 525
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
530 535 540
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
545 550 555 560
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
565 570 575
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
580 585 590
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
595 600 605
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
610 615 620
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
625 630 635 640
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
645 650 655
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
660 665 670
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
675 680 685
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
690 695 700
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
705 710 715 720
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
725 730 735
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
740 745 750
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
755 760 765
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
770 775 780
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
785 790 795 800
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
805 810 815
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
820 825 830
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
835 840 845
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
850 855 860
<210> 50
<211> 869
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 50
Pro Val Thr Ile Asn Asn Phe Asn Tyr Asn Asp Pro Ile Asp Asn Asn
1 5 10 15
Asn Ile Ile Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg Tyr
20 25 30
Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Ile Pro Glu Arg
35 40 45
Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly Ile
50 55 60
Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn Thr
65 70 75 80
Asn Asp Lys Lys Asn Ile Phe Leu Gln Thr Met Ile Lys Leu Phe Asn
85 90 95
Arg Ile Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met Ile Ile
100 105 110
Asn Gly Ile Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu Phe
115 120 125
Asn Thr Asn Ile Ala Ser Val Thr Val Asn Lys Leu Ile Ser Asn Pro
130 135 140
Gly Glu Val Glu Arg Lys Lys Gly Ile Phe Ala Asn Leu Ile Ile Phe
145 150 155 160
Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr Ile Asp Ile Gly Ile
165 170 175
Gln Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly Ile Met Gln Met
180 185 190
Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gln Glu Asn
195 200 205
Lys Gly Ala Ser Ile Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro Ala
210 215 220
Leu Ile Leu Met His Glu Leu Ile His Val Leu His Gly Leu Tyr Gly
225 230 235 240
Ile Lys Val Asp Asp Leu Pro Ile Val Pro Asn Glu Lys Lys Phe Phe
245 250 255
Met Gln Ser Thr Asp Ala Ile Gln Ala Glu Glu Leu Tyr Thr Phe Gly
260 265 270
Gly Gln Asp Pro Ser Ile Ile Thr Pro Ser Thr Asp Lys Ser Ile Tyr
275 280 285
Asp Lys Val Leu Gln Asn Phe Arg Gly Ile Val Asp Arg Leu Asn Lys
290 295 300
Val Leu Val Cys Ile Ser Asp Pro Asn Ile Asn Ile Asn Ile Tyr Lys
305 310 315 320
Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly Lys
325 330 335
Tyr Ser Ile Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu Met
340 345 350
Phe Gly Phe Thr Glu Thr Asn Ile Ala Glu Asn Tyr Lys Ile Lys Thr
355 360 365
Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys Ile Lys Asn
370 375 380
Leu Leu Asp Asn Glu Ile Tyr Thr Ile Glu Glu Gly Phe Asn Ile Ser
385 390 395 400
Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gln Asn Lys Ala Ile Asn
405 410 415
Lys Gln Ala Tyr Glu Glu Ile Ser Lys Glu His Leu Ala Val Tyr Lys
420 425 430
Ile Gln Met Cys Val Asp Glu Glu Lys Leu Tyr Asp Asp Asp Asp Lys
435 440 445
Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Asp Val Asp Asn Glu Asp
450 455 460
Leu Phe Phe Ile Ala Asp Lys Asn Ser Phe Ser Asp Asp Leu Ser Lys
465 470 475 480
Asn Glu Arg Ile Glu Tyr Asn Thr Gln Ser Asn Tyr Ile Glu Asn Asp
485 490 495
Phe Pro Ile Asn Glu Leu Ile Leu Asp Thr Asp Leu Ile Ser Lys Ile
500 505 510
Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr Asp Phe Asn Val Asp
515 520 525
Val Pro Val Tyr Glu Lys Gln Pro Ala Ile Lys Lys Ile Phe Thr Asp
530 535 540
Glu Asn Thr Ile Phe Gln Tyr Leu Tyr Ser Gln Thr Phe Pro Leu Asp
545 550 555 560
Ile Arg Asp Ile Ser Leu Thr Ser Ser Phe Asp Asp Ala Leu Leu Phe
565 570 575
Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp Tyr Ile Lys Thr Ala
580 585 590
Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly Trp Val Lys Gln Ile
595 600 605
Val Asn Asp Phe Val Ile Glu Ala Asn Lys Ser Asn Thr Met Asp Ala
610 615 620
Ile Ala Asp Ile Ser Leu Ile Val Pro Tyr Ile Gly Leu Ala Leu Asn
625 630 635 640
Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu Asn Ala Phe Glu Ile
645 650 655
Ala Gly Ala Ser Ile Leu Leu Glu Phe Ile Pro Glu Leu Leu Ile Pro
660 665 670
Val Val Gly Ala Phe Leu Leu Glu Ser Tyr Ile Asp Asn Lys Asn Lys
675 680 685
Ile Ile Lys Thr Ile Asp Asn Ala Leu Thr Lys Arg Asn Glu Lys Trp
690 695 700
Ser Asp Met Tyr Gly Leu Ile Val Ala Gln Trp Leu Ser Thr Val Asn
705 710 715 720
Thr Gln Phe Tyr Thr Ile Lys Glu Gly Met Tyr Lys Ala Leu Asn Tyr
725 730 735
Gln Ala Gln Ala Leu Glu Glu Ile Ile Lys Tyr Arg Tyr Asn Ile Tyr
740 745 750
Ser Glu Lys Glu Lys Ser Asn Ile Asn Ile Asp Phe Asn Asp Ile Asn
755 760 765
Ser Lys Leu Asn Glu Gly Ile Asn Gln Ala Ile Asp Asn Ile Asn Asn
770 775 780
Phe Ile Asn Gly Cys Ser Val Ser Tyr Leu Met Lys Lys Met Ile Pro
785 790 795 800
Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn Thr Leu Lys Lys Asn
805 810 815
Leu Leu Asn Tyr Ile Asp Glu Asn Lys Leu Tyr Leu Ile Gly Ser Ala
820 825 830
Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu Lys Thr Ile Met Pro
835 840 845
Phe Asp Leu Ser Ile Tyr Thr Asn Asp Thr Ile Leu Ile Glu Met Phe
850 855 860
Asn Lys Tyr Asn Ser
865
<210> 51
<211> 865
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 51
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn
865
<210> 52
<211> 871
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 52
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn
865 870
<210> 53
<211> 680
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 53
Glu Ser Asn Gln Pro Glu Lys Asn Gly Thr Ala Thr Lys Pro Glu Asn
1 5 10 15
Ser Gly Asn Thr Thr Ser Glu Asn Gly Gln Thr Glu Pro Glu Lys Lys
20 25 30
Leu Glu Leu Arg Asn Val Ser Asp Ile Glu Leu Tyr Ser Gln Thr Asn
35 40 45
Gly Thr Tyr Arg Gln His Val Ser Leu Asp Gly Ile Pro Glu Asn Thr
50 55 60
Asp Thr Tyr Phe Val Lys Val Lys Ser Ser Ala Phe Lys Asp Val Tyr
65 70 75 80
Ile Pro Val Ala Ser Ile Thr Glu Glu Lys Arg Asn Gly Gln Ser Val
85 90 95
Tyr Lys Ile Thr Ala Lys Ala Glu Lys Leu Gln Gln Glu Leu Glu Asn
100 105 110
Lys Tyr Val Asp Asn Phe Thr Phe Tyr Leu Asp Lys Lys Ala Lys Glu
115 120 125
Glu Asn Thr Asn Phe Thr Ser Phe Ser Asn Leu Val Lys Ala Ile Asn
130 135 140
Gln Asn Pro Ser Gly Thr Tyr His Leu Ala Ala Ser Leu Asn Ala Asn
145 150 155 160
Glu Val Glu Leu Gly Pro Asp Glu Arg Ser Tyr Ile Lys Asp Thr Phe
165 170 175
Thr Gly Arg Leu Ile Gly Glu Lys Asp Gly Lys Asn Tyr Ala Ile Tyr
180 185 190
Asn Leu Lys Lys Pro Leu Phe Glu Asn Leu Ser Gly Ala Thr Val Glu
195 200 205
Lys Leu Ser Leu Lys Asn Val Ala Ile Ser Gly Lys Asn Asp Ile Gly
210 215 220
Ser Leu Ala Asn Glu Ala Thr Asn Gly Thr Lys Ile Lys Gln Val His
225 230 235 240
Val Asp Gly Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
245 250 255
Asp Asp Asp Lys Asn Lys Ala Leu Asn Leu Gln Cys Ile Lys Ile Lys
260 265 270
Asn Glu Asp Leu Thr Phe Ile Ala Glu Lys Asn Ser Phe Ser Glu Glu
275 280 285
Pro Phe Gln Asp Glu Ile Val Ser Tyr Asn Thr Lys Asn Lys Pro Leu
290 295 300
Asn Phe Asn Tyr Ser Leu Asp Lys Ile Ile Val Asp Tyr Asn Leu Gln
305 310 315 320
Ser Lys Ile Thr Leu Pro Asn Asp Arg Thr Thr Pro Val Thr Lys Gly
325 330 335
Ile Pro Tyr Ala Pro Glu Tyr Lys Ser Asn Ala Ala Ser Thr Ile Glu
340 345 350
Ile His Asn Ile Asp Asp Asn Thr Ile Tyr Gln Tyr Leu Tyr Ala Gln
355 360 365
Lys Ser Pro Thr Thr Leu Gln Arg Ile Thr Met Thr Asn Ser Val Asp
370 375 380
Asp Ala Leu Ile Asn Ser Thr Lys Ile Tyr Ser Tyr Phe Pro Ser Val
385 390 395 400
Ile Ser Lys Val Asn Gln Gly Ala Gln Gly Ile Leu Phe Leu Gln Trp
405 410 415
Val Arg Asp Ile Ile Asp Asp Phe Thr Asn Glu Ser Ser Gln Lys Thr
420 425 430
Thr Ile Asp Lys Ile Ser Asp Val Ser Thr Ile Val Pro Tyr Ile Gly
435 440 445
Pro Ala Leu Asn Ile Val Lys Gln Gly Tyr Glu Gly Asn Phe Ile Gly
450 455 460
Ala Leu Glu Thr Thr Gly Val Val Leu Leu Leu Glu Tyr Ile Pro Glu
465 470 475 480
Ile Thr Leu Pro Val Ile Ala Ala Leu Ser Ile Ala Glu Ser Ser Thr
485 490 495
Gln Lys Glu Lys Ile Ile Lys Thr Ile Asp Asn Phe Leu Glu Lys Arg
500 505 510
Tyr Glu Lys Trp Ile Glu Val Tyr Lys Leu Val Lys Ala Lys Trp Leu
515 520 525
Gly Thr Val Asn Thr Gln Phe Gln Lys Arg Ser Tyr Gln Met Tyr Arg
530 535 540
Ser Leu Glu Tyr Gln Val Asp Ala Ile Lys Lys Ile Ile Asp Tyr Glu
545 550 555 560
Tyr Lys Ile Tyr Ser Gly Pro Asp Lys Glu Gln Ile Ala Asp Glu Ile
565 570 575
Asn Asn Leu Lys Asn Lys Leu Glu Glu Lys Ala Asn Lys Ala Met Ile
580 585 590
Asn Ile Asn Ile Phe Met Arg Glu Ser Ser Arg Ser Phe Leu Val Asn
595 600 605
Gln Met Ile Asn Glu Ala Lys Lys Gln Leu Leu Glu Phe Asp Thr Gln
610 615 620
Ser Lys Asn Ile Leu Met Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile
625 630 635 640
Gly Ile Thr Glu Leu Lys Lys Leu Glu Ser Lys Ile Asn Lys Val Phe
645 650 655
Ser Thr Pro Ile Pro Phe Ser Tyr Ser Lys Asn Leu Asp Cys Trp Val
660 665 670
Asp Asn Glu Glu Asp Ile Asp Val
675 680
<210> 54
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
peptide"
<220>
<221> MOD_RES
<222> (2)..(2)
<223> D-Phe
<220>
<221> MOD_RES
<222> (5)..(5)
<223> D-Trp
<220>
<221> misc_feature
<222> (9)..(9)
<223> /note="C-terminal-alcohol"
<400> 54
Cys Phe Cys Phe Trp Lys Thr Cys Thr
1 5
<210> 55
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<220>
<221> MOD_RES
<222> (27)..(27)
<223> Norleucine
<400> 55
His Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln
1 5 10 15
Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg Cys
20 25 30
<210> 56
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<220>
<221> MOD_RES
<222> (1)..(1)
<223> PhAc-Tyr
<220>
<221> MOD_RES
<222> (2)..(2)
<223> D-Arg
<220>
<221> MOD_RES
<222> (6)..(6)
<223> Phe(4-Cl)
<220>
<221> MOD_RES
<222> (9)..(9)
<223> Homoarginine
<220>
<221> MOD_RES
<222> (10)..(10)
<223> Tyr(Me)
<220>
<221> MOD_RES
<222> (15)..(15)
<223> Alpha-aminobutyric acid
<220>
<221> MOD_RES
<222> (27)..(27)
<223> Norleucine
<220>
<221> MOD_RES
<222> (28)..(28)
<223> D-Arg
<220>
<221> MOD_RES
<222> (29)..(29)
<223> Homoarginine
<400> 56
Tyr Arg Asp Ala Ile Phe Thr Ala Arg Tyr His Lys Val Leu Xaa Gln
1 5 10 15
Leu Ser Ala His Lys Leu Leu Gln Asp Ile Leu Arg Arg Cys
20 25 30
<210> 57
<211> 893
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 57
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Asp Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val
450 455 460
Tyr Arg Pro Cys Trp Gln Val Ala Leu Ala Lys Arg Leu Val Leu Gln
465 470 475 480
Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp
485 490 495
Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr
500 505 510
Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu
515 520 525
Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu Leu Pro
530 535 540
Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val Phe
545 550 555 560
Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr
565 570 575
Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu Thr
580 585 590
Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe
595 600 605
Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly Leu
610 615 620
Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn Ile
625 630 635 640
Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val Ile Ile
645 650 655
Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly
660 665 670
Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu Glu
675 680 685
Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr
690 695 700
Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys
705 710 715 720
Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met Val
725 730 735
Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile Asn Tyr
740 745 750
Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys
755 760 765
Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile
770 775 780
Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile Ser
785 790 795 800
Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val Thr
805 810 815
Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn Lys
820 825 830
Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser His
835 840 845
Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val Asn
850 855 860
Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn
865 870 875 880
Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
885 890
<210> 58
<211> 902
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 58
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Tyr Asn Trp Asn Ser
885 890 895
Phe Gly Leu Arg Phe Gly
900
<210> 59
<211> 905
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 59
Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val
1 5 10 15
Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val
20 25 30
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp
35 40 45
Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala
50 55 60
Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp
65 70 75 80
Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg
85 90 95
Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg
100 105 110
Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val
115 120 125
Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg
130 135 140
Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile
145 150 155 160
Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg
165 170 175
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr
180 185 190
Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly
195 200 205
Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu
210 215 220
Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg
225 230 235 240
Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu
245 250 255
Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe
260 265 270
Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys
275 280 285
Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly
290 295 300
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr
305 310 315 320
Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys
325 330 335
Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn
340 345 350
Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe
355 360 365
Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr
370 375 380
Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe
385 390 395 400
Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys
405 410 415
Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly
420 425 430
Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys Asn Lys Ala
435 440 445
Leu Asn Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
450 455 460
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
465 470 475 480
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
485 490 495
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
500 505 510
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
515 520 525
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
530 535 540
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
545 550 555 560
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
565 570 575
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
580 585 590
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
595 600 605
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
610 615 620
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
625 630 635 640
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
645 650 655
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
660 665 670
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
675 680 685
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
690 695 700
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
705 710 715 720
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
725 730 735
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
740 745 750
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
755 760 765
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
770 775 780
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
785 790 795 800
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
805 810 815
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
820 825 830
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
835 840 845
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
850 855 860
Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
865 870 875 880
Ser Ala Leu Val Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg
885 890 895
Gly Ile Arg Pro Val Gly Arg Phe Gly
900 905
<210> 60
<211> 915
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 60
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ala
465 470 475 480
Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
485 490 495
Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro
500 505 510
Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys
515 520 525
Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser
530 535 540
Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile
545 550 555 560
Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro
565 570 575
Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr
580 585 590
Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val
595 600 605
Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser
610 615 620
Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys
625 630 635 640
Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu
645 650 655
Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser
660 665 670
Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly
675 680 685
Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly
690 695 700
Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu
705 710 715 720
Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile
725 730 735
Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp
740 745 750
Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln
755 760 765
Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala
770 775 780
Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly
785 790 795 800
Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser
805 810 815
Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile
820 825 830
Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val
835 840 845
Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile
850 855 860
Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg
865 870 875 880
Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn
885 890 895
Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu
900 905 910
Tyr Phe Asn
915
<210> 61
<211> 916
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 61
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
485 490 495
Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
500 505 510
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
515 520 525
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
530 535 540
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
545 550 555 560
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
565 570 575
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
580 585 590
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
595 600 605
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
610 615 620
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
625 630 635 640
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
645 650 655
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
660 665 670
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
675 680 685
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
690 695 700
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
705 710 715 720
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
725 730 735
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
740 745 750
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
755 760 765
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
770 775 780
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
785 790 795 800
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
805 810 815
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
820 825 830
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
835 840 845
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
850 855 860
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
865 870 875 880
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
885 890 895
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
900 905 910
Glu Tyr Phe Asn
915
<210> 62
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 62
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 63
<211> 932
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 63
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu
485 490 495
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
500 505 510
Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
515 520 525
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
530 535 540
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
545 550 555 560
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
565 570 575
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
580 585 590
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
595 600 605
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
610 615 620
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
625 630 635 640
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
645 650 655
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
660 665 670
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
675 680 685
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
690 695 700
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
705 710 715 720
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
725 730 735
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
740 745 750
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
755 760 765
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
770 775 780
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
785 790 795 800
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
805 810 815
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
820 825 830
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
835 840 845
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
850 855 860
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
865 870 875 880
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
885 890 895
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
900 905 910
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
915 920 925
Glu Tyr Phe Asn
930
<210> 64
<211> 927
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 64
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Leu Ala Gly Gly
485 490 495
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Ala
500 505 510
Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp
515 520 525
Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp
530 535 540
Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser
545 550 555 560
Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu
565 570 575
Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile
580 585 590
Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr
595 600 605
Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr
610 615 620
Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr
625 630 635 640
Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala
645 650 655
Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr
660 665 670
Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val
675 680 685
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu
690 695 700
Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu
705 710 715 720
Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr
725 730 735
Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu
740 745 750
Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp
755 760 765
Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile
770 775 780
Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys
785 790 795 800
Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu
805 810 815
Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys
820 825 830
Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser
835 840 845
Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu
850 855 860
Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp
865 870 875 880
Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys
885 890 895
Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr
900 905 910
Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
915 920 925
<210> 65
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 65
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ala Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 66
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 66
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 67
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 67
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Lys Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 68
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 68
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Lys Arg
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 69
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 69
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Asn Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 70
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 70
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Lys Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 71
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 71
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Lys Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Lys Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 72
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 72
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Asn Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 73
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 73
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Asn
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 74
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 74
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Asn Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 75
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 75
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Glu Ala Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 76
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 76
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Glu Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 77
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 77
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Glu Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 78
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 78
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 79
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 79
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Glu Ser Tyr Arg Lys
450 455 460
Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 80
<211> 915
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 80
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ala
465 470 475 480
Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
485 490 495
Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro
500 505 510
Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys
515 520 525
Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser
530 535 540
Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile
545 550 555 560
Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro
565 570 575
Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr
580 585 590
Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val
595 600 605
Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser
610 615 620
Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys
625 630 635 640
Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu
645 650 655
Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser
660 665 670
Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly
675 680 685
Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly
690 695 700
Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu
705 710 715 720
Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile
725 730 735
Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp
740 745 750
Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln
755 760 765
Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala
770 775 780
Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly
785 790 795 800
Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser
805 810 815
Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile
820 825 830
Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val
835 840 845
Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile
850 855 860
Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Arg
865 870 875 880
Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn
885 890 895
Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu
900 905 910
Tyr Phe Asn
915
<210> 81
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 81
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 82
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 82
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 83
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 83
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ala Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Ala Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 84
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 84
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Ala Ala Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Met Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 85
<211> 920
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 85
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Leu Ser
465 470 475 480
Arg Gln Gln Gly Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly
485 490 495
Ser Gly Gly Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys
500 505 510
Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu
515 520 525
Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr
530 535 540
Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro
545 550 555 560
Ile Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu
565 570 575
Pro Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr
580 585 590
Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys
595 600 605
Leu Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu
610 615 620
Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala
625 630 635 640
Glu Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala
645 650 655
Asn Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr
660 665 670
Leu Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro
675 680 685
Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala
690 695 700
Phe Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe
705 710 715 720
Thr Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu
725 730 735
Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val
740 745 750
Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser
755 760 765
Arg Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser
770 775 780
Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr
785 790 795 800
Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu
805 810 815
Asn Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn
820 825 830
Ile Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn
835 840 845
Met Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr
850 855 860
Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val
865 870 875 880
Gly Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn
885 890 895
Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys
900 905 910
Asp Ile Ile Asn Glu Tyr Phe Asn
915 920
<210> 86
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 86
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Ser Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 87
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 87
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys His Val Asp Ala Ile Phe Thr Thr Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 88
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 88
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Leu Asn
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 89
<211> 917
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 89
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp
435 440 445
Asp Asp Asp Lys Tyr Ala Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys
450 455 460
Val Leu Ala Gln Leu Ser Ala Arg Lys Ala Leu Gln Asp Ile Leu Ser
465 470 475 480
Arg Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
485 490 495
Gly Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg
500 505 510
Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu
515 520 525
Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys
530 535 540
Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro
545 550 555 560
Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn
565 570 575
Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val
580 585 590
Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn
595 600 605
Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly
610 615 620
Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val
625 630 635 640
Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val
645 650 655
Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys
660 665 670
Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
675 680 685
Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr
690 695 700
Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro
705 710 715 720
Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys
725 730 735
Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp
740 745 750
Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr
755 760 765
Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr
770 775 780
Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr
785 790 795 800
Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys
805 810 815
Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys
820 825 830
Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro
835 840 845
Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu
850 855 860
Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val
865 870 875 880
Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro
885 890 895
Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile
900 905 910
Asn Glu Tyr Phe Asn
915
<210> 90
<211> 916
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 90
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Ile
435 440 445
Glu Gly Arg Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Lys Val
450 455 460
Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg
465 470 475 480
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
485 490 495
Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
500 505 510
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
515 520 525
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
530 535 540
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
545 550 555 560
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
565 570 575
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
580 585 590
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
595 600 605
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
610 615 620
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
625 630 635 640
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
645 650 655
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
660 665 670
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
675 680 685
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
690 695 700
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
705 710 715 720
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
725 730 735
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
740 745 750
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
755 760 765
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
770 775 780
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
785 790 795 800
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
805 810 815
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
820 825 830
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
835 840 845
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
850 855 860
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
865 870 875 880
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
885 890 895
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
900 905 910
Glu Tyr Phe Asn
915
<210> 91
<211> 916
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 91
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Ile
435 440 445
Glu Gly Arg Tyr Ala Asp Ala Ile Phe Thr Ala Ser Tyr Arg Asn Val
450 455 460
Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg
465 470 475 480
Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
485 490 495
Gly Ser Ala Leu Ala Leu Gln Cys Ile Lys Val Lys Asn Asn Arg Leu
500 505 510
Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn
515 520 525
Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe
530 535 540
Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile Asn Pro Glu
545 550 555 560
Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro Leu Asn Leu
565 570 575
Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp
580 585 590
Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn
595 600 605
Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr
610 615 620
Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu Lys Val Asn
625 630 635 640
Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn Glu Val Val
645 650 655
Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu Asp Lys Ile
660 665 670
Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
675 680 685
Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala
690 695 700
Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala
705 710 715 720
Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile
725 730 735
Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys Arg Trp Lys
740 745 750
Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg Ile Thr Thr
755 760 765
Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln
770 775 780
Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser
785 790 795 800
Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn
805 810 815
Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe
820 825 830
Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys
835 840 845
Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu
850 855 860
Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp
865 870 875 880
Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr Met Pro Phe
885 890 895
Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn
900 905 910
Glu Tyr Phe Asn
915
<210> 92
<211> 910
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 92
His Val Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln
1 5 10 15
Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Asn Arg Asn Asn Asn
20 25 30
Asn Asn Asn Asn Asn Asn Asn Thr Trp Pro Val Lys Asp Phe Asn Tyr
35 40 45
Ser Asp Pro Val Asn Asp Asn Asp Ile Leu Tyr Leu Arg Ile Pro Gln
50 55 60
Asn Lys Leu Ile Thr Thr Pro Val Lys Ala Phe Met Ile Thr Gln Asn
65 70 75 80
Ile Trp Val Ile Pro Glu Arg Phe Ser Ser Asp Thr Asn Pro Ser Leu
85 90 95
Ser Lys Pro Pro Arg Pro Thr Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro
100 105 110
Ser Tyr Leu Ser Thr Asp Glu Gln Lys Asp Thr Phe Leu Lys Gly Ile
115 120 125
Ile Lys Leu Phe Lys Arg Ile Asn Glu Arg Asp Ile Gly Lys Lys Leu
130 135 140
Ile Asn Tyr Leu Val Val Gly Ser Pro Phe Met Gly Asp Ser Ser Thr
145 150 155 160
Pro Glu Asp Thr Phe Asp Phe Thr Arg His Thr Thr Asn Ile Ala Val
165 170 175
Glu Lys Phe Glu Asn Gly Ser Trp Lys Val Thr Asn Ile Ile Thr Pro
180 185 190
Ser Val Leu Ile Phe Gly Pro Leu Pro Asn Ile Leu Asp Tyr Thr Ala
195 200 205
Ser Leu Thr Leu Gln Gly Gln Gln Ser Asn Pro Ser Phe Glu Gly Phe
210 215 220
Gly Thr Leu Ser Ile Leu Lys Val Ala Pro Glu Phe Leu Leu Thr Phe
225 230 235 240
Ser Asp Val Thr Ser Asn Gln Ser Ser Ala Val Leu Gly Lys Ser Ile
245 250 255
Phe Cys Met Asp Pro Val Ile Ala Leu Met His Glu Leu Thr His Ser
260 265 270
Leu His Gln Leu Tyr Gly Ile Asn Ile Pro Ser Asp Lys Arg Ile Arg
275 280 285
Pro Gln Val Ser Glu Gly Phe Phe Ser Gln Asp Gly Pro Asn Val Gln
290 295 300
Phe Glu Glu Leu Tyr Thr Phe Gly Gly Leu Asp Val Glu Ile Ile Pro
305 310 315 320
Gln Ile Glu Arg Ser Gln Leu Arg Glu Lys Ala Leu Gly His Tyr Lys
325 330 335
Asp Ile Ala Lys Arg Leu Asn Asn Ile Asn Lys Thr Ile Pro Ser Ser
340 345 350
Trp Ile Ser Asn Ile Asp Lys Tyr Lys Lys Ile Phe Ser Glu Lys Tyr
355 360 365
Asn Phe Asp Lys Asp Asn Thr Gly Asn Phe Val Val Asn Ile Asp Lys
370 375 380
Phe Asn Ser Leu Tyr Ser Asp Leu Thr Asn Val Met Ser Glu Val Val
385 390 395 400
Tyr Ser Ser Gln Tyr Asn Val Lys Asn Arg Thr His Tyr Phe Ser Arg
405 410 415
His Tyr Leu Pro Val Phe Ala Asn Ile Leu Asp Asp Asn Ile Tyr Thr
420 425 430
Ile Arg Asp Gly Phe Asn Leu Thr Asn Lys Gly Phe Asn Ile Glu Asn
435 440 445
Ser Gly Gln Asn Ile Glu Arg Asn Pro Ala Leu Gln Lys Leu Ser Ser
450 455 460
Glu Ser Val Val Asp Leu Phe Thr Lys Val Cys Val Asp Lys Ser Glu
465 470 475 480
Glu Lys Leu Tyr Asp Asp Asp Asp Lys Asp Arg Trp Gly Ser Ser Leu
485 490 495
Gln Cys Ile Lys Val Lys Asn Asn Arg Leu Pro Tyr Val Ala Asp Lys
500 505 510
Asp Ser Ile Ser Gln Glu Ile Phe Glu Asn Lys Ile Ile Thr Asp Glu
515 520 525
Thr Asn Val Gln Asn Tyr Ser Asp Lys Phe Ser Leu Asp Glu Ser Ile
530 535 540
Leu Asp Gly Gln Val Pro Ile Asn Pro Glu Ile Val Asp Pro Leu Leu
545 550 555 560
Pro Asn Val Asn Met Glu Pro Leu Asn Leu Pro Gly Glu Glu Ile Val
565 570 575
Phe Tyr Asp Asp Ile Thr Lys Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr
580 585 590
Tyr Leu Glu Ser Gln Lys Leu Ser Asn Asn Val Glu Asn Ile Thr Leu
595 600 605
Thr Thr Ser Val Glu Glu Ala Leu Gly Tyr Ser Asn Lys Ile Tyr Thr
610 615 620
Phe Leu Pro Ser Leu Ala Glu Lys Val Asn Lys Gly Val Gln Ala Gly
625 630 635 640
Leu Phe Leu Asn Trp Ala Asn Glu Val Val Glu Asp Phe Thr Thr Asn
645 650 655
Ile Met Lys Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Val Ile
660 665 670
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Ser Ala Leu Arg
675 680 685
Gly Asn Phe Asn Gln Ala Phe Ala Thr Ala Gly Val Ala Phe Leu Leu
690 695 700
Glu Gly Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Val Phe Thr Phe
705 710 715 720
Tyr Ser Ser Ile Gln Glu Arg Glu Lys Ile Ile Lys Thr Ile Glu Asn
725 730 735
Cys Leu Glu Gln Arg Val Lys Arg Trp Lys Asp Ser Tyr Gln Trp Met
740 745 750
Val Ser Asn Trp Leu Ser Arg Ile Thr Thr Gln Phe Asn His Ile Asn
755 760 765
Tyr Gln Met Tyr Asp Ser Leu Ser Tyr Gln Ala Asp Ala Ile Lys Ala
770 775 780
Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu Asn
785 790 795 800
Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys Ile
805 810 815
Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser Val
820 825 830
Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu Asn
835 840 845
Lys Phe Asp Leu Arg Thr Lys Thr Glu Leu Ile Asn Leu Ile Asp Ser
850 855 860
His Asn Ile Ile Leu Val Gly Glu Val Asp Arg Leu Lys Ala Lys Val
865 870 875 880
Asn Glu Ser Phe Glu Asn Thr Met Pro Phe Asn Ile Phe Ser Tyr Thr
885 890 895
Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn
900 905 910
<210> 93
<211> 977
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 93
Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp Pro Val Asp Asn Lys
1 5 10 15
Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr Leu Ala Asn Glu Pro
20 25 30
Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp Val Ile Pro Asp Arg
35 40 45
Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys Pro Pro Arg Val Thr
50 55 60
Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr Leu Ser Thr Asp Ser
65 70 75 80
Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr Arg Leu Ser Thr Asp
100 105 110
Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile Asn Thr Phe Asp Phe
115 120 125
Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr Arg Gln Gly Asn Asn
130 135 140
Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val Ile Ile Thr Gly Pro
145 150 155 160
Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr Phe Lys Leu Thr Asn
165 170 175
Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala Leu Ser Ile Ile Ser
180 185 190
Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn Ala Thr Asn Asp Val
195 200 205
Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys Met Asp Pro Ile Leu
210 215 220
Ile Leu Met His Glu Leu Asn His Ala Met His Asn Leu Tyr Gly Ile
225 230 235 240
Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val Thr Ser Asn Ile Phe
245 250 255
Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala Glu Ile Tyr Ala Phe
260 265 270
Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser Ala Arg Lys Tyr Phe
275 280 285
Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile Ala Lys Arg Leu Asn
290 295 300
Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn Lys Tyr Ile Gly Glu
305 310 315 320
Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe Val Val Glu Ser Ser
325 330 335
Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val Glu Leu Tyr Asn Glu
340 345 350
Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala Lys Ile Tyr Asn Val
355 360 365
Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr Thr Pro Val Thr Ala
370 375 380
Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln Asn Gly Phe Asn Ile
385 390 395 400
Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly Gln Asn Leu Ser Arg
405 410 415
Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn Met Leu Tyr Leu Phe
420 425 430
Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg Ser Leu Tyr Asn Lys
435 440 445
Thr Leu Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe
450 455 460
Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp
465 470 475 480
Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val
485 490 495
Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp
500 505 510
Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu
515 520 525
Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn
530 535 540
Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp
545 550 555 560
Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys
565 570 575
Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val
580 585 590
Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe
595 600 605
Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val
610 615 620
Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser
625 630 635 640
Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr
645 650 655
Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala
660 665 670
Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr
675 680 685
Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr
690 695 700
Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn
705 710 715 720
Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala
725 730 735
Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp
740 745 750
Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp
755 760 765
Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu
770 775 780
Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp
785 790 795 800
Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu
805 810 815
Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys
820 825 830
Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe
835 840 845
Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe
850 855 860
Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
865 870 875 880
Gly Ser Ala Leu Val Met Lys Pro Ile Gln Lys Leu Leu Ala Gly Leu
885 890 895
Ile Leu Leu Thr Trp Cys Val Glu Gly Cys Ser Ser Gln His Trp Ser
900 905 910
Tyr Gly Leu Arg Pro Gly Gly Lys Arg Asp Ala Glu Asn Leu Ile Asp
915 920 925
Ser Phe Gln Glu Ile Val Lys Glu Val Gly Gln Leu Ala Glu Thr Gln
930 935 940
Arg Phe Glu Cys Thr Thr His Gln Pro Arg Ser Pro Leu Arg Asp Leu
945 950 955 960
Lys Gly Ala Leu Glu Ser Leu Ile Glu Glu Glu Thr Gly Gln Lys Lys
965 970 975
Ile
<210> 94
<211> 988
<212> PRT
<213> Artificial Sequence
<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"
<400> 94
Thr Trp Pro Val Lys Asp Phe Asn Tyr Ser Asp Pro Val Asn Asp Asn
1 5 10 15
Asp Ile Leu Tyr Leu Arg Ile Pro Gln Asn Lys Leu Ile Thr Thr Pro
20 25 30
Val Lys Ala Phe Met Ile Thr Gln Asn Ile Trp Val Ile Pro Glu Arg
35 40 45
Phe Ser Ser Asp Thr Asn Pro Ser Leu Ser Lys Pro Pro Arg Pro Thr
50 55 60
Ser Lys Tyr Gln Ser Tyr Tyr Asp Pro Ser Tyr Leu Ser Thr Asp Glu
65 70 75 80
Gln Lys Asp Thr Phe Leu Lys Gly Ile Ile Lys Leu Phe Lys Arg Ile
85 90 95
Asn Glu Arg Asp Ile Gly Lys Lys Leu Ile Asn Tyr Leu Val Val Gly
100 105 110
Ser Pro Phe Met Gly Asp Ser Ser Thr Pro Glu Asp Thr Phe Asp Phe
115 120 125
Thr Arg His Thr Thr Asn Ile Ala Val Glu Lys Phe Glu Asn Gly Ser
130 135 140
Trp Lys Val Thr Asn Ile Ile Thr Pro Ser Val Leu Ile Phe Gly Pro
145 150 155 160
Leu Pro Asn Ile Leu Asp Tyr Thr Ala Ser Leu Thr Leu Gln Gly Gln
165 170 175
Gln Ser Asn Pro Ser Phe Glu Gly Phe Gly Thr Leu Ser Ile Leu Lys
180 185 190
Val Ala Pro Glu Phe Leu Leu Thr Phe Ser Asp Val Thr Ser Asn Gln
195 200 205
Ser Ser Ala Val Leu Gly Lys Ser Ile Phe Cys Met Asp Pro Val Ile
210 215 220
Ala Leu Met His Glu Leu Thr His Ser Leu His Gln Leu Tyr Gly Ile
225 230 235 240
Asn Ile Pro Ser Asp Lys Arg Ile Arg Pro Gln Val Ser Glu Gly Phe
245 250 255
Phe Ser Gln Asp Gly Pro Asn Val Gln Phe Glu Glu Leu Tyr Thr Phe
260 265 270
Gly Gly Leu Asp Val Glu Ile Ile Pro Gln Ile Glu Arg Ser Gln Leu
275 280 285
Arg Glu Lys Ala Leu Gly His Tyr Lys Asp Ile Ala Lys Arg Leu Asn
290 295 300
Asn Ile Asn Lys Thr Ile Pro Ser Ser Trp Ile Ser Asn Ile Asp Lys
305 310 315 320
Tyr Lys Lys Ile Phe Ser Glu Lys Tyr Asn Phe Asp Lys Asp Asn Thr
325 330 335
Gly Asn Phe Val Val Asn Ile Asp Lys Phe Asn Ser Leu Tyr Ser Asp
340 345 350
Leu Thr Asn Val Met Ser Glu Val Val Tyr Ser Ser Gln Tyr Asn Val
355 360 365
Lys Asn Arg Thr His Tyr Phe Ser Arg His Tyr Leu Pro Val Phe Ala
370 375 380
Asn Ile Leu Asp Asp Asn Ile Tyr Thr Ile Arg Asp Gly Phe Asn Leu
385 390 395 400
Thr Asn Lys Gly Phe Asn Ile Glu Asn Ser Gly Gln Asn Ile Glu Arg
405 410 415
Asn Pro Ala Leu Gln Lys Leu Ser Ser Glu Ser Val Val Asp Leu Phe
420 425 430
Thr Lys Val Cys Val Asp Lys Ser Glu Glu Lys Leu Tyr Asp Asp Asp
435 440 445
Asp Lys Asp Arg Trp Gly Ser Ser Leu Gln Cys Ile Lys Val Lys Asn
450 455 460
Asn Arg Leu Pro Tyr Val Ala Asp Lys Asp Ser Ile Ser Gln Glu Ile
465 470 475 480
Phe Glu Asn Lys Ile Ile Thr Asp Glu Thr Asn Val Gln Asn Tyr Ser
485 490 495
Asp Lys Phe Ser Leu Asp Glu Ser Ile Leu Asp Gly Gln Val Pro Ile
500 505 510
Asn Pro Glu Ile Val Asp Pro Leu Leu Pro Asn Val Asn Met Glu Pro
515 520 525
Leu Asn Leu Pro Gly Glu Glu Ile Val Phe Tyr Asp Asp Ile Thr Lys
530 535 540
Tyr Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu
545 550 555 560
Ser Asn Asn Val Glu Asn Ile Thr Leu Thr Thr Ser Val Glu Glu Ala
565 570 575
Leu Gly Tyr Ser Asn Lys Ile Tyr Thr Phe Leu Pro Ser Leu Ala Glu
580 585 590
Lys Val Asn Lys Gly Val Gln Ala Gly Leu Phe Leu Asn Trp Ala Asn
595 600 605
Glu Val Val Glu Asp Phe Thr Thr Asn Ile Met Lys Lys Asp Thr Leu
610 615 620
Asp Lys Ile Ser Asp Val Ser Val Ile Ile Pro Tyr Ile Gly Pro Ala
625 630 635 640
Leu Asn Ile Gly Asn Ser Ala Leu Arg Gly Asn Phe Asn Gln Ala Phe
645 650 655
Ala Thr Ala Gly Val Ala Phe Leu Leu Glu Gly Phe Pro Glu Phe Thr
660 665 670
Ile Pro Ala Leu Gly Val Phe Thr Phe Tyr Ser Ser Ile Gln Glu Arg
675 680 685
Glu Lys Ile Ile Lys Thr Ile Glu Asn Cys Leu Glu Gln Arg Val Lys
690 695 700
Arg Trp Lys Asp Ser Tyr Gln Trp Met Val Ser Asn Trp Leu Ser Arg
705 710 715 720
Ile Thr Thr Gln Phe Asn His Ile Asn Tyr Gln Met Tyr Asp Ser Leu
725 730 735
Ser Tyr Gln Ala Asp Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys
740 745 750
Lys Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn
755 760 765
Leu Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile
770 775 780
Asn Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met
785 790 795 800
Leu Pro Lys Val Ile Asp Glu Leu Asn Lys Phe Asp Leu Arg Thr Lys
805 810 815
Thr Glu Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly
820 825 830
Glu Val Asp Arg Leu Lys Ala Lys Val Asn Glu Ser Phe Glu Asn Thr
835 840 845
Met Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp
850 855 860
Ile Ile Asn Glu Tyr Phe Asn Leu Glu Gly Gly Gly Gly Ser Gly Gly
865 870 875 880
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val
885 890 895
Met Lys Pro Ile Gln Lys Leu Leu Ala Gly Leu Ile Leu Leu Thr Trp
900 905 910
Cys Val Glu Gly Cys Ser Ser Gln His Trp Ser Tyr Gly Leu Arg Pro
915 920 925
Gly Gly Lys Arg Asp Ala Glu Asn Leu Ile Asp Ser Phe Gln Glu Ile
930 935 940
Val Lys Glu Val Gly Gln Leu Ala Glu Thr Gln Arg Phe Glu Cys Thr
945 950 955 960
Thr His Gln Pro Arg Ser Pro Leu Arg Asp Leu Lys Gly Ala Leu Glu
965 970 975
Ser Leu Ile Glu Glu Glu Thr Gly Gln Lys Lys Ile
980 985
Claims (18)
- 말단비대증의 치료에서 이용되는 폴리펩티드로서, 상기 폴리펩티드는
(a) 신경내분비 종양 세포에 함유된 세포외배출성 융합체(exocytic fusion apparatus)의 단백질을 절단할 수 있는 비-세포독성 프로테아제로서, 상기 비-세포독성 프로테아제는 클로스트리듐 신경독소(clostridial neurotoxin) 엔도펩티다제 또는 IgA 프로테아제를 포함하는 것인 비-세포독성 프로테아제;
(b) 신경내분비 종양 세포의 결합부위에 결합하고, 상기 결합부위는 세포내이입(endocytosis)의 대상이 되어 상기 신경내분비 종양 세포 내부의 엔도솜에 통합(incoproate)될 수 있는 것인 펩티드 표적화 성분(Targeting Moiety, TM)으로서, 상기 펩티드 TM은 성장호르몬-분비 호르몬(GHRH) 펩티드, 소마토스타틴 펩티드, 코르티스타틴 펩티드, 그렐린 펩티드, 봄베신 펩티드, 우로텐신 펩티드, 멜라닌-농축 호르몬 펩티드, KISS-1 펩티드, 고나도트로핀-분비 호르몬(GnRH) 펩티드, 또는 프로락틴-방출 펩티드를 포함하는 것인 펩티드 표적화 성분(TM); 및
(c) 상기 프로테아제를 엔도솜 외부로, 엔도솜막을 관통하여, 상기 신경내분비 종양 세포의 사이토졸 속으로 이동시키는 클로스트리듐 신경독소 전위(translocation) 도메인을 포함하고,
상기 폴리펩티드는 클로스트리듐 신경독소의 원형(native) Hcc 결합 도메인을 갖지 않고, 신경근육 접합부(neutromuscular junction)의 신경 말단에 결합할 수 없고,
상기 신경내분비 종양 세포는 뇌하수체 종양 세포인 것인 폴리펩티드. - 삭제
- 삭제
- 제1항에 있어서, 상기 TM은 성장호르몬-분비 호르몬(GHRH) 수용체; 소마토스타틴(SST) 수용체; 코르티스타틴(CST) 수용체; 그렐린 수용체; 봄베신 수용체; 우로텐신 수용체; 멜라닌-농축 호르몬 수용체 1; KiSS-1 수용체; 고나도트로핀-분비 호르몬(GnRH) 수용체; 및 프로락틴-방출 펩티드 수용체로 이루어진 군에서 선택되는 수용체에 결합하는 것인 폴리펩티드.
- (a) 신경내분비 종양 세포에 함유된 세포외배출성 융합체의 단백질을 절단할 수 있는 비-세포독성 프로테아제;
(b) 신경내분비 종양 세포의 결합부위에 결합하고, 상기 결합부위는 세포내이입의 대상이 되어 상기 신경내분비 종양 세포의 내부에 있는 엔도솜에 통합될 수 있는 것인 표적화 성분(TM); 및
(c) 상기 프로테아제를 엔도솜 외부로, 엔도솜막을 관통하여, 상기 신경내분비 종양 세포의 사이토졸 속으로 이동시키는 전위 도메인을 포함하는 폴리펩티드로서,
상기 폴리펩티드는 클로스트리듐 신경독소의 원형 Hcc 결합 도메인을 갖지 않고, 신경근육 접합부의 신경 말단에 결합할 수 없으며, 및
상기 폴리펩티드는 서열번호 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 또는 94 중 어느 하나의 아미노산 서열을 포함하고,
상기 신경내분비 종양 세포는 뇌하수체 종양 세포인 것인 폴리펩티드. - 삭제
- 제5항에 있어서, 상기 TM은 성장호르몬-분비 호르몬(GHRH) 수용체; 소마토스타틴(SST) 수용체; 코르티스타틴(CST) 수용체; 그렐린 수용체; 봄베신 수용체; 우로텐신 수용체; 멜라닌-농축 호르몬 수용체 1; KiSS-1 수용체; 고나도트로핀-분비 호르몬(GnRH) 수용체; 및 프로락틴-방출 펩티드 수용체로 이루어진 군에서 선택되는 수용체에 결합하는 것인 폴리펩티드.
- 제5항 또는 제7항에 따른 폴리펩티드를 코딩하는 핵산.
- 제5항 또는 제7항에 따른 폴리펩티드 또는 상기 폴리펩티드를 코딩하는 핵산을 포함하는, 말단비대증의 치료용 약학적 조성물.
- 말단비대증의 치료를 위해 사용하기 위한, 제5항 또는 제7항에 따른 폴리펩티드, 또는 상기 폴리펩티드를 코딩하는 핵산.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0810785.6 | 2008-06-12 | ||
GB0810782.3 | 2008-06-12 | ||
GB0810785A GB0810785D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of neuroendocrine diseases |
GBGB0810782.3A GB0810782D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of cancers |
GB0820884A GB0820884D0 (en) | 2008-11-14 | 2008-11-14 | Suppression of neuroendocrine diseases |
GB0820884.5 | 2008-11-14 | ||
GB0820965A GB0820965D0 (en) | 2008-11-17 | 2008-11-17 | Suppression of cancers |
GB0820965.2 | 2008-11-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110038017A KR20110038017A (ko) | 2011-04-13 |
KR101642363B1 true KR101642363B1 (ko) | 2016-07-25 |
Family
ID=41417177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117000251A KR101642363B1 (ko) | 2008-06-12 | 2009-06-11 | 신경내분비계 질환의 억제 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110171191A1 (ko) |
EP (3) | EP3590956A1 (ko) |
JP (2) | JP5728380B2 (ko) |
KR (1) | KR101642363B1 (ko) |
CN (2) | CN104328100B (ko) |
AU (1) | AU2009259033B2 (ko) |
BR (1) | BRPI0915888E2 (ko) |
CA (1) | CA2727082C (ko) |
ES (2) | ES2750651T3 (ko) |
IL (1) | IL209855A (ko) |
WO (1) | WO2009150469A2 (ko) |
ZA (1) | ZA201008536B (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
US20110171191A1 (en) * | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
CA2959670C (en) * | 2014-09-15 | 2024-02-20 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | ペプチド模倣大環状分子およびその使用 |
US20170326166A1 (en) * | 2014-10-17 | 2017-11-16 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
EP3519430A1 (en) | 2016-09-29 | 2019-08-07 | Ipsen Biopharm Limited | Hybrid neurotoxins |
EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
JOP20190276A1 (ar) * | 2017-05-31 | 2019-11-27 | Napo Pharmaceuticals Inc | طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة |
MX2020007596A (es) | 2018-01-29 | 2020-09-03 | Ipsen Biopharm Ltd | Neurotoxinas botulinicas para escindir una proteina de receptor de union a factor sensible a n-etilmaleimida soluble (snare) no neuronal. |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
CN113257370B (zh) * | 2021-05-12 | 2022-09-02 | 中国医学科学院北京协和医院 | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025976A1 (en) | 2004-08-27 | 2006-03-09 | Allergan, Inc. | Methods for treating cancer |
WO2006099590A2 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
IT1105131B (it) | 1977-06-08 | 1985-10-28 | Merck & Co Inc | Peptidi analoghi della somatostatina dotati di piu' lunga e maggiore attivita' biologica e relativo procedimento di protezione |
US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
ATE14226T1 (de) | 1981-12-24 | 1985-07-15 | Ciba Geigy Ag | Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung. |
FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
US4632979A (en) | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4803261A (en) | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
US5084555A (en) | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
WO1989002897A1 (en) | 1987-09-24 | 1989-04-06 | The Administrators Of The Tulane Educational Fund | Therapeutic peptides |
EP0329295A1 (en) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
ZA895838B (en) | 1988-08-18 | 1991-03-27 | Syntex Inc | Pharmaceutical compounds |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990003980A1 (en) | 1988-10-14 | 1990-04-19 | Administrators Of The Tulane Educational Fund | Therapeutic peptides |
US5171835A (en) | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
WO1990012811A1 (en) | 1989-04-26 | 1990-11-01 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
CA2046594A1 (en) | 1989-12-08 | 1991-06-09 | David H. Coy | Octapeptide analogs of somatostatin having threonine at the sixth position |
ES2076393T3 (es) | 1990-04-06 | 1995-11-01 | Univ Tulane | Analogos de lhrh. |
EP0527914A4 (en) | 1990-05-04 | 1993-08-11 | The Administrators Of The Tulane University Educational Fund | Novel synthetic grf analogs |
JPH05506862A (ja) | 1990-05-09 | 1993-10-07 | ジ・アドミニストレイターズ・オブ・ザ・トゥーラン・エデュケイショナル・ファンド | 環状および鎖状の治療用ペプチド |
IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
US6083915A (en) | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
US5240561A (en) | 1992-02-10 | 1993-08-31 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
US5656727A (en) | 1992-09-15 | 1997-08-12 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
WO1994011397A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
WO1994011396A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
PT1288223E (pt) | 1993-08-09 | 2005-03-31 | Sod Conseils Rech Applic | Derivados de peptidos terapeuticos |
US5550212A (en) | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
AUPM985694A0 (en) | 1994-12-02 | 1995-01-05 | Farmer, Mostyn | Golf training aid |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
DE69504634T2 (de) | 1995-03-13 | 1999-03-25 | Biomeasure Inc | Bombesin-Analogen |
AU5441096A (en) | 1995-04-14 | 1996-10-30 | The Administrators Of The Tulane Eductional Fund | Analogs of growth hormone-releasing factor |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
US5942489A (en) | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
AU3215597A (en) | 1996-08-30 | 1998-03-19 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
US5968903A (en) | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
PL346361A1 (en) | 1998-07-30 | 2002-02-11 | Sod Conseils Rech Applic | Methods of using a somatostatin analogue |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
EP1189941B1 (en) | 1999-06-04 | 2013-01-09 | Ipsen Pharma | Neuromedin b and somatostatin receptor agonists |
WO2001014570A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US20060153876A1 (en) * | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7892565B2 (en) * | 2004-09-01 | 2011-02-22 | Allergan, Inc. | Degradable clostridial toxins |
GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059093A2 (en) * | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
ATE463506T1 (de) | 2005-09-19 | 2010-04-15 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
CA2657521A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
AU2009259034B2 (en) * | 2008-06-12 | 2013-10-31 | Ipsen Bioinnovation Limited | Suppression of cancers |
US20110171191A1 (en) * | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
US10057187B1 (en) | 2015-05-27 | 2018-08-21 | Amazon Technologies, Inc. | Dynamic resource creation to connect client resources in a distributed system |
-
2009
- 2009-06-11 US US12/996,643 patent/US20110171191A1/en not_active Abandoned
- 2009-06-11 CA CA2727082A patent/CA2727082C/en not_active Expired - Fee Related
- 2009-06-11 EP EP19175007.4A patent/EP3590956A1/en active Pending
- 2009-06-11 KR KR1020117000251A patent/KR101642363B1/ko active IP Right Grant
- 2009-06-11 ES ES13179177T patent/ES2750651T3/es active Active
- 2009-06-11 EP EP09762018.1A patent/EP2310028B1/en active Active
- 2009-06-11 JP JP2011513056A patent/JP5728380B2/ja active Active
- 2009-06-11 ES ES09762018.1T patent/ES2614990T3/es active Active
- 2009-06-11 CN CN201410295607.7A patent/CN104328100B/zh not_active Expired - Fee Related
- 2009-06-11 BR BRC10915888A patent/BRPI0915888E2/pt not_active IP Right Cessation
- 2009-06-11 WO PCT/GB2009/050665 patent/WO2009150469A2/en active Application Filing
- 2009-06-11 EP EP13179177.4A patent/EP2719392B1/en active Active
- 2009-06-11 AU AU2009259033A patent/AU2009259033B2/en not_active Ceased
- 2009-06-11 CN CN200980130069.3A patent/CN102112145B/zh not_active Expired - Fee Related
-
2010
- 2010-11-29 ZA ZA2010/08536A patent/ZA201008536B/en unknown
- 2010-12-08 IL IL209855A patent/IL209855A/en not_active IP Right Cessation
-
2014
- 2014-04-21 JP JP2014087047A patent/JP5891258B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
WO2006025976A1 (en) | 2004-08-27 | 2006-03-09 | Allergan, Inc. | Methods for treating cancer |
WO2006099590A2 (en) | 2005-03-15 | 2006-09-21 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
Also Published As
Publication number | Publication date |
---|---|
CN104328100A (zh) | 2015-02-04 |
CN102112145B (zh) | 2014-07-30 |
EP2719392B1 (en) | 2019-07-24 |
CA2727082C (en) | 2019-02-26 |
CN104328100B (zh) | 2019-08-23 |
AU2009259033A1 (en) | 2009-12-17 |
IL209855A0 (en) | 2011-02-28 |
JP2011522560A (ja) | 2011-08-04 |
EP2719392A1 (en) | 2014-04-16 |
JP5891258B2 (ja) | 2016-03-22 |
AU2009259033B2 (en) | 2013-11-07 |
EP2310028A2 (en) | 2011-04-20 |
BRPI0915888E2 (pt) | 2020-09-01 |
EP2310028B1 (en) | 2016-11-16 |
JP2014195454A (ja) | 2014-10-16 |
JP5728380B2 (ja) | 2015-06-03 |
US20110171191A1 (en) | 2011-07-14 |
BRPI0915888A2 (pt) | 2020-06-30 |
ZA201008536B (en) | 2012-05-30 |
WO2009150469A2 (en) | 2009-12-17 |
WO2009150469A3 (en) | 2010-07-15 |
KR20110038017A (ko) | 2011-04-13 |
CN102112145A (zh) | 2011-06-29 |
ES2750651T3 (es) | 2020-03-26 |
IL209855A (en) | 2013-09-30 |
ES2614990T3 (es) | 2017-06-02 |
CA2727082A1 (en) | 2009-12-17 |
EP3590956A1 (en) | 2020-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101642363B1 (ko) | 신경내분비계 질환의 억제 | |
KR101731655B1 (ko) | 암 억제 방법 | |
US8796216B2 (en) | Suppression of neuroendocrine diseases | |
JP5658152B2 (ja) | 非細胞毒性融合タンパク質 | |
JP2012500018A5 (ko) | ||
US20110158973A1 (en) | Suppression of cancers | |
JP2016509997A (ja) | 骨粗鬆症を抑制するための治療 | |
WO2007138336A2 (en) | Treatment of pain by single chain, polypeptide fusion protein | |
AU2014200449B2 (en) | Suppression of neuroendocrine diseases | |
AU2011202225B2 (en) | Non-cytotoxic protein conjugates | |
AU2011203062A1 (en) | Suppression of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |